B 7

# PCT

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|---|---|
| (51) International Patent Classification 7 : C07K 14/00 | A2 | (11) International Publication Number: **WO 00/21985** |
| | | (43) International Publication Date: 20 April 2000 (20.04.00) |

(21) International Application Number: PCT/IB99/01729

(22) International Filing Date: 13 October 1999 (13.10.99)

(30) Priority Data:
60/104,299      14 October 1998 (14.10.98)      US

(71) Applicant *(for all designated States except US)*: GENSET [FR/FR]; 24, rue Royale, F–75008 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BOUGUELERET, Lydie [FR/FR]; 108, avenue Victor Hugo, F–92170 Vanves (FR). MALEKZADEH, Kattayoun [IR/FR]; 41, rue des Laitieres, F–94300 Vincennes (FR).

(74) Common Representative: GENSET; 24, rue Royale, F–75008 Paris (FR).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*Without international search report and to be republished upon receipt of that report.*

(54) Title: GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF

(57) Abstract

The invention concerns the genomic sequence and coding regions of a new olfactory receptor gene cluster. The invention also concerns polypeptides encoded by the olfactory receptor genes as well as to methods and kits for detecting these polynucleotides and screening substances interacting with these polypeptides. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the olfactory receptor gene useful in genetic analysis.

# GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF

## FIELD OF THE INVENTION

The present invention pertains to a purified or isolated nucleic acid comprising ten open

5   reading Frames (ORFs) encoding ten different olfactory receptor-like proteins, non-coding regions flanking the ORFs as well as fragments thereof. The invention also provides recombinant expression vectors and recombinant cell hosts containing a nucleic acid encoding said olfactory receptor proteins. The invention also concerns the olfactory receptor proteins encoded by these ORFs as well as polypeptides that are homologous to said olfactory receptor proteins and the peptide fragments of

10  both the olfactory receptor proteins and their homologous polypeptide counterparts. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.  The invention further encompasses biallelic markers of the olfactory receptor gene useful in genetic analysis. The invention also deals with methods and kits for the detection of the olfactory receptor proteins and with methods and kits for screening ligand molecules binding to

15  these proteins.

## BACKGROUND OF THE INVENTION

Throughout this application, various bibliographic publications are cited. Full bibliographic references for these publications may be found at the end of this application, preceding the sequence listing and the claims.

20  **OLFACTORY SYSTEM**

The olfactory receptor cells, the first cells in the pathway that give rise to the sense of smell, lie in a small patch of membrane, the olfactory epithelium, in the upper part of the nasal cavity. These cells are specialized afferent neurons that have an enlarged extension analogous to a dendrite. Several long hairlike processes extend out from this extension along the surface of the olfactory

25  epithelium where they are bathed in mucus. The hairlike processes contain the receptor proteins for olfactory stimuli. The axons of these neurons form the olfactory nerve.

For the detection of an odorous substance which is called an odorant, molecules of the substance must first diffuse into the air and pass into the nose to the region of the olfactory epithelium. Once there, they dissolve in the mucus that covers the epithelium and then bind to

30  specific receptor proteins on the cilia.

Although there are many thousands of olfactory neurons, each contains one, or at most a few, of the 1,000 or so different receptor types, each of which responds only to a specific chemically related group of odorant molecules. Each odorant has characteristic chemical groups that distinguish it from other odorants, and each of these groups activates a different receptor type. Thus the identity

of a particular odorant is determined by the activation of a precise combination of receptors, each of which is contained in a distinct group of olfactory neurons.

The axons of the olfactory neurons synapse in the brain structures known as olfactory bulbs, which lie on the undersurface of the frontal lobes. Axons from olfactory neurons sharing a common

5 receptor specificity synapse together on certain olfactory-bulb neurons, thereby maintaining the specificity of the original stimuli.

## OLFACTORY RECEPTORS

In contrast with the immunoglobulin system, the diversity of olfactory receptors is encoded by a large germ-line repertoire of olfactory receptor genes. The size of the olfactory receptor gene

10 family in the human genome is unknown but it has been estimated to encompass 200 to 1,000 genes.

The locations of only a few human genes have been determined to date. The picture that has emerged so far is that several large clusters of olfactory genes and pseudogenes span hundreds of kilobases on several chromosomes. Using FISH analyses, more than 25 distinct locations of olfactory receptors gene have been identified in the human genome.

15 In mammals, the olfactory epithelium appears to be organized into distinct topographic regions or zones in which expression of a particular receptor gene appears to be restricted to one of the four zones in the epithelium. Within the zone, the distribution of neurons expressing a given receptor is random. Chromosomal mapping studies have revealed clusters of odorant receptor genes at a single locus, and numerous such loci have been mapped to different chromosomes. However,

20 receptors expressed in the same zone map to different loci, and a single locus can contain genes expressed in different zones. A putative odorant receptor promoter, consisting of the 6.7 kb DNA fragment upstream of the receptor coding region, has been shown to be sufficient to direct olfactory receptor expression in a tissue-specific, zonal-specific manner.

Olfactory receptors share a seven-transmembrane domain structure (TM1 to TM7) with

25 many neurotransmitter and hormone receptors. They show a high degree of sequence similarity in some conserved domains (TM2 and TM7) as well as regions of diversity (TM3, TM4, TM5, and TM6). They are responsible for the recognition and G protein-mediated transduction of odorant signals. The genes encoding these receptors are devoid of introns within their coding regions.

Olfactory receptors display all hallmarks of the G-protein coupled receptor superfamily but

30 have also some unique motifs. Most notably they appear to be minimal in structure with very short cytoplasmic and extracellular loops. In addition, they display a striking structural diversity in the third, fourth and fifth transmembrane domains which are supposed to form the hydrophobic core of these proteins, and may form the ligand binding site of the receptors.

An understanding of the genetic basis of olfaction and a knowledge of olfactory receptors

35 are important to enable the design of fragrance, the identification of compounds which control appetite, or the detection of compounds which can be harmful or dangerous.

## SUMMARY OF THE INVENTION

This invention provides a nucleic acid molecule encoding ten different olfactory receptor-like proteins (OLF).

The invention also deals with a nucleic acid molecule comprising a nucleotide sequence

5   encoding an olfactory receptor-like protein, which nucleotide sequence is selected from the group consisting of SEQ ID Nos 2-11, as well as with the corresponding polypeptide encoded by this nucleotide sequence and with antibodies directed against the corresponding polypeptide.

Oligonucleotide probes or primers hybridizing specifically with an olfactory receptor genomic sequence are also part of the present invention, as well as DNA amplification and detection

10   methods using said primers and probes.

The invention also concerns a purified and/or isolated biallelic marker located in the sequence of the olfactory receptor gene cluster of the invention, wherein said biallelic marker is useful as a diagnostic tool in order to detect an allele associated with a specific phenotype as regards to the olfaction system, including an alteration of the olfactory perception of substances or

15   molecules.

A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described above, and in particular of recombinant vectors comprising a sequence encoding an olfactory receptor protein, as well as of cell hosts and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

20   A further object of the invention consists of methods for screening substances or molecules interacting with an olfactory receptor encoded by any of the nucleic acid molecule described above.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 : Alignment of the amino acid sequences of the olfactory polypeptides encoded by

25   the Open Reading Frames of the olfactory receptor gene cluster of the invention. The lower line represents the consensus sequence. The locations of the seven transmembrane domains TM1 to TM7 are boxed.

## BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

30   SEQ ID No 1 contains the olfactory receptor genomic sequence.

SEQ ID Nos 2-11 contains the nucleotide sequences of the open reading frame sequences of SEQ ID No 1 encoding the OLF1 to OLF10 polypeptides.

SEQ ID No 12-21 contain the amino acid sequence of OLF1 to OLF10 polypeptides encoded by the open reading frames of SEQ ID Nos 2-11.

4

SEQ ID Nos 22-25 contain the amplification primers used for FISH experiments described
in Example 1.

SEQ ID No 26 contains a primer containing the additional PU 5' sequence described further
in Example 3.

5          SEQ ID No 27 contains a primer containing the additional RP 5' sequence described further
in Example 3.

In accordance with the regulations relating to Sequence Listings, the following codes have
been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences
·and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences

10    indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine.
The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while
the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the
polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences
indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine.

15    The code "s" in the sequences indicates that one allele of the polymorphic base is a guanine, while
the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the
polymorphic base is an adenine, while the other allele is an thymine.

The nucleotide code of the original allele for each biallelic marker is the following:

| Biallelic marker | Original allele |
|---|---|
| 99-13670-305 | G |
| 99-13669-471 | G |
| 99-13666-275 | A |
| 99-13664-221 | T |
| 99-13663-218 | G |
| 99-13660-277 | C |
| 99-13652-407 | G |
| 99-13652-357 | A |
| 99-13652-308 | A |
| 99-13671-396 | A |
| 99-13649-286 | C |
| 99-13648-259 | G |
| 99-13647-278 | G |

20

25

30

## DETAILED DESCRIPTION OF THE INVENTION

35          The aim of the present invention is to provide polynucleotides and polypeptides related to
novel olfactory receptors, notably useful in order to design suitable means for detecting specific
odorant molecules in a material sample, particularly in a material sample suspected to contain an
odorant molecule that consists of one of the specific ligands for the olfactory receptors of the
invention.

## DEFINITIONS

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

### General definitions

5      The terms "olfactory receptor gene" or "OLF1 to OLF10" genes, when used herein, encompasses genomic, mRNA and cDNA sequences encoding the OLF1 to OLF10 olfactory receptor proteins.

The term "heterologous protein", when used herein, is intended to designate any protein or polypeptide other than the OLF1 to OLF10 proteins.

10      The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide

15   could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly

20   contemplated. As an example, purification from 0.1 % concentration to 10 % concentration is two orders of magnitude. The term "purified polynucleotide" is used herein to describe a polynucleotide or polynucleotide vector of the invention which has been separated from other compounds including, but not limited to other nucleic acids, carbohydrates, lipids and proteins (such as the enzymes used in the synthesis of the polynucleotide), or the separation of covalently closed polynucleotides from

25   linear polynucleotides. A polynucleotide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polynucleotide typically comprises about 50%, preferably 60 to 90% weight/weight of a nucleic acid sample, more usually about 95%, and preferably is over about 99% pure. Polynucleotide purity or homogeneity is indicated by a number of means well

30   known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polynucleotide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of

35   polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term

polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications

5  known in the art, both naturally occurring and non-naturally occurring.

The term "recombinant polypeptide" is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

10   The term "purified polypeptide" is used herein to describe a polypeptide of the invention which has been separated from other compounds including, but not limited to nucleic acids, lipids, carbohydrates and other proteins. A polypeptide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises about 50%, preferably 60 to 90% weight/weight of a protein sample,

15   more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or homogeneity is indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

As used herein, the term "non-human animal" refers to any non-human vertebrate, birds and

20   more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term "animal" is used to refer to any vertebrate, preferable a mammal. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which

25   are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as wells as fragments, including Fab,

30   Fab', F(ab)$_2$, and F(ab')$_2$ fragments.

As used herein, an "antigenic determinant" is the portion of an antigen molecule, in this case a OLF1 to OLF10 polypeptide, that determines the specificity of the antigen-antibody reaction. An "epitope" refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope

35   comprises at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional

nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506.

Throughout the present specification, the expression "nucleotide sequence" may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the

5   expression "nucleotide sequence" encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

As used interchangeably herein, the terms "nucleic acids", "oligonucleotides", and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide

10   in either single chain or duplex form. The term "nucleotide" as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term "nucleotide" is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a

15   phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. The term "nucleotide" is also used herein to encompass "modified nucleotides" which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064.

20   The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, *ex vivo* generation, or a combination thereof, as well as utilizing any purification methods known in the art.

A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell required to initiate the specific transcription of a gene.

25   A sequence which is "operably linked" to a regulatory sequence such as a promoter means that said regulatory element is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the nucleic acid of interest. As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the

30   transcription of the coding sequence. More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to be "operably linked" if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding

35   polynucleotide.

The term "vector" is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one

polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or multicellular host organism.

The term "primer" denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves
5  as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

The term "probe" denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined hereinbelow) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence
10  complementary of the specific polynucleotide sequence to be identified.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic
15  polymorphism has two forms. Diploid organisms may be homozygous or heterozygous for an allelic form.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention, a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term "genotyping" a sample
20  or an individual for a biallelic marker involves determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

The term "mutation" as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

The term "polymorphism" as used herein refers to the occurrence of two or more alternative
25  genomic sequences or alleles between or among different genomes or individuals. "Polymorphic" refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A "polymorphic site" is the locus at which the variation occurs. A single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide also gives rise to single nucleotide
30  polymorphisms. In the context of the present invention, "single nucleotide polymorphism" preferably refers to a single nucleotide substitution. Typically, between different individuals, the polymorphic site may be occupied by two different nucleotides.

The term "biallelic polymorphism" and "biallelic marker" are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the
35  population. A "biallelic marker allele" refers to the nucleotide variants present at a biallelic marker site.

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide

5   immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the

10  polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on.

Biallelic markers can be defined as genome-derived polynucleotides having between 2 and 100, preferably between 20, 30, or 40 and 60, and more preferably about 47 nucleotides in length,

15  which exhibit biallelic polymorphism at one single base position. Each biallelic marker therefore corresponds to two forms of a polynucleotide sequence included in a gene which, when compared with one another, present a nucleotide modification at one position.

The term "upstream" is used herein to refer to a location which is toward the 5' end of the polynucleotide from a specific reference point.

20  The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another be virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

25  The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. For the purpose of the present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary

30  bases are, generally, A and T (or A and U), or C and G. "Complement" is used herein as a synonym from "complementary polynucleotide", "complementary nucleic acid" and "complementary nucleotide sequence". These terms are applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

**Variants and fragments**

<u>1- Polynucleotides</u>

The invention also relates to variants and fragments of the polynucleotides described herein, particularly of an olfactory receptor gene containing one or more biallelic markers according to the

5   invention.

Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques,

10  including those applied to polynucleotides, cells or organisms. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

Variants of polynucleotides according to the invention include, without being limited to, nucleotide sequences at least 95% identical to a nucleic acid selected from the group consisting of

15  SEQ ID Nos 1-11, or to any polynucleotide fragment of at least 12 consecutive nucleotides from a nucleic acid selected from the group consisting of SEQ ID Nos 1-11, and preferably at least 99% identical, more particularly at least 99.5% identical, and most preferably at least 99.8% identical to a nucleic acid selected from the group consisting of SEQ ID Nos 1-11, or to any polynucleotide fragment of at least 12 consecutive nucleotides from a nucleic acid selected from the group

20  consisting of SEQ ID Nos 1-11.

Changes in the nucleotide of a variant may be silent, which means that they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides.

25  The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

In the context of the present invention, particularly preferred embodiments are those in which the polynucleotides encode polypeptides which retain substantially the same biological

30  function or activity as the mature olfactory receptor protein, or those in which the polynucleotides encode polypeptides which maintain or increase a particular biological activity, while reducing a second biological activity.

A polynucleotide fragment is a polynucleotide which sequence is fully comprised within part of a given nucleotide sequence, preferably the nucleotide sequence of an olfactory receptor gene

35  of the invention, and variants thereof. The fragment can be a portion of a coding or non-coding region of the olfactory receptor gene cluster. Preferably, such fragments comprise at least one of the biallelic markers A1 to A13 or the complements thereto or a biallelic marker in linkage

disequilibrium with one or more of the biallelic markers A1 to A13, for which the respective locations in the sequence listing are provided in Table 2.

Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region.

5    However, several fragments may be comprised within a single larger polynucleotide.

As representative examples of polynucleotide fragments of the invention, there may be mentioned those which have from about 4, 6, 8, 15, 20, 25, 40, 10 to 30, 30 to 55, 50 to 100, 75 to 100 or 100 to 200 nucleotides in length. Preferred are those fragments having about 47 nucleotides in length, such as those comprising at least one of the biallelic markers A1 to A13 of the olfactory

10   receptor gene. Optionally, such fragments may consist of, or consist essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500 or 1000 nucleotides in length. A set of preferred fragments contain at least one of the biallelic markers A1 to A13 of the olfactory receptor gene which are described herein or the complements thereto.

## 2- Polypeptides

15   The invention also relates to variants, fragments, analogs and derivatives of the polypeptides described herein, including mutated olfactory receptor proteins.

The variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid

20   residues includes a substituent group, or 3) one in which the mutated olfactory receptor is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mutated olfactory receptor, such as a leader or secretory sequence or a sequence which is employed for purification of the mutated olfactory receptor or a preprotein sequence. Such variants are deemed to

25   be within the scope of those skilled in the art.

In the case of an amino acid substitution in the amino acid sequence of a polypeptide according to the invention, one or several amino acids can be replaced by "equivalent" amino acids. The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of

30   peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Generally, the following groups of amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

More particularly, a variant olfactory receptor polypeptide comprises amino acid changes

35   ranging from 1, 2, 3, 4, 5, 10 to 20 substitutions, additions or deletions of one aminoacid, preferably from 1 to 10, more preferably from 1 to 5 and most preferably from 1 to 3 substitutions, additions or deletions of one amino acid. The preferred amino acid changes are those which have little or no

influence on the biological activity or the capacity of the variant olfactory receptor polypeptide to bind to antibodies raised against a native olfactory receptor protein.

A specific, but not restrictive, embodiment of a modified peptide molecule of interest according to the present invention, which consists in a peptide molecule which is resistant to

5   proteolysis, is a peptide in which the -CONH- peptide bond is modified and replaced by a ($CH_2NH$) reduced bond, a (NHCO) retro inverso bond, a ($CH_2$-O) methylene-oxy bond, a ($CH_2$-S) thiomethylene bond, a ($CH_2CH_2$) carba bond, a (CO-$CH_2$) cetomethylene bond, a (CHOH-$CH_2$) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH- bond.

The polypeptide according to the invention could have post-translational modifications. For

10   example, it can present the following modifications: acylation, disulfide bond formation, prenylation, carboxymethylation and phosphorylation.

A polypeptide fragment is a polypeptide which sequence is fully comprised within part of a given polypeptide sequence, preferably a polypeptide encoded by an olfactory receptor gene and variants thereof.

15   Such fragments may be "free-standing", i.e. not part of or fused to other polypeptides, or they may be comprised within a single larger polypeptide of which they form a part or region. However, several fragments may be comprised within a single larger polypeptide.

As representative examples of polypeptide fragments of the invention, there may be mentioned those which have from about 5, 6, 7, 8, 9 or 10 to 15, 10 to 20, 15 to 40, or 30 to 55

20   amino acids long. Preferred polypeptide fragments according to the invention comprise a contiguous span of at least 6 amino acids, preferably at least 8 or amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of one amino acid sequence. Preferred are those fragments containing at least one amino acid mutation in the olfactory receptor protein under consideration.

**Identity between nucleic acids or polypeptides**

25   The terms "percentage of sequence identity" and "percentage homology" are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise

30   additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using either any of the

35   variety of sequence comparison algorithms and programs known in the art, or by eye inspection. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson

et al., 1994; Higgins et al., 1996; Altschul et al., 1990; Altschul et al., 1993). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In particular, five specific BLAST programs are used to perform the following task:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

(3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

(5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990). The BLAST programs may be used with the default parameters or with modified parameters provided by the user.

## Stringent Hybridization Conditions

By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 X $10^6$ cpm of $^{32}$P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2

x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1 X SSC at 50°C for 45

min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS,

or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals.

Following the wash steps, the hybridized probes are detectable by autoradiography. Other

5    conditions of high stringency which may be used are well known in the art and as cited in Sambrook

et al., 1989; and Ausubel et al., 1989. These hybridization conditions are suitable for a nucleic acid

molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions

described above are to be adapted according to the length of the desired nucleic acid, following

techniques well known to the one skilled in the art. The suitable hybridization conditions may for

10   example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985)

or in Sambrook et al.(1989).


## HOMOLOGIES OF THE NOVEL OLFACTORY RECEPTOR GENE WITH KNOWN OLFACTORY RECEPTORS

A comparison analysis of various olfactory receptor amino acid sequences, including the

15   novel sequences of the invention, has been performed with the alignment program Pileup and the

translation program MAP (Winsconsin Package version 8, GCG). The protein sequences were sorted

into different families and subfamilies, taking into account their Amino acid Sequence Identity

(ASI). It was observed the Open Reading Frames of the OLF1 to OLF10 genes are genetically

clearly distinguished from the already known olfactory receptor sequences. For example, the

20   olfactory receptor OLF2 presents respectively 39.9 %, 43.1 % and 44.2 % of identity with prior art

olfactory receptors referred in Genbank as L35475, U58675_1 and Y10530. In addition, the

nucleotide sequences of Orf-2 to Orf-10 according to the invention are all grouped together, whereas

the nucleotide Orf-1 of the invention forms a new family by itself. These amino acid sequence

comparison data clearly indicate that the novel olfactory receptor sequences of the invention share

25   common genetic characteristics (Orf-2 to Orf-10) or have specific characteristics (Orf-1) that are not

found in the prior art olfactory receptor sequences.


### A. OLF1 TO OLF10 GENE POLYNUCLEOTIDES.

The cluster of ten olfactory receptor genes has been found by the inventors to be located on

the human chromosome 11, more precisely within the 11q12-q13 locus of said chromosome as

30   described in Example 1.


### 1. Genomic sequences of the olfactory receptor gene

The present invention concerns the genomic sequence of an olfactory receptor cluster. The

present invention encompasses the olfactory receptor gene, or olfactory receptor genomic sequences

consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 1, a sequence

complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with

5 a nucleotide sequence of SEQ ID No 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as

10 well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the olfactory receptor gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the olfactory receptor sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with the nucleotide sequence of SEQ ID No 1 or a complementary sequence thereto,

15 under stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide

20 positions of SEQ ID No 1: 1-113643, 114064-127488, 127855-144460. Additional preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000,

25 10001-20000, 20001-30000, 30001-40000, 40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-100000, 100001-110000, 110001-120000, 120001-130000, 130001-140000, and 140001-144460. Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the

30 complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, 95001-100000, 100001-105000, 105001-110000, 110001-115000,

35 115001-120000, 120001-125000, 125001-130000, 130001-135000, 135001-140000, and 140001-144460.

The olfactory receptor genomic nucleic acid comprises 10 open reading frames, each carried
by a single exon and encoding a polypeptide designated OLF1 to OLF10. The open reading frames
positions of OLF1 to OLF10 in SEQ ID No 1 are given as features in the sequence listing and are
also detailed below in Table A.

5          Two truncated ubiquitin polypeptides Ubi1 and Ubi2, unrelated to olfactory receptor coding
sequences, are encoded on the complementary strand of the olfactory receptor gene. The
complementary sequence of the Ubi1 ORF is located between the nucleotide in position 114063 and
the nucleotide in position 113644 of the nucleotide sequence of SEQ ID No 1. The complementary
sequence of the Ubi2 ORF is located between the nucleotide in position 127854 and the nucleotide
10  in position 127489 of the nucleotide sequence of SEQ ID No 1.

### Table A

| Coding regions | | | Non-coding regions | | |
|---|---|---|---|---|---|
| Name | Position in SEQ ID No 1 | | Name | Position in SEQ ID No 1 | |
| | Beginning | End | | Beginning | End |
| OLF1 | 2406 | 2600 | NC1 | 1 | 2405 |
| OLF2 | 9711 | 10658 | NC2 | 2601 | 9710 |
| OLF3 | 24851 | 25369 | NC3 | 10659 | 24850 |
| OLF4 | 45714 | 46661 | NC4 | 25370 | 45713 |
| OLF5 | 80198 | 81115 | NC5 | 46662 | 80197 |
| OLF6 | 96291 | 96902 | NC6 | 81116 | 96290 |
| OLF7 | 110758 | 111564 | NC7 | 96903 | 110757 |
| OLF8 | 122525 | 122887 | NC8 | 111565 | 122524 |
| OLF9 | 132454 | 133389 | NC9 | 122888 | 132453 |
| OLF10 | 143398 | 143577 | NC10 | 133390 | 143397 |
| | | | NC11 | 143578 | 144460 |

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising
a nucleotide sequence selected from the group consisting of the 10 open reading frames of the
15  olfactory receptor gene, or a sequence complementary thereto.

The nucleic acid of SEQ ID No 1 also comprises non coding portions flanking each of the
ten olfactory receptor open reading frames of the sense DNA strand.

The invention also embodies purified, isolated, or recombinant polynucleotides comprising a
nucleotide sequence selected from the group consisting of the non-coding regions contained in the
20  olfactory receptor gene cluster of SEQ ID No 1, or a sequence complementary thereto as well as
their fragments or variants. The term "non-coding" sequence refers to any nucleotide sequence
which does not encode an amino acid. The non-coding sequences encompass upstream and
downstream regions of the olfactory receptor ORFs of the invention, as well as regions located

17

between two successive olfactory receptor ORFs, as indicated in Table A which lists the 11 non-coding regions named from NC1 to NC11.

The nucleic acids defining the non-coding sequences of the polynucleotide of SEQ ID No 1 described above, as well as their fragments and variants, may be used as oligonucleotide primers or

5    probes in order to detect the presence of a copy of one of the olfactory receptor genes of the invention in a test sample, or alternatively in order to amplify a target nucleotide sequence within the cluster of olfactory receptor encoding sequences according to the invention.

While this section is entitled "Genomic Sequences of the olfactory receptor gene," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the

10   polynucleotides described in this section, flanking the genomic sequences of olfactory receptor on either side or between two or more such genomic sequences.

## 2. Coding regions of the olfactory receptor gene

The 10 olfactory receptor open reading frames are presented individually as SEQ ID Nos 2-11 in the appended sequence listing.

15     Thus, another object of the invention is a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2-11, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant olfactory receptor cDNAs consisting of, consisting essentially of, or comprising a sequence selected from the

20   group consisting of SEQ ID Nos 2-11.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2-11, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group

25   consisting of SEQ ID Nos 2-11, or a sequence complementary thereto or a biologically active fragment thereof.

Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of SEQ ID Nos 2-11, or a sequence

30   complementary thereto or a biologically active fragment thereof.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof. Additional preferred embodiments of

35   the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the

complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the

following nucleotide positions of said selected sequence : 1-50, 51-100, 101-150, 151-200, 201-250,

251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-

800, 801-850, 851-900, 901- the terminal nucleotide of the olfactory receptor coding regions, to the

5    extent that such nucleotide positions are consistent with the lengths of the particular olfactory

receptor coding region being referred to. Further preferred embodiments of the invention include

isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15,

18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence

selected from the group consisting of SEQ ID Nos 2, 4, 7, 9 and 11, or the complements thereof,

10   wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide

positions of said selected sequence: 1-25, 26-50, 51-75, 76-100, 101-125, 126-150, 151-175, 176-

200, 201-225, 226-250, 251-275, 276-300, 301-325, 326-350, 351-375, 376-400, 401-425, 426-450,

451-475, 476-500, 501-525, 526-550, 551-575, 576-the terminal nucleotide of the olfactory receptor

coding regions, to the extent that such nucleotide positions are consistent with the lengths of the

15   particular olfactory receptor coding region being referred to.

The present invention also embodies isolated, purified, and recombinant polynucleotides

encoding olfactory receptor polypeptides, wherein olfactory receptor polypeptides comprise an

amino acid sequence selected from the group consisting of SEQ ID Nos 12-21, a nucleotide

sequence complementary thereto, a fragment or a variant thereof. The present invention also

20   embodies isolated, purified, and recombinant polynucleotides which encode polypeptides

comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more

preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the

group consisting of SEQ ID Nos 12-21. In a preferred embodiment, the present invention embodies

isolated, purified, and recombinant polynucleotides which encode polypeptides comprising a

25   contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at

least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting

of SEQ ID Nos 12-21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following

amino acid positions in said selected sequence: 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-

140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-the terminal

30   amino acid of the olfactory receptor proteins, to the extent that such amino acid positions are

consistent with the lengths of the particular olfactory receptor protein being referred to. In another

preferred embodiment, the present invention embodies isolated, purified, and recombinant

polynucleotides which encode polypeptides comprising a contiguous span of at least 6 amino acids,

preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100

35   amino acids of a sequence selected from the group consisting of SEQ ID Nos 12, 14, 17, 19 or 21

wherein said contiguous span includes at least 1, 2, 3, 5 or 7 of the following amino acid positions in

said selected sequence: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-

110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180, 181-190, 191-the terminal amino acid of the olfactory receptor proteins, to the extent that such amino acid positions are consistent with the lengths of the particular olfactory receptor protein being referred to.

In further preferred embodiments, the present invention embodies isolated, purified, and recombinant polynucleotides which encode olfactory receptor polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID No 12-21, wherein said contiguous span includes at least one amino acid at the following positions of said selected sequence:

i)     1-3, 10, 16, 21, 28, 33, 34, 36, 42-44, 46, 49, 53, 54, 57, 59, 63, and 64 for SEQ ID No 12;

ii)    2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120, 139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 295, 298, 299, 301, 311, and 313-315 for SEQ ID No 13;

iii)   2-4, 6, 18, 21, 25, 34, 37, 98, 99, 102, 113, 114, 133, 143, 148, 158-163, 166, 167, 169, and 170 for SEQ ID No 14;

iv)    2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 54, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120, 139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 298, 299, 311, and 313-315 for SEQ ID No 15;

v)     3, 18, 20, 25, 34, 47, 49, 67, 97, 100, 107, 108, 112, 113, 126, 135, 142, 146, 147, 157, 159-160, 194, 196, 228, 245, 264, 265, 269, 279, 298, and 302 for SEQ ID No 16;

vi)    2, 6, 18, 20, 33, 34, 37, 65, 68, 69, 72, 86, 88, 101, 107, 113, 114, 148, 158, 161, 164, 195, and 198 for SEQ ID No 17;

vii)   2, 6, 7, 52, 56, 67, 88, 94, 97, 110, 113, 116, 119, 120, 127, 135, 150, 153, 164, 174, 175, 180, 184, 217, 221, 259, 261, and 268 for SEQ ID No 18;

viii)  17, 18, 20, 28, 33, 35, 49-52, 105, 111, and 112 for SEQ ID No 19;

ix)    17, 20, 33, 35, 49-53, 56, 111, 112, 132, 138, 141, 147, 154, 157, 160, 163, 164, 194, 197, 204, 211, 214, 218, 219, 252, 265, 286, 295, 301, 303, 305, 306 and 309 for SEQ ID No 20; and

x)     9, 18, 26-28, 34, 47 and 50 for SEQ ID No 21, to the extent that such amino acid lengths are consistent with the lengths of the particular olfactory receptor protein being referred to.

Additional preferred fragments of the nucleotide sequences of SEQ ID Nos 2-11 are those encoding olfactory receptor polypeptide fragments located outside the transmembrane domains of the corresponding protein as located in boxes in Figure 1.

The above disclosed polynucleotides that contain only coding sequences derived from the olfactory receptor ORFs may be expressed in a desired host cell or a desired host organism, when said polynucleotides are placed under the control of suitable expression signals. Such a polynucleotide, when placed under suitable expression signals, may be inserted in a vector for its

5 expression.

While this section is entitled " Coding regions of the olfactory receptor gene," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of olfactory receptor on either side or between two or more such genomic sequences.

10 **3. Polynucleotide Constructs**

The terms "polynucleotide construct" and "recombinant polynucleotide" are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment.

15 DNA Construct That Enables Directing Temporal And Spatial olfactory receptor Gene Expression In Recombinant Cell Hosts And In Transgenic Animals.

In order to study the physiological and phenotypic consequences of a lack of synthesis of the olfactory receptor protein, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional

20 expression of a specific allele of the olfactory receptor genomic sequence or cDNA and also of a copy of this genomic sequence or cDNA harboring substitutions, deletions, or additions of one or more bases as regards to the olfactory receptor nucleotide sequence of SEQ ID Nos 1-11, or a fragment thereof, these base substitutions, deletions or additions being located in the coding regions of the olfactory receptor genomic sequence or within the olfactory receptor open reading frames of

25 SEQ ID Nos 2-11. In a preferred embodiment, the olfactory receptor sequence comprises a biallelic marker of the present invention. In a preferred embodiment, the olfactory receptor sequence comprises a biallelic marker of the present invention, preferably one of the biallelic markers A1 to A13.

The present invention embodies recombinant vectors comprising any one of the

30 polynucleotides described in the present invention. More particularly, the polynucleotide constructs according to the present invention can comprise any of the polynucleotides described in the "Genomic sequences of the olfactory receptor gene" section, the "Coding regions of the olfactory receptor Gene" section, and the "Oligonucleotide probes and primers" section.

### DNA Constructs Allowing Homologous Recombination: Replacement Vectors

A first preferred DNA construct will comprise, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised in the olfactory receptor genomic sequence; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycine resistance (*neo*); and (c) a

5   second nucleotide sequence that is comprised in the olfactory receptor genomic sequence, and is located on the genome downstream the first olfactory receptor nucleotide sequence (a).

In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream the nucleotide sequence (a) or downstream the nucleotide sequence (c). Preferably, the negative selection marker comprises the thymidine kinase (*tk*) gene (Thomas et al.,

10   1986), the hygromycine beta gene (Te Riele et al., 1990), the *hprt* gene ( Van der Lugt et al., 1991; Reid et al., 1990) or the Diphteria toxin A fragment (*Dt-A*) gene (Nada et al., 1993; Yagi et al.1990). Preferably, the positive selection marker is located within an olfactory receptor open reading frame sequence so as to interrupt the sequence encoding an olfactory receptor protein. These replacement vectors are described, for example, by Thomas et al.(1986; 1987), Mansour et al.(1988) and Koller

15   et al.(1992).

The first and second nucleotide sequences (a) and (c) may be indifferently located within an olfactory receptor regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequences (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to

20   6 kb and most preferably from 2 to 4 kb.

### DNA Constructs Allowing Homologous Recombination: Cre-LoxP System.

These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs *lox*P site. The *lox*P site is composed of two palindromic sequences of 13 bp separated by a 8

25   bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two *lox*P sites having an identical orientation leads to the deletion of the DNA fragment.

The Cre-*lox*P system used in combination with a homologous recombination technique has been first described by Gu et al.(1993, 1994). Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two *lox*P sites in the same orientation

30   and located at the respective ends of a nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant cell host. The recombinase enzyme may be brought at the desired time either by (a) incubating the recombinant cell hosts in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki et al.(1995), or by

35   lipofection of the enzyme into the cells, such as described by Baubonis et al.(1993); (b) transfecting the cell host with a vector comprising the *Cre* coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter being optionally inducible, said vector being

22

introduced in the recombinant cell host, such as described by Gu et al.(1993) and Sauer et al.(1988);
(c) introducing in the genome of the cell host a polynucleotide comprising the *Cre* coding sequence
operably linked to a promoter functional in the recombinant cell host, which promoter is optionally
inducible, and said polynucleotide being inserted in the genome of the cell host either by a random
5    insertion event or an homologous recombination event, such as described by Gu et al.(1994).

In a specific embodiment, the vector containing the sequence to be inserted in the olfactory
receptor gene by homologous recombination is constructed in such a way that selectable markers are
flanked by *lox*P sites of the same orientation, it is possible, by treatment by the Cre enzyme, to
eliminate the selectable markers while leaving the olfactory receptor sequences of interest that have
10   been inserted by an homologous recombination event. Again, two selectable markers are needed: a
positive selection marker to select for the recombination event and a negative selection marker to
select for the homologous recombination event. Vectors and methods using the Cre-*lox*P system are
described by Zou et al.(1994).

Thus, a second preferred DNA construct of the invention comprises, from 5'-end to 3'-end:
15   (a) a first nucleotide sequence that is comprised in the olfactory receptor genomic sequence; (b) a
nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said
nucleotide sequence comprising additionally two sequences defining a site recognized by a
recombinase, such as a *lox*P site, the two sites being placed in the same orientation; and (c) a second
nucleotide sequence that is comprised in the olfactory receptor genomic sequence, and is located on
20   the genome downstream of the first olfactory receptor nucleotide sequence (a).

The sequences defining a site recognized by a recombinase, such as a *lox*P site, are
preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide
sequence for which the conditional excision is sought. In one specific embodiment, two *lox*P sites
are located at each side of the positive selection marker sequence, in order to allow its excision at a
25   desired time after the occurrence of the homologous recombination event.

In a preferred embodiment of a method using the third DNA construct described above, the
excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase,
preferably two loxP sites, is performed at a desired time, due to the presence within the genome of
the recombinant host cell of a sequence encoding the Cre enzyme operably linked to a promoter
30   sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and
most preferably a promoter sequence which is both inducible and tissue-specific, such as described
by Gu et al.(1994).

The presence of the Cre enzyme within the genome of the recombinant cell host may result
from the breeding of two transgenic animals, the first transgenic animal bearing the olfactory
35   receptor-derived sequence of interest containing the *lox*P sites as described above and the second
transgenic animal bearing the *Cre* coding sequence operably linked to a suitable promoter sequence,
such as described by Gu et al.(1994).

Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or *in vivo* infection of organs, for delivery of the Cre enzyme, such as described by Anton and Graham (1995) and Kanegae et al.(1995).

5      The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably an olfactory receptor genomic sequence or an olfactory receptor coding region sequences, and most preferably an altered copy of an olfactory receptor genomic or coding region sequences, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous

10   recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce an olfactory receptor genomic sequence or an olfactory receptor coding region sequence comprising at least one biallelic marker of the present invention, preferably at least one biallelic

15   marker selected from the group consisting of A1 to A13.


## Nuclear Antisense DNA Constructs

Other compositions containing a vector of the invention comprising an oligonucleotide fragment of the nucleic sequence SEQ ID Nos 2-11, preferably a fragment including the start codon of the olfactory receptor gene, as an antisense tool that inhibits the expression of the corresponding

20   olfactory receptor gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995) or those described in PCT Application No WO 95/24223.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of olfactory receptor that contains the translation initiation codon ATG.

25   Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense polynucleotides being incapable of export from the nucleus, such as described by Liu et al.(1994). In a preferred embodiment, these olfactory receptor antisense polynucleotides also comprise, within the ribozyme

30   cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation, such as the structure described by Eckner et al.(1991).


## 4. Oligonucleotide probes and primers

Polynucleotides derived from the olfactory receptor gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1-11, or a fragment,

35   complement, or variant thereof in a test sample, preferably a human olfactory epithelium tissue or isolated human olfactory epithelium cells.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide

5  positions of SEQ ID No 1: 1-113643, 114064-127488, 127855-144460. Additional preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000,

10  10001-20000, 20001-30000, 30001-40000, 40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-100000, 100001-110000, 110001-120000, 120001-130000, 130001-140000, and 140001-144460. Further preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements

15  thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, 95001-100000, 100001-105000, 105001-110000, 110001-115000, 115001-120000, 120001-

20  125000, 125001-130000, 130001-135000, 135001-140000, and 140001-144460.

Other particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45 or 50 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the

25  following nucleotide positions of said selected sequence : 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901- the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide positions are consistent with the lengths of the particular olfactory receptor coding region being referred to. Further preferred probes and primers of the invention

30  include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 22 or 25 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2, 4, 7, 9 and 11, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of said selected sequence: 1-25, 26-50, 51-75, 76-100, 101-125, 126-150, 151-175, 176-200, 201-225, 226-250, 251-275, 276-300, 301-325, 326-350,

35  351-375, 376-400, 401-425, 426-450, 451-475, 476-500, 501--525, 526-550, 551-575, 576-the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide

positions are consistent with the lengths of the particular olfactory receptor coding region being referred to.

Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected
5 from the group consisting of SEQ ID Nos 1-11, a variant thereof and a sequence complementary thereto.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 and the complement thereof, wherein said span includes an olfactory receptor-related
10 biallelic marker in said sequence; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein said contiguous span is 18 to 47 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is
15 at the center of said polynucleotide; optionally, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide; and optionally, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. In a preferred embodiment, said probes comprises, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P13 and the complementary
20 sequences thereto, for which the respective locations in the sequence listing are provided in Table 3.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1, or the complements thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is
25 located within 20 nucleotides upstream of an olfactory receptor-related biallelic marker in said sequence; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said olfactory receptor-related biallelic marker in said sequence; and optionally, wherein said polynucleotide consists essentially of a sequence
30 selected from the following sequences: D1 to D13 and E1 to E13, for which the respective locations in the sequence listing are provided in Table 4.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B11 and C1 to C11, for which the respective locations in the sequence
35 listing are provided in Table 1.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for

determining the identity of the nucleotide at an olfactory receptor-related biallelic marker in SEQ ID No 1, or the complements thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising an olfactory receptor-related biallelic marker in SEQ ID No 1, or the complements thereof; optionally, wherein said olfactory receptor-related biallelic marker is selected

5 from the group consisting of A1 to A13, and the complements thereof.

A probe or a primer according to the invention has between 8 and 1000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 nucleotides in length. More particularly, the length of these probes and primers can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30

10 nucleotides. Shorter probes and primers tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes and primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art. A preferred probe or

15 primer consists of a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P13 and the complementary sequence thereto, B1 to B11, C1 to C11, D1 to D13, and E1 to E13.

Primers and other oligonucleotides according to the invention are synthesized to be "substantially" complementary to a strand of the olfactory receptor gene of the invention to be

20 amplified. The primer sequence does not need to reflect the exact sequence of the DNA template. Minor mismatches can be accommodated by reducing the stringency of the hybridization conditions. Among the various methods available to design useful primers, the OSP computer software can be used by the skilled person (see Hillier & Green, 1991). All primers contained a common upstream oligonucleotide tail enabling the easy systematic sequencing of the resulting amplification

25 fragments.

The formation of stable hybrids depends on the melting temperature (Tm) of the DNA. The Tm depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in

30 the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979),

35 the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs
such as, for example peptide nucleic acids which are disclosed in International Patent Application
WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444;
5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional

5   dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and
nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that
the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of
the probe can be functionalized with the capture or detection label to thereby consume or otherwise
block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or

10  modified, U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993 describes
modifications, which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by
incorporating any label known in the art to be detectable by spectroscopic, photochemical,
biochemical, immunochemical, or chemical means. For example, useful labels include radioactive

15  substances (including, $^{32}$P, $^{35}$S, $^{3}$H, $^{125}$I), fluorescent dyes (including, 5-bromodesoxyuridin,
fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at
their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described
in the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In
addition, the probes according to the present invention may have structural characteristics such that

20  they allow the signal amplification, such structural characteristics being, for example, branched
DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807
(Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either
the primer or a primer extension product, such as amplified DNA, on a solid support. A capture

25  label is attached to the primers or probes and can be a specific binding member which forms a
binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin).
Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be
employed to capture or to detect the target DNA. Further, it will be understood that the
polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For

30  example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it
may be selected such that it binds a complementary portion of a primer or probe to thereby
immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself
serves as the binding member, those skilled in the art will recognize that the probe will contain a
sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer

35  itself serves as the capture label, at least a portion of the primer will be free to hybridize with a
nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA or Northern hybridization to mRNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the OLF1 to OLF10 genes or mRNA using other techniques. Generally, the probes

5   are complementary to the OLF1 to OLF10 gene coding sequences, although probes complementary to non-coding sequences are also contemplated. The probes of the present invention can also be useful for genotyping the biallelic markers of the cluster of olfactory receptor genes of the present invention.

Any of the polynucleotides, primers and probes of the present invention can be conveniently

10  immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of

15  microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent.

20  Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to

25  immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other

30  configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

35  Consequently, the invention also comprises a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-11, a

fragment or a variant thereof and a complementary sequence thereto in a sample. said method comprising the following steps of:

    a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence selected from the group consisting of the nucleotide sequences

5  of SEQ ID Nos 1-11, a fragment or a variant thereof and a complementary sequence thereto and the sample to be assayed; and

    b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

    The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-11, a fragment or a variant

10  thereof and a complementary sequence thereto in a sample, said kit comprising:

    a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-11, a fragment or a variant thereof and a complementary sequence thereto; and

    b) optionally, the reagents necessary for performing the hybridization reaction.

15      In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group

20  consisting of the nucleotide sequences of P1 to P13 and the complementary sequence thereto, B1 to B11, C1 to C11, D1 to D13, E1 to E13 or a biallelic marker selected from the group consisting of A1 to A13 and the complements thereto.


Oligonucleotide arrays

    A substrate comprising a plurality of oligonucleotide primers or probes of the invention may

25  be used either for detecting or amplifying targeted sequences in the olfactory receptor gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the olfactory receptor gene.

    Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention may be attached in

30  an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a

35  substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the

polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination

5   of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854;

10  and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence

15  information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the olfactory receptor gene. For this particular purpose, probes are specifically designed to have a nucleotide sequence

20  allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the olfactory receptor gene that have been identified according to, for example, the technique used by Huang et al.(1996) or Samson et al.(1996).

Another technique that is used to detect mutations in the olfactory receptor gene is the use of

25  a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the olfactory receptor genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild gene sequence, measure its amount, and detect differences between the target sequence and the reference

30  wild gene sequence of the olfactory receptor gene. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference

35  sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a

"footprint" for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an
5 array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P13, B1 to B11, C1 to C11, D1 to D13, E1 to E13, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, and at least one sequence
10 comprising a biallelic marker selected from the group consisting of A1 to A13 and the complements thereto.

The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P13, B1 to B11, C1 to C11, D1 to D13, E1 to E13, the sequences complementary thereto, a fragment thereof of at least 8 consecutive
15 nucleotides thereof, and at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A13 and the complements thereof.

## B. OLF1 TO OFL10 PROTEINS AND POLYPEPTIDE FRAGMENTS

The proteins encoded by the Open Reading Frames of the OLF1 to OLF10 genes are listed individually in the sequence listing as SEQ ID Nos 12-21.
20 The term "olfactory receptor polypeptides" is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies olfactory receptor proteins from humans, including isolated or purified olfactory receptor proteins consisting of, consisting essentially of, or comprising the
25 sequences of SEQ ID Nos 12-21 or naturally-occurring variants or fragments thereof.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 12-21. In a preferred embodiment, the present invention embodies isolated, purified, and recombinant polypeptides
30 comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 12-21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions in SEQ ID Nos 12-21: 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-the terminal amino acid of the olfactory receptor
35 proteins, to the extent that such amino acid positions are consistent with the lengths of the particular olfactory receptor protein being referred to. In another preferred embodiment, the present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6

amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40,

50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12, 14, 17,

19 and 21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid

positions of said selected sequence: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90,

5   91-100, 101-110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180, 181-190, 191-

the terminal amino acid of the olfactory receptor proteins, to the extent that such amino acid

positions are consistent with the lengths of the particular olfactory receptor protein being referred to.

In further preferred embodiments, the present invention embodies isolated, purified, and

recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least

10   8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a

sequence selected from the group consisting of SEQ ID Nos 12-21, wherein said contiguous span

includes at least one amino acid at the following positions of said selected sequence

        i)        1-3, 10, 16, 21, 28, 33, 34, 36, 42-44, 46, 49, 53, 54, 57, 59, 63, and 64 for SEQ ID
                    No 12;

15        ii)        2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120,
                    139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 295, 298, 299, 301, 311, and
                    313-315 for SEQ ID No 13;

        iii)     2-4, 6, 18, 21, 25, 34, 37, 98, 99, 102, 113, 114, 133, 143, 148, 158-163, 166, 167,
                    169, and 170 for SEQ ID No 14;

20        iv)     2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 54, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120,
                    139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 298, 299, 311, and 313-315
                    for SEQ ID No 15;

        v)      3, 18, 20, 25, 34, 47, 49, 67, 97, 100, 107, 108, 112, 113, 126, 135, 142, 146, 147,
                    157, 159-160, 194, 196, 228, 245, 264, 265, 269, 279, 298, and 302 for SEQ ID No

25              16;

        vi)     2, 6, 18, 20, 33, 34, 37, 65, 68, 69, 72, 86, 88, 101, 107, 113, 114, 148, 158, 161,
                    164, 195, and 198 for SEQ ID No 17;

        vii)    2, 6, 7, 52, 56, 67, 88, 94, 97, 110, 113, 116, 119, 120, 127, 135, 150, 153, 164, 174,
                    175, 180, 184, 217, 221, 259, 261, and 268 for SEQ ID No 18;

30       viii)  17, 18, 20, 28, 33, 35, 49-52, 105, 111, and 112 for SEQ ID No 19;

        ix)     17, 20, 33, 35, 49-53, 56, 111, 112, 132, 138, 141, 147, 154, 157, 160, 163, 164,
                    194, 197, 204, 211, 214, 218, 219, 252, 265, 286, 295, 301, 303, 305, 306 and 309
                    for SEQ ID No 20; and

        x)      9, 18, 26-28, 34, 47 and 50 for SEQ ID No 21, to the extent that such amino acid

35                  lengths are consistent with the lengths of the particular olfactory receptor protein
                  being referred to.

Other preferred OLF1 to OLF10 polypeptide fragments are those located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for binding to ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory receptor polypeptides of the

5    invention. Such transmembrane domains TM1 to TM7 are boxed in Figure 1. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the olfactory receptor protein sequence.

The invention also encompasses a purified, isolated, or recombinant polypeptides

10   comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID Nos 12-21 or a fragment thereof.

The invention also encompasses an olfactory receptor polypeptide or a fragment or a variant thereof in which at least one peptide bound has been modified as defined in the "Definitions" section.

15   A further object of the invention concerns a purified or isolated polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 1-11 or fragment or variants thereof.

Such mutated olfactory receptor proteins may be the target of diagnostic tools, such as specific monoclonal or polyclonal antibodies, useful for the detecting the mutated olfactory receptor

20   proteins in a sample.

Olfactory receptor proteins are preferably isolated from human or mammalian tissue samples or expressed from human or mammalian genes.

The olfactory receptor polypeptides of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the

25   use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

In addition, shorter protein fragments may also be prepared by the conventional methods of chemical synthesis, either in a homogenous solution or in solid phase. As an illustrative embodiment

30   of such chemical polypeptide synthesis techniques, it may be cited the homogenous solution technique described by Houbenweyl in 1974. For solid phase synthesis the technique described by Merrifield (1965) may be used in particular.

Alternatively, the proteins of the invention can be made using routine expression methods known in the art as described below and in the section "Expression of a OLF1 to OLF10 coding

35   polynucleotide ". Briefly, the polynucleotide encoding the desired polypeptide, is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems is used in forming recombinant polypeptides. The polypeptide is then isolated from lysed cells or from

the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.

5    Any olfactory receptor cDNA, including SEQ ID Nos 12-21, may be used to express olfactory receptor proteins and polypeptides. The nucleic acid encoding the olfactory receptor protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The olfactory receptor insert in the expression vector may comprise the full coding sequence for the olfactory receptor protein or a portion thereof. For example, the olfactory receptor

10   derived insert may encode a polypeptide comprising at least 10 consecutive amino acids of the olfactory receptor protein of SEQ ID Nos 12-21, including any of the polypeptide fragment defined in this section.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety

15   of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

20   In one embodiment, the entire coding sequence of the olfactory receptor cDNA through the poly A signal of the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the olfactory receptor protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the olfactory receptor cDNA lacks a poly A

25   signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene).

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification.

30   Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

The above procedures may also be used to express a mutant olfactory receptor protein responsible for a detectable phenotype or a portion thereof.

Purification of the recombinant protein or peptide according to the present invention may be

35   realized by passage onto a Nickel or Copper affinity chromatography column. The Nickel chromatography column may contain the Ni-NTA resin (Porath et al., 1975). The polypeptides or peptides thus obtained may be purified, for example by high performance liquid chromatography,

such as reverse phase and/or cationic exchange HPLC, as described by Rougeot et al. (1994). The
reason to prefer this kind of peptide or protein purification is the lack of side products found in the
elution samples which renders the resultant purified protein or peptide more suitable for a
therapeutic use.

5       The expressed protein may also be purified using other conventional purification techniques
such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The
protein encoded by the nucleic acid insert may also be purified using standard immunochromatography
techniques. In such procedures, polyclonal or monoclonal antibodies capable of specifically binding to
the expressed olfactory receptor protein sof SEQ ID Nos 12-21, or a fragment or a variant thereof, have
10    been previously immobilized onto a chromatography matrix. Such antibodies are described in the
section "Antibodies that bind olfactory receptor polypeptides" below. Then, a solution containing the
expressed olfactory receptor protein or portion thereof, such as a cell extract, is applied to the
chromatography column in conditions allowing the expressed protein to bind to the antibodies in the
immunochromatography column. Thereafter, the column is washed to remove non-specifically bound
15    proteins. The specifically bound expressed protein is then released from the column and recovered
using standard techniques.

        If antibody production is not possible, the nucleic acids encoding the olfactory receptor protein
or a portion thereof is incorporated into expression vectors designed for use in purification schemes
employing chimeric polypeptides. In such strategies the nucleic acid encoding the olfactory receptor
20    protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera.
The other half of the chimera is β-globin or a nickel binding polypeptide encoding sequence. A
chromatography matrix having antibody to β-globin or nickel attached thereto is then used to purify the
chimeric protein. Protease cleavage sites is engineered between the β-globin gene or the nickel binding
polypeptide and the olfactory receptor protein or portion thereof. Thus, the two polypeptides of the
25    chimera is separated from one another by protease digestion.

        One useful expression vector for generating β-globin chimeric proteins is pSG5 (Stratagene),
which encodes rabbit β-globin. Intron II of the rabbit β-globin gene facilitates splicing of the expressed
transcript, and the polyadenylation signal incorporated into the construct increases the level of
expression. These techniques are well known to those skilled in the art of molecular biology. Standard
30    methods are published in methods texts such as Davis et al., (1986) and many of the methods are
available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be
produced from the construct using in vitro translation systems such as the In vitro Express™ Translation
Kit (Stratagene).

        To confirm expression of the olfactory receptor protein or a portion thereof, the proteins
35    expressed from host cells containing an expression vector containing an insert encoding the olfactory
receptor protein or a portion thereof can be compared to the proteins expressed in host cells containing
the expression vector without an insert. The presence of a band in samples from cells containing the

expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the olfactory receptor protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the olfactory receptor protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as

5   glycosylation, ubiquitination, or enzymatic cleavage.

Other suitable techniques for producing and purifying the olfactory receptor proteins of the invention or their fragments or variants are also described under the heading "Methods for scrreening substances or molecules interacting with an olfactory receptor protein".

Thus, the present invention also concerns a method for the producing a polypeptide of the

10   invention, and especially a polypeptide selected from the group of SEQ ID Nos 12-21 or a fragment or a variant thereof, wherein said methods comprises the steps of :

a) culturing, in an appropriate culture medium, a cell host previously transformed or transfected with the recombinant vector comprising a nucleic acid encoding an olfactory receptor polypeptide of the invention, or a fragment or a variant thereof;

15   b) harvesting the culture medium thus conditioned or lyze the cell host, for example by sonication or by an osmotic shock;

c) separating or purifying, from the said culture medium, or from the pellet of the resultant host cell lysate the thus produced polypeptide of interest.

d) optionally characterizing the produced polypeptide of interest.

20   In a specific embodiment of the above method, step a) is preceded by a step wherein the nucleic acid coding for an olfactory receptor polypeptide, or a fragment or a variant thereof, is inserted in an appropriate vector, optionally after an appropriate cleavage of this amplified nucleic acid with one or several restriction endonucleases. The nucleic acid coding for an olfactory receptor polypeptide or a fragment or a variant thereof may be the resulting product of an amplification

25   reaction using a pair of primers according to the invention (by PCR, SDA, TAS, 3SR NASBA, TMA etc.).

## C. ANTIBODIES THAT BIND OLFACTORY RECEPTOR POLYPEPTIDES

Any olfactory receptor polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed olfactory receptor protein or fragments thereof as

30   described.

One antibody composition of the invention is capable of specifically binding or specifically bind to the variant of the olfactory receptor protein of SEQ ID Nos 12-21. For an antibody composition to specifically bind to a first variant of olfactory receptor protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for a first variant of the

35   olfactory receptor protein than for a second variant of the olfactory receptor protein in an ELISA, RIA, or other antibody-based binding assay.

In a preferred embodiment, the invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or that selectively bind to an epitope-containing a polypeptide comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments". Preferred peptide fragments are portions of OLF1 to OLF10 polypeptides

5  that are located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for binding to ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory receptor polypeptides of the invention.

The invention also concerns a purified or isolated antibody capable of specifically binding to

10  a mutated olfactory receptor protein or to a fragment or variant thereof comprising an epitope of the mutated olfactory receptor protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of an olfactory receptor protein.

In a preferred embodiment, the invention concerns the use in the manufacture of antibodies

15  of a polypeptide comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments". Preferred peptide fragments are portions of OLF1 to OLF10 polypeptides that are located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for recognition of ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory

20  receptor polypeptides of the invention.

The olfactory receptor expressed from a DNA comprising at least one of the nucleic sequences of SEQ ID Nos 1-11 or a fragment or a variant thereof may also be used to generate antibodies capable of specifically binding to the expressed olfactory receptor or fragments or variants thereof. In a preferred embodiment, any of the polynucleotide fragment encoding a

25  polypeptide described in the section " Coding regions of the olfactory receptor gene" may be used to generate such antibodies.

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the olfactory receptor protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an

30  Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibodies to the protein can then be prepared as follows:

## 1. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the olfactory receptor of the present invention or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler and

35  Milstein, (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the considered olfactory receptor or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are

fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of

5   antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al.

### 2. Polyclonal Antibody Production by Immunization

10      Polyclonal antiserum containing antibodies to heterogeneous epitopes in the olfactory receptor of the present invention or a portion thereof can be prepared by immunizing suitable animals with the considered olfactory receptor or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal, preferably a non-human mammal, is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been

15  enriched for olfactory receptor concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example. methylated bovine serum albumin

20  (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen

25  and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. (1971).

30      Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum. Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for

35  example, by Fisher, (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances

in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Non-human animals or mammals, whether wild-type or transgenic, which express a different
5  species of olfactory receptor than the one to which antibody binding is desired, and animals which do not express olfactory receptor (i.e. an olfactory receptor knock out animal as described herein) are particularly useful for preparing antibodies. Olfactory receptor knock out animals will recognize all or most of the exposed regions of an olfactory receptor protein as foreign antigens, and therefore produce antibodies with a wider array of olfactory receptor epitopes. Moreover, smaller
10  polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the olfactory receptor proteins. In addition, the humoral immune system of animals which produce a species of olfactory receptor that resembles the antigenic sequence will preferentially recognize the differences between the animal's native olfactory receptor species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique
15  will be particularly useful in obtaining antibodies that specifically bind to any one of the olfactory receptor proteins.

The present invention also includes, chimeric single chain Fv antibody fragments (Martineau et al., 1998), antibody fragments obtained through phage display libraries (Ridder et al., 1995; Vaughan et al., 1995) and humanized antibodies (Reinmann et al., 1997; Leger et al., 1997).

20  The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

Consequently, the invention is also directed to a method for detecting specifically the presence of a polypeptide according to the invention in a biological sample, said method comprising the following steps :

25  a) bringing into contact the biological sample with an antibody according to the invention;

b) detecting the antigen-antibody complex formed.

Is also part of the invention a diagnostic kit for in vitro detecting the presence of a polypeptide according to the present invention in a biological sample, wherein said kit comprises:

30  a) a polyclonal or monoclonal antibody as described above, optionally labeled;

b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

35  ## D. OLFACTORY RECEPTOR-RELATED BIALLELIC MARKERS

The invention also concerns olfactory receptor-related biallelic markers. As used herein the term "olfactory receptor-related biallelic marker" relates to a set of biallelic markers in linkage

disequilibrium with the olfactory receptor gene. The term olfactory receptor-related biallelic marker includes the biallelic markers designated A1 to A13.

The biallelic markers of the present invention, namely A1 to A13, are disclosed in Table 2 of Example 4. The 13 olfactory receptor-related biallelic markers, A1 to A13, are all located in the

5 genomic non coding regions of the olfactory gene cluster of the invention. Their precise location on the olfactory receptor genomic sequence and their single base polymorphism are indicated in Table 2 and also as features in the sequence listing for SEQ ID No 1. Appropriate pairs of primers allowing the amplification of a nucleic acid containing the polymorphic base of the disclosed olfactory receptor biallelic marker are also listed in Table 1 of Example 3 and in features of SEQ ID No 1.

10 In the present invention, the biallelic markers can be defined by nucleotide sequences corresponding to oligonucleotides of 47 bases in length comprising at the middle one of the polymorphic base. More particularly, the biallelic markers can be defined by the polynucleotides P1 to P13.

The biallelic markers contained in the olfactory gene cluster of the present invention, or a

15 busset of such biallelic markers, are useful tools to perform association studies, preferably to perform association studies between the statistically significant occurrence of an allele of said biallelic marker in the genome of an individual and a specific phenotype, including a phenotype consisting of an alteration of the olfactory perception of odorant substances or molecules by said individual. The biallelic markers of the invention can also be used, for example, in linkage analysis

20 in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, such as an alteration of olfactory perception. In addition, the biallellic markers of the invention may be included in the generation of any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

## 1. Identification of biallelic markers

25 Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

30 In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried

35 out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually shows a sufficient degree of informativeness to be useful in conducting association studies.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A

5   biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will, however, be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may allow in some cases the direct identification of

10   causal mutations, which may, depending on their penetrance, be rare mutations.

The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.


Genomic DNA Samples

The genomic DNA samples from which the biallelic markers of the present invention are

15   generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as

20   many markers as possible and to generate statistically significant results.

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and

25   various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA

30   from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 2. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.


DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated

35   through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art.

Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A- 320 308, WO 9320227 and EP-A-439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli J.C., et al.(1990) and in Compton

5   J.(1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al.(1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs

10  are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused

15  product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a

20  complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

25  For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al.(1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

30  The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along

35  with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are

extended. Thereafter, another cycle of denaturation, hybridization. and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195; 4,683,202; and 4,965,188.

5       The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 3.

One of the aspects of the present invention is a method for the amplification of the human olfactory receptor gene, particularly of a fragment of the genomic sequence of SEQ ID No 1 or of

10   the coding region sequences of SEQ ID Nos 2-11, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. This method comprises the steps of:

a) contacting a test sample with amplification reaction reagents comprising a pair of amplification primers as described above and located on either side of the polynucleotide region to be amplified, and

15       b) optionally, detecting the amplification products.

The invention also concerns a kit for the amplification of an olfactory receptor gene sequence, particularly of a portion of the genomic sequence of SEQ ID No 1 or of the coding region sequences of SEQ ID Nos 2-11, or a variant thereof in a test sample. wherein said kit comprises:

a) a pair of oligonucleotide primers located on either side of the olfactory receptor region to

20       be amplified;

b) optionally, the reagents necessary for performing the amplification reaction.

In one embodiment of the above amplification method and kit. the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers

25   comprise a sequence which is selected from the group consisting of the nucleotide sequences of B1 to B11, C1 to C11, D1 to D13, and E1 to E13.

In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified

30   from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms

35       The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to

those of ordinary skill in the art. Such methods are for example disclosed in Sambrook et al.(1989).
Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee
et al.(1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing
5   reactions using a dye-primer cycle sequencing protocol. Following gel image analysis and DNA
sequence extraction, sequence data are automatically processed with adequate software to assess
sequence quality.

A polymorphism analysis software is used that detects the presence of biallelic sites among
individual or pooled amplified fragment sequences. Polymorphism search is based on the presence
10  of superimposed peaks in the electrophoresis pattern. These peaks which present distinct colors
correspond to two different nucleotides at the same position on the sequence. The polymorphism has
to be detected on both strands for validation.

Validation Of The Biallelic Markers Of The Present Invention

The polymorphisms are evaluated for their usefulness as genetic markers by validating that
15  both alleles are present in a population. Validation of the biallelic markers is accomplished by
genotyping a group of individuals by a method of the invention and demonstrating that both alleles
are present. Microsequencing is a preferred method of genotyping alleles. The validation by
genotyping step may be performed on individual samples derived from each individual in the group
or by genotyping a pooled sample derived from more than one individual. The group can be as
20  small as one individual if that individual is heterozygous for the allele in question. Preferably the
group contains at least three individuals, more preferably the group contains five or six individuals,
so that a single validation test will be more likely to result in the validation of more of the biallelic
markers that are being tested. It should be noted, however, that when the validation test is
performed on a small group it may result in a false negative result if as a result of sampling error
25  none of the individuals tested carries one of the two alleles. Thus, the validation process is less
useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that
there is a *bona fide* biallelic marker at a particular position in a sequence. All of the genotyping,
haplotyping, association, and interaction study methods of the invention may optionally be
performed solely with validated biallelic markers.

30  **2. Genotyping of biallelic markers**

The polymorphisms identified above can be further confirmed and their respective
frequencies can be determined through various methods using the previously described primers and
probes. These methods can also be useful for genotyping either new populations in association
studies or individuals in the context of detection of alleles of biallelic markers which are known to
35  be associated with a given trait. Those skilled in the art should note that the methods described
below can be equally performed on individual or pooled DNA samples.

Once a given polymorphic site has been found and characterized as a biallelic marker as described above, several methods can be used in order to determine the specific allele carried by an individual at the given polymorphic base.

The identification of biallelic markers described previously allows the design of appropriate
5    primers to amplify a region of the olfactory receptor gene cluster containing the polymorphic site of interest and for the detection of such polymorphisms.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic
10   fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and genetic analysis applications.

In one embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at an olfactory receptor-related biallelic marker or the
15   complement thereof in a biological sample; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein said biological sample is derived from a single subject; optionally, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, wherein said biological sample is derived
20   from multiple subjects; Optionally, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; Optionally, said method is performed *in vitro*; optionally, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; Optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant
25   vector comprising an origin of replication and said fragment in a host cell; optionally, wherein said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

Source of Nucleic Acids for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting
30   nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired: DNA or RNA may be extracted from cells, tissues, body fluids and the like as described above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification Of DNA Fragments Comprising Biallelic Markers

      Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various

5   purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present

10  invention. Amplification of DNA may be achieved by any method known in the art. Amplification techniques are described above in the section entitled, "DNA amplification."

      Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described below.

15      The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the amplification of a DNA fragment comprising a biallelic marker of the present invention.

20      In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. Preferred amplification primers are listed in Example 3. It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention are also of use.

25      The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which

30  allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers".

Methods of Genotyping DNA samples for Biallelic Markers

      Any method known in the art can be used to identify the nucleotide present at a biallelic

35  marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the

DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot

5 analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al.(1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al.(1991), White et al.(1992), Grompe et al.(1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant

10 nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing" is generally used herein to refer to polymerase

15 extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

**1) Sequencing Assays**

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as

20 described above. DNA sequencing methods are described in "Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms".

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

25 **2) Microsequencing Assays**

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one

30 single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883.

35 Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 5.

Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al.(1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein–labeled primer in the presence of

5    allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time.

10   Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smirnov, 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase

15   microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase

20   extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator regent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if

25   more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner,

30   oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of antifluorescein antibody conjugated with alkaline phosphatase, followed by

35   incubation with a chromogenic substrate (such as p-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated

streptavidin with o-phenylenediamine as a substrate (WO 92/15712). As yet another alternative

solid-phase microsequencing procedure, Nyren et al.(1993) described a method relying on the

detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate

detection assay (ELIDA).

5       Pastinen et al.(1997) describe a method for multiplex detection of single nucleotide

polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide

array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are

further described below.

        In one aspect the present invention provides polynucleotides and methods to genotype one or

10  more biallelic markers of the present invention by performing a microsequencing assay. Preferred

microsequencing primers include the nucleotide sequences D1 to Dn and E1 to En. It will be

appreciated that the microsequencing primers listed in Example 5 are merely exemplary and that,

any primer having a 3' end immediately adjacent to the polymorphic nucleotide may be used.

Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic

15  marker or any combination of biallelic markers of the present invention. One aspect of the present

invention is a solid support which includes one or more microsequencing primers listed in Example

5, or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof, to

the extent that such lengths are consistent with the primer described, and having a 3' terminus

immediately upstream of the corresponding biallelic marker, for determining the identity of a

20  nucleotide at a biallelic marker site.

**3) Mismatch detection assays based on polymerases and ligases**

        In one aspect the present invention provides polynucleotides and methods to determine the

allele of one or more biallelic markers of the present invention in a biological sample, by mismatch

detection assays based on polymerases and/or ligases. These assays are based on the specificity of

25  polymerases and ligases. Polymerization reactions places particularly stringent requirements on

correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides

hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site,

especially at the 3' end. Methods, primers and various parameters to amplify DNA fragments

comprising biallelic markers of the present invention are further described above in "Amplification

30  Of DNA Fragments Comprising Biallelic Markers".

**Allele Specific Amplification Primers**

        Discrimination between the two alleles of a biallelic marker can also be achieved by allele

specific amplification, a selective strategy, whereby one of the alleles is amplified without

amplification of the other allele. For allele specific amplification, at least one member of the pair of

35  primers is sufficiently complementary with a region of an olfactory receptor gene comprising the

polymorphic base of a biallelic marker of the present invention to hybridize therewith and to initiate

the amplification. Such primers are able to discriminate between the two alleles of a biallelic marker.

This is accomplished by placing the polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3'end of the primer, a mismatch at or
5   near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

## Ligation/Amplification Based Methods

10      The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable
15   of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as described by Nickerson et al.(1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are
20   described above in "DNA Amplification". LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a
25   biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when
30   they hybridize to the target molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

35      Ligase/Polymerase-mediated Genetic Bit Analysis[TM] is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide

present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

**4) Hybridization Assay Methods**

5       A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

10      Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are

15  often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions,

20  under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Although such hybridization can be performed in solution, it is preferred to employ a solid-

25  phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to

30  either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

35      Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the

accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be

5    assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally

10   quenched fluorophore (Tyagi et al., 1998).

The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to

15   hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in

20   Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P13 and the sequences complementary thereto. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center

25   of the said polynucleotide, more preferably at the center of said polynucleotide.

Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in "Oligonucleotide Probes and Primers". The probes can be non-extendable as described in "Oligonucleotide Probes and Primers".

By assaying the hybridization to an allele specific probe, one can detect the presence or

30   absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridization in array format is specifically encompassed within "hybridization assays" and are described below.

**5) Hybridization To Addressable Arrays Of Oligonucleotides**

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants.

35   Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g., the chip) at selected

positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains,

5   and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary

10   to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280 describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tiled" for a large number of specific polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as

15   preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of

20   biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain

25   number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of

30   hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No. 5,424,186.

35   Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of amplicons listed

in table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising
at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50
consecutive nucleotides and containing a polymorphic base. In preferred embodiments the
polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more

5    preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an
array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports
and polynucleotides of the present invention attached to solid supports are further described in
"Oligonucleotide Probes And Primers".

**6) Integrated Systems**

10          Another technique, which may be used to analyze polymorphisms, includes multicomponent
integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary
electrophoresis reactions in a single functional device. An example of such technique is disclosed in
US patent 5,589,136 which describes the integration of PCR amplification and capillary
electrophoresis in chips.

15          Integrated systems can be envisaged mainly when microfluidic systems are used. These
systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer
included on a microchip. The movements of the samples are controlled by electric, electroosmotic
or hydrostatic forces applied across different areas of the microchip to create functional microscopic
valves and pumps with no moving parts.

20          For genotyping biallelic markers, the microfluidic system may integrate nucleic acid
amplification, microsequencing, capillary electrophoresis and a detection method such as laser-
induced fluorescence detection.


**E. EXPRESSION OF AN OL1 TO OLF10 CODING POLYNUCLEOTIDE**

            Any of the coding polynucleotides of the invention may be inserted into recombinant vectors
25   for expression in a recombinant host cell or a recombinant host organism.

            Thus, the present invention also encompasses a family of recombinant vectors that contains
a coding polynucleotide from the group of coding polynucleotides OLF1 to OLF10 genes.
Consequently, the present invention further deals with a recombinant vector comprising a
polynucleotide comprising any of the coding sequence of SEQ ID No 1, preferably those selected

30   from the group consisting of SEQ ID Nos 2-11.

            In a first preferred embodiment, the present invention relates to expression vectors which
include nucleic acids encoding an olfactory receptor protein described herein under the control of an
exogenous regulatory sequence.

            In a second preferred embodiment, a recombinant vector of the invention is used to amplify

35   the inserted polynucleotide derived from an olfactory receptor genomic sequence selected from the
group consisting of the nucleic acids of SEQ ID No 1 and of olfactory receptor cDNAs, for example

the open reading frames of SEQ ID Nos 2-11, in a suitable cell host , this polynucleotide being amplified at every time that the recombinant vector replicates.

More particularly, the present invention relates to expression vectors which include nucleic acids encoding an olfactory receptor protein, preferably the olfactory receptor proteins of the amino
5  acid sequence of SEQ ID Nos 12-21 or variants or fragments thereof, under the control of an exogenous regulatory sequence.

Generally, a recombinant vector of the invention may comprise any of the polynucleotides described herein, including regulatory sequences, and coding sequences, as well as any olfactory receptor primer or probe as defined above. More particularly, the recombinant vectors of the present
10 invention can comprise any of the polynucleotides described in the "Coding Regions of the olfactory receptor gene" section, "Genomic sequence of the olfactory receptor gene" section, the "Oligonucleotide Probes And Primers" section and the "Polynucleotide constructs" section.

Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

15 **Vectors**

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may consist of a chromosomal, non-chromosomal and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit
20 comprising an assembly of

(1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp that act on the promoter to increase the transcription.

(2) a structural or coding sequence which is transcribed into mRNA and eventually
25 translated into a polypeptide, and

(3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-
30 terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural
35 sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.

The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicine or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria.

For facilitating the purification of the expressed protein and increasing its stability, the

5    coding sequence of an olfactory receptor according to the invention can be fused in its N- or C-terminus with protein such as MBP (maltose binding protein) and GST (Glutathione S transferase) or with tag such as poly-histidine tag, Strep tag, Bio tag, and flag peptide epitope tag, those being detailed below. Thioredoxin can be eventually inserted between the olfactory receptor and the tag.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA

10   sequence encoding a desired polypeptide with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.

As a representative but non-limiting example, useful expression vectors for bacterial use can

15   comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of suitable vectors and promoters are known to those of skill in the art, and

20   commercially available, such as bacterial vectors : pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); or eukaryotic vectors : pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); baculovirus transfer vector pVL1392/1393 (Pharmingen); pQE-30 (QIAexpress).

25   A suitable vector for the expression of the olfactory receptor above-defined or their peptide fragments is baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N°CRL 1711) which is derived from *Spodoptera frugiperda*.

30   Other suitable vectors for the expression of an olfactory receptor or their peptide fragments or variants in a baculovirus expression system include those described by Chai et al. (1993), Vlasak et al. (1983) and Lenhard et al. (1996).

Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and

35   acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter,

57

enhancer, splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

**Promoters**

The suitable promoter regions used in the expression vectors according to the present
5  invention are chosen taking into account of the cell host in which the heterologous gene has to be expressed.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with
10  respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Thus, the promoter is selected among the group comprising :

- an internal or an endogenous promoter, such as the natural promoter associated with the structural gene coding for the desired olfactory receptor polypeptide or the fragment or
15  variant thereof; such a promoter may be completed by a regulatory element derived from the vertebrate host, in particular an activator element;

- a promoter derived from a cytoskeletal protein gene such as the desmin promoter (Bolmont et al., 1990; Zhenlin et al., 1989) or a promoter derived from a gene specifically expressed in epithelial cells and most preferably in olfactory epithelial cells.

20  Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983.; O'Reilly et al., 1992), the lambda $P_R$ promoter or also the trc promoter.

Promoter regions can be selected from any desired gene using, for example, CAT
25  (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors. Particularly preferred bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

30  The choice of a determined promoter, among the above-described promoters is well in the ability of one skill in the art, guided by his knowledge in the genetic engineering technical field, and by being also guided by the book of Sambrook et al. in 1989 or also by the procedures described by Fuller et al. in 1996 (Fuller S.A. et al., 1996).

A preferred constitutive promoter that is used  is one of the internal promoters that are active
35  in the resting fibroblasts such the promoter of the phosphoglycerate kinase gene (PGK-1). The PGK-1 promoter is either the mouse promoter or the human promoter such as described by Adra et al.(

1987). Other constitutive promoters may also be used such that the beta-actin promoter (Kort et al.,
1983) or the vimentin promoter (Rettlez and Basenga, 1987).

The vector containing the appropriate DNA sequence as described above, more preferably a
OLF1 to OLF10 coding polynucleotide, can be utilized to transform an appropriate host to allow the
5   expression of the desired polypeptide or polynucleotide.

**Other types of vectors**

The *in vivo* expression of an olfactory receptor polypeptide encompassed by the invention or
a fragment or a variant thereof may be useful in order to correct a genetic defect related to the
expression of the native gene in a host organism or to the production of biologically active olfactory
10  receptor proteins.

Consequently, the present invention also deals with recombinant expression vectors mainly
designed for the *in vivo* production of a therapeutic peptide fragment by the introduction of the
genetic information in the organism of the patient to be treated. This genetic information may be
introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell
15  being subsequently reintroduced in the said organism, directly *in vivo* into the appropriate tissue, and
preferably in the olfactory epithelium.

One specific embodiment for a method for delivering the corresponding protein or peptide to
the interior of a cell of a vertebrate *in vivo* comprises the step of introducing a preparation
comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for
20  the polypeptide into the interstitial space of a tissue comprising the cell, whereby the naked
polynucleotide is taken up into the interior of the cell and has a physiological effect.

In a specific embodiment, the invention provides a composition for the *in vivo* production of
an olfactory receptor polypeptide described therein containing a naked polynucleotide operatively
coding for an olfactory receptor selected from the group of OLF1 to OLF10 or a fragment or a
25  variant thereof, in solution in a physiologically acceptable carrier and suitable for introduction into a
tissue to cause cells of the tissue to express the said protein or polypeptide.

Advantageously, the composition described above is administered locally, near the site in
which the expression of the olfactory receptor polypeptide under consideration or a fragment or a
variant thereof is sought.

30      The polynucleotide operatively coding for an olfactory receptor polypeptide or a fragment or
variant thereof may be a vector comprising the genomic DNA or the complementary DNA (cDNA)
coding for the corresponding protein and a promoter sequence allowing the expression of the
genomic DNA or the complementary DNA in the desired eukaryotic cells, such as vertebrate cells,
specifically mammalian cells.

35      This vector may also contain one origin of replication that allows it to replicate in the
eukaryotic host cell such as an origin of replication from a bovine papillomavirus. Alternatively, the
vector can contain several, for example two, origins of replication of different origins in order to

allow said vector to replicate in different host cells, typically both in a prokaryotic cell such as *E. coli* and in an eukaryotic cell such as a mammalian epithelial cell, preferably a mammalian olfactory epithelial cell.

Compositions comprising a polynucleotide are described in the PCT application N° WO
5  90/11092 (Vical Inc.) and also in the PCT application N° WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al. (1996) and of Huygen et al. (1996).

In another embodiment, the DNA to be introduced is complexed with DEAE-dextran (Pagano et al., 1967) or with nuclear proteins (Kaneda et al., 1989), with lipids (Felgner et al., 1987) or encapsulated within liposomes (Fraley et al., 1980).

10  In another embodiment, the polynucleotide encoding an olfactory receptor polypeptide of the invention or a fragment or a variant thereof may be included in a transfection system comprising polypeptides that promote its penetration within the host cells as it is described in the PCT application WO 95/10534 (Seikagaku Corporation). They can also be encapsulated in polymer microparticles as it is described in the PCT Application No WO 94/27238.

15  The vector according to the present invention may advantageously be administered in the form of a gel that facilitates their transfection into the cells. Such a gel composition may be a complex of poly-L-lysine and lactose, as described by Midoux (1993) or also poloxamer 407 as described by Pastore (1994). Said vector may also be suspended in a buffer solution or be associated with liposomes.

20  The amount of the vector to be injected to the desired host organism vary according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

In another embodiment of the vector according to the invention, said vector may be introduced in vitro in a host cell, preferably in a host cell previously harvested from the animal to be
25  treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired olfactory receptor polypeptide or the desired fragment or variant thereof is implanted back into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

Suitable vectors for the *in vivo* expression of an olfactory receptor polypeptide of the
30  invention or a fragment or a variant thereof are described hereunder.

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenoviruses vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al. (1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the adenovirus described by Ohwada et al. (1996) or the human
35  adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin ( French patent application N° FR-93.05954).

60

Among the adenoviruses of animal origin it can be cited the adenoviruses of canine (CAV2, strain Manhattan or A26/61[ATCC VR-800]), bovine, murine (Mav1, Beard et al., 1980) or simian (SAV).

Preferably, the inventors are using recombinant defective adenoviruses that may be prepared
5   following a technique well-known by one skill in the art, for example as described by Levrero et al. (1991) or by Graham (1984) or in the European patent application N° EP-185.573. Another defective recombinant adenovirus that may be used according to the present invention, as well as a composition of matter containing such a defective recombinant adenovirus, is described in the PCT application N° WO 95/14785.

10   Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous polynucleotides *in vivo* , particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.

The use of recombinant retrovirus vectors containing a nucleic acid according to the
15   invention is also encompassed within the scope of the invention. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication defective retroviruses has increased the utility of retroviruses for *in vivo* gene delivery, and defective retroviruses are well characterized for use in
20   gene transfer. Thus, recombinant retroviruses can be constructed in which a part of the retroviral coding sequence (*gag, pol, env*) has been replaced by nucleic acid encoding an olfactory receptor rendering the retrovirus defective. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* and *in vivo* with such viruses can be found in "Current Protocols in Molecular Biology" (1989).

25   Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle, as described for example in the PCT Application No WO 93/25234 or in the PCT Application No WO 94/ 06920. For instance, strategies for the modification of the infection spectrum of retroviral vectors include : coupling antibodies specific for cell surface
30   antigens to the viral *env* protein (Julan et al., 1992) or coupling cell surface receptor ligands to the viral *env* protein (Neda et al., 1991). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an
35   ecotropic vector into an amphotropic vector.

Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the group

consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley et al., 1976), Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190;

5   PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Another preferred retroviral vector is that described by Roth et al. (Roth J.A. et al., 1996).

Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires

10  another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

15  **Cell hosts**

Another object of the invention consists in host cell that have been transformed or transfected with one of the polynucleotides described therein, and more precisely a polynucleotide comprising the coding sequence of any of the olfactory receptor polypeptide having the amino acid sequence of SEQ ID Nos 12-21 or fragments or variants thereof. Are included host cells that are

20  transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

A recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein. More particularly, the cell hosts of the present invention can comprise any of the polynucleotides described in the "Coding regions of the olfactory receptor gene"

25  section, "Genomic sequence of olfactory receptor gene " section, the "Oligonucleotide Probes And Primers" section, the "Polynucleotide constructs" section.and the " Expression of an OLF1 to OLF10 coding polypeptide" section.

Suitable prokaryotic hosts for transformation include *E. coli, Bacillus subtilis*, as well as various species within the genera of *Streptomyces* or *Mycobacterium*. Suitable eukaryotic hosts

30  comprise yeast, insect cells, such as Drosophila and Sf9. Various mammalian cell hosts can also be employed to express recombinant protein. Examples of mammalian cell hosts include the COS-7 lines of monkey kidney fibroblasts (Guzman, 1981), and other cell lines capable of expressing a compatible vector, for example the C127, 3T3, CHO, HeLa and BHK cell lines. The selection of an host is within the scope of the one skilled in the art.

35  Preferred cell hosts used as recipients for the expression vectors of the invention are the followings :

a) Prokaryotic host cells : *Escherichia coli* strains (I.E. DH5-α strain) or *Bacillus subtilis*.

b) Eukaryotic host cells : HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), Cv 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL1650; N°CRL1651), Sf-9 cells (ATCC N°CRL1711).

The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

5          Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

10         Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

**Transgenic animals**

The terms "transgenic animals" or "host animals" are used herein designate animals that
15   have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention.

20         The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising an olfactory receptor coding sequence selected from the group OLF1 to OLF10 an olfactory receptor regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

25         More particularly, transgenic animals according to the invention contain in their somatic cells and/or in their germ line cells any of the polynucleotides described in the "Coding regions of the olfactory receptor gene" section, "Genomic sequence of olfactory receptor gene " section, the "Oligonucleotide Probes And Primers" section, the "Polynucleotide constructs" section and the " Expression of an OLF1 to OLF10 coding polypeptide" section.

30         The replacement of the native genomic olfactory receptor sequence by a defective copy of said sequence may be preformed by techniques of gene targeting. Such techniques are notably described by Burright et al. (1997), Bates et al. (1997), Mangiarini et al. (1997), Davies et al. (1997).

Second preferred transgenic animals of the invention have the murine olfactory receptor gene replaced either by a defective copy of the murine olfactory receptor gene or by an interrupted
35   copy of the human olfactory receptor gene. A "defective copy" of a murine or a human olfactory receptor gene, is intended to designate a modified copy of these genes that is not or poorly transcribed in the resulting recombinant host animal or a modified copy of these genes leading to the

absence of synthesis of the corresponding translation product or alternatively leading to a modified

and/or truncated translation product lacking the biological activity of the wild type olfactory receptor

protein. The altered translation product thus contains amino acid modifications, deletions and

substitutions. Modifications and deletions may render the naturally occurring gene nonfunctional,

5    thus leading to a "knockout animal". These transgenic animals are critical for the creation of animal

models of human diseases, and for eventual treatment of disorders related to alteration of the

olfactory perception of odorant substances or molecules. Examples of such knockout mice are

described in the PCT Applications Nos WO 97/34641, WO 96/12792 and WO 98/02354.

The endogenous murine olfactory receptor gene can be interrupted by the insertion, between

10   two contiguous nucleotide of said gene, of a part of all of a marker gene placed under the control of

the appropriate promoter, for example the endogenous promoter of the endogenous murine olfactory

receptor gene. The marker gene may be the neomycin resistance gene (*neo*) that may be operably

linked to the phosphoglycerate kinase-1 (PGK-1) promoter, as described in the PCT Application No

WO 98/02534.

15   Thus, the invention is also directed to a transgenic animal contain in their somatic cells

and/or in their germ line cells a polynucleotide selected from the following group of

polynucleotides:

a) a defective copy of the human olfactory receptor gene;

b) a defective copy of the endogenous olfactory receptor gene, wherein the expression

20   "endogenous olfactory receptor gene" designates an olfactory receptor gene that is naturally present

within the genome of the animal host to be genetically modified.

The invention also concerns a method for obtaining transgenic animals, wherein said

methods comprise the steps of :

a) replacing the endogenous copy of the animal olfactory receptor gene by a nucleic acid

25   selected from the group consisting of a defective copy of the human olfactory receptor gene and a

defective copy of the endogenous olfactory receptor gene in animal cells, preferably embryonic stem

cells (ES);

b) introducing the recombinant animal cells obtained at step a) in embryos, notably

blastocysts of the animal;

30   c) selecting the resulting transgenic animals, for example by detecting the defective copy of

an olfactory receptor gene with one or several primers or probes according to the invention.

Optionally, the transgenic animals may be bred together in order to obtain homozygous

transgenic animals for the defective copy of the olfactory receptor gene introduced.

The transgenic animals of the invention thus contain specific sequences of exogenous

35   genetic material such as the nucleotide sequences described above in detail.

In a preferred embodiment, these transgenic animals may be good experimental models in

order to study the diverse pathologies related to disorders associated to alteration of the olfactory

perception of odorant substances or molecules, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native olfactory receptor protein, or alternatively a mutant olfactory receptor protein.

Third preferred transgenic animals according to the invention contains in their somatic cells
5   and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides
:

a) purified or isolated nucleic acid encoding an olfactory receptor polypeptide selected from OLF1 to OLF10, or a polypeptide fragment or variant thereof.

b) a purified or isolated nucleic comprising at least 8 consecutive nucleotides of the
10   nucleotide sequence SEQ ID No 1, a nucleotide sequence complementary thereto or a fragment or a variant thereof;

c) a purified or isolated nucleic acid comprising a nucleotide sequence selected from the group of SEQ ID 2-11, a sequence complementary thereto or a fragment or a variant thereof.

The transgenic animals of the invention thus contain specific sequences of exogenous
15   genetic material such as the nucleotide sequences described above in detail.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to screen the candidate substance of interest interacting with the olfactory receptor under consideration.

Since it is possible to produce transgenic animals of the invention using a variety of different
20   sequences, a general description will be given of the production of transgenic animals by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to incorporate the DNA sequences into animals. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to Sandou et al. (1994) and also to US Patents Nos 4,873,191, issued Oct.10, 1989, 5,968,766, issued Dec. 16,
25   1997 and 5,387,742, issued Feb. 28, 1995.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that incorporates exogenous genetic material which is integrated into the genome. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a coding sequence, a non-coding polynucleotide or a DNA sequence
30   encoding an antisense polynucleotide of an olfactory receptor selected from the group OLF1 to OLF10 such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is made using electroporation. The cells subjected to electroporation are screened (e.g. Southern blot analysis) to find positive cells which have integrated the exogenous recombinant
35   polynucleotide into their genome. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al. (1988). Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice. The blastocysts are then

inserted into a female host animal and allowed to grow to term. The offsprings of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a
5  recombinant expression vector or a recombinant host cell according to the invention.

**Recombinant Cell Lines Derived From The Transgenic Animals Of The Invention.**

A further object of the invention comprises recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or an
10  olfactory receptor gene disrupted by homologous recombination with a knock out vector.

Recombinant cell lines may be established *in vitro* from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing *onc*-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al.(1991).

15  **F. METHODS FOR SCREENING SUBSTANCES OR MOLECULES INTERACTING WITH AN OLFACTORY RECEPTOR PROTEIN**

The present invention pertains to methods for screening substances of interest, in particular odorant substances or molecules that interact with an olfactory receptor protein selected from the group consisting of OLF1 to OLF10, or one peptide fragment or variant thereof. In one embodiment,
20  the candidate substance is devoid of odorant propriety but it is able to bind the olfactory receptor and to trigger the transduction of signals.

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the olfactory receptor protein or one of its fragments or variants or to modulate the expression of the
25  polynucleotide coding for olfactory receptor or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the olfactory receptor protein is brought into contact with the corresponding purified olfactory receptor protein, for example the corresponding purified recombinant olfactory receptor protein produced by a recombinant cell host as described
30  herein, in order to form a complex between this protein and the putative ligand molecule to be tested.

As an illustrative example, to study the interaction of the olfactory receptor protein, or a fragment comprising comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments" with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described
35  by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997) can be used.

In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the olfactory receptor protein, or a fragment comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments" may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such

5    as a fluorescent , radioactive, or enzymatic tag and placed in contact with immobilized olfactory receptor protein, or a fragment thereof under conditions which permit specific binding to occur, such as affinity columns. In some embodiments, chimeric proteins containing the olfactory receptor protein fused to proteins facilitating purification, such as glutathion S transferase (GST) are used. After removal of non-specifically bound molecules, bound molecules are detected using appropriate

10   means.

In one embodiment, proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry interacting with the olfactory receptor protein, or a fragment or a variant thereof can also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo et al. (1995). The main advantage of the method is that it

15   allows the determination of the association rate between the olfactory receptor protein and molecules interacting with the olfactory receptor protein. It is thus possible to select specifically ligand molecules interacting with the olfactory receptor protein, or a fragment thereof, through strong or conversely weak association constants.

Another object of the present invention comprises methods and kits for the screening of

20   candidate substances that interact with olfactory receptor polypeptide.

The present invention pertains to methods for screening substances of interest that interact with an olfactory receptor protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to an olfactory receptor protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both *in vitro* and *in vivo*. *In vitro*, said

25   interacting molecules may be used as detection means in order to identify the presence of an olfactory receptor protein in a sample, preferably a biological sample.

A first method for the screening of a candidate substance interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, or fragments or variants thereof, comprises the following steps :

30            a) providing a polypeptide selected from the group consisting of the polypeptides comprising, consisting essentially of, or consisting of the amino acid sequences of SEQ ID Nos 12-21 , or a peptide fragment or a variant thereof;

b) obtaining a candidate substance;

c) bringing into contact said polypeptide with said candidate substance; and

35            d) detecting the complexes formed between said polypeptide and said candidate substance.

Various candidate substances or molecules can be assayed for interaction with an olfactory
receptor polypeptide. These substances or molecules include, without being limited to, natural or
synthetic organic compounds or molecules of biological origin such as polypeptides. When the
candidate substance or molecule comprises a polypeptide, this polypeptide may be the resulting

5 expression product of either a phage clone belonging to a phage-based random peptide library, or of
a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

In one embodiment of the screening method defined above, the complexes formed between
the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a
monoclonal antibody that specifically binds to the olfactory receptor protein of the invention under

10 consideration or to said peptide fragment or variant thereof.

In another embodiment of the present screening method, increasing concentrations of a
substance competing for binding to the olfactory receptor with the considered candidate substance is
added, simultaneously or prior to the addition of the candidate substance or molecule, when
performing step c) of said method. By this technique, the detection and optionally the quantification

15 of the complexes formed between the olfactory receptor protein or the peptide fragment or variant
thereof and the candidate substance or molecule to be screened allows the one skilled in the art to
determine the affinity value of said substance or molecule for said olfactory receptor protein or the
peptide fragment or variant thereof.

The olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide

20 fragment or a variant thereof, can be overexpressed and purified in a bacterial system such as E coli
as described in Kiefer et al. (1996) and Tucker et al. (1996). The olfactory receptor coding sequence
can be fused to its N-terminus with GST (Glutathione S transferase) or MBP (Maltose Binding
Protein) and to its C-terminus with poly-histidine tag, Bio tag or Strep tag for facilitating the
purification of the expressed protein. The Bio tag is 13 amino acid residues long, is biotinylated *in*

25 *vivo* in E. coli, and will therefore bind to both avidin and streptavidin. The Strep tag is 9 amino acid
residues long and binds specifically to streptavidin, but not to avidin. Therewith, a purification step
by affinity can be carried out based on the interaction of a poly-histidine tail with immobilized metal
ions, of the biotinylated Bio tag with monomeric avidin, of the Strep tag with streptavidin, of the
GST segment with the glutathione, or of the MBP segment with the maltose. Thioredoxin can be

30 eventually inserted between the receptor C-terminus and the tag and could increase the expression
level. The fusion protein is solubilized in 1% N-laurroyl sarcosine, and 0.2 % digitonin is added. It is
purified by affinity chromatography. The MBP, GST or tag segment can be then removed. After the
olfactory receptor protein purification, sarcosyl can be replaced with digitonin which is a detergent
widely used to stabilize the G protein-coupled receptors. The purified receptor is reconstituted into

35 lipid vesicles preferably composed of phosphatidylcholine: phosphatidylglycerol (4:1) by adding the
lipid dissolved in dodecyl maltoside and removing the detergent.

The olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, can also be overexpressed and purified in a baculovirus/Sf9 system as described in Nekrasova et al. (1996). The olfactory receptor gene, or a fragment thereof, is preferably expressed with a "flag" peptide epitope tag and/or a poly-histidine tag to either its N- or

5    C-terminus for facilitating the purification of the expressed protein. Therefore, the olfactory receptor gene, or a fragment or a variant thereof, is preferably subcloned into the baculovirus transfer vector pAcSGHisNT to create constructs that encoded olfactory receptor with amino-terminal poly-histidine tag. The resulting transfer vector is transfected preferably with BaculoGold DNA into Sf9 cells. The expressed olfactory receptors are then solubilized either in 1 % N-lauryl sarcosine or 1.5

10   % lysophosphatidylcholine, but preferably in lysophosphatidylcholine. After solubilization, the olfactory receptors are purified by affinity chromatography on nickel nitrilotriacetic acid resin and by cation-exchange chromatography with carboxymethyl sepharaose cation-exchange column. The tag segment can be then removed. The purified receptor is reconstituted into lipid vesicles preferably composed of dimyritoylglycerophosphocholine, cholesterol, dialmitoylgycerophosphoserine and

15   dipalmitoylglycerophosphoethanolamine (in molecular ratio 54:35:10:1)

Once the olfactory receptor protein or one of its peptide fragments or variants has been obtained as described above, candidate substances or molecules can then be assayed for their capacity to bind thereto.

The candidate substance or molecule to be assayed for interacting with an olfactory receptor

20   of the invention may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as peptide. It can comprise aromatic or aliphatic compounds with various functional groups such as alcohol, aldehyde, ester, ether, ketone, carboxylic, amine. An example of a substance panel which can be used is provided by Zhao et al. (1998).

25   The screening of substances or molecules interacting with an olfactory receptor, or a fragment thereof, is carried out by photoaffinity labeling experiments described in Kiefer et al. (1996). The odorant is labeled, preferably radiolabeled, and incubated with lipid vesicles including the purified olfactory receptor. The odorants bound to the olfactory receptors are crosslinked by exposure to ultraviolet light. Then, the samples are subjected to SDS polyacrylamide gel

30   electrophoresis. Proteins are visualized by Coomassie-blue staining and the odorants are revealed, preferably by autoradiography. In another embodiment, the proteins can be visualized by Western Blot with a polyclonal or monoclonal antibody that specifically binds to the olfactory receptor under consideration. Once a substance binding to the considered olfactory receptor is identified, the binding specificity of this substance is confirmed with competition experiments demonstrating that

35   increasing concentrations of unlabeled ligand accomplish a dose-dependent displacement of the radioactive ligand.

The identification of a first substance specific to one of the olfactory receptors of the present invention facilitates the screening of other substances. Indeed, the binding capacity of the screened substances to this olfactory receptor can be carried out through a competition experiments against the first identified substance which is labeled.

5       The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a polypeptide selected form the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the considered olfactory receptor polypeptide or its peptide fragment or variant and the candidate substance. In a

10     preferred embodiment, the kit can comprise an already identified substance specific of the olfactory receptor under consideration which is labeled, preferably radiolabeled, and a monoclonal or polyclonal antibody directed against the considered olfactory receptor.

A second screening method embodiment consists of a method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of

15     SEQ ID Nos 12-21, wherein said method comprises :

a) providing a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group comprising, consisting essentially of, or consisting the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, or variants or fragments thereof;

20     b) preparing membrane extracts of said recombinant eukaryotic host cell;

c) bringing into contact the membrane extracts prepared at step b) with a selected ligand molecule; and

d) detecting the production level of second messengers metabolites.

The baculovirus-Sf9 cell system enables a foreign DNA encoding an olfactory receptor

25     selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, to be expressed with high efficiency. Moreover, it can be used to couple a heterologous expressed olfactory receptor to the second messenger cascades. Therefore, the binding specificity of an olfactory receptor can be assessed through an assay of odorant-induced generation of cAMP or inositol triphosphate (InsP3) described in Raming et al. (1993).

30     Briefly, a cell line derived from Sf9 is infected by baculovirus, such as baculovirus transfer vector pVL1393, harboring DNA encoding the olfactory receptor or a fragment thereof downstream from a strong promoter, preferably the polyhedrin promoter. Recombinant virus are purified and used to infect $1.5 \times 10^8$ Sf9 cells in 100 ml spinner cultures at high multiplicity of infection. Cells are collected after a postinfection delay, preferably 48 h, and membrane fractions are isolated as follow.

35     Cells are pelleted (at 250g for 10 min at 4°C), washed with Ringer solution (120 mM NaCl, 5 mM KCl, 1.6 mM $K_2HPO_4$, 1.2 mM $MgSO_4$, 25 mM $NaHCO_3$, 5 mM glucose, pH7.4) and disrupted using a glass homogenizer in homogenization buffer (10 mM Tris-HCl, pH 8.0, 2 mM

EGTA, 3 mM MgCl2) containing antiproteases. The homogenate is centrifuged and the pellet is washed. Supernatants are centrifuged at 33,000g for 20 min. The final pellet is resuspended in homogenization buffer and the protein concentration is determined.

Assay of odorant substance-induced generation of second messengers cAMP and InsP3 is
5    performed as follow. Suspensions of Sf9 cell membrane preparations (300 μg protein) are rapidly mixed with a stimulation buffer (200 mM NaCl, 10 mM EGTA, 50 mM MOPS, 2.5 mM MgCl$_2$, 1 mM DTT, 0.05 % Na-cholate, 1 mM ATP, 1 μM GTP, and 0.02 μM free Ca$^{2-}$) containing the candidate substances at the appropriate concentrations. The reaction is stopped after a short time, preferably 1 sec, by injecting 10 % Perchloric acid. Quenched samples are assayed for second
10   messenger concentrations. The quenched and cooled samples are vortexed and centrifuged for 5 min at 2500g at 4°C. 400 μl of the supernatants are transferred to a separate tube containing 100 μl of 10 mM EDTA (pH 7). The sample are neutralized by adding 500 μl of a 1:1 (v/v) mixture of 1,1,2 trichlorofluoroethane, followed by thorough mixing. After centrifugation for 2 min at 500g, three phases are obtained. The upper phase, which contains all water soluble components, is used for
15   carrying out the concentration measurements. cAMP and InsP3 concentrations are determined according the procedure of Steiner et al. (1972) and Palmer et al. (1989), respectively.

The invention also concerns a kit for the screening of odorant ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, wherein said kit comprises :
20                    a) a recombinant eukaryotic host cell containing a nucleic acid encoding a
        polypeptide selected from the group comprising, consisting essentially of, or consisting of
        the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21 or variants or
        fragments thereof; and
                    b) optionally, reagents necessary for the measurement of second messenger
25      metabolites in a sample.

The screening of substances or molecules interacting with an olfactory receptor, or a fragment thereof, can also be carried out through the measurement of the increase of the response to odorants in an olfactory epithelium overexpressing an olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, as described in Zhao et al.
30   (1998). The response is assessed by electro-olfactogram which measures a transepithelial potential resulting from the summed activity of many olfactory neurons. In order to overexpress the olfactory receptor, or a fragment thereof, in an olfactory epithelium, an adenovirus containing the olfactory receptor gene is generated. To aid in electro-olfactogram electrode placements, the olfactory receptor coding sequence is preferably combined in the adenovirus with the physiological marker
35   green fluorescent protein (GFP) in such manner that the two proteins are simultaneously expressed. The olfactory epithelium of an animal, preferably of a rat, is infected by the adenovirus. Animals are killed 3 to 8 days after infection and the nasal cavity is opened, exposing the medial surface of the

nasal turbinates. Under fluorescent illumination, the GFP clearly marked the pattern of viral infection and olfactory receptor expression. Odorant substance are applied to the olfactory epithelium in the vapor phase by injecting a pressurized pulse of odorant vapor into a continuous stream of humidified clean air. Electro-olfactogram recordings are obtained with a glass capillary

5   electrode placed on the surface of the epithelium and connected to a differential amplifier. The olfactory receptor specificity is assessed from the increase of response in infected animals compared to uninfected animals. To account for the variability between animals, a standard odorant to which all other odorant responses are normalized is used.

A third screening method embodiment consists of a method for the screening of ligand

10  molecules interacting with an olfactory receptor polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, wherein said method comprises :

a) providing an adenovirus containing a nucleic acid encoding a polypeptide selected from the group comprising, consisting essentially of, or consisting of the polypeptides

15      comprising the amino acid sequences SEQ ID Nos 12-21, or variants or fragments thereof;

b) infecting an olfactory epithelium with said adenovirus;

c) bringing into contact the olfactory epithelium b) with a selected ligand molecule; and

d) detecting the increase of the response to said ligand molecule.


20  **G. METHODS FOR INHIBITING THE EXPRESSION OF AN OLFACTORY RECEPTOR GENE**

Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of olfactory receptor as an antisense tool or a triple helix tool that inhibits the expression of the corresponding olfactory receptor gene. A

25  preferred fragment of the nucleic sequence of olfactory receptor comprises an allele of at least one of the biallelic markers A1 to A13.


**Antisense Approach**

Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995).

30      Preferred antisense polynucleotides are described in the section entitled "Nuclear Antisense DNA Constructs".

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the olfactory receptor mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for

35  use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984).

In some strategies, antisense molecules are obtained by reversing the orientation of the olfactory receptor coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate

5    the transcript. Another approach involves transcription of olfactory receptor antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al.(1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European

10   Patent Application No. EP 0 572 287 A2

An alternative to the antisense technology that is used according to the present invention comprises using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme

15   comprises (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense

20   ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al.(1995), the specific preparation procedures being referred to in said article.


**Triple Helix Approach**

The olfactory receptor genomic DNA may also be used to inhibit the expression of the

25   olfactory receptor gene based on intracellular triple helix formation.

Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity when it is associated with a particular gene.

Similarly, a portion of the olfactory receptor genomic DNA can be used to study the effect

30   of inhibiting olfactory receptor transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the olfactory receptor genomic DNA are contemplated within the scope of this invention.

35   To carry out gene therapy strategies using the triple helix approach, the sequences of the olfactory receptor genomic DNA are first scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting olfactory

receptor expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting olfactory receptor expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the olfactory receptor gene.

5          The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced olfactory receptor expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to 10  monitor the transcription levels of the olfactory receptor gene in cells which have been treated with the oligonucleotide.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above in the antisense approach at a dosage calculated based on the in vitro results, as described in antisense approach.

15         In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al.(1989).

## 20  H. COMPUTER-RELATED EMBODIMENTS

As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any of the polynucleotides described in the "Coding Regions of the olfactory receptor gene" section, "Genomic sequence of the olfactory receptor gene" section and the "Oligonucleotide Probes And Primers" section, or variants 25  thereof, or complementary sequences thereto. Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention.

30         As used herein the term "polypeptide codes of the invention" encompass the polypeptide sequences comprising any of the polypeptides described in the " OLF1 to OFL10 proteins and polypeptide fragments".

It will be appreciated that the nucleic acid and polypeptide codes of the invention can be represented in the traditional single character format or three letter format respectively (See the inside 35  back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any

other format or code which records the identity of the nucleotides or the amino acid respectively in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of the invention and polypeptide codes of the invention can be stored, recorded, and manipulated on any medium which can

5    be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid codes of the invention, or one or more of the polypeptide codes of the invention. Another aspect of the present invention is a computer readable

10   medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of the invention.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media

15   may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, DVD, RAM, or ROM as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which contain the sequence information described herein. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to store and/or analyze

20   the nucleotide sequences of the nucleic acid codes of the invention, the amino acid sequences of the polypeptide codes of the invention, or other sequences. The computer system preferably includes the computer readable media described above, and a processor for accessing and manipulating the sequence data.

In some embodiments, the computer system may further comprise a sequence comparer for

25   comparing the nucleic acid codes or polypeptide codes of the invention stored on a computer readable medium to reference nucleotide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals the sequences or structures of

30   which are stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent

35   specification are particularly contemplated for use in this aspect of the invention.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of the invention or a

polypeptide code of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of the invention or polypeptide code of the invention and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences

5   compared or identify structural motifs in the nucleic acid code of the invention and polypeptide codes of the invention or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or polypeptide codes of the invention.

10        Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of the invention and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program

15   may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of the invention through the use of the computer program and determining homology

20   between the nucleic acid codes and reference nucleotide sequences.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of the invention differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and

25   identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of the invention. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of the invention contain one or more single nucleotide polymorphisms (SNP) with respect to a reference nucleotide sequence. These single nucleotide polymorphisms may each comprise a single

30   base substitution, insertion, or deletion.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of the invention and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of the invention and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the

35   polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of the invention differs at one or more nucleotides from a reference nucleotide

sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program

5 which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

10 An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention.

In one embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of the invention. In some

15 embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling

20 technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of the invention. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the

25 protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely

30 folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as

35 QUANTA. According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural

equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these

5  low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszódi et al., (1997)).

he results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of the invention.

Accordingly, another aspect of the present invention is a method of identifying a feature

10  within the nucleic acid codes of the invention or the polypeptide codes of the invention comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer

15  program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or the polypeptide codes of the invention through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

20  The nucleic acid codes of the invention or the polypeptide codes of the invention may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, they may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence

25  comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of the invention or the polypeptide codes of the invention. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of the invention or the polypeptide codes of the invention. The programs and databases which may be used include, but are not limited to: MacPattem (EMBL), DiscoveryBase

30  (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, 1990), FASTA (Pearson and Lipman, 1988), FASTDB (Brutlag et al., 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius$^2$.DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight

35  II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler

(Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular
Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular
Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.),
the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug

5     Data Report data base, the Comprehensive Medicinal Chemistry database, Derwents's World Drug
Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database.
Many other programs and data bases would be apparent to one of skill in the art given the present
disclosure.

        Motifs which may be detected using the above programs include sequences encoding

10    leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and
beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded
proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches,
enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.


15        Throughout this application, various publications, patents and published patent applications
are cited. The disclosures of these publications, patents and published patent specification
referenced in this application are hereby incorporated by reference into the present disclosure to
more fully describe the sate of the art to which this invention pertains.


## EXAMPLES


20 ## EXAMPLE 1: LOCALIZATION OF THE OLFACTORY RECEPTOR GENE OLF3 AND OLF5 ON THE HUMAN CHROMOSOMES.


**Metaphase chromosome preparation**

        Metaphase chromosomes were prepared from phytohemagglutinin (PHA)-stimulated blood
cell donors. PHA stimulated lymphocytes from healthy males were cultured for 72 h in RPMI-1640

25    medium. For synchronization, methotrexate (10 μM) was added for 17 h, followed by addition of 5-
bromodeoxyuridine (5-BrdU, 0.1 mM) for 6 h. Colcemid (1 mg/ml) was added for the last 15 min
before harvesting the cells. Cells were collected, washed in RPMI, incubated with a hypotonic
solution of KCl (75 mM) at 37°C for 15 min and fixed in three changes of methanol:acid acetic
(3:1). The cell suspension was dropped onto a glass slide, air-dried and kept in darkness at –20°C

30    until use.


**Probes:**

        - The BAC H0526H04 containing Olf3 and Olf5 genes was used to generate probe by Alu-
PCR. PCR amplification of BAC recombinant DNA (50 ng) was carried out as described by Romana
et al. (1993).

- Two DNA fragments carrying respectively Olf3 and Olf5 sequences were generated by
long range PCR with specific primers (SEQ ID 96-99) and used as probes to confirm the localization
of each genes. Olf3 and Olf5 amplicons are respectively 2.8 kb and 3.2 kb fragments.

Probes were labeled by nick translation with bio-16-dUTP (Boehringer Mannheim), and
5  purified over a Sephadex G50 column.

**Fluorescence In Situ Hybridization**

To determine the chromosomal localization of both genes, the BAC probe was initially
hybridized to human metaphase cells. When biotinylated PCR products of BAC DNA were used in
hybridization experiment, 75 ng of probe was precipitated with 75 µg of competitor DNA (human
10  Cot1 DNA, GIBCO-BRL) and resuspended in 10 µl of hybridization buffer (50% formamide, 2 X
SSC, 10% dextran sulfate, 1 mg/ml sonicated herring DNA, pH 7). When long range PCR products
of Olf3 or Olf5 genes were used as probe, 5 ng of biotinylated probe were mixed with 5 µg of
human Cot1 DNA. Prior to hybridization, the probe was denatured at 70°C for 10 min and
preannealed at 37°C for 2 h.

15  Slides were treated for 1 h at 37°C with Rnase A (100 µg/ml), rinsed three times in 2 X SSC
and dehydrated in an ethanol serie. Chromosome preparations were denatured in 70% formamide, 2
X SSC (pH 7), for 2 min at 70°C, then dehydrated at 4°C. The slides were treated with proteinase K
(10 µg/ml in 20 mM Tris-HCl, 2 mM CaCl2) at 37°C for 8-10 min and dehydrated. After
preannealing, the hybridization mixture containing the probe was placed on the slide, covered with a
20  coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37°C. After
hybridization and post hybridization washes, the biotinylated probe was detected by avidin-FITC (5
µg/ml, Vector Laboratories) and amplified once with additional layers of biotinylated goat anti-
avidin (5 µg/ml, Vector Laboratories) and avidin-FITC. For chromosomal localization, fluorescent
R-Bands were obtained as described by Cherif et al. (1990). The slides were observed under a
25  LEICA fluorescent microscope (DMRXA). Chromosomes were counterstained with propidium
iodide and the fluorescent signal of the probe appeared as two symmetrical yellow-green spots on
both chromatids of the fluorescent R-band chromosome.

**Localization**

A specific signal (a double yellow-green spot) was observed on band 11q12-q13 on at least
30  on chromosome 11 in >80% of the metaphases with all the probes.

**EXAMPLE 2 : IDENTIFICATION OF BIALLELIC MARKERS: DNA
EXTRACTION**

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a
French heterogeneous population. The DNA from 100 individuals was extracted and tested for the
35  detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA.

Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by

a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution

was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red

5   cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed

of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M

- 200 µl SDS 10%

10                - 500 µl K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After

vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous

supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was

15   rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm.

The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA

concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 µg/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was

determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used

20   in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.


## EXAMPLE 3 : IDENTIFICATION OF BIALLELIC MARKERS: AMPLIFICATION OF GENOMIC DNA BY PCR

The amplification of specific genomic sequences of the DNA samples of example 2 was

25   carried out on the pool of DNA obtained previously. In addition, 50 individual samples were

similarly amplified.

PCR assays were performed using the following protocol:

| | |
|---|---|
| Final volume | 25 µl |
| DNA | 2 ng/µl |
| MgCl₂ | 2 mM |
| dNTP (each) | 200 µM |
| primer (each) | 2.9 ng/µl |
| Ampli Taq Gold DNA polymerase | 0.05 unit/µl |
| PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl | 1x |

30

35   Each pair of first primers was designed using the sequence information of the olfactory

receptor gene cluster disclosed herein and the OSP software (Hillier & Green, 1991). This first pair

of primers was about 20 nucleotides in length and had the sequences disclosed in Table 1 in the
columns labeled PU and RP.

Table 1

| Amplicon | Position range of the amplicon in SEQ ID 1 | | Primer name RP | Position range of amplification primer in SEQ ID No 1 | | Primer name PU | Complementary position range of amplification primer in SEQ ID No 1 | |
|---|---|---|---|---|---|---|---|---|
| 99-13670 | 7362 | 7824 | B1 | 7362 | 7380 | C1 | 7805 | 7824 |
| 99-13669 | 8120 | 8662 | B2 | 8120 | 8140 | C2 | 8643 | 8662 |
| 99-13666 | 14308 | 14757 | B3 | 14308 | 14328 | C3 | 14740 | 14757 |
| 99-13664 | 19346 | 19845 | B4 | 19346 | 19366 | C4 | 19826 | 19845 |
| 99-13663 | 20298 | 20800 | B5 | 20298 | 20318 | C5 | 20781 | 20800 |
| 99-13660 | 76752 | 77223 | B6 | 76752 | 76772 | C6 | 77205 | 77223 |
| 99-13652 | 90967 | 91494 | B7 | 90967 | 90987 | C7 | 91474 | 91494 |
| 99-13671 | 133925 | 134393 | B8 | 133925 | 133945 | C8 | 134375 | 134393 |
| 99-13649 | 139807 | 140351 | B9 | 139807 | 139826 | C9 | 140331 | 140351 |
| 99-13648 | 140912 | 141434 | B10 | 140912 | 140932 | C10 | 141416 | 141434 |
| 99-13647 | 143828 | 144309 | B11 | 143828 | 143847 | C11 | 144292 | 144309 |

5       Preferably, the primers contained a common oligonucleotide tail upstream of the specific
bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5' sequence :
TGTAAAACGACGGCCAGT; primers RP contain the following RP 5' sequence :
CAGGAAACAGCTATGACC. The primer containing the additional PU 5' sequence is listed in

10   SEQ ID No 26. The primer containing the additional RP 5' sequence is listed in SEQ ID No 27.

The synthesis of these primers was performed following the phosphoramidite method, on a
GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10
min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at

15   72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the
amplification products obtained were determined on 96-well microtiter plates, using a fluorometer
and Picogreen as intercalant agent (Molecular Probes).

## EXAMPLE 4 : IDENTIFICATION OF BIALLELIC MARKERS: SEQUENCING OF AMPLIFIED GENOMIC DNA AND IDENTIFICATION OF POLYMORPHISMS.

20       The sequencing of the amplified DNA obtained in example 3 was carried out on ABI 377
sequencers. The sequences of the amplification products were determined using automated dideoxy
terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of
the sequencing reactions were run on sequencing gels and the sequences were determined using gel
image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data were further evaluated using the above mentioned polymorphism analysis software designed to detect the presence of biallelic markers among the pooled amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

5       11 fragments of amplification were analyzed. In these segments, 13 biallelic markers referred to as A1 to A13 in the BM column were detected. The localization of these biallelic markers is as shown in Table 2.

**Table 2**

| Amplicon | BM | Marker Name | Localization in *OLF* gene cluster | Polymor-phism | BM position in SEQ ID No 1 |
|---|---|---|---|---|---|
| 99-13670 | A1 | 99-13670-305 | Between Orf1 and Orf2 | A/C | 7521 |
| 99-13669 | A2 | 99-13669-471 | Between Orf1 and Orf2 | A/C | 8192 |
| 99-13666 | A3 | 99-13666-275 | Between Orf2 and Orf3 | A/T | 14483 |
| 99-13664 | A4 | 99-13664-221 | Between Orf2 and Orf3 | A/G | 19625 |
| 99-13663 | A5 | 99-13663-218 | Between Orf2 and Orf3 | C/T | 20583 |
| 99-13660 | A6 | 99-13660-277 | Between Orf4 and Orf5 | G/T | 76947 |
| 99-13652 | A7 | 99-13652-407 | Between Orf5 and Orf6 | G/C | 91088 |
| 99-13652 | A8 | 99-13652-357 | Between Orf5 and Orf6 | C/T | 91138 |
| 99-13652 | A9 | 99-13652-308 | Between Orf5 and Orf6 | C/T | 91187 |
| 99-13671 | A10 | 99-13671-396 | Between Orf9 and Orf10 | C/T | 133998 |
| 99-13649 | A11 | 99-13649-286 | Between Orf9 and Orf10 | A/G | 140066 |
| 99-13648 | A12 | 99-13648-259 | Between Orf9 and Orf10 | C/T | 141176 |
| 99-13647 | A13 | 99-13647-278 | After Orf10 | C/T | 144033 |

10       **Table 3**

| BM | Marker Name | Position range of probes in SEQ ID No 1 | | Probes |
|---|---|---|---|---|
| A1 | 99-13670-305 | 7498 | 7544 | P1 |
| A2 | 99-13669-471 | 8169 | 8215 | P2 |
| A3 | 99-13666-275 | 14460 | 14506 | P3 |
| A4 | 99-13664-221 | 19602 | 19648 | P4 |
| A5 | 99-13663-218 | 20560 | 20606 | P5 |
| A6 | 99-13660-277 | 76924 | 76970 | P6 |
| A7 | 99-13652-407 | 91065 | 91111 | P7 |
| A8 | 99-13652-357 | 91115 | 91161 | P8 |
| A9 | 99-13652-308 | 91164 | 91210 | P9 |
| A10 | 99-13671-396 | 133975 | 134021 | P10 |
| A11 | 99-13649-286 | 140043 | 140089 | P11 |
| A12 | 99-13648-259 | 141153 | 141199 | P12 |
| A13 | 99-13647-278 | 144010 | 144056 | P13 |

## EXAMPLE 5 : VALIDATION OF THE POLYMORPHISMS THROUGH MICROSEQUENCING

The biallelic markers identified in example 4 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each

5   individual DNA sample described in Example 2.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 1).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the

10   primers used in microsequencing are detailed in Table 4.

### Table 4

| Marker Name | BM | Mis. 1 | Position range of microsequencing primer mis 1 in SEQ ID No 1 | | Mis. 2 | Complementary position range of microsequencing primer mis. 2 in SEQ ID No 1 | |
|---|---|---|---|---|---|---|---|
| 99-13670-305 | A1 | D1 | 7502 | 7520 | E1 | 7522 | 7540 |
| 99-13669-471 | A2 | D2 | 8173 | 8191 | E2 | 8193 | 8211 |
| 99-13666-275 | A3 | D3 | 14464 | 14482 | E3 | 14484 | 14502 |
| 99-13664-221 | A4 | D4 | 19606 | 19624 | E4 | 19626 | 19644 |
| 99-13663-218 | A5 | D5 | 20564 | 20582 | E5 | 20584 | 20602 |
| 99-13660-277 | A6 | D6 | 76928 | 76946 | E6 | 76948 | 76966 |
| 99-13652-407 | A7 | D7 | 91069 | 91087 | E7 | 91089 | 91107 |
| 99-13652-357 | A8 | D8 | 91119 | 91137 | E8 | 91139 | 91157 |
| 99-13652-308 | A9 | D9 | 91168 | 91186 | E9 | 91188 | 91206 |
| 99-13671-396 | A10 | D10 | 133979 | 133997 | E10 | 133999 | 134017 |
| 99-13649-286 | A11 | D11 | 140047 | 140065 | E11 | 140067 | 140085 |
| 99-13648-259 | A12 | D12 | 141157 | 141175 | E12 | 141177 | 141195 |
| 99-13647-278 | A13 | D13 | 144014 | 144032 | E13 | 144034 | 144052 |

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the non-coding strand of the olfactory receptor gene or with the coding strand of the olfactory receptor

15   gene.

The microsequencing reaction was performed as follows :

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20µl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH

20   9.5, 65 mM $MgCl_2$), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples

25   were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before

being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

5      The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is

10     categorized classification as homozygous or heterozygous type based on the height ratio.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein by the one skilled in the art without departing from the spirit and scope of the invention.

15                                    **REFERENCES :**

Adra et al.,1987, Gene, **60**:65-74

Beard et al., 1980, Virology, Vol. 75:81

Beaucage et al., *Tetrahedron Lett* 1981, **22**: 1859-1862

Bolmont et al., J. of Submicroscopic cytology and pathology, 1990, 22:117-122

20     Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979;**68**:109-151

Chai H. et al., 1993, Biotechnol. Appl. Biochem., **18**:259-273

Cherif D, Julier C, Delattre O, Derré J, Lathrop GM and Berger R, *P.N.A.S. USA* (1990) **87**: 6639-6643

Compton J. *Nature*. 1991 Mar 7; **350**(6313): 91-92.

25     Current Protocols in Molecular Biology, 1989, Ausubel FM et al. (eds), Greene Publishing Associates, Sections 9.10-9.14.

Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2

Engvall E, 1980, Methods Enzymol, **70**(A):419-439

Feldman and Steg, 1996, Medecine/Sciences, synthese, **12**:47-55

30     Felgner et al., 1987, Proc. Natl. Acad. Sci., **84**:7413

Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Flotte et al., 1992, Am. J. Respir. Cell Mol. Biol., **7** : 349-356.

Fraley et al., 1980, J. Biol. Chem., **255**:10431).

35     Fuller S.A. et al., 1996, Immunology in Current Protocols in Molecular Biology, Ausubel et al. Eds, John Wiley & Sons, Inc., USA

Graham, 1984, EMBO J., **3**:2917

Guatelli JC et al., 1990, Proc. Natl. Acad. Sci. USA, **87** : 1874-1878.

Guzman, 1981, Cell, **23** : 175

Hames BD and Higgins SJ, 1985, "Nucleic acid hybridization : a practical approach", Hames and Higgins Ed., IRL Press, Oxford.

Harju L, et al., *Clin Chem* 1993;39(11Pt 1):2282-2287

Hartley JW, Rowe WP, *J Virol* 1976;19(1):19-25

Hillier L. and Green P. *Methods Appl.,* 1991, **1**: 124-8.

Houbenweyl, 1974, in Meuthode der Organischen Chemie, E. Wunsch Ed., Volume 15-I et 15-II, Thieme, Stuttgart

Huygen et al., 1996, Nature Medicine, **2**(8):893-898

Julan et al., 1992, J. Gen. Virol., **73** : 3251 – 3255.

Kaneda et al., 1989, Science, **243**:375

Kiefer H et al., 1996, Biochemistry, **35**(50):16077-16084.

Koch Y., 1977, Biochem. Biophys. Res. Commun., **74**:488-491

Kohler G. and Milstein C., 1975, Nature, **256** : 495.

Kort et al., 1983, Nucleic Acids Research, **11**:8287-8301

Lenhard T. et al., 1996, Gene, **169**:187-190

Levrero et al., 1991, Gene, **101**:195

Lin Z, Floros J, 1998, Biotechniques, **24**(6):937-940

Livak KJ, and Hainer JW., 1994, Hum Mutat., **3**(4): 379-385.

Mackey K, Steinkamp A, Chomczynski P, 1998, Mol Biotechnol, **9**(1):1-5

Mansour SL, Thomas KR, Capecchi MR, *Nature* 1988;336(6197):348-52

McLaughlin et al., 1989, J. Virol., **62** : 1963 – 1973.

Merrifield RB 1965 *Nature.* **207**: 522-523.

Merrifield RB 1965 *Science.* **150**: 178-185.

Midoux, 1993, Nucleic Acids Research, **21**:871-878

Muzyczka et al., 1992, Curr. Topics in Micro. and Immunol., **158** : 97-129.

Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979;68:90-98

Neda et al., 1991, J. Biol. Chem., **266** : 14143 – 14146.

Nekrasova E, Sosinskaya A, Natochin M, Lancet D, Gat U, *Eur J Biochem* 1996;238(1):28-37

O'Reilly et al., 1992, Baculovirus expression vectors : a Laboratory Manual. W.H. Freeman and Co., New York Adra et al., 1987, Gene, **60**:65-74

Ohno et al., 1994, Sciences, **265**:781-784

Ohwada A, Hirschowitz EA, Crystal RG, *Hum Gene Ther* 1996;7:1567-76

Ouchterlony, O. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973)

Pagano et al., 1967, J. Virol., **1**:891

Palmer S et al., 1989, Biochim Biophys Acta, **1014**(3):239-246.

Pastore, 1994, Circulation, 90:I-517

PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press

5   Pearson WR, Lipman DJ, *Proc Natl Acad Sci U S A* 1988;85(8):2444-8

Porath J et al., 1975, Nature, **258**(5536) : 598-599.

Raming K et al., 1993, Nature, 361(6410):353-356

Rettlez and Basenga, 1987, Mol. Cell. Biol., 7:1676-1685

Romana SP, Tachdjian G, Druart L, Cohen D, Berger R, Cherif D *Eur J Hum Genet* (1993) 1: 245-

10  251.

Roth J.A. et al., 1996, Nature Medicine, 2(9):985-991

Rougeot, C. et al., *Eur. J. Biochem.* **219** (3): 765-773, 1994

Sambrook, J. Fritsch, E. F., and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2ed.

Cold Spring Harbor Laboratory, Cold spring Harbor, New York

15  Samulski et al., 1989, J. Virol., **63** : 3822-3828.

Sanchez-Pescador R., 1988, J. Clin. Microbiol., **26**(10):1934-1938

Sczakiel G. et al., 1995, Trends Microbiol., 1995, 3(6):213-217

Smith et al., 1983, Mol. Cell. Biol., 3:2156-2165.

Steiner AL et al., 1972, J Biol Chem, 247(4):1106-1113

20  Syvanen AC, et al., 1994, Hum Mutat., 3(3): 172-179.

Tacson et al., 1996, Nature Medicine, 2(8):888-892

Tucker J, Grisshammer R, *Biochem J* 1996;317( Pt 3):891-899

Urdea M.S., 1988, Nucleic Acids Research, **11**: 4937-4957

Urdea MS et al., 1991, Nucleic Acids Symp Ser., **24**: 197-200.

25  Vaitukaitis J. et al., 1971, J. Clin. Endocrinol. Metab., **33** : 988-991

Vlasak R. et al., 1983, Eur. J. Biochem., **135**:123-126

White, B.A. Molecular Cloning to Genetic Engineering Ed. in Methods in Molecular Biology **67**:

Humana Press, Totowa 1997

Zhao H et al., 1998, Science, 279(5348):237-242

30  Zhenlin et al., Gene, 1989, **78**:243-254.

## SEQUENCE LISTING FREE TEXT

The following free text appears in the accompanying Sequence Listing :

open reading frame

ubiquitin 1 pseudogene complement

5          ubiquitin 2 pseudogene complement

polymorphic base

or

complement

probe

10         sequencing oligonucleotide PrimerPU

sequencing oligonucleotide PrimerRP

## What is claimed:

1. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID No 1: 1-113643, 114064-
5   127488, 127855-144460.

2. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof.

10

3. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 or the complement thereof, wherein said span includes an olfactory receptor-related biallelic marker in said sequence.

15      4. A polynucleotide according to claim 3, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof.

5. A polynucleotide according to claims 3 or 4, wherein said contiguous span is 18 to 47 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said
20  polynucleotide.

6. A polynucleotide according to claim 5, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: P1 to P13, and the complementary sequences thereto.

25

7. A polynucleotide according to any one of claims 1, 2 or 3, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide.

8. A polynucleotide according to claims 3 or 4, wherein the 3' end of said contiguous span is
30  located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

9. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 or the complement thereof, wherein the 3' end of said
35  contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said

polynucleotide is located within 20 nucleotides upstream of an olfactory receptor-related biallelic marker in said sequence.

10. A polynucleotide according to claim 9, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said olfactory receptor-related biallelic marker in said sequence.

11. A polynucleotide according to claim 10, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D13, and E1 to E13.

12. A polynucleotide according to claim 7 consisting essentially of a sequence selected from the following sequences: B1 to B11 and C1 to C11.

13. An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12-21.

14. A polynucleotide for use in a genotyping assay for determining the identity of the nucleotide at an olfactory receptor-related biallelic marker or the complement thereof.

15. A polynucleotide according to claim 14, wherein the polynucleotide is used in an assay selected from the group consisting of: a hybridization assay, a sequencing assay, an enzyme-based mismatch detection assay, and an amplification of a segment of nucleotides comprising said biallelic marker.

16. A polynucleotide according to any one of claims 1-15 attached to a solid support.

17. An array of polynucleotides comprising at least one polynucleotide according to claim 16.

18. An array according to claim 17, wherein said array is addressable.

19. A polynucleotide according to any one of claims 1-15, further comprising a label.

20. A recombinant vector comprising a polynucleotide according to any one of claims 1-15.

21. A host cell comprising a recombinant vector according to claim 20.

22. A non-human host animal or mammal comprising a recombinant vector according to claim 20.

23. A mammalian host cell comprising an olfactory receptor gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-15.

24. A non-human host mammal comprising an olfactory receptor gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-15.

25. An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12-21.

26. An isolated or purified antibody composition are capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 25.

27. A method of genotyping comprising determining the identity of a nucleotide at an olfactory receptor-related biallelic marker or the complement thereof in a biological sample.

28. A method according to claim 27, wherein said biological sample is derived from a single subject.

29. A method according to claim 28, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome.

30. A method according to claim 27, wherein said biological sample is derived from multiple subjects.

31. A method according to claim 27, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.

32. A method according to claim 31, wherein said amplifying step is performed by PCR.

33. A method according to claim 27, wherein said determining is performed by an assay selected from the group consisting of: a hybridization assay, a sequencing assay, a microsequencing assay, and an enzyme-based mismatch detection assay.

34. A method according to claim 27 wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13 and the complements thereof.

5       35. A method for the screening of a candidate substance interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, or fragments or variants thereof, comprises the following steps :

a) providing a polypeptide selected from the group consisting of the sequences of SEQ ID Nos 12-21 , or a peptide fragment or a variant thereof;

10       b) obtaining a candidate substance;

c) bringing into contact said polypeptide with said candidate substance; and

d) detecting the complexes formed between said polypeptide and said candidate substance.

36. A method for the screening of ligand molecules interacting with an olfactory receptor
15 polypeptide selected from the group consisting of SEQ ID Nos 12-21, wherein said method comprises :

a) providing a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21;

20       b) preparing membrane extracts of said recombinant eukaryotic host cell;

c) bringing into contact the membrane extracts prepared at step b) with a selected ligand molecule; and

d) detecting the production level of second messengers metabolites.

25       37. A method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, wherein said method comprises :

a) providing an adenovirus containing a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21;

30       b) infecting an olfactory epithelium with said adenovirus;

c) bringing into contact the olfactory epithelium b) with a selected ligand molecule; and

d) detecting the increase of the response to said ligand molecule.

## FIGURE 1

```
                                                                   TM1
                      1                                                      50
list1.msf{orf-8}   -MRRNFTLVT  EFILLGLTNH  QELQILLFML  FLAIYMVTVA  GNLSMIALIQ
list1.msf{orf-9}   -MRRNCTLVT  EFILLGLTSR  RELQILLFTL  FLAIYMVTVA  GNLGMIVLIQ
list1.msf{orf-7}   ----------  ----------  ----------  ----------  -----LPSSR
list1.msf{orf-2}   MFSPNHTIVT  EFILLGLTDD  PVLEKILFGV  FLAIYLITLA  GNLCMILLIR
list1.msf{orf-4}   MLSPNHTIVT  EFILLGLTDD  PVLEKILFGV  FLAIYLITLA  GNLCMILLIR
list1.msf{orf-5}   MSNTNGSAIT  EFILLGLTDC  PELQSLLFVL  FLVVYLVTLL  GNLGMIMLMR
list1.msf{orf-6}   MVRGNSTLVT  EFILLGLKDL  PELQPILFVL  FLLIYLITVG  GNLGMLVLIR
list1.msf{orf-10}  MSRRNYTELT  EFVLLGLTSR  PELRVAFLAL  FLFVYIATVV  GNLGMIILIK
list1.msf{orf-3}   MLKKNHTAVT  EFVLLGLTDR  AELQSLLFVV  FLVIYLITVI  GNVSMILLIR
list1.msf{orf-1}   ----------  ----------  ----------  ----------  ----MSFLIR
       Consensus   M-R-N-T-VT  EFILLGLTD-  PELQ-LLF-L  FLAIYLITVA  GNLGMI-LIR


                                          TM2
                      51                                                     100
list1.msf{orf-8}   ANARLHTPMY  FFLSHLSFLD  LCFSSNVTPK  MLEIFLSEKK  SISYPACLVQ
list1.msf{orf-9}   ANAWLHMPMY  FFLSHLSFVD  LCFSSNVTPK  MLEIFLSEKK  SISYPACLVQ
list1.msf{orf-7}   PTPRLHTPMY  FFLSNLSFVD  LCFSSNVTPR  MLEIFLSEKK  SISYPARLVQ
list1.msf{orf-2}   TNSHLQTPMY  FFLGHLSFVD  ICYSSNVTPN  MLHNFLSEQK  TISYAGCFTQ
list1.msf{orf-4}   TNSQLQTPMY  FFLGHLSFLD  ICYSSNVTXN  MLHNFLSEQK  TISYAGCFTQ
list1.msf{orf-5}   LDSRLHTPMY  FFLTNLAFVD  LCYTSNATPQ  MSTNIVSE.K  TISFAGCFTQ
list1.msf{orf-6}   IDSRLHTPMY  FFLASLSCLD  LYYSTNVTPK  MLVNFFSDKK  AISYAACLVQ
list1.msf{orf-10}  VDSRLHTPM-  ----------  ----------  ----------  ----------
list1.msf{orf-3}   SDSTLHTPMY  FFLSHLSFVD  LCYTTNVTPQ  MLVNFLSKRK  TISFIGCFIQ
list1.msf{orf-1}   SDSTLHTPMC  LFLSHLSFVD  LYYATNATPP  MLVNFFPRE  KPFPLLVALS
       Consensus   -DSRLHTPMY  FFLSHLSFVD  LCYSSNVTP-  ML-NFLSEKK  TISYA-C-VQ


                          TM3                             TM4
                      101                                                    150
list1.msf{orf-8}   CYLYIILVHV  EIYILAVMAF  D---------  ----------  ----------
list1.msf{orf-9}   CYLFIALVHV  EIYILAVMAF  DRYMAICNPL  LYGSRMSKSV  CSFLITVPYV
list1.msf{orf-7}   CYLFITLVHV  ELYILAVMAF  DRYMAICNPL  LYGSRMSKSV  CSFLITVLYV
list1.msf{orf-2}   CLLFIALVIT  EFYFLASMAL  DRYVAICSPL  HYSSRMSKNI  CISLVTVPYM
list1.msf{orf-4}   CLLFIALVIT  EFYFLASMAL  DRYVAICSPX  HYSSRMSKNI  CISLVTVPYM
list1.msf{orf-5}   CYIFIALLLT  EFYMLAAMAY  DRYVAIYDPL  RYSVKTSRRV  CICLATFPYV
list1.msf{orf-6}   CYFFIAVVIT  EYYMLAVMAY  DRYVAICNPL  LYSSKMSKGL  CIRLIAGPYV
list1.msf{orf-10}  ----------  ----------  ----------  ----------  ----------
list1.msf{orf-3}   FHFFIALVIT  DYYMLTVMAY  DRYMAICKPL  LYGSKMTRQV  CLCLAAAPYI
list1.msf{orf-1}   NFTFSLHW--  ----------  ----------  ----------  ----------
       Consensus   CYLFIALVIT  E-Y-LAVMA-  DRYVAIC-PL  LYSSRMSK-V  CI-L-TVPYV


                          TM4                                         TM5
                      151                                                    200
list1.msf{orf-8}   ----------  ---------  ----------  ----------  ----------
list1.msf{orf-9}   YGALTGLMET  MWTYNLAFCG  PNEINHFYCA  DPPLIKLACS  DTYNKELSMF
list1.msf{orf-7}   YGALTGLMET  MWTYNLAFCG  PSEINHFYCV  DPPLIKLACS  DTYNKEVSMF
list1.msf{orf-2}   YGFLNGLSQT  LLTFHLSFCG  SLEINHFYCA  DPPLIMLACS  DTRVKKMAMF
list1.msf{orf-4}   YGXLNGLSQT  LLTFHLSFCG  SLEINHFYCA  DPPLIMLACS  DTRVKKMAMF
list1.msf{orf-5}   YGFSDGLFQA  ILTFRLTFCR  SNVINHFYCA  DPPLIKLSCS  DTYVKEHAMF
list1.msf{orf-6}   YGFLSGLMET  MWTYHLTFCG  SNIINHFYCA  DPPLIRLSCS  DTFIKETSMF
list1.msf{orf-10}  ----------  ---------  ----------  ----------  ----------
list1.msf{orf-3}   YGFANGLSTD  HPDASSVLLW  TQ--------  ----------  ----------
list1.msf{orf-1}   ----------  ---------  ----------  ----------  ----------
       Consensus   YGFL-GL--T  --T--L-FCG  S-EINHFYCA  DPPLI-LACS  DT--KE--MF
```

# FIGURE 1 (continued)

```
                          TM5                                           TM6
                       201                                                    250
list1.msf{orf-8}    ----------  -----------  -----------  ------------  -----------
list1.msf{orf-9}    IVAGWNLSFS  LFIICISYLY   IFPAILKIRS   TEGRQKAFST    CGSHLTAVTI
list1.msf{orf-7}    VVAGFNFTYP  LLIILISYLY   IFPATLRICS   TEGRHKAFST    CGSHLTAVTI
list1.msf{orf-2}    VVAGFTLSSS  LFIILLSYLF   IFAAIFRIRS   AEGRHKAFST    CASHLTIVTL
list1.msf{orf-4}    VVAGFTLSSS  LFIILLSYLF   IFAAIFRIRS   AEGRHKAFST    CASHLTIVTL
list1.msf{orf-5}    ISAGFNLSSS  LTIVLVSYAF   ILAAILRIKS   AEGRHKAFST    CGSHMMAVTL
list1.msf{orf-6}    VVA-------  ----------   ----------   -----------   -----------
list1.msf{orf-10}   ----------  ----------   ----------   -----------   -----------
list1.msf{orf-3}    ----------  ----------   ----------   -----------   -----------
list1.msf{orf-1}    ----------  ----------   ----------   -----------   -----------
       Consensus    VVAGF-LS-S  L-IIL-SYL-   IF-AI-RI-S   -EGRHKAFST    C-SHLT-VT-


                          TM6                                TM7
                       251                                                    300
list1.msf{orf-8}    ----------  ----------   --------   -----------   --------
list1.msf{orf-9}    FYATLFFMYL  RPPSKESVEQ   GKMVAVFYTT   VIPMLNLIIY   SLRNKNVKEA
list1.msf{orf-7}    FYSALFFMYL  RRPSEESMEQ   GKMVAVFYTT   VIPMLNPMIY   SLRNKDVKEA
list1.msf{orf-2}    FYGTLFCMYV  RPPSEKSVEE   SKITAVFYTF   LTPMLNPLIY   SLRNTDVILA
list1.msf{orf-4}    FYGTLFCMYV  RPPSEKSVEE   SKIIAVFYTF   LSPMLNPLIY   SLRNRDVILA
list1.msf{orf-5}    FYGTLFCMYI  RPPTDKTVEE   SKIIAVFYTF   VSPVLNPLIY   SLRNKDVKQA
list1.msf{orf-6}    ----------  ----------   --------   -----------   --------
list1.msf{orf-10}   ----------  ----------   --------   -----------   --------
list1.msf{orf-3}    ----------  ----------   --------   -----------   --------
list1.msf{orf-1}    ----------  ----------   --------   -----------   --------
       Consensus    FY-TLF-MY-  RPPS--SVE-   -K--AVFYT-   --PMLNP-IY   SLRN-DV--A


                       301          315
list1.msf{orf-8}    ----------   -----
list1.msf{orf-9}    LIKELSMKIY   FS---
list1.msf{orf-7}    LCKELFKRKL   FSK--
list1.msf{orf-2}    MQQMIRGKSF   HKIAV
list1.msf{orf-4}    IQQMIRGKSF   CKIAV
list1.msf{orf-5}    LKNVLR----   -----
list1.msf{orf-6}    ----------   -----
list1.msf{orf-10}   ----------   -----
list1.msf{orf-3}    ----------   -----
list1.msf{orf-1}    ----------   -----
       Consensus    ----------   -----
```

<110> Genset SA

<120> Genes encoding olfactory receptors and biallelic markers thereof.

<150> US 60/104,299
<151> 1999-10-13

<160> 27

<170> Patent.pm


<210> 1
<211> 144460
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> 2406..2600
<223> open reading frame 1

<220>
<221> CDS
<222> 9711..10658
<223> open reading frame 2

<220>
<221> CDS
<222> 24851..25369
<223> open reading frame 3

<220>
<221> CDS
<222> 45714..46661
<223> open reading frame 4

<220>
<221> CDS
<222> 80198..81115
<223> open reading frame 5

<220>
<221> CDS
<222> 96291..96902
<223> open reading frame 6

<220>
<221> CDS
<222> 110758..111564
<223> open reading frame 7

<220>
<221> CDS
<222> 122525..122887
<223> open reading frame 8

<220>
<221> CDS
<222> 132454..133389
<223> open reading frame 9

<220>

```
<221> CDS
<222> 143398..143577
<223> open reading frame 10

<220>
<221> misc_feature
<222> 113644..114063
<223> ubiquitin 1 pseudogene complement

<220>
<221> misc_feature
<222> 127489..127854
<223> ubiquitin 2 pseudogene complement

<220>
<221> allele
<222> 7521
<223> 99-13670-305 : polymorphic base G or T

<220>
<221> allele
<222> 8192
<223> 99-13669-471 : polymorphic base G or T

<220>
<221> allele
<222> 14483
<223> 99-13666-275 : polymorphic base A or T

<220>
<221> allele
<222> 19625
<223> 99-13664-221 : polymorphic base C or T

<220>
<221> allele
<222> 20583
<223> 99-13663-218 : polymorphic base A or G

<220>
<221> allele
<222> 76947
<223> 99-13660-277 : polymorphic base A or C

<220>
<221> allele
<222> 91088
<223> 99-13652-407 : polymorphic base G or C

<220>
<221> allele
<222> 91138
<223> 99-13652-357 : polymorphic base A or G

<220>
<221> allele
<222> 91187
<223> 99-13652-308 : polymorphic base A or G

<220>
<221> allele
<222> 133998
<223> 99-13671-396 : polymorphic base A or G
```

```
<220>
<221> allele
<222> 140066
<223> 99-13649-286 : polymorphic base C or T

<220>
<221> allele
<222> 141176
<223> 99-13648-259 : polymorphic base A or G

<220>
<221> allele
<222> 144033
<223> 99-13647-278 : polymorphic base A or G

<220>
<221> primer_bind
<222> 7362..7380
<223> 99-13670.rp

<220>
<221> primer_bind
<222> 7805..7824
<223> 99-13670.pu complement

<220>
<221> primer_bind
<222> 8120..8140
<223> 99-13669.rp

<220>
<221> primer_bind
<222> 8643..8662
<223> 99-13669.pu complement

<220>
<221> primer_bind
<222> 14308..14328
<223> 99-13666.rp

<220>
<221> primer_bind
<222> 14740..14757
<223> 99-13666.pu complement

<220>
<221> primer_bind
<222> 19346..19366
<223> 99-13664.rp

<220>
<221> primer_bind
<222> 19826..19845
<223> 99-13664.pu complement

<220>
<221> primer_bind
<222> 20298..20318
<223> 99-13663.rp

<220>
<221> primer_bind
```

```
<222> 20781..20800
<223> 99-13663.pu complement

<220>
<221> primer_bind
<222> 76752..76772
<223> 99-13660.rp

<220>
<221> primer_bind
<222> 77205..77223
<223> 99-13660.pu complement

<220>
<221> primer_bind
<222> 90967..90987
<223> 99-13652.rp

<220>
<221> primer_bind
<222> 91474..91494
<223> 99-13652.pu complement

<220>
<221> primer_bind
<222> 133925..133945
<223> 99-13671.rp

<220>
<221> primer_bind
<222> 134375..134393
<223> 99-13671.pu complement

<220>
<221> primer_bind
<222> 139807..139826
<223> 99-13649.rp

<220>
<221> primer_bind
<222> 140331..140351
<223> 99-13649.pu complement

<220>
<221> primer_bind
<222> 140912..140932
<223> 99-13648.rp

<220>
<221> primer_bind
<222> 141416..141434
<223> 99-13648.pu complement

<220>
<221> primer_bind
<222> 143828..143847
<223> 99-13647.rp

<220>
<221> primer_bind
<222> 144292..144309
<223> 99-13647.pu complement
```

```
<220>
<221> misc_binding
<222> 7498..7544
<223> 99-13670-305.probe

<220>
<221> misc_binding
<222> 8169..8215
<223> 99-13669-471.probe

<220>
<221> misc_binding
<222> 14460..14506
<223> 99-13666-275.probe

<220>
<221> misc_binding
<222> 19602..19648
<223> 99-13664-221.probe

<220>
<221> misc_binding
<222> 20560..20606
<223> 99-13663-218.probe

<220>
<221> misc_binding
<222> 76924..76970
<223> 99-13660-277.probe

<220>
<221> misc_binding
<222> 91065..91111
<223> 99-13652-407.probe

<220>
<221> misc_binding
<222> 91115..91161
<223> 99-13652-357.probe

<220>
<221> misc_binding
<222> 91164..91210
<223> 99-13652-308.probe

<220>
<221> misc_binding
<222> 133975..134021
<223> 99-13671-396.probe

<220>
<221> misc_binding
<222> 140043..140089
<223> 99-13649-286.probe

<220>
<221> misc_binding
<222> 141153..141199
<223> 99-13648-259.probe

<220>
<221> misc_binding
<222> 144010..144056
```

```
<223> 99-13647-278.probe

<220>
<221> primer_bind
<222> 7502..7520
<223> 99-13670-305.mis

<220>
<221> primer_bind
<222> 7522..7540
<223> 99-13670-305.mis complement

<220>
<221> primer_bind
<222> 8173..8191
<223> 99-13669-471.mis

<220>
<221> primer_bind
<222> 8193..8211
<223> 99-13669-471.mis complement

<220>
<221> primer_bind
<222> 14464..14482
<223> 99-13666-275.mis

<220>
<221> primer_bind
<222> 14484..14502
<223> 99-13666-275.mis complement

<220>
<221> primer_bind
<222> 19606..19624
<223> 99-13664-221.mis

<220>
<221> primer_bind
<222> 19626..19644
<223> 99-13664-221.mis complement

<220>
<221> primer_bind
<222> 20564..20582
<223> 99-13663-218.mis

<220>
<221> primer_bind
<222> 20584..20602
<223> 99-13663-218.mis complement

<220>
<221> primer_bind
<222> 76928..76946
<223> 99-13660-277.mis

<220>
<221> primer_bind
<222> 76948..76966
<223> 99-13660-277.mis complement

<220>
```

```
<221> primer_bind
<222> 91069..91087
<223> 99-13652-407.mis

<220>
<221> primer_bind
<222> 91089..91107
<223> 99-13652-407.mis complement

<220>
<221> primer_bind
<222> 91119..91137
<223> 99-13652-357.mis

<220>
<221> primer_bind
<222> 91139..91157
<223> 99-13652-357.mis complement

<220>
<221> primer_bind
<222> 91168..91186
<223> 99-13652-308.mis

<220>
<221> primer_bind
<222> 91188..91206
<223> 99-13652-308.mis complement

<220>
<221> primer_bind
<222> 133979..133997
<223> 99-13671-396.mis

<220>
<221> primer_bind
<222> 133999..134017
<223> 99-13671-396.mis complement

<220>
<221> primer_bind
<222> 140047..140065
<223> 99-13649-286.mis

<220>
<221> primer_bind
<222> 140067..140085
<223> 99-13649-286.mis complement

<220>
<221> primer_bind
<222> 141157..141175
<223> 99-13648-259.mis

<220>
<221> primer_bind
<222> 141177..141195
<223> 99-13648-259.mis complement

<220>
<221> primer_bind
<222> 144014..144032
<223> 99-13647-278.mis
```

<220>
<221> primer_bind
<222> 144034..144052
<223> 99-13647-278.mis complement


<400> 1
```
caattaaagt tttgttcact ataagtcttt tttggaaaag agagagaaac attcaaatta      60
tttacatacc agtttccatt agcatgtgaa gaacaaacag aaacactttt cagggtgaac     120
aaaattcctg ctacagttat aaaatcctgc atatactctt tactttgtga ttctgaaaaa     180
caccgttcta cctggtttat tgaaatgtgt gaaagctcta atgcaatgtt attttttaca     240
ttttgtaaca cttaagtcat aaagccaagc tattctcaaa ccttgatgaa acatgttgga     300
agaaattatg ttttagtgtt tggtgaaaac attatgtttc gtcacttaag gtgataaatt     360
gtactcatta aagaactttg aaagttcaca catagccaat ggtttaaaat gcactaattt     420
agattcccaa ttctcacaaa ggccagttac tctggaccat tcaatcgcca aagaggaaaa     480
ctgggggcat tcccatcccg ggatatggga agtccccgag cttccagcct ggtccttgtg     540
gccgaaaaat ggcatgtttt gcttttgctt ttggatcctg ttcgtgccgc caaaaatgtt     600
ctgtgtgggg aaagtgcgag gggagagaaa agacacggac atgatacgtt taagggtaaa     660
caacgtttat cccatgtaag tggccatgca gatatagtaa gcaaatgata taataataag     720
caaatgatat aataagcaga ttgatataat aagtagattg caatggaacg gggaaaaggg     780
aaaatacatc tacattcacc agactatgga ggattcaaca acagactggg acgcaacagc     840
ctgggctcca gagtcagata ggtaggcaaa gagatcctag ttctatacag atacgtacca     900
tggagcagtt ccactttcct aagcacattc agttgtgata aaaatagatg agtttcaagg     960
gctgatacat tacatgccac actcaaagtt gtgttgttaa acaatttcaa ttgttgttac    1020
aatttcaaat aaaagcaatg tttacaacca tgggttcaag agaagtctaa gtgaacacat    1080
ataataaaga cttgcaaaat aataaaagat aaggctcttt aactatcaaa agacttgcag    1140
aaaagaacca cagaaaacca tttttaaatat aactgccttc gtatgtaaga aattctacat    1200
tatttttgat gttaaaacat caatctcatg cttactaggc tatttcttaa tgacacatgt    1260
atttacaaat ttgagagaag aggaagaaat atcaggtgac accactgggt taatgcataa    1320
atgacaaacc taaatgcatt ttaatttcct tttctttaaa tcgagctgag cttcagcccc    1380
ttctttttgt ggtgttctta gtcatctacc ttatcacagt aatcacaatg taagcatgat    1440
cttctttttt ttttttaagt gcacaatatt tttaactgtt aacaatatac ctattgttac    1500
ctatgggcac aatgatatac agcatatctc tagaatttat tcttgcaaaa ctataacttt    1560
atacctgctg aacagcaaca ccccatttct cccttttcctc cagccgctgc aaccaccttc    1620
tattctctgt ttctatgagt ttgactattt tggattcctc atataaattt aatcatgcag    1680
tatttgtcct tccgtgcctg gcttatttca cttaacataa tgtcctccag gttcatcata    1740
tgacaggatt tcttcttttt cttaatgatg aataatattc cattacatgt gtgtactaca  ·1800
ttttcttcat ctttcaatgg acatttaggt tgtttctata tctggactat tgtaaataat    1860
ggtgcaatga acataagagt acctatgtct cttcaagagc ttgatttaaa ttcttttgga    1920
tatatgccca gaagtgcaat tgctggttta tatgataatt cgatttttaa ttatttgaag    1980
actcatcata ctgttttta tagtggctgc acaattttat attcccacca atgttgtaca    2040
agggttccaa tttcttcata tgtcaccaat atttgttgtc ttttggattt ttttaaaata    2100
aagtaacagc catcataaca aatgtgatat catgcttttg tttcatatgc attttcctga    2160
tgattagtgt gttgagcacc ttttcatttt tatttattta tttatttata ctctaagttc    2220
tgggatacat ctgcagaaca cgcaggtttg ttacataggt atacatgtgc catggtggtt    2280
tgctgcgccc attaacctgt catctacatt aggtatttct gctaatacta tcccctcccc    2340
agcccccgac cccctgacag gtcctggtgt gtgatgtttc ccttcctgtg tccatgtgtg    2400
tgagcatgag cttcttaata agaagtgatt caacactaca cactccaatg tgcttgttcc    2460
tcagtcatct ctcctttgta gatctctatt atgccaccaa tgccactcct ccgatgctgg    2520
ttaactttt tttccaaga gaaaaaccgt ttcctttatt ggttgcttta tccaatttca    2580
ccttttcatt gcactggtga tcacagatta tcatatgctc acagtgatgg tgtatgacca    2640
ctacatggcc atctgcaagc ctttgttata tggaagcaaa atgtccaggt gtgtctgcct    2700
ctgtctcact gctgctccct atatttatgg ctctgcaaat ggtctggtac aggtcatcct    2760
gatgctttgt ctgttcttct gtgaacccaa tgagatcaac cactttttt ttttttggag    2820
aaaatgcatt atatgcacat ttaattccac tataaatttt tgaatggacg gttggagagg    2880
aagggagaaa tacatattaa cggagagaat accacccaga aagtatatac aatgggagaa    2940
aggaacctgt tgatccaagt ttccatattc ttattatggc atataaggtc atgattattt    3000
tctcagtatg aagcatctcc cagggctgac tctgatgtaa aattggagat caaccacttt    3060
tattatgcag aaccacccct cttagtcctc gcctgcttgg atacttatgt caaagaaact    3120
gccatgttca tggtggctgg ttccaacctc atctgccctc tcactatcat ctttatttcc    3180
tacactttca tcttcacaga cattctgcat atctgcactg ctgagggaag gtacaatgcc    3240
ttctccacct gcgggtccct tgtgactgcc gtcactgtct ttcaaggaac gctgtttcac    3300
atgtgcctga ggccccttc tgaggcatct gtagaacagg ggaaaattgt agctgctttt    3360
```

9

```
tatatctttg tgagtcctac gttaaaccca ttgatctacc gtctgaggaa taaaaatgtt   3420
aaaagaacaa taagggaagt tatccaaaag aaactgtttg ctaagtaagg tagatatttt   3480
agttgcaggt tatgtaatac attattttta tcttaccaat taacgagcat tataaattaa   3540
caaatcactt tctgtcattg agtgtttttt gtcttttgta acttgcatat gggaattgaa   3600
agtgtatacc aaattattag ctagagttga cagtgtcatc tcagtgaatt taagaagaaa   3660
tcatagaaat ttaaatagaa gacttatggc atgtaaaagt caataaagaa cagtgattcc   3720
ttctttagta ctcatattgg tagcaaacga taaaagacag aatgcaatgg aaattacagt   3780
tcattacatt tttatagtac ttaataactt ccaaactatt ttctagacac cttttcaaaca   3840
tagtatatga agttttctcc tttcttttat acagataatg caacaataaa gatcactgat   3900
gtagggaaaa gagagatcag actgttactg tgtctatgta gaaaggaag gcataagaaa   3960
cttcattttg acttgtaccc tgaacaattg ttttgtcctg agatgctgtt aatctgtaac   4020
tttgccccaa ccttgagctt ataaaaacat gtgttgtatg gaatcaaggt ttaagggatc   4080
tagggctgtg caggatgtgc cttgttagca gaatgtatac aggcagtatg cttggtaaaa   4140
gtcatcgcca ttctccagtc tccataaacc aggggcacaa tgcactgtgg aaagtcacag   4200
ggacctctgc cctggaaagc cgggtattgc caaggtttct ccccatgtga tagtctgaaa   4260
tatggcctcg tgggatggga aagacctgac cggcccccag cctgacaccc gtgaagggtc   4320
tgtgctcggg aggattagta aaagaggatg gcctcttata gctgagataa gaggaaggcc   4380
tctgtctcct gcctgcccct gggaactgaa tgtctcggta taaaacctga ttgcaccttt   4440
cttctattct gagataggag aaaaaccgcc ctgtggcggg aggcgagaca tgttggcagc   4500
aatgctgctt tgttattctt tactccactg agatgtttgg gtggagagaa ggaaaaatct   4560
ggcttacgtg cacatccagg catagtacct cccccttgaac ttatttgtga cacagattcc   4620
tttgctcaca tgtttttcttg ctgaccttct..ccctattatc accctgttct cctaccacat   4680
tcctcttgct gagatagtga aaatagtaat caataaaaac tgagggatct cagagaccgg   4740
tgccgatgca ggtcttccat atgctgagcg ccagtcccct ggggccactg ttctttctct   4800
atactttgtc tctgtgtctt atttcttttc tcagtctctc atcccacctg acgagatata   4860
cccacaggtg cagagggca ggccacccct tcaattgaag tatatctcag aatactactt   4920
tgagatacag tcttagaatt atattttgag ccaatgaaat cttctttctt gaagctttg   4980
aagcaatgcc aaatttccgt tagtaggctt tataaatatc attgtttgca ttaccaggag   5040
gcattcacat caatatgtga cctcacttct ccactctttc attgccattg aagcagatac   5100
tttcaagtat gtcttaatat attgatttttt atcttctcat tgggggaaca tgggaagtgt   5160
cacatgtggg actacaccgt aatttgggta tttgtagtct taaggttttc atgaagcttc   5220
gtgtgggcct ccatttctct agaacgattt gatgtgttcg ttttttatcc ttcacagcaa   5280
cacatgctta ggcagatgaa tcactgcagc agcatttaga cacatttgtg attcagggat   5340
agatagctct tcagtaggat ggtgtgaatt ttgggataat ggcacatact aaaacagaa   5400
ctaccttttg acccagcaat cccattactg ggtatataca ccaaggaata taaatcattc   5460
caccataaag acacatgcat gtgtatgttc atcacaacag tattcacaat agcaaagaca   5520
tggaatcaac ctaaatgccc ttcaacagta gattggatac aaaaaaatgt ggtatatata   5580
catcatggaa tgctatgcag ccgtaaaaaa aaagaatgag attatgtctt ttgtagcaac   5640
acggatgaag ctggaggaca atatccaaag caaaccaatg caggaacagg aaaccaaatg   5700
ctgcaagttc tcacttacat gtggaagcta aacattgaat acacatggac acaaaaaagg   5760
gaacaacagg caccaggacc tacttgaggg tgaagtgtgg gaggagggta aggattgaaa   5820
ctctgcctat caggcactgt gcttatcaac tgggtgatga ataacctgt acaccaaaac   5880
cctgtgacat ggaatttacc tttataacaa agctgcacat ggaccctga acctaaaata   5940
aaagttaaaa aagaaatct gtcccaagga gactgttttc tcttaatgtg ctgcatcctg   6000
cttaatgaac tatggatttc atgcattctt tttcaagatt atattgccta cctgattgta   6060
gacagtttga tgcattttac atagtatcag ttaaacatta aacataatta agagcatttg   6120
gcttcaaaat aatagtaaat gggtagaatt tattatggtt atagtactac tcatacaaat   6180
aataatacaa catcagtgat gtagtgtcta gtgagcatga cactattata gaacacttct   6240
taggctggat tttgataata atagcatgct ataactttg aataaaaata gtaaattgaa   6300
taatcacaaa caagtaaaaa tctaaagggc cagtagtatg tattcaacta gcttaccagt   6360
gtatcatttg tgtagctaaa tccattcgct gtccctctag cagacacaca tgctagttat   6420
tgcagtggaa gaaaaatgaa atgaactaag gaattaatgt ctttgagtaa tataaacaga   6480
gccttctgga ggttttctat gaaaaataac ataagtatgt gtaaaactct tctttgagta   6540
agtatcatac acatagctaa attctgtatt ttctattcat tgctgtataa ataaattaac   6600
attgccttct ttcgtgtgga catctgatca tgtgattcca tacttaaaat tacatatact   6660
ttgctctttc taaatgaaaa tagcccattc atctatactt ttcatctaac cattcagtta   6720
ttatagggct agttttattt ttgtcagaaa attcactttg taaatcttat gttttattat   6780
gtagccattg tataccaaca tataaaagaa aatacataca tacatacaca catacattag   6840
ggaatttttt cttcaaagtg aaagcagtct acttaaaaat tatccaaatc ttcaacattt   6900
ttatgcaaaa caaggtacct ctacattaag ggaggaggaa atgagggaca ccagtttat   6960
aatcttatga tacccttatat tccatcttaa tttttttttt tgagatgaag tctcgctctg   7020
tcacccaggc tgaggtgcag tggtgtaatt ttggctcatt gcaacctctg cctcctgggt   7080
tcaagcaatt ctccctgcct cagcctcctg agtagctggg attacaggca cgcaccacca   7140
```

```
aacctggcta agttttgtat ttttagtaga gacagggttt cgccatgttg gccaggctgg   7200
cctcaaactc ttgacctcag gtgatctagc ggccttggcc tcccaaagtg ctgggattat   7260
aggcaagagc caccgtgccc ggcttccaaa atatttaagc aatattattg cattttacaa   7320
ttttagtaat gcaaggaacc aaaataaaac agaataattg agatagagaa gactttacac   7380
atcaatttga aataaacata taggaatgcc ctatattctc aaatttcatg ggatgtaaca   7440
aatctacatt ttgattttga tatatagcta tattttatta aatgatttct cagagtataa   7500
cccaccaccc gcaactctaa kaaaattagg gatgattctc cgtcttggtc agactgtact   7560
ttgatccatt tgtgctaacc tggaactata tgtgcactgg aagatacaga ctaatgaacg   7620
catctctagg tccctttgtc ctccaacaaa tacagtgcta cacaattttc aaatattctc   7680
attctatttg caattccctt tctaaatcaa caattttatg catcatcaat tttataaata   7740
gccctggttc tgagaccttt gatgattagc atgttaatat taaccttgat agtgcagact   7800
agttccaaaa taaatccata acgcccgtcc tccaaaggat cctgggccct gaccaatact   7860
tctgcctcct tctactgatt atgccactct tctgctctca cagtctttga aatctttcat   7920
cttctcaaat gtctcacctg ccacaacttc ctacccctca ctcattagat gacctcactg   7980
cagtgtttat aggcaaaagc tgaagagttc tgatgagaat tccttgtttt catcatacta   8040
aaaaggcaga agttatctac ccatgttttc ctcttccatg ttattgaaag ggatggctaa   8100
tttctctgtt tgtactaagg atctcatgca cacttgtacc gaaactctac ataaatgtaa   8160
aataggaatt ttatcctcgc aggagagtct akctccagga agcatcaaat gaaggttatg   8220
ctcttgagga acaaagcata ttttaattgg ctctttagaa ttagtttaaa aatactctag   8280
ggaagatacc taataaatat attgtaaatc ttgctacctt gttttcataa gatatggtcc   8340
attaacatta acaggtaggt cattttctac atttgttcac taaaaataca atttgtgtgt   8400
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtagag ataagtattc catcaatggg   8460
gaaaacaaat attttctcca atttcactag acttttctat ccatatgtta gtattgcatt   8520
gactctctac aatcaattat atgtaagctc ttttgatgta tacatgagaa ctaaataaac   8580
aatggcttta aggtggaatt tttggagtag aaatttttac aatcttatgt tactttcaaa   8640
gagaactgag agggagtggc ttgagttgga agctaagacc ccttttaaaa attatctgtg   8700
catacctaaa caatattgtc atgagtgggt tagtggcaca aaaatgggaa caaaaaaaat   8760
ccacactttc cccaaatagt agaattgcat atctgctgtt taaatgctgc attcctagaa   8820
agatcttctt tgagtggtca tctaaaagca tcctacattc atgttttctt cacagaaaag   8880
tggtttgcct gaaattgtat gtaacttttt ctgtgtgttt aatctctgtt ccctctatta   8940
taatgtgtgc tctgctccct ctattataat gtgtgctccc tgagctggga gacttgttta   9000
ctgtagtaac cgcaggaatt ggaacagaaa gaaatgaagc tatacagtat acatgagtaa   9060
acaggcagtg acattacaaa gtggaaaaaa acaagtcttc attttgtacc ctcttagcca   9120
tatatcagat agaaattaat ttctctagtt taatcgttcc tgaataaagg taaggcacac   9180
aactatgggt cttaattgaa aatgctttgc ttttctttct tcattttgta tctgaaacaa   9240
tacaatatca gagctggagg tataataaag atcagacttc ctttatttat ccatttgaaa   9300
gatgcaaata acctagggtt tttgtattta attttcattc ctttggattt tttgtttcct   9360
cacgaagttt gaataaaatt accaaatgtg gagtacacca agaagacagg tataaatgta   9420
ggaatgaata aacttatgta tgtatacatg tatggcagag agaaatagag aatatgtatg   9480
tttgtgtaag ttatgtgggt ttgatgtata gaaagataca gattaaaaca gacatatagg   9540
gagacaatgt tatgtaaaat ttccgatgtg attattgaaa caagagaagt aattgtcacc   9600
tagataaata gatgaatgag cgaatgataa atggatgaaa caaatgccaa atctgaatca   9660
gagagaaatc ctcacattct ttgtcacttt cagtttcaag agataagaag atgttctccc   9720
caaaccacac catagtgaca gaattcattc tcttgggact gacagacgac ccagtgctag   9780
agaagatcct gtttggggta ttccttgcga tctacctaat cacactggca ggcaacctgt   9840
gcatgatcct gctgatcagg accaattccc acctgcaaac acccatgtat ttcttccttg   9900
gccacctctc ctttgtagac atttgctatt cttccaatgt tactccaaat atgctgcaca   9960
atttcctctc agaacagaag accatctcct acgctggatg cttcacacag tgtcttctct  10020
tcatcgccct agtgatcact gagtttttact tccttgcttc aatggcattg gatcgctatg  10080
tagccatttg cagccctta cattacagtt ccaggatgtc caagaacatt tgcatctctc  10140
tggtcactgt gccttacatg tatggcttcc ttaatgggct ctctcagaca ctgctgacct  10200
ttcacttatc cttctgtggc tcccttgaaa tcaatcattt ctactgcgct gatcctcctc  10260
ttatcatgct ggcctgctct gacacccgtg tcaaaaagat ggcaatgttt gtagttgcag  10320
gctttactct ctcaagctct ctcttcatca ttcttctgtc ctatctttc attttttgcag  10380
cgatcttcag gatccgttct gctgaaggca ggcacaaagc ctttttctacg tgtgcttccc  10440
acctgacaat agtcacttg tttttatggaa ccctcttctg catgtacgta aggcctccat  10500
cagagaagtc tgtagaggag tccaaaataa ctgcagtctt ttatactttt ttgaccccaa  10560
tgctgaaccc attgatctat agcctacgga acacagatgt aatccttgcc atgcaacaaa  10620
tgattagggg aaaatccttt cataaaattg cagtttaggc ttgtgtttat ttgcagtcac  10680
gaattgcttg tggagtaaca aactggcttt tgaaatggaa aaacctagtg tagtcgtgat  10740
ttatttaaca tcatggactg tcagtaacca ctttacttttc ttatccaaat gaaaaccttg  10800
aagattgatt tcttagaaat aaaagcctta atgttgagaa atttaaaatg ttttatttgt  10860
cagaaattct atgaaaataa attttttagt atctaataat tctatatgaa aatactatgt  10920
```

```
ttacttactt ggggggtggg taaattttta actaacttag cctgagagaa attctgaaaa 10980
ttcatctcct ttgaatatga tggtccacag agccataatg aggttcaaga tagggtggat 11040
aattttacac ttttttaaaaa atgaaattat ttctacttca atatggtgtc ttgaacaata 11100
gctcagctac ctttgtgctt attgtaatca atgtgcaaaa aatataaata tatgggtcac 11160
tgatacgtta aatttgctgt aagtgttccc caaacccatc ttgtaaatat cttgagaagc 11220
ttcttttttg ttcatgtgat aatactggtt atcgtccttg attctgaaaa tcaactctca 11280
acaccttttt atgagtttcc aagtgtatgg atccaattct atcatcaaac tactttaact 11340
gcattccagt tatgttttcc agtgccgtac ctctgactta ggactaattc agtaggagtc 11400
aatagggtct attaactgcc ctgtgcatac ccataaatgt cttgaaacag tatacaaata 11460
aatagggggtg tatatatgtt tctggaggaa atactcagtg tttattttgc ttcatgaagc 11520
tttctgtggc ccattatttt taaaataagg gtgttctagt agttcttgaa gctgctatag 11580
agaaaatcaa tctcagagag gctacctaag gagacacatt aatccatgca ttattagtca 11640
accagatgac tgcatattga tacatatgta tttagcccta ataaattgcc tcatatgttt 11700
ggcattttaa tattttgcac tctgatatta actaacacca tacagaatat gctacagaaa 11760
atgtctgtat gatatcaact actatatcta ctataaagtg ttcaaatggt tttccagaat 11820
attaagcaga tgacttgcag tttttgtaaa atgggggcat attcttgagt ctcatttgat 11880
taagtctggt tctagccaaa tcctctttca gaaacagtat ctgaaaaaga aggaaggcaa 11940
atttcggtga caagaattta acaattacat tttagcactg tttgtttttg tatttgcttg 12000
gttttggcaa tgatggtggg acaacagagg aaggtcatct gcagagacaa caatgaagca 12060
gaaaagctgg gaattgagtg acacagagtc ctcacttcct ttttgagggc cagcatcatt 12120
tcatcggtgg ggtatttctt tattttatga gaaatttcca tctattaggc aaagcattgt 12180
attccatttc tggcaagcag aatggtctca tatccagatt tgaaacccta tttgaaaatt 12240
ggattttaga atgagtgcaa aaaatactct atatttggcc taaataactg tacgattcca 12300
tttattttct agttatgaga attgctctgg cttgcagcaa ccattttaa actttgacat 12360
ccttttagtc aaaatgactg acctgtttct aattgatttt taataaaata ttttatttat 12420
ttctatttgt gatttaattt tttccttctg catgtctttg ggtaaaagtc acctcagaaa 12480
ttctttggag ataggataga acataaatcg acatgaataa aagtaattat aagagttgca 12540
gtcacagtgt agtgctgatt ttaggaacac tttattttaa tcttcataaa tgaaataatg 12600
agagaattat tatctccatt tacaacattg gagcctgagg cacggagaga ttaaatttct 12660
tgcccaaagt catttggcca ctcagtagga caaaagcagg tttcttggtt tcaaattctc 12720
tctctttcta attcatactg tagttgttat taaagaaatt ctcaaaacac tgcaaatgct 12780
tggtggaatg ttggagatta tgaattgatg agattattgc tatagatgaa atagtggtta 12840
ttatgtgata gttatatgta tcctaagaat agctaatgag aatttccctt gaaaattccg 12900
gttaacataa tttataggca ttataattaa aattgtctta acgtccatgt gaagggagaa 12960
aattttgata tacagaagac atatatgcta tttaggctgc attttattaa tatattttcc 13020
cagtcgcaaa ggcatacata ttcatattaa ttaattacca ggtacagaca aatatgaggg 13080
agtaaaattt atgagggatc tgtcctgtga caaaggatac attttcttta tattttgtta 13140
catttcttct caataagttt atatgcgtac atgttactaa aatgcatcaa gcaaatgtga 13200
aatcacttat catatacaaa tttgaacact gattttcact tgatataatg tatgcacctt 13260
tatatagatt aaatatttct gatgaacatc atgttgaatg tcatataata gttagatcat 13320
atgaccttaa tacaataata atacatatca attgtagaaa actgactgaa ccatattgac 13380
atacataaga catagaagca acatttactt ataatcacct acctgaagag agctgaactc 13440
agcattcact tgtgttttat tccatttgat tatcttgcaa accatgattc catcatatca 13500
atgtatctta gtgttttat gactgatgta tctgtgcatc tctaattgtt ccttttgtgt 13560
atgttcccag aagtggaact gctgaattaa atgttttcaa tgcttttgaa actcctgcta 13620
aattttttcta tgggtaaatt tttctccaga aagcttctag caacttaaac ctgtactaga 13680
aatatttgag aataatcatt tcactataac tctatcagta gtaggagctc ttgtttatgg 13740
ttatttgctt ctttgatgtc tcaagggaag tcttagaaaa taattctgtt ctaataagca 13800
cagaataaaa attgaagcat atattgaaca aatgaaggct acacataagg ttgataattt 13860
ctcttcatgc tattgctgat aatttcttgc atgaataatg tttgtatttc tatttggaaa 13920
aatgtgacct tttgcttatt gctgttatgt aagtttcct catcctaaaa ttgaaaaaac 13980
aagcacttat attcattgca atatttgata gtgatatcag gaattatttt agatataata 14040
cattttgta ctgtgttgta atattaaaaa ttatctttc cctcttattt ttaaccaatt 14100
tcctcccact atttattaag caatgctttg ttttcaact gatttgtgat gtcacctta 14160
ttataccata agtgaatcta tttctgccta tttcctcttt atgtttggcc acaatataca 14220
tatattttaa actaaattcg tatgattagt gtacacttaa aatatgtttt aatttctgat 14280
ggaaaaatgt tatcttcact tttctcttag gagactgcaa atcatctgat gattgctttt 14340
agatatccag tattttttaac ccataaatta tgcatactat tgttcaattt agaaactata 14400
tgcatacttt atatatgcaa atatatattt caatgtggct atacatgaaa tacttaaaca 14460
ctgtaaatta tttgaaaaac aawgaaaact attttcctct ctatggggggc cataggaaaa 14520
ctgcttattg ttaagtttgt tttccagaaa ggcaggaaaa cgttggtggc ctgtgagtaa 14580
ggagaaaaca cttaaccttg gtatattaat tctatcgatt cattaacaac tttatacaaa 14640
catttatttt tataccatac cggcgttcat aataaaacac ttttttttcaa caaatatctc 14700
```

```
taaatacaga ttcttttctc taactatgct gacttttgc caacaactcc acccaaaaga 14760
gttgacatgc ccacatatat tcttctgcta ggaatcattt caaacactga aaaaaccta 14820
ttaattagaa ttaaaataaa tattaaacat ttaaataatc agagaaaaat tactctgtgc 14880
ttcctaagaa tgggaatact tcacagtaat actgttgctt taatttgaca ataaaactat 14940
ttaaaaataa gacccaccct acagtctggc aatgtatttg tcacaaataa gacaaagtgg 15000
cacaattact gaaatatgtt atgttaatat aaatcatttg aagcactaaa acatgaccat 15060
ataaataaat gttgaatact atacgtagaa aattgattaa aatacaaaat gctaaaatta 15120
acgcagaaaa tagtggcagc taaaaacatg aagtacaata ctgtttatgt gtctatattt 15180
aagacagctg aaaaagtcta gcacgttcat acattggttg attaatggta taaaatttt 15240
ctagaaataa atacaatatt attaatattt taaggagtca aatgtttcta taatttttatt 15300
cagctattcc aaatttaaga atctactgaa ggcataatta gaaacttgtg tgaagagttt 15360
catggtgttc atttttataat caagaaaaag caaacaaatg atgttcgaaa tacaagtagc 15420
tcccacttag caccgtacca tgtaacagaa acctttctat atggcaaacg tgtcttgttt 15480
tgcatggttc ttacttagat attacaaaat ctcaaagtga ggactgcctg ctttggataa 15540
ctggtaaagc acaggcatct accagatggg gtagaaggtg tttctaaata actagaatgt 15600
catcagcctt gatcatgaag gaaagtgtaa agtacagttt aatttttttt tcttagaatg 15660
ttatacagct attaaagtga ggatgttcct agttaagaaa aaggtaaatc attttgtgta 15720
atatattatg tgcaaagaca tatccaatgc tacatatgga tatcttgtaa aatatcaggg 15780
ataaagagaa acaaaactta ttaatagcta tgtccaaatt ttccatgata agcaattgtt 15840
gctattacat tgagaaaata agctaacaaa aactttgtat gcccagttta attcagatct 15900
caggatatat aattacagga tgcttatttta taatagtaga atttaaaaat aaaagtagga 15960
aaaagcaagg agttaaaaac ttgttgtaga gcgtgatggc agaagaggag gtgctcagtt 16020
ctggtttcca gaacagaatg accagttagc aacttctcac agataagaat gcctaggtaa 16080
aaattccata acccaagggt gaggtggggc acactcttgg agcacagaaa ctgggaaaag 16140
tcatattaga agtgtaaggg gagcagtttc actttgactg tgttgcttct ttcccgacca 16200
aacagtgtca cactgaaagg gatttcttgg gcctgcgttc tctagtggag aaaagagagc 16260
ccacggcaga catccaactt ccctgtgttc cagggcactt cccaggggc ctagttctgt 16320
ctaatcttgt ggggaataat ggaggaattg gcagggcttg accccttatg gtcagttcat 16380
aactacctcc ttctacaacc cattctgtat tccctttacc ttcagcaagc accttagcag 16440
gacacggttt tttacctggt ggagtgacac aaatcttcat tcctgatggg tctgggccat 16500
ttgtagtttt gcctggattg ggttgttgta gtttctcact gaccttaatc acaggacatg 16560
gtaatactgt gacgtcctat gggatctcct gtattccaca aatactcttc cttaacctcc 16620
attgtggagt agtagtttga tttcatcttg atagtctggg tcagtcaccc cagccaacac 16680
tgtacctccc ttcttagcct gttgacttag aggcaggaag agctcaaagt ggccaggtgg 16740
caaacttatc ttccagtttg atggaatcat ctttctgtct tctggtggca aagttcctcc 16800
ctccggaacg aagacctcta ggcccacaga acataatgtc acagaaacag gaaggaaaat 16860
tttgctagtg ggtcagtaga ggtgatggta agtggcacca cttccacttc caccccttga 16920
ttcctgcatt cttggatcct ggctatggaa gaaacagtac cacatattgg atgcctactc 16980
agagcataca aagacttctg gagaaatttg ccccaggcct gcatttttt tttttttt 17040
tgtaaaatga agtcctgctg tgtcttccag aggcctatag tgcagtgtca cgatcttggg 17100
tcactgcaac ctctgcctcc caggttcatg cgattctctt gtctcagcct cccgaatagc 17160
tgggattaca ggcatgtgcc accacggctg gctaactttt gtatttttag tatggatgag 17220
ggttcaccat gttggctagg ctggtctcga actcctgacc tcaagtgatc cacccgcttc 17280
agcctcccaa agtgctggga ttacaggcat gagccaccgt gcccagcccc tgtaataaag 17340
tatcacctag ttgttgtaac tgttacttca aaaggctttt ccacctttct atcaatccat 17400
ctgctttagg ataatgggaa acatggtaag acaagtatat cccatgagca tgagcccact 17460
gtcttattct ttagctgtaa aatgagtgcc ttggtcagag gcaatggtct gtggaatacc 17520
atgacagtgg ataaggcatt ctgggagtcc acgaatggta atcttggcag aagcattgca 17580
tgagagatag gtaaacctat atccagagga agtgtctaat gtgactaatc cactctagaa 17640
ttctaatcac ccaaagcttt tggattcctc cctctacatt aaaccaggga agatctggca 17700
tttcaaggtc gctcacagta ggccatcctt tgatccatat ttcagctaat aaactattag 17760
aacattttt aactccctga tttgtaacat tgagtgcaga atctctgctt agtgggccca 17820
tatcaataca ttcagcctga tccaacttta tattcctccc accattatcc cacaccctta 17880
atatccattc ctacacctgt tctccagaat tctgcttata taaactagaa aactcaagca 17940
gctctttag ggtgtagcac acctccttgt agacttttgg cttacaccaa ctagcaccag 18000
atcttggaag gagaaaaggg attaaagtct gaatgtattt cctaagaag aagaccaacc 18060
aaaataggtt atttaaatat ttggctattc taagtccaaa gctactcttt aaaaggaagc 18120
catatttaac cactccatgt aatatgtaat tatgtcttga catacagaac taggtaatgc 18180
aataattaaa ggtatttggt caccataatt ttttctaaa aacggagaaa tgtgcaaatt 18240
atttacctac cagtttacac aaacaggcaa agcaaaaaca aaagcacttg tcaaggtgga 18300
caaaaatgct gctacagtta aaaatctgca tatactcttt actttgtcat tcttaaaaat 18360
gtgtttctgg gtagttggtt tactgaaata ggtgaaagct gtactgtaat gtcatttttta 18420
aattttgtaa cactttttgt aacattttgt aacatttggt gaagaaatta tgtttcttca 18480
```

13

```
cttaaggaga taaattgtgt tcattataga actttgaaag tgaacgacca aaccaaatgt 18540
gcaaaaattg actgaatatg aattactttta cacttatgtg tgaaaataat cttcaacatt 18600
atgtattcca tacacatgtt tttggtgttt taaattatct ccgggctttc ctaaattcaa 18660
gttggagaag cagaattagt tagatttata gcacactcac tatagaaaac atattttgaa 18720
aacttgtttt accacatctc tgttcagctg gatggggctc ctgtgaaaga acaaagcaat 18780
tacatagaat tttacacaga attgtaaaac ctgcaaattt tttttaacat tttctttacc 18840
ttatctgata gcacagcaca tacgttgcaa ctcttactct gaaaactact atcacttctg 18900
aatgtttatt aaataacagc cataggtgtg cgaaggattt acaaatggat agccacattt 18960
actgccaatg aaaaacaaag tttatttaac atgtgcagta tctttgtgat atatatatta 19020
ctccttattt ggtacagatg aaaacgctga agctcagaag aatgaaataa tgttttccag 19080
gaacacagca agagctaggt ttcaattaaa atattattct cgtagctact tctgggttga 19140
ctctagaaac accccaagcc acatgggttt gttaagatgt ttaactgggt aattattttt 19200
atgggtaatt atgtttcaga cagttttaca attttacaga tataaaaata tatatgaaaa 19260
agatatatat atgttgtaat gcatatatat atattcatat ttcatatgaa gaaggcacaa 19320
gaggaacact cagtgcctag gtaaaaagaa tggagttgga tagtaggtta atagtggttg 19380
atgagataag aagtagtcat ggtcatgact tactttcctg gtgtcatgca atttctattg 19440
acagcatttc ttcaaagttg taattttat tgagaataaa ttaataaaac tctgtaagat 19500
tttaagataa aagatctccc aatattttca aagcatcatt acaaccttct ttaaagtttc 19560
tagcaattgt atcaatttct ttattcttat tttcattgta gaaaaaaatt gatttttgag 19620
gtatyttaaa agtcatagag aaaatatttg gccatggaaa gggtccaaaa tgggaggagg 19680
aaattaaaaa ggactgagat ttctgaaaca catacattgt tccaagggag taccaagcat 19740
gctacaaagg aggcagagga ttgaatgact gaagaaaaga ttttgaagga cactttgagg 19800
tgttcttcct acaccttcca tcatcctatc tcaggagggt gaatggattg gagagattat 19860
aaaaagagtt attgtgatgg ccttgatgtt agtccaaaac atccttttct agtctatgtg 19920
attgataagg atgctgaagc tgttcatggc tgtggaaagg gaaggggaga ggagagttat 19980
cccattgctg tactgtatct gagtgacttc acctcagagg aaaggaacag agaagcatct 20040
ctaaaccaca ttctcaaatc caaattcacc agcaataatg ctagtaattt tcatatctga 20100
ctcccatgtg tagactctaa ttgagtcagg atccaaaagg agggcaattc aatggctcct 20160
ttaagttcta acatgatgaa tgtagaagta ttccaaattt ttagctaaaa taatatttat 20220
cataatagtt attattactg ctactaactc actgcaagac ttatggaata actactatat 20280
gatgctctgg ccaggatctg agatgtccac aattctactc atatgtttta gctaaagaga 20340
atttaatgaa aagacagaga ataaaaaggt aaagttaaag gaatcagcca aagggttaa 20400
aaaagtcaag gctaactgta gaaaaccatt tccatctttta ggtctgaagg accaaggaca 20460
gtggcttctg tcacagagct cagtgagagc tgaagccagg aagaaatccc ttgccaacat 20520
cttcccaaga cacacatccc aagacattct ccagggaggg atgcagccaa tttagcacac 20580
ttrtaatgaa gcaggaaggg aatgagaaag aaattgaggt aattccctat ctttcccact 20640
tctgacatcc tagagagtct tctcaaaagc caaggtcagc tggaaaccag acaccatagg 20700
tgccctgttg accaggtcca taggagccca actccaggtg aacaatgcaa ggcacagaag 20760
agaagacaat agatgtgaat gggagtaggg tggaaaagga gaatcaccag cacacctata 20820
ttatctataa atccaaaatg ttccacactt acacattact atccctatta aaaagataaa 20880
tgtacaaaac tcaaaattga tatatcacta gttcaagttc aacaaagtt agtttatctt 20940
ccaatggtgt tccagactct gaaaccttct cccgatacca tccactatac ttgctgtaag 21000
caggaactta atatttccca aagtctaaca tattaaatta tttgggagta aagtaaaata 21060
aataatgaat cccattccta catcactctt gggggatgcg attccctgaa gacagtgtgg 21120
agttggcaaa actcatgtgc tccgtgagct taggattttc agaagaatcg aaatattgtg 21180
gttgttcata atttgaatga cttttttgcta gaaataattg acctgcaggg atttggtctc 21240
cacacagtaa ttgcattata aactctacag gttctcaata cccattctgt aatcatgaaa 21300
tcatgcttct ttctcaggta ggattagata tatttttttaa aaagtttaaa atccggcagt 21360
aaatatttta attgatagaa ataaatggag ctgaaacata ttctgatgaa ttagaaaatg 21420
tttatattaa agtgttgcta ttctttttcag agtactggtg tttacagagt gtttgcataa 21480
tgaaaagaaa ataggccaaa agaatttta tttcatcaat aattattgac tgcctccaat 21540
tcaggaggca caaatctagg tgctgctgag tctataacta gatcagataa aaatccttga 21600
ccctaaagga gctcatgctt tgatgttgag tttcgttcta gactagacct ggatcattca 21660
ccaaataata ctagtagcct caattttgtta agcatgtagt acatgacaga tatatttttaa 21720
aaacttttac tgaattaact ttctcatcaa gagagaatgg ctattaatca aattttatgg 21780
ataagaaaac tgaggcacac agaaattaat aacttgcccc aggccacaca ggtaggaact 21840
agaggcactg ggtttttcac ccaggaagtg tgactgcaaa ctcccagtaa ctgtcccact 21900
ctgctggctt tcaatagtaa actatgctta ctgtttatac ttgatttaga acaatcaaga 21960
tctggtatta aatcatcctt ctgattcatt ttgtgttaac aatgccactc tttactatta 22020
taagagctgt atcatgtaat attttatagc cctttcataa agaatgggct acttttaggt 22080
ttatagccta tattacttaa aaataataaa aatatgtttt gtgaagctgc cttctctaga 22140
tttcttttttc cactccaaat tgaaccatga ccactttcca aggagacacc actcttgtta 22200
aagacaaaga ccaaccttct agactctttg taggacagaa tagaagaagc aagcattcac 22260
```

```
atgggaatgt ctcagtgtag ggtgcatgtc aggagagcac aggctcagat gcctccaaag 22320
ccatttctgt ccaattgcag aagcttctcc ctgagatttc cttgctcaaa gcagtaggat 22380
attgtgttct tgtttttca gaagaaagac tatttccaca aaattctcag ttaaattatt 22440
tggactattt attgcttgca ttacttcaac ttccaataga aaaaaaaaa gactcataaa 22500
aaaacagatg aattgagaag ttattttgaa gggtgattaa tatttcaata aaaaagccca 22560
ttaaaaatgt aattaggcgg ggcacggtgg ctcccgcctg ttatcccagt actttgggag 22620
gctgaagcgg gtggattgcc tgaggacagg agttcaagac cagcttggcc aacatagtga 22680
aaccccgttt ctactaaaaa tacaaaaaaa ttagctgaac gtggtggtgg gcacctgtaa 22740
tcccagctac tcgggaggtt gaggcagcag tattgcttga acctgggaga cagaggttgc 22800
agtgagctga gattgcacca ttgcactcca gcctgggcga caagagtgaa actccgccac 22860
acacacacac acaaatgaaa tccagcacca aaacagtatt tgcctatttg gcaattaaat 22920
gtaccatcaa acagagggat agagaatgtg gtatattata tatatcat acattataat 22980
gtgatataat atataataca ccacagtttc tttatccact tgttgtttga tggatatata 23040
catatatatt atatgtaata tatatacaaa atgtatatga tggaatacta ctcagccata 23100
aaaagggatg aagtaatggc attcacagca acttggatgg gattggagac taatattcta 23160
agtgaagtaa ttcagaaata aaataccaaa tatagtgtgt tctcactcat aagtggaaac 23220
taagctgtca ggatgcaaag gcataagaat gacacaaagg acttcgggga cttgggggaa 23280
acggtggagg aggtgaggga taaaaggcta cacattgggt tcattgtata ctgtttggat 23340
gatgggtgca ccaaaatctc acaaatcacc actaaagaac ttactcatgt aaccaaatac 23400
cacctttcc cccaaaacct atggaaataa aaaataaaaa taaaaaccaa aagaaattca 23460
attggaccct gtgagcttta acaaggtaat tatgattcta ttgatttagg tgacttatct 23520
tctaacttat taccctaggc agaagcccaa tgtccttttg tgtagaatga gataatacgg 23580
tggacaagtt ttgaacattg aatttacaga gtgctttatt tatgaagtga cctgtttcca 23640
gtgttggcat ggtagttatt aaaaaaaagt tagtataaca ttgtcaagtc tggatatgtg 23700
tcatagaaga aacacgtcga ttgttccatc atgatcttca tggtcacttt tatcttgccc 23760
aaatgttgag agattcaggt caggatattt taagtatggt ctcagtcatg ttgttaatat 23820
gattatgatt tcactttgat ctgttacatg ttttaacaaa ttcatattga acttgtgttc 23880
caatgttttt tcttagtttt tcaagtgtta gaatgaggta gagttaaaac aacagcattt 23940
tagtttgagg ataagtttct tcatcatttt atccttattg ccccctccc caggagccct 24000
ttgatacact attgttttct ttatatccct atcaacattt aataccatca atacaggtgc 24060
acttgtgtat ctatatacca tgcaaatgta tatggtttat gtattatgtg catatgtatt 24120
ataaatacaa atatgtaata tctactttca ttccccaaga accaatttt gccccttgg 24180
acaaaaatat acaaaatgaa gaaatgtagc ttggtcttta aagttaaaaa agatttgttg 24240
ataagagggc cagctgaggt agaataaagt gaagaaaatg ggcacacatt agagggtgag 24300
ggaagatctg gaaaatgatc tccagttcac aggggcaggc aaagcgattc ttgttctaca 24360
gggatgtata ccaggcatca gtcccacttt cctaagcacg ttcagttgtg ataaacctgg 24420
agggtttcaa aggctgatac tttagatccc acattcaaag gtgtgttgtt aaacaaagaa 24480
ttacagtttc aaagaaaagc aatgtttaca accatgggtt caagaaaagt ctaagtgaac 24540
acatataaca aagacttgca aaaagataaa agataaggct ctttaactat caaaagactt 24600
gcagaaaaga accacagaaa accattttaa atattattgc ctttgtatat taaaaaactc 24660
tatattagtt tagatgttta aagcatcaat cacatgctca ctaggctatt tcttaatgtc 24720
acatgtattt acattttgag agaagaggaa gaaatagcag atgacaccac tggggtaatg 24780
cataaatgac aaacctaaat gcattttaat ttccttttat ttagatgtca tttgaagcca 24840
agcaaacaca atgttaaaga aaaaccatac agccgtgact gagtttgttc tcctgggact 24900
gacagatcgg gctgagctgc agtcccttct ttttgtggta tttctagtca tctaccttat 24960
cacagtaatc ggcaatgtga gcatgatctt gttaatcaga agtgactcga cactacacac 25020
tccaatgtac ttcttcctca gtcacctctc ctttgtagat ctctgttata ccaccaatgt 25080
tactcctcag atgctggtta acttttatc caagagaaaa accatttcct tcatcggctg 25140
ctttatccaa tttcactttt tcattgcact ggtgattaca gattattata tgctcacagt 25200
gatggcttat gaccgctaca tggccatctg caagcccttg ttatatggaa gcaaaatgac 25260
caggtgtgtc tgcctctgtc tggctgctgc tccctatatt tatggctttg caaatggtct 25320
aagcacagac caccctgatg cttcgtctgt ccttctgtgg acccaatgac atcaaccact 25380
tttactgtgc ggacccaccc ctcttagtcc tcgcctgctc agatacttat gtcaaagaga 25440
ccgccatgtt ggtggtggct ggttccaacc tcatttgctc tctcaccgtc atcctcattt 25500
cctacacttt catcttcact gccattctgc gtatccacac tgctgagggg aggcgcaagg 25560
ccttctccac ctgcgggtct catgtgaccg ctgtcactgt cttctatggg acactgttct 25620
gcatgtacct gaggcccct tctgagacat ctatacaaca ggggaaaatt gtagctgttt 25680
tttatatctt tgtgagtccg atgttaaacc cattgatcta cagcctgagg aataaagacg 25740
ttaaaagaag tataaggaaa gttattcaaa agaaactgtt tgctaagtaa ggtagatatt 25800
ttggtcatag gcgttggaat ctgttcttat tatctgacca attaatgaac atttaaaatt 25860
aacaaatcaa tctgtcattg agtgttttt gtcctttgta atttgcatat gggacttaaa 25920
agtgtatgtc aaattattag ctagagctta cactgccacc tcagtaaatt gaaaatgaaa 25980
gcatagaaat tcaaatataa gactagaaga cattgttcta gctctgtaaa aagtaatgaa 26040
```

15

```
gtacagatga ttccattatt agtactcata gtactaatat atcatagtac tatatcatag  26100
tactaatata tcatagtact atatcatagt actaatatat catagtacta tatcatagta  26160
ctaatatatc atagtactat atcatagtac taatatatca tagtactata tcatagtact  26220
aatatatcat agtactatat catagtacta atatatcata gtactatatc atagtactaa  26280
tatatcatag tactatatca tagtactgta tcatagtact aatatatcat agtactgtat  26340
catagtacta atatatcata gtactgtatc atagtactaa tatatcatag tactgtatca  26400
tagtactata tatcatagta ctatatatca tagtactata tcatagtata ctatatatca  26460
tagtactata tcatactata aaatatcata aaagacagaa ttatcaattg ctgagaaaat  26520
gacagctcat tacatttttt taaatgtttt tgtttgtccc tttgaatgaa tggaggatat  26580
ctacctaact tctatgtatt cagaatctca catgaggcag cacatttagc acacttgttt  26640
agttgtaatc ttctatgctt atcttcgtga gtctgtttga aaagttggat aaatggcaat  26700
gagtgactac atttgctaat tacatttat aatacttaat aagcctccaa gctattttcc  26760
agaaacttgc caaccatagt agatgaggtt tctgttttc ttttatacat attatataga  26820
aatgaagatc ctttaggtgt actttggatt attactttaa gttatatcct tagaatgata  26880
tcatagatcc aatgaaaccc tatttcataa ggctttttcat ggaaatgcca aatttccttt  26940
agaaagagtt tttaattgtt tgtatgttgt accagtaagg attcccatca acatgtgaac  27000
tcaattcttc actcttttat taccattgcc tgtttccttt gaataaataa attgaattga  27060
atgttttatc cacgaatgca tgtggatatt tgtgtgtttt atgtgtgtat gtaggtgtgt  27120
gtgtgtattt tgattacaat ataacatttt cttttttta attgcttatt caaattttt  27180
tggtgagaat caaggtcgta tgcctttttt tttttttttt tttttttga cagagtattg  27240
ctctgttgct caggctggag tacagtggcg cgatctcggc tcactgaaag ctccgcctcc  27300
cgggttcacg ccattctcct gcctcagcct cccgagtagc tgggactaca ggcgcccgcc  27360
accacgcccg gctaattttt tgtattttta gtagagacgg ggtttcaccg tgttagccag  27420
gatggtcttg atctcctgac ctcgtgatcc gcccgcctcg gcctcccaaa gtactgggat  27480
tacaggcatg agccaccgcg cccagctgct tcacctgttt ttaaattgtg gtgtttatat  27540
gttttcttat ttatttcaga tatttctcaa tgatataaac atgttttgt tatatataca  27600
ggtgtagcaa ttgtatatat atacacatga attccatttt atctcttcta ttgtgtcttt  27660
tccaaagtta atattttatc attttaaatt ttctcaatat ttttttattt cactttattg  27720
tgtctttttt tactttagg aagttaagt tatgccacct atgatcatgt ggatttttac  27780
atatattatt aaattatttt catggtttcg cttgttaatt ttttcttatg aactattttt  27840
aatatacatc taaaatagaa aataatataa agactccttt gtaagcacaa ctaatcacta  27900
ttaaatcttc acagaatgcc ccatttgttt cagttatttc agaaatttaa aacttacaaa  27960
gatacatctc tcctgactga ttctgtctct tgtcccattt cttgctgtaa actctattac  28020
aaatttaatg tttcttatcc ttctgtagag ttacatcatt ggataggtgt ttatatattc  28080
atagaaatat gtagtactga tttgctacat ttaaaacttg aaataaatgc atccactcta  28140
tgtatctttc tgcaatttat ttatcttgca ctaaatattg ttggatgtat ctgtggtgaa  28200
tcatgcagca gcaatttta gtggtatagt ctatgccaat atataaatat gcctcaatat  28260
gtgtatttat tctacgattt ttttttttt ttgagacaga gtctcactct tgttgcccag  28320
gctggggtgc aatggcacga tctcggctca ccgcaaactc cgccccccag ggtcaagcga  28380
ttctcctgtc tagcctccta gtagctggga ttacaggtgc ccaccaccat gccaggctaa  28440
ttttgtattt ttaatagaga cgggatttca ccatgttagc caggatggtc ttgatcacct  28500
gaccttgtga tcctcccgcc tcagcctccc aaattgtatt ttatttctac tgttggtgaa  28560
gagttacatt ttccagtttc ttgataatat gaaaatccat taataaatgt tttgtgtgta  28620
attatgaatg tgtaccacgt aaggagttcc tctcaggtag gttggtaatt tcttggtcat  28680
aagatataag tatctttaaa tttactatat attgccaatt gttttactga tttatatttc  28740
tatcaacagt ttgtgagtgt tacctttaca tcactttatt cttgccaaaa ctaggtgttg  28800
tcagacttta aatgtttct aatctgatgg gtaaacaatg aattctcatt tggtgtttaa  28860
ggttgaattg ttattacaag tgaaactaag tatttttaag tatattgatg ctaatctcat  28920
atttctcttt cacttatatg tccatatact ttgttaactt ttcaggtagg gtgatttgtc  28980
tttatttcat acatttataa tagttcctta tgtaccaaat gctacataca aatcttttgg  29040
tgttatatgc catttaacct taaaaaccta gggtaataat gccaggcagt gtggctcaca  29100
catgtaatcc cagtactttg ggaggctgag gcaggaggat tgcttgagcc caggagtttt  29160
aggccaaact acacaagata gagactccgt ctttacaaaa aaataaaaaa aaattagcca  29220
gttgtggtgg gatgcccttg tggtcccagc tacatgggaa gctgaggcag gaggatcact  29280
tgagcctggg aggtagaggc ttcagtgaac catgttgtca ccacgacact ccagtctgga  29340
tgacagagga tggatgacag agcctggatg actccagcct ggatgaccct gtctcaataa  29400
aacaaaacaa accccaaaaa acctagggtg agatgaacag atgaacgtta tttcttgaat  29460
gcctcagcaa atagcctatag gtatctattt ttctggtagc tgcaatttga ttgggacaag  29520
tttggaattt cagctcattg gacaagtatt ttcataatag atattttccc agtaggattg  29580
gatttttttt ttccacatag tgaatgctta tatgtgagca taaaatgttt cccacagatt  29640
gggattggat aaattatatg aagtgtgatc ctagtatatt gctttgccat tgaaatactg  29700
gttattaccc aaatagaaaa ttaacattta aaagagccaa caggctgggc aaagtggctt  29760
aggcctgtaa tcccagcctt ttgggaggcc aaggcccaca gatcacttga gttcaggagt  29820
```

16

```
tcgagactaa cctgggcaac atgaggaaac cctgtctcta aaaaaaccac aaaaattagt  29880
taggtctggt ggcaagtgtc tgtagtccaa gctactcagg aggctgatgt gggaggatgg  29940
cttcagcctg ggaggcaaag gttgcagtga gctgagatca tgccagtgca ctccagcctg  30000
ggtaacagag taagatcctg tcttaaaaaa ataataaaat aggccaggtg cagtagttca  30060
tgcctgtaat cccagcactt tgggaggccg aggcaggtga atcacaaggt caggagttcg  30120
agaccagcct ggccaagatg gcgaaacccc gtctctacta aaaatacaaa aattagccgg  30180
gtgcagtggt gggtgcctgt aattccagct acttgggagg ctgaggcagg agaatcgctt  30240
gaacccgggg ggcagaggtt gccatgagcc aagatcgtgc cactgtactc tagccttggt  30300
gacagagcca gactccaact caaaaataaa taaataaata aataaaataa taaaatataa  30360
tataataaga atgccaacag aataattctg atttcagcta cagtttatgc tttttatga  30420
gaaattcaac tccaatcttt taattttatt ctcctttatt ctgttgttca gacattgcat  30480
attaaaaagg cattttttt cttaaccaat agttttatcc ttattgctgt ccttattctg  30540
gagagaactt catatttcaa ggcacagccc aaatatcaac tcccttgtcc tttcatgagc  30600
aaacagttgc acatacccat tcctgtgatt gtgtagatat tgcaactcta tttgtctgtt  30660
agtcacacag aaaattcata ataatacaat gccatgtttc ctaatatatt ctgagagttc  30720
tgtgagaaat gaaacctatt gtatcggtta agtactgaag atggccgaat aggaacagct  30780
ccagtctaca gctcccagcg tgagcgacgc agaagatggg tgatttctgc atttccatct  30840
gaggtaccgg gttcatctca ctagggagtg gcagacagtg ggccgaggtc agtgggtgcg  30900
cgcaccctgc gcgagccgaa gcagggtgag gcattgcctc actctggaag cacaaggggt  30960
cagggagttc cctttcctag tcaaagaaag gggtgacaga tggcacctgg aaaatcgggt  31020
cactcccacc ccaatactgt gcttttccaa cgggcttaaa aaatggcaca ccaggagatt  31080
atatcccgca cctggctcag agagtcctat gcccacggag tctcactgat tgctagcaca  31140
gcagtctgag atcaaactgc aaggcggcag cgaggctggg ggaggggtgc ccaccattgc  31200
ccaggcatgc ttaggtaaac aaagcagcca ggaagctcga actgggtgga gcccaccaca  31260
gctcaaggag gcctgcctgc ctctgtaggc tccacctctg ggggcaggac acagacaaac  31320
aaaagacagc agtaacctct gcggacttaa atgtccctga cagctttgaa gagagcagtg  31380
gttctcccag cacgcagctg gagatctgag aaagggcaga cttcctcctc aagtgggtcc  31440
ctgacccctg accccgagc agcataactg ggaggcaccc cccagcatgg gcagactgac  31500
acctcacacg gccgggtact ccaacagacc tgcagctaag ggtcctgtct gttagaagga  31560
aaactaacaa acagaaagga catccacacc gaaaacccat ctgtacatca ccatcatcaa  31620
agaccaaaag cagataaaac cacaaagata gggaaaaaac agagcagaaa aactggaaac  31680
tctaaaaagc agagcacctc tcctcctcca aaggaaagca gttcctcacc agcaacggaa  31740
caaagctgga tggagaacga ctttgacgag atgagagaag aaggcttcag atgatcaaat  31800
tactccaagc tacgggaggt cattcaaacc aaaggcaaag aagttgaaaa ctttgaaaaa  31860
aatttagaag aatgtataac tagaataaca aatagagaga agtgcttaaa ggagctgatg  31920
gagctgaaaa ccaaggctcg agaactacgt gaagaatgaa gaagcctcag gagccgatgc  31980
gatcaactgg aagaaagggg atcagcaatg gaagatgaat tgaatgaaat gaagcaagaa  32040
gggaagttta gagaaaaaag aataaaaaga aatgagcaaa gcctccaaga aatatgggac  32100
tatgtgaaaa gaccaaatct atgtctgatt ggtgtacctg aaagtgacag ggagaatgga  32160
accaagttgg aaaacactct gcaggatatt atccaagaga acttccccaa tctagcaagg  32220
caggccaaca tccagattca ggaaatacag agcacaccac aaagatactc ctcgagaaga  32280
gcaactccaa gacacataat tgtcagatac accaaagatg aaatgaagga aaaaatgtta  32340
agggcagcca gagagaaagg tcgggttacc ttcaaaggga agcccatcag actaacagcg  32400
gatctctcag cagaaactct acaagccaga agagagtggg ggccaatatt caacattatt  32460
aaagaaaaga attttcaacc cagaatttca tatccagcca aactaagctt cataagtgaa  32520
ggagaaataa aatactttac agacaaccaa atgctgagag attttgtaac caccaggccg  32580
accctaaaag agctcctgaa ggaagcacta aacatggaaa ggaacaaccg gtaccagccg  32640
ctgcaaaatc atgccaaaat gtaaagacca tcaagactag gaagaaactg catcaactaa  32700
cgagcaaaat aaccagttaa catcataatt acaggatgaa attcacacat aacaatatta  32760
actttaaaca caaatggact aaatgctcca attaaaagac atagactggc aaattggata  32820
aagagtcaag acccatcagt gtactgtatt caggaaaccc atctcacatg cagagacaca  32880
cataggctca aaataaaagg atggaggaag atctaccaag caaatggaaa acaaaaaaag  32940
gaaggggttg caatcctagt ctctgataaa acagacttta aaacaacaaa gatcaaaaga  33000
gacaaagaag gccattacat aatggtaaag ggatcaattc aacaagaaga gctaactatc  33060
ctaaatacat atgcacccaa tacaggagca cccagattca taaagcaagt cctgagtgac  33120
ctacaaagag acttagactc ccacacatta ataatgggag actttaacac cccactgtca  33180
acattagaca gatcaacgag acagaaagtc aacaaggata cccaggaatt gaactcagct  33240
ctgcaccaag catacctaat agacatctac agaactctcc accccaaatc aacagaatat  33300
acattttttt cagcaccaca ccacacctgc tccaaaattg accacatact ggaagtaaa   33360
gctcttctca gcaaatgtaa aagaacagaa attataacaa actatctctc agaccacagt  33420
gcaatcaaac tagaactcag gattaagaat ctcactcaaa accactcaac tacatggaaa  33480
ctgaacaacc tactcctgaa tgactactgg gtacataacg aaatgaaggc agaaataaag  33540
atgttctttg aaaccaacga gaacaaagac acaacatacc agaatctctg ggacacattc  33600
```

17

```
aaagcagtgt gtagagggaa atttatagca ctgaatgccc acaagagaaa gcaggaaaga   33660
tccaaaattg acaccctaac atcacaatta aaagaactag aaaagcaaga gcaaacacat   33720
tcaaaagcta gcagaaggca agaaataact gaaatcagag cagaactgaa ggaaatggag   33780
acacaaaaaa cccttcaaaa aattaatgaa tccaggagct ggttttttga aaggatcaac   33840
aaaattgata aaccgctagc aagactaata aagaaaaaaa gagagaagaa tcaaatagag   33900
gcaataaaaa atgataaagg ggatatcacc accgatccca cagaaataca aactaccatc   33960
agaggatact acaaacacct ctatgcaaat agactagaaa atctagaaga aatggataaa   34020
ttcctcaaca catacactct cccaaactaa accaggaaga agttgaatct ctgaataggc   34080
caataacagg atctgaaatt gtggcaataa tcaatagctt accaacgaaa aagagttcag   34140
gaccagatgg attcacagcc gaattccacc agaggtacaa ggaggaactg gtaccattcc   34200
ttctgaaact attccaatca atagaaaaag agggaatcct ccctatctca ttttatgagg   34260
ccagcatcat cccgatacca aagcctggca gagacacaac caaaaaagag aattttagac   34320
caatatcctt gatgaacatt gatgcaaaaa tcctcagtaa aatactggca aaccgaatcc   34380
agcagcacat caaaaagctt atccaccatg atcaagtgga cttcatccct gggatgcaag   34440
gctggttcaa tatatgcaaa tcaataaatg taatccagca tataaacaga accaaagaca   34500
aaaaccacat gattatctca atagatgcag aaaaggcctt tgacaaaatt caacaacact   34560
tcatgctaaa aactctcaat aaattaggta ttgatgggac gtatttcaaa ataataagag   34620
ctatctatga caaacccaca gccaatatca tactgaatgg gcaaaaactg gaagcattcc   34680
ctttgaaaac tggcacaagg cagggatgcc ctctctcacc actcctattc aatatagtgt   34740
tggaagttct ggccagggca attaggcagg agaaggaaat aaagggtatt caattaggaa   34800
aagaggaagt caaattgtcc ctgtttgcag atgacatgat tgtatatcta gaaaaccca    34860
tcatctcagc cccaaatctc cttaagctga taagcaactt cagcaaagtc tcagaataca   34920
aaatcaatgt gcaaaaatca caagcattct tatacaccaa caacagacaa acagagagcc   34980
aaatcatgag tgaaatccca ttcacagttg cttcaaagag aataaaatac ctaggaatcc   35040
aacttacaag ggatgtgaag gacctcttca aggagaacta caaaccactg ctcaaggaaa   35100
taaaagagga tacaaacaaa tggaagaaca ttccatgctc atgggtagga agaattaata   35160
tcttgaaaat gtccatactg cccaaggtaa tttacagatt caatgccatc cccatcaagc   35220
taccaagggc tttcttcaca gaattggaaa aaactacttt aaagttcata tggaaccgaa   35280
aaagagcccg catcgccaag tcaatcctaa gccaaaagaa caaagctgga ggcatcacac   35340
tacctgactt caaactatac tacaaggcta cagtaaccaa aacagcatgg tactggtagc   35400
aaaacagaga tatagatgaa tggaacagaa cagagccctt agaaataacg ccgcatatct   35460
acaactatct gatctttgac aaacctgagg aaaacaagca atggggaaag gattccctat   35520
ttaataaatg gtgcagggaa aactggctag ccatatgtag aaagctgaaa ctggatccct   35580
tccttacacc ttatacaaaa atcaattcaa gatggattaa agacttaaat gttagaccta   35640
aaaccataaa aaccctagaa gaaacctag gcattaccat tcaggacata ggcatgggca   35700
aggactttat gtctaaaaca ccaaaagcaa tggcaacaaa agccaaaatt tacaaatggg   35760
atctaattaa actaaagagc ttctgcacag caaaagaaac taccatcaga gtgaacaggc   35820
aacctacaaa atgggagaaa attttcacaa cctactcatc tgacaaaggg ctaatatcca   35880
gaatctacaa tgaactcaaa caaatttaca agaaaaacaa acaaccctgt caaaaagtgg   35940
gtgaaggaca tgaacagaca cttctcaaaa gaagacattt atgcagccaa aagacacatg   36000
aaaaaatgct catcatcact ggccatcaga gaaatgcaaa tcaaaagcac aatgagatac   36060
catctcacac cagctagaat ggcaatcatt aaaaagtcag gaaactacag gtgctggaga   36120
ggatgtggag aaataggaac acttttacac tgttggtggg actgtaaact agttcaacca   36180
ttgtggaagt cagtgtggcg attcctcagg gatctagaac tagaaaaacc atttgaccca   36240
gccatcccat tactgggtat atacccaaag gactataaat catgctgcta taaagacaca   36300
tgcacacgta tgtttattgc ggcattattc acaatagcaa agacttggaa ccaacggaaa   36360
tgtccaacaa tgatagactg gattaagaaa atgtggcaca tatacaccat ggaatactat   36420
gcagccataa aaaatgatga gttcatgtcc tttgtaggga tatggatgaa attggaaatc   36480
atcattctca gtaaactatc gcaagaacaa aaaaccaaac actgcatatc ctcactcata   36540
gatgggaatt gaacaatgag aacacatgga cacaggaagg ggaacatcac actctgggga   36600
cggttgtggg gtgggggag ggggaggga ttgcattggg agatatacct aatgctagat   36660
gacgagttag tgggtgcagg gcaccagcaa ggcacatgta tacatatgta actaacctgc   36720
acattgtaca catgtaccct aaaacttaaa gtataataat agtaataata ataaattaaa   36780
aaacagaaac attatatcta tctccttgtt ttcatagcaa gtcatcaata catgtttcta   36840
aattgagaaa gaataattac aattgaaggc acatagtgat gaaagaaaaa ttgttgattc   36900
tgacatttgg agctgaaaat atttaatagc tacaatcttt aaaagtcagt atttgaaatg   36960
aaaagttctt ttatatatgg ttgggtgatc tgttggataa tgtttattc ttcttaaagc   37020
aaggtgtcct tgttctttgg acatattttc agtgttgtga gttgtctttc cttgtctctg   37080
tctctttctc tctgttgccc tctctgtatc actgcctttc tctcaattcc tatttcataa   37140
tttggtttag cttatattgt gtcttacaga ctcttacat gttggcctca gccttacata   37200
ctttcaggac aatctcagta cagacaaggc tgctgcttgt ttttggaaat gactcctctt   37260
gcctgaaatg gctcaagtgc acagcaggtg tatgtgtgtt tgttggtgtg tatgtattgt   37320
gtatgttcat gtatggtgct ggtggaggtg caatcataca acgagaataa ttttttgctct  37380
```

```
acaatagcta ctaccattta ttttactttt tgcagtaaaa tttttttctt acccactgct   37440
ctgttcatta acaaacttct agttaggtaa gaaggtgtta ttaactaaga gtttgttaat   37500
gatagtttat cctgttcaga tgtgagaaag aatgttaaaa ctagtgtcta ctctattagg   37560
agatacatta gatgatctca catgcacaat tcctatgtcc attttgcaaa catatttact   37620
gcactgccta ttataatgca tagaattctg ttggtggaaa aatacaagtg tgtccagaca   37680
ttttcgcact ggtttgctat gctaatattg ttatatgttg aaagtgcatg atttgagatt   37740
gactgatgca ttgtcatttt ccccataact tgccatatta gatcactaca ttaatttatt   37800
ttgcttgctg actgtctatt tgttctaaca ttatttttta aaacaatcag aaacttctta   37860
gtagtatatg atactcgcac ataattgttt ggactaaatt agcagtttga ccatccttat   37920
gaggatcaga acaaaatcag atcataagac atgacagaac acatatagct ttgagactaa   37980
aaccttaaaa atgtgactgt tttccttctc tttttttgagg cttcttagag ttgaaagctt   38040
catgtgtttt ctcttttctg tttctgttat actgcctgac agaaacatca ctttacttac   38100
catgcttatt cagtgtacct gcttttcaag gaaaatgtaa tttgtgtgtt ggaaaggaat   38160
ttgaaaagtc actggtcaca tcagcccaca tggatactct ggattcttat ctccatagag   38220
aaggccaata accatttgcc ttgaccacac ccaattccta cttaaaactc tttatctaac   38280
atctaagttt ctcttcttct tctctccttc ttcttatttt ttttttttct tttaaccagg   38340
cttccatgat actggggaca aaaaaagaga agataagaga tgaactagtg gctttctgga   38400
ctctcaactt gaattatttg ttttaaaaaa gtatagggga aaatgggttt gaggaacacc   38460
ttagctttcg atgcttaagc ttttgacttg ttgtaatcct gggtatggaa agaactctga   38520
taactttgtg gctctgtttt ctatttggtt ttgttttaa tgattctctg gatgttaaac   38580
atctagcaag taatttgatt tgcttaattc tgaggaaaga aaaaatttcc tttgagttaa   38640
atttatgggg taaattcact tacattaaat gtaggaactt taagtgtgca gttcagtaaa   38700
gtttgacaaa tgtgtacagc catgttatca caattccaat tttcaaggct actgtgcagc   38760
tgggaagtgt gagaataggg caagtaaaga tgccacaaag ttcactgtcc ttaccaagat   38820
tcaggaattt tttcttgaat aaatactcac ggaattgttg caagcttttg attactttct   38880
agtatccaga aacagttgac ttttgacttt tttttagtgt tctcatggtt ttcatggagg   38940
gacagttttg ggaaggtcat tactatgtca atcagaaagt tgattcttag atagatagat   39000
agatagatag atgatagatt catcaagatt gtatgaacag tttgttcatt tttattgctg   39060
agagtagtaa cccattatag ggatatacta taattggttc atctatgcat ctgctgatac   39120
atgtttgaga ctctgtatgg atatgtcttc ttttgccttg gataaatact gaagagcaaa   39180
atttctgtgt catagtttta tgatgaacta taaatttata taaaatttta taaagggcca   39240
ccagtttttc acagcccatt gaattatttt cattattata tcttgttatg tgttataaga   39300
gtttcagttg cttcacatta tcattgttaa tctttgtatt gtcaatattt tttattcctc   39360
ccattgaagt gagtgtgaag tgttacaaag ataaacaaag ccagctacca gttaaagtag   39420
taaggacaga ttttattcag taatatacta ttgcaatgga caggtaggtt cactgtaaac   39480
tgaactctaa ttttgttttc acagagataa ctgtgtattc taaaggtaga atgaggaaat   39540
aggaagaggc atgagcaggg ctcaagagag tcagagaagt aaaaaaatta caaaaagtgt   39600
gaaaggagtg ttgatccatg tgaaacccac ccagttttgc caactggctc ctaccctccc   39660
ttgggagcta gtagacaaga gctctttctc cacatattgg ctgaaacaga cagtatcttt   39720
tgttggcagc cttgagtttt ctcaggcagg ttcttccagg agtactacag tcatcccagg   39780
gatatggcct tgagctgtta gccactgtgt ttgtgttttg ttcaagtctt tttaggccaa   39840
ggttgaggcc tagtcaagaa agtgctcaga ggattctttc tagagtttgg tccaggagga   39900
aatctttgtt atgcggtgtt tcataatggg cataatttac atttcttga caaatgcaga   39960
tgttgaattt cttttcatgt gatcgtttgc tgttcatgta tcttctttta tgaagtgtct   40020
gctcacaact tagactttct ttttttttt aattgaactg tttatatttg gaccagtgaa   40080
ttgtgggaga tatttatatg ttcttaatac caatcatttg tcagaattac ttactatgaa   40140
tagtcttcct agtctatggt ttgccttttc attatcttag cattattttg aagaatgcgt   40200
gttttaaaat ttgatgacac acacacactt tatatatata taattatata tatatatttt   40260
attcacaatt agtgctttta ttttcttcct aagaaatctt tgctttcctc aagatcataa   40320
agctattctt ccattttttt tttttcctg gaggacttgt agatttagca tttacattta   40380
gaatttttat ttccaccaat ttagtttga gtattggcat gtggtgtgtt ataggaagtt   40440
aaatatttta atgaacatat ccatattttc cagtagcagt ctccattaaa atacctttgc   40500
acctttgttc aaaaatccat tggctacata tacgagtgga tctatttgtg atctctttat   40560
tctgtacact taacctcttc atcatcctta gatccacaca ctgctttgaa tgctatactt   40620
cttagtaact cttaggtgga tgatattaac ttaagggaca gttttttcaca tactttattt   40680
ttttcaagaa agccttcaga aacccctgtt caacttgtgt ttgaagacat taaatgttta   40740
gttaacctga ttttacttca attacaatga tcaattgatt gatgtctgct agaagtgcac   40800
ctaattaatt agttatgtaa atactacaat ggtcagataa ttggacacat ggtactgacc   40860
atggacattt aagtagtgca aattatgcaa caatatttgt tcactttcca aaggggtttt   40920
tgtgtttta tgacagcatt tattttagaa tcagatcatg aagtttgca aacatcatcc   40980
tgctgaaatt tgatagaagt ggctttaaaa ttattgatag atttaggaag aattaacaca   41040
ttgactatat tgaatattct aatgcacaag tgagacgtat gtctttatta tttaggtctt   41100
ctttaatttc gctctgcaga cgtttgtgct tttcagtgtg tatctttgc acactttta    41160
```

```
ttttttgtttc tgagtagctt atgattttat gtgatatttt taagtttat attctactgt  41220
gtattgcttt tatgtaactg tatgagtgtt tttgggtttt tttattttgt tttgttttgt  41280
tttttagac agagtcccgc tctgtcaccc agattggagt gaagtggtat aatcttggct  41340
ctatgcaatg tctgcctccc aggttcaacg gattctcctg cctctgcctc ccaagtagct  41400
ggggctacag gcacgttgcc atcacaccgg tttcactatg ttggctaggc tagtctcaaa  41460
ctccctacct caaataatct gcccacctca ggctcccaaa gtgctgggat tacagttgtg  41520
agccatcgca cctggcctgt atgagtggtt tttgtgtatt gaatttgtaa ttgtaatcat  41580
atcatcttcc aaaatataca cttaatttcc catttgtata ttttaaaata acttttataa  41640
taaagcatca tgtcatctgt gaataacaca gatttgtttc ttttcaattt gtatactttt  41700
tatttagtag gtaggacttt cagtaccata ttgaaccgac tacaacttt aaataaaaaa  41760
tagccaattg agtaatcaca aacacacaag taaaatctta agggccaata ggatgtatcc  41820
aactgtctga acatggtgtc atttgtatag ctaaatccat taggtgttcc actagcagac  41880
atacatcaat tggtccttcc agcagaagca aagtgacatc gactaaataa actaatgtgt  41940
tcagtaatat agatagataa tataaaactt tctgaaggct ttctatgaaa cataaaataa  42000
gcatgtgtaa aactcatctt tgagttagta taatatacat agctaaatct gtattcccta  42060
accaaatcta taagtaaatt aatgtcacct tctaatgtgt ggacatctga tcatgtgatc  42120
ccatattaaa atttttgaga ctttgctctt cctcatcaaa aataaccaat ccattacttt  42180
ttgtctatcc attcagttat tattgagcca gaatcatttg tagtcagaag agtcattttg  42240
taactcttat gttttattga aatgttattg catattaaca tatgtaagaa aacaaataaa  42300
tgaatataca tatacataca cacatactat agggcatatt gccttcaaat tgaaagctgc  42360
cattctgttt aacaaagagc caaattgtca attagtttta tgcattaagg gatgaggaaa  42420
tgagagacac cagtattata gtcctatatg acccttcatt ctatagaaat atttaagaaa  42480
taccatttta ttttattta tttatttatt tatttatttt ttatttattt ttattattat  42540
tattatactt taagttttag ggtacatgtg cacaatgtgc aggtttgtta catatgtata  42600
catgtgccat gttggtgtgc tgcactcatt aactcgtcat ttagcattag gtatatctcc  42660
taatgctatc cctccccct ccccccactc cacaacagtc cctggagcgt gatgttcccc  42720
ttcctatgtc catgtgttct cattgttcaa ttccaaccta tgagtgagaa catgtggtgt  42780
ttggtttct gtccttgcga tagtttgctg agaatttgct gaaaattgag tttccagttt  42840
catccatgtc cctacaaagg acaagaactc ttcattttt atggctgcat agtattccat  42900
ggtgtatatg tgccacattt tcttaatcca gtctatcgtt gttggacatt taggttggtt  42960
tcaagtcttt gctattgtga atagtgcccc aataaacaca cgtgtgcatg tgtctttata  43020
gcagcatgat ttataatcct ttgggtatat actcagtaat gggatggctg ggtcaaaaga  43080
aataccattt tacttttaaa ttagtgcaag gaatcaaaac catacagata aaaactgaga  43140
taaggcttta aactcaattt gaggaaaaaa atagctatgc tcaaatctct caaatttcat  43200
gggatgtaac aaatctacat tttgatttg atatatagct atattgtgtt gactgatttc  43260
tcaaagaata accaccattt gtgatctaag agaattaggg atgcctcttc tgtcttggtc  43320
agagcccatt ttgattcatt tgtgctaacc tggaactatc agtgcactgg aaaatacaga  43380
ctaatgaaca catgtctagc ttcccttatc atctaacaaa tgcagtgtaa acaagtttta  43440
aatattcttc cttctatttt cagccctatt cctaagtcaa caattttatg actcatcaat  43500
tttataaacg gtcctggtct cagacctgtc tttgattctt agcttgttaa tgactttcaa  43560
tagggcagac tagttccagc ataaatccag aacgtccgtc ctccaaagga cctgggccct  43620
gaccaatact tctgcttcct tctactgatt atgttgtcac tctgctgctc tccacatcct  43680
tacaaatcct tccttttcctc aagtctttca gctgccacac ctttctaccc ctcacccctca 43740
gtaaaggacc tcaccccagt gtctatagac aaaactggag agttctgatg aaaaccttct  43800
tggtttatt atattaaaat tacaaaactt atctatctat attttccttc ttccatatta  43860
ttgaaagtga tggctagttt ctctgtttgt gctaaagctc tgatgaacac atgtaacaaa  43920
actgtacata aatgttgtat agggatttca tcttcaaagg agaatctagc tgttcaaact  43980
atcaaataaa tgttaagccc ttgaggaaca aatgatatta taattggttc tttagaatta  44040
ctttaaaaat actctaggga atatagctaa gaaatatata tcttgccacc ttgctttaca  44100
aactatggtg agttaacatt aacaggtagg tcatttgcta catttgttca ctaaaaatac  44160
aacttttct gtgtgtggag attagtatcc aatcaataga ggaaacccat attttcatca  44220
atttcactgg acttttctat tcatatgtta acatttcatt gactctaaaa tcaattatat  44280
gcaagctcct ctgatgtata tgtgagagct aaataagcaa tttctttagg gtgcaaattt  44340
ttgagcaata atttttacag tcatagctta ttttcatgaa gaactcagag agagtggctt  44400
gagttggcag caaagactgc ttttaacaat gttctgtgat tctctaacaa tatttttaata 44460
agtagtttag tggcatataa atggagacaa aaaaacttca ctctcttcct tcaggtgcta  44520
taattgttta tttactgttc aaatgttgca ttctcagaaa aggctacttt gaatagtcat  44580
ctaaaagaat ctcacattca ttgttcttca cagacccagc tttttacttga aattataata  44640
tgtatctttc tctgtgggtt taaccattat ttctcatatt ataatgtgag ctccatgaaa  44700
ctggaaaatt tgttcactcc aataacccca ggaattgtaa tacacacaaa aaaatcaagc  44760
tatgcagtca gtgtacatga ataaacaggc aggtaaaatt tcaaagtgaa aaaacagttc  44820
ttggttttgt atattcttag ccatatatca agcactaagt ttaactaatt taatgttcac  44880
tgacaatcat aggtttctgt ttgtttgttt gtttgtttgt ttgagacgga gtctcgctct  44940
```

```
gtcgcccaga ctggagtgcc ctggtgtgat ctcggctcac tgcaagctcc gcctcccggg   45000
ttcacgccat tctcctgcct cagcctcccg gtagcttgga ctacaggcac ccgccactac   45060
gcctggctac ttttttgtat tttgagtgga gatggggttt cacagtgtta gccaggatgg   45120
tcttgatctc ctgacctcgt gatctgcccg cctcggcctc ccaaagtgct aggattacag   45180
gcgtaagcca ccgcgcccgg ccgacagtca taggttttaa gtgaaaatgc taccttaatt   45240
tttttcttct gttttgtatc tgaaataata agatatcaga catggaggga aactgaagat   45300
tggacttcct acatttattt atttaaatga tgctaatatt aatatctgat attcatttct   45360
ttgttttttt tgttccctca caaaccttga aaataattac caaatgtaga attcaccaag   45420
aagacaagta taaatgcatt aatgtataaa tttataaatg tatatatata agagacagaa   45480
atagagaatg tgcctgtgtg tgtgtgggtt tgagatacaa aaagagacag aaaacacaca   45540
catataaaga gaaaacgttg tgcagaaatt ctgatgtgtt tattgaaaaa agtaattggt   45600
gcctagatga atagatgaat gagtgaatga taaatggatg aaacaaatgc caaatctgga   45660
tcagagagaa tcctcacatt ctttgtcact ttcagttttc aagaaataag aagatgttgt   45720
ccccaaacca caccatagtg acagaattca ttctcttagg actgacagac gacccagtgc   45780
tagagaagat cctgtttggg gtgttcctgg cgatctacct aatcacactg gcaggcaacc   45840
tgtgcatgat cctgctgatc aggaccaatt cccaactgca aacacccatg tatttcttcc   45900
ttggtcacct ctccttttta gacatttgct attcttccaa tgttactcca aatatgctgc   45960
acaatttcct ctcagaacag aagaccatct cctacgctgg atgcttcaca cagtgtcttc   46020
tcttcatcgc cctagtgatc actgagtttt acttccttgc ttcaatggca ttggatcgct   46080
atgtagccat ttgcagccct ttacattaca gttccaggat gtccaagaac atttgcatct   46140
ctctggtcac tgtgccttac atgtatggct tccttaatgg gctctctcag acactgctga   46200
cctttcactt atccttctgt ggctcccttg aaatcaatca tttctactgc gctgatcctc   46260
ctcttatcat gctggcctgc tctgacaccc gtgtcaaaaa gatggcaatg tttgtagttg   46320
caggctttac tctctcaagc tctctcttca tcattcttct gtcctatctt ttcatttttg   46380
cagcgatctt caggatccgt tctgctgaag gcaggcacaa agccttttct acgtgtgctt   46440
cccacctgac aatagtcact ttgtttttatg gaaccctctt ctgcatgtac gtaaggcctc   46500
catcagagaa gtctgtagag gagtccaaaa taattgcagt cttttatact tttttgagcc   46560
caatgctgaa cccattgatc tatagcctac ggaacagaga tgtaatcctt gccatacaac   46620
aaatgattag gggaaaatcc ttttgtaaaa ttgcagttta ggcctgtgtt tatttgtaat   46680
ccctaagtgc ctgtggggta acaaactgaa atggaaaaac ctagtgtagt tattatttaa   46740
cagtatgggc tcttagtaac cactttagtt tcttctcaaa attaacactt tgaagattta   46800
gtttttaaaa ataaaaagct taatgttgaa attaataatg ttttatttgt cagagattct   46860
atgaatataa attgtttggt ttctaataat tctgtatgaa aatactgggc ttacttactt   46920
gggggtaaac ttttaactaa cttagcctga gagaaactct gaaaatccaa cccctttgaa   46980
tattactatc catagagcca tagtgaggct ccagataggg tggctaattt tacatttttta   47040
aaaaaatgat gccgggcatg gtggctcaca tctgtaatcc cagcactttg ggagccagag   47100
ataggtggat cacctgaggt caggagtttg agaccagctt ggccaacatg gtgaaacccc   47160
gtctctccta aaattacaaa attagctggt tgtggtggca catgcctgta atcccagcta   47220
ctcaggaggc tgaggctgga gaatagcttg aacctgggag gcggaggttg cagtgagtca   47280
agatcacgcc attgtactta ctccacttgg gcgacaagag cgaaactcca tctccaaaaa   47340
aataaataaa taaataaata aaagaaaac gaaaaagaa aaaattgtt tctacttcaa   47400
tgtggtgtct tgaacaatag ttctgaaacc tgtgaactta ttgtaatcac tgtgcaaaaa   47460
atgtaaatat atgaatcacc tataagttaa attttctgta agtattctca aaacccacac   47520
tgtaaacatc gtgagaagct tcttattggt tcatgtggta ataccagtta tggtcctcaa   47580
ttctgaaaat caactctcaa cacccttttt tttttttga gttttcaagt gcatggatcc   47640
atttctatca tcaaaatact tcaattgcat tccacgtatg ttttccagtg aagtacctct   47700
gacttaggaa taatttagta ggaatcaata gggtttatca attgatattt gcatatgcat   47760
aaatgacttt gttagtggaa aaaggggtct tgatccagat cccagcaggg ggttcttgga   47820
tctacagagg aaaaatttca agataagctg caaagtgcag tgagagaga tagttcatta   47880
aatgctactc caaagagatc atttattaaa ggctattgca ttacagagta aggtgttccc   47940
agaaagcaag tggaggaatg caccctcttt aagttttttt aatggtcttt tatctacgta   48000
cagactaaag taagttgtgg ctacatgtgg gtaggctgac ggcatgacaa aatttatcat   48060
tgtgttgatt aaagaaaac gatccttgat atttttagtgt gtgcataact attattatca   48120
tgataaaagc atatactctt atgagaattg ggacacctag gttctcttgc tgcattatta   48180
gcgtgttctt gtaggtattt ttaggctgtt tcctaaacta taagcatctt atgaacatgg   48240
gtcatgaccg gccaggactg tgccttgtta acctcaagac agagttgatt ttaaaatgtt   48300
gtcaccctgg atctcctaga ctcctgcttc tttaacaccc tgaaacagta taaaaattaa   48360
taggggcgta cgtatctttt tggaggaaat agtgtttatt ttgcttcaca caactgtctg   48420
tggcacatta tttttttaca ttagggtatt ctagttctca aagctactac agggaaaatc   48480
aatcacaaag aggctaaata aagatacaca ttaatcaatg tattattttag tcaaccagat   48540
gactgcatat taatacatac atatttagcc ctattaaatt gcctcttatg tttgacattt   48600
taatattttg cactctgctt ttaactaaca ctatacagaa aatgctacag aaaatgctta   48660
tatgatatca actactgtat ctactataaa atgttcaagt ggttttccag aatattaaac   48720
```

```
agatgactaa cagttttgt  aaaattgggt tatattctta agtgtcagtt ggttgaataa  48780
gtctggttct atccaaatct gctttagaa  acagtaactg aaaaagaaag aaggcaattt  48840
tgggcagcaa caatttaata tttacctttt agcactattt gtgtatttgc ctggtttttgg 48900
caatggcagt ggcacaacag aagcaggtga tctgtagaga caagagtgaa gcagaagagc  48960
tgggaactga gtgacacagc gtccttactt cctttttagag gcccagcatc atttcatctg 49020
tgggatattt cttttatctta tgacaacatc atttaatctg .tgggatagct cttttatatta 49080
ttctttttatc ttcctctttt ggttaggcaa agcattgtgt tcaatttcta gcaagtagag  49140
tggtctgata ctctatttga aaactgtatt ttagaattgg tacaaacaca ctctatattt  49200
tgcctaaata actgtatact tccttttatt ttctagttat gagaattgct gtggcttgca  49260
gcaaccaaac ttaaactttg acacctttgt aacccaaatg cttgacctgt ttgtaatctc  49320
ttttttttaa aatatgtatt tatttattct atttgtaatt taattttta  attgtgcaag  49380
cccttgggta aaagttatct cagaaaattct ttggagatag aatagaacat aaatggacat  49440
gaatagaaat agtgacaatt gatgtaatca tagtgtattg ctaattttag gattactgtt  49500
ttttctttac ttaaatgaaa atgaagtagt gagagaatta ttatcttcat ttacaatatt  49560
tggagtctta dacacagaga gatgaaatga cttgcctaac gtcatttggc cactcagtag  49620
cacaaaagca gatttcttgg tttaaatttt  tctctcttc  taattcatac tgaagtggtt  49680
attaagccat tcttcaacac acttcaaatg ctggggggaa tattggagac tatgaattaa  49740
taagagtgtt actatagatt aaatagtggt tattatgtga tagtgagatg tatcctaaca  49800
acagctaatg tgaattttcc ctgacagtca ggctaatgtg atcatttata tgcatgataa  49860
ttaaaattgt cttaatatcc atgtgaaggg agaaaatttt gatatatggg aaacctttat  49920
gcttcttagg ctgcatttta ttaatatatt ttcccaatta taaaagcaca catatttata  49980
ttaattaatt tccaggtaca dacaaatata aaaacataaa atttattaag gacctgctat  50040
gacaaggaat aagttttgtt tatattttgt tatatttctt ctcaataaat gtatatgact  50100
acatgttact ataatgcaca aaacaaatat aaagttactc accatataat aatatgaata  50160
cagattttca tttgatacta taatgtatgc acctttacat agattaaata ttttatgaac  50220
attttaatg  tcatatttta attagcttgt gtgatcctaa tacaatatta atacatgtca  50280
aatgtagaaa accaatgaac catattggca tacataagaa atagaagcaa tgcttacttg  50340
taatcaacta cctgaaaaga gttgctctca gcattcacat gtgttttatt ccatttgatt  50400
atcttgcaaa tcatgattcc atcatatcaa tgtatcttag tattttgatg accgacgtat  50460
ctgtacgtct ctctctaatt gttcctttttg ttatgttccc agaagtgtaa ttgctgaatt  50520
aaatgttttg aacatttta  aaggtcttgc taaacatttc tatggataaa tttttatcca  50580
gaaagcttgt aacaaacctg taccactaat gtttgaaaac aatcatttta ctataactct  50640
atcagcagta ggagctcttg tttatggtta tatgctactt tgatctctca aaggaagttt  50700
tagaaacaaa ttctgtttta atttgcacag attagaaatt gaagaatata tttaacaaat  50760
aaaggctaca tataataatt ttctttcatg ttatgatggt gtcttacatg aagaatattt  50820
gtatttttat ggagaaaaat tatattttgt ttattgttgt tttgtaactt tttcttatgc  50880
cacaattgaa taaacaagca cttatatggg gttattggct ttcattgcaa tattttatgg .50940
gaatatcatg aattatcctg gatataattt tgttgcatgt tttaatgttg taaattactt  51000
ttgtgccctc acatttttaa ccaacttcct ccaagtgtta ttaagcactg ctttcccact  51060
gatttgtgat gtcacctttta ttataccttaa agtcaatcta tttctgccca tttccactgt  51120
ttttttttgtc tgaattataa atatattttta aactaaattc ttatcattaa attgaacata  51180
tattttaatt tctggtgaag atattttttgt cttcaatttt ctcttaggag attgaaaatc  51240
agatactttt agctatccaa attttttaact cagaaattat aatattatga ttcaatttag  51300
aaactgtatg tatagttgta taatttttgaa tgtagttgta catacaatac ttatacatta  51360
taaagcaatt aaaaaataag gaaaattatt ttactgtcta tggtggccat agggagaact  51420
gcttaaggat gaaatatttt gaatgagttg tttgttttcc agaaagtcag gaagatgctg  51480
gtgtctggta agtgaggaga aaacacctaa ccttggtata ttaattctat ggatttatta  51540
acactgttat acaaatactt atgttttcac cataccagtg tatggtgaaa tcatcatgta  51600
acatttttttt tcaacaaata tctctaaata cagtctcttt ttcttacaaa gaggtttttt  51660
tcccagcaat taccccccaaa agaactgaga gggccacata tgtttttcca ctatgagtca  51720
cttcaaacac tgaacaaaaa aggattaatc agaaagaaaa taaatattta aatttaaata  51780
atcagagaat aatatatctg tgcttcataa cagtgggaaa aatttgtagt aaaaagagta  51840
agcaaattgc tttaatttga agataaaact atttaaaatt aagaggcacc ctacaatttg  51900
gcaatgtatt tgccacaaac aagataaatt ggtaaaatta ttgaaataca agaaattaat  51960
aaaaataatt tgaagcacta aagaatcaat atataaatat caaagactat aagtaaaaaa  52020
ttgattaaaa tacaaaaatg ctaaaattaa cacacaaaat attagcaacc aaaaatatga  52080
tgtaagatat tgtttgatat atctacattt aaaagagctg atatagattg gcactttcat  52140
acattgattg attaagggta taaagttttt ctgaaaataa atttaatatt taataggttg  52200
gtacaaaagt aatcttgttt ttttgccatt aaaagtaaca gcacttattt tttttcttac  52260
caacctaata ttattatcat attaaggaga caaaattttc ttatgctttt attcagctat  52320
ttcaatttta agaatctact gaaggcataa gaaacttgtg tgaagagttt catggtgttg  52380
.ttttttatttt ataatcaaga caaagtaaac acatgatgta ttaaatacaa atagttcctg  52440
cttggcatgg taccatgtaa cagaaacctt tccatactgg aaacgtgtct tagttttttgt  52500
```

```
ggttcttagt tcctacaaaa tcacaaagtg agaactgcct gcatttaata actggtaaaa 52560
tacaggcatc caccagatgg gatagaagct gtctctaact aagtagaatg tcattagcct 52620
tgatcatgaa ggaaagtgta aagtacaggt gaaacgtttt ttgtaataga aagttataca 52680
gccattaaag tgaggatgtt cctagttaag aaaaaggtaa ttcattttat gtaatatatt 52740
atgtgcaaag atatatccta tgctgtatac agtgtgatat cttgtaaaat attagggata 52800
aggggaaata aaacttgtta ttaatagcta tgtccatatt taaatagtca ttgctattgt 52860
gagaaaataa ggcaacaaaa actgtgtatt ttcagtttag tccagatctc aggatgtata 52920
attacaggat acttatttat taatattgga atttaaatat gaaagtaagg aaaagcaagg 52980
aaaaagcaag gtaagaaaaa gaagaggtcc ccaattctgg tttccagcac agaatgacca 53040
atgaacaact tctcagagaa aaatgcccat gtgaaaattc cgtaacccat gggtgaggtg 53100
gggcacactc ttggagcata aaaactggaa aaaaccacat tagaattgtt aagaggagca 53160
gtttcacttg cttctttccc agccaaacac agtgtcacac tgaaagagat tccctgggcc 53220
tgtggtttcc ccagtgaaga aaagagagcc cacggcagac atccagcttc cctatgttcc 53280
agagaacttc ccaagaggcc cattctgtct aaccttgtgg gtaataacgg aagacttggc 53340
aaagcttggc caccccagtc agctcataac aaagttaagg ggtgtagctt acggcaacca 53400
gcacccgatc ttggtggtgg catcatgttc tagctggcag ctttatgtga ccagagagcc 53460
cagccactag cattgctcac atgtggagct gagttggcag gccctttcgg tcaggaggca 53520
tgttgaacag ttctgtctgg ctgtggtacc agtcagtaag ctggaccagc tgcagagcac 53580
agcctagagc accacccaac cacaaagcac aacttgcagc ccacccact caggtagaga 53640
tccaagccag caaccccact caaccgctgg gcatagcctg cagtcccatc tgacgacgga 53700
gtctggtcaa ttatctctcc aaactacaga gcacatccag taaaacttcc caattatgga 53760
tcagcttgca gccccaaaaa actgcaggaa atagccagtg gccctatctg gccaagagat 53820
ctggtcagtg atctcaccta aatttggagc aaaggcagtg accccatcaa tctgtggacc 53880
acagccagca gccccactcg aatacatacc acagtgaatg gtcttacctg attatggagc 53940
ccagtcagca gccctgagtg attttggatc ctagccagca tactcaccca cctcagagca 54000
caggcagcag tcagaggtca tgtgactaga gtcagctttc aaattcatca agtcctggtt 54060
ccacctctta ctccctatga aatctcaggc aaattattta acctctactc ctatgcccca 54120
atttgtttgt ttgtttgttt tcacagtact tatcatcacc tgccatatat ttgtttgtgg 54180
gtgtatttgt catctatctc ctccagcaaa aaacattatc aataaagtag ttttttaattt 54240
tttttgagca acagctatat tgagttatat agtggctata ctaatttaca tttttgccaa 54300
taatgtacga gcattccttt ttctgtgtat ccttgcaaac ctctgttcat ttttttgtct 54360
ttttaatgac aatcattaca aattggttga ggttatactt cattatggtc ttgatttgca 54420
tttcatttat gattagtgaa ttaaaccttt ttttcatata cctgctgaca atttgaatat 54480
cttctttttg aagcttttga taaaatccaa catctcttca taataataat aataaaaaaa 54540
tactcaacaa actaggcatt gaagagacat acctcaaaat aataagagcc atctatggca 54600
aacccacagc caacatcata ctaaatggga aaaagctgaa agcattccac ctaataaatg 54660
gaacaagaca aagatgtcct ctctcatcat tcctatttca catagtactg caagttctag 54720
ccagagcaat aaagccagag aaagaaatat aaggcatcca aataggaaaa gaagtcaagc 54780
tatctctctt cactgataat atgattttat acctagaaaa ccctaaagac tacaccaaaa 54840
agctcctaga tctgataaac aactttatta aagttcagg atacaaaatc aatgtataaa 54900
aatattagca tctctatact cccataacat tcaagctgag agctaaatca agaatgtaat 54960
cccatttaca atagccacac gcacaaaaat aaaacaccta ggaaaacaac aaaccaagga 55020
ggtgaaagat ctctacaagg agaactacaa aacactactg gaagaaatca tagatgatat 55080
aacaaatgga aaatcatccc atgtttatga attagaagaa tcagaatgct aaaacagcta 55140
tattgcctaa agcaatctac agattcaaca ctattgccat caagctaatg acactattta 55200
catagaattt gagaaaactt gcctaaaatt tatatggagc caaaaaagag actgaatagt 55260
caaagcaatc ctaagcaaaa agaacaatac tggcagcatc aaataaccca acttcgaact 55320
atactacaag gctacagtaa ccaaaaaagc atggtactgg tacaagaaa gacccataga 55380
caaaatgaaa cagtgaaccc agaaataaag tcagacatct acaactgtct gatctttaat 55440
aagttgatag taataaacaa tagggaaaga actacctatt caataaatgg agccaggata 55500
actatttagc catgtgcaga agagtgaaac tggacccata cctgtcacca catataaaaa 55560
ttaactcaag atggattaaa gacttaaata taaggcctaa agctataaaa atcctggaag 55620
aaaactgagg aaataccact ccggacattg gcctcagcaa aaaatttatg aataagtctc 55680
cagaagcaat tgcaataaaa ataaaaattg aaaaatggga tgtaattaaa ctaaagagct 55740
actgcataga aaataaatta acagagtaag caatctaaag aatgaaagaa aatgttcaaa 55800
aatgataaat ccaacaaaaa tctaatatcc agaatatata agaaacataa acaattcaac 55860
aggcaagaaa cctcccccta aaaccattaa aacacatgga cacagggagg ggaacatcac 55920
acactggggc cttttgtggg gtgggaggct aggtaaggga taccattagg agaaatacct 55980
aatgtagata acggattgat gggtgcagca agccaccatg gcatgtgtat acctgtgtaa 56040
caaacctgca cgttctgcac atgtacccca gatcttaaag tataataaaa aataggcaaa 56100
agacataaac agacacttct caaaatgaag catacatgtg gccaaaaaat atattaaaaa 56160
tacagtatca ttaatcatca gagaaatgta tatcacaact acaatgagat aacatctcac 56220
accggtcaga atggctatta ttaaaaagtg aaataaataa cagacattgg tgaggttgtg 56280
```

```
gagaaaatgg aatccttata cacttttggt gggaatgtaa attagttcat ccactgtgga   56340
agcagtttgg aaatttctca aagaacttaa aacacaagta ccatttgacc cagcaatcct   56400
attactgggt ataaacccaa aggaaagtaa ataattttac caaaaccaca tgcacttgtg   56460
caatcattgc agcactatac actgtagcaa agacatggaa tcaacgtaga taaccatcaa   56520
tgatgaacgg gataaagaaa atatgataca tacacactat tgaatactat gaagccatga   56580
aaatgaaatc atgtcttttg cagcaacata gatgcagctg aaggccatta tcctaagtga   56640
attaatgtag gaacagaaaa ccaaatgtgc ccatgttctt attaaaggta tgagagaaac   56700
attgaataca catgaaaaat aaaggagaac aagcaacact gggggttaat agaaggggaa   56760
gagctgggga gtgcagactg aaaaatgatc agaccaatgg aacagaatag agagcccaga   56820
aataagacca cacatctatg accatctgat cttcaacaaa gctgacaaaa acaggcaatg   56880
ggaaaaggac tccctattta ataaatggtg ctgggataac tggctagcca tatgcggaag   56940
attgaagctg gaccccttc cctataccac acacaacaat caactcaaga tggattagag   57000
acttaaatgc aaaaccccaa actgtgaaaa ccctaggaga aaatgtcggc agtatcatcc   57060
tagaaaaga aatgggcaat gatttcatga caaagacaca aaaagcaatt gcaaaaagaa   57120
aaaagcaaaa attgacaagt aggatctaat taaacttaag agcttcttca cagcaaaaca   57180
aactgttaac agagtaaaaa gacagcctat ggaatagaag aaaatatttc caaactatgt   57240
atctgacaaa ggtctaatat tcagcatgtt taagaaactt aaatttacaa gagaaaagca   57300
aacaacacat ttaaaagtgg gctaagatgc tggcaacagt ggctcatgcc agtaatccca   57360
gcactttggg aggcagaggc aggtggatta tctgaggtca ggagttcaag accagcctgg   57420
ccaacatggc aaaaccctgt ttctactaaa aatacaaaaa ataactgggc atggtggtgc   57480
gtgcctgtaa tcccagctac tctagaggct gaggctggag aatcacttga actcaggagg   57540
tagaggttgc agtgagccga gattgcacca ctgcactcca gcctgggcga cagagtgaga   57600
ttctgtctca taaataaata aataaataaa taaataaaat acataataaa agtgggcaaa   57660
gaacataaac acttctcaaa agaagacata catgcagcca acaattatat gaaaaaaggt   57720
caatatcact gattattaga gaaatgcaaa tcaaaaccac aatgagatgc catcttacac   57780
cagtcagaat gactattatt aaaaagtaaa aaaataacag atgctggtga ggttgcaaaa   57840
aaaaaggaac attttttatac tgttagtggg agtgtaaact cgttcagcca ctgtggaaag   57900
cagtatggca attcctcaaa gagctaaaag cagaactacc atttgatcca acaatcccat   57960
tactaggtat atacccacag aattataaat cattctacca taaagataca ttcatgtgac   58020
tgttcatttt ggtactattc acaatagcaa aggcatggaa tcaacttaaa tgcccatcaa   58080
tgacagtttg gataaagaaa atgtggtgca tacacaccat gtaatactac atagccataa   58140
agaagaagaa gatcgtgtct tttgcaggaa catggatgga tctggaggct attatcttta   58200
acaaactaat gctgaagcag aaaaccaagt accgtatgtt cttatttata agtgggagct   58260
aaatgattag aacttacaaa cacaaagaag gaaacaacag acactggggt cttcttgagg   58320
ggggagggtg ggaggaggga taggagcaga aaagataatt atgggtacaa ggcttaatac   58380
tctggtgatg aaataatctg tgcaacaaac tcccatcaca catgttcacc tatgtaacaa   58440
accttacat gtatccccaa aactaaaata aaagtttttt tttttaaagg aaaactgttg   58500
ggtactatgc tcactacctg ggtgatggga tcatttgtat accaaatatc agtgacattc   58560
aatttaccta tgtaacaaac ttgcacatat acccctgaaa ctaaaaatag aaaaaattat   58620
taaaatacaa caaaaagaa aaaagatgaa aaagagatat ctataatcat ttgcacattt   58680
caatcagatt tttaaaaatt tatttatttt gaaattgagt tgttcaaatt tcctatgtaa   58740
cctgaatatt agtcccttgt cagatgaatg atttgtaagt attttctccc attgtgtagg   58800
ttgtcttttc actctataga ttacttcttt tgctgtgcag agatttcttt tgtttgatga   58860
aatcctgttt atctatattt ggttttgttg cctgtgcttt agaggcctta tccaaaaact   58920
ctttacctag accaatgtct aaaagtattt tcccagagtt ttcttctagt agatttatag   58980
tttcaggtca tacatttgtc tttaaaacat tttgattaga tttttgtata gtagtctatg   59040
atagtctttt atatgtctga ggaattgatt gtaatgtcac ctttgtcatt tctgatcgtg   59100
ctgatttgga tcttctttct tattttcttt gttaatctag ctagcagtct atccattttg   59160
tgtatccttt caaataaact tttggtttta ttggtttttg gatgtatttt ggggtctcag   59220
tttcattcag ttttactctg atttagttat ttatttctt ttactggctt tggagttagt   59280
ttgttgtttt atagttcctc taggtgagat gttagatcat taatttgaga actttctaac   59340
ttttgaggg aagtgtttag cgctgtacac tttccttta acactgattt tgctgcatcc   59400
cagagatttc ggtaagttgt gtctctgttt ttatttattt caaatatata ttttgttaat   59460
ttctggttta gttgtttgcc caaaagtcat tcagtagcaa attgtttaat tcccatataa   59520
ttttgtggtt ttgagagatc ttggtattga tttttatttt tattccagtg ttctccaaga   59580
gggagtttga catgatttta tttcttaatt gattgacact ggctttatgg cctagtatgt   59640
gatcaacctt ccagtatgtt ccaggtgcag aggacaagaa cgtatattct gtggttatgg   59700
gtggagtact ccgcagatgt ctattaggtc caattaatca agtgtcaaat ttaagtccag   59760
aatttattag ttttcagacc ttgatgacct aaggctgtaa ttggggtgtt gaattcccct   59820
actgctattg tgtggctttt taggtctttt tgtcagtcta gaagtacttg ttttatgaat   59880
ttgggtgctc caatgtgggg tgtgtatatg tgtaggatag ttaagtcttc ttgtttaatt   59940
gaaccctatg tcattaggca gtgccctttt tgtcatttt tccagttttt ggtttacagc   60000
ttcttttatc tgacataaca atagcaaccc ctgctgtctt ttatttttca tttgtctagt   60060
```

24

```
agattatttt tcatcctttt actttgagcc tatgtgagat agatctcttg aaaattgcag  60120
atggatggat cttatttttt atctaacttg ctactctagt atatgcctgt ctttataggt  60180
aaatttcttg aagacagcac atacttgagt attgattttt gtttgtttgt tttttcttttg  60240
ttttactttt ttttccattg agcagtcact cagcgtcttt taattgtaga attttgtcta  60300
ttaacattga agagtattat tgttaggtaa gagtttacta ctgccatttt gttatttctt  60360
tgcttgttgt tttctaaatc ctttatttct tgtgttctat cttactgtat tactctgtag  60420
ttaagtaatt ttctttagaa gtatgttttg attccatgct atgtttttgt gtatctgtca  60480
taggtttttg ttttgtgggt accgtgaggt ttacaaaaaa aatctatagt ataacagttc  60540
gttttgaaca gataatgact taattttgat tgcaaataaa agcatcaaaa accaactcta  60600
cacttttaat atgccctaca cacattttga cttttggtgt ttcaatgtac atgtttttat  60660
attgcctact tctaaactgt agttattgat ggttttaata gttttgtatt ttattcttca  60720
tactatgat acaagtggtt tatttaccac aattatagta tgacagtatt ctgatttttga  60780
atgttctttt acgagggaat tttatacatt ccaatgtttt cctgttacat gttagtaccc  60840
atttctttca gactgaagaa ctctctttag catttcttga aaaacaggtc tggtgttgat  60900
gaatttcctc agcttttgtt tttctgcgaa aaaaaaatct ttatttcacc ttcatgttcg  60960
aagaataact ttaatgcaca taatattctt ccttgaaaga ttttttctct tatcatcttg  61020
agtatagcat accatttcct cttgacctgc tagcttctgt gagaaatctg ctgaaagcca  61080
tattcaagct ctgtattact ctgttctcac attgctaaac aaaattacct tagcctgagt  61140
agtttataaa gtgaagaggt ttaattgaca cacagttcca caggctgtac aggaggcatg  61200
gctgggaggc ttcaggaaac ttacaatcat gatggaaggt gaaggggaag caagcacatc  61260
ttcacatggc gacagaggag agagggtaaa ggggaaagtg ctacacactt ttaaacaaac  61320
agatctcatg agaactctat cataagatag cactagggga atggtattaa accattagaa  61380
aacaccccga tgatccattc acctcccacc aggccccacc tccaaaactg ggggattaca  61440
attcaatata aggcttaggt gggaacacag agtcaaacca tatcattctg tcccggtccc  61500
tcccaaattt catgttcttc tcacatttca aaacgcaatc atgtcttccc aatagttccc  61560
caaagtttta actcattcca gcacaaactt aaatgtccaa ttcctcatgt ccaaatgtcc  61620
aaatgtccaa aatctcatct gagacaaggt ccacaggtaa gcctgtaaaa ctaaaaacaa  61680
gttatttatt tctaagatac aagggagtta caggcagtgg ataaatgctt ctgttccaaa  61740
aggaagaaat tggccaaaat aaaggagcta catatgccat gcaagtccaa aatccagaag  61800
ggcagtcatt aaatcttaaa gctccaaaat aatctccttt gactccatgt ttcacatcca  61860
ggccacacta atgcaagggt tgctctctca aggcctgggg caactccacc ctcatggctc  61920
tgcagggtgc agccctgttg gctgctttca caggctgatt ttgagtgctt gtggctttttc  61980
cagatgcatg gcacaagctg tgagtggagc taccattctg gtttctgaaa gatagtgtcc  62040
ctttcttac agatccatta cgcaggaccc agtgggaact cggtgtgggg gctccaaccc  62100
cacattttcc ctctgcattg cactagtaga ggctctctgt gaggattctg cccctgcagc  62160
agacttctgc ctggatatcc aggcatttgc atacaacctc taaaacttag gcaaagttc  62220
ccaagcctta attcatgtct tctgcacacc cacaggccag acactatgtg gaacttgcca  62280
aagcttgggg cttgcaccct ctgaagcaat ggcccaagct gtaccttggc acttttttagt  62340
cctgactgga gttggagtgg ctaggacgca ggtcatcatg ttctgaggct acacagagca  62400
ctgcagacct gggtctggcc cccgacatca ttttttccta tttgccctct gagcctgtga  62460
tgggagtggc tgtaataaag gtctctgaaa tttcttggag gcattttccc cactgtcttg  62520
gctattaaca tgtagctcct ctttatttat gcaaacttct gcagccttga attcctccct  62580
ataaaatggg ttttttctttt ctaccacatg ttcaggctgc aaatttttca aactttcatg  62640
ctctgctttc cttttaaata taaattccaa tttcagacca tctctttgaa aatagagaag  62700
aagccaggct aattcttgaa tgctttgctg cttagaaatt tcttccacca gatacctgaa  62760
ttcatctctc tcaaattcaa agttccacag ctctctagag caggggcaca atgccaccag  62820
tctctttgtt aaagcatagc aagagttacc tttactccac ttcctaataa gttctacatc  62880
tccatctgag accacctcag cctggacttc actctccata ttactattag tattttgttc  62940
accaccactc aacaagtctc taggaagttc caaactttct cctcttcctg tcttcttctg  63000
agccctccaa actgttccaa cctctgcttg ttacccaatt acaaagtcga ttccacattt  63060
ttgggtatct ataggaatgc cccacttctc tggtaccaat tttatgtatt agtccattct  63120
cacatcactg taaagaacta actgagattg agtaatttat gaagaaaaga ggtttaatcg  63180
attcaccgtt ccttaggctg tataggtagc atggttgaga aggcctcaga aaactaacaa  63240
tcatggtgga agggcaaagg gaaacaagc acatggcaag aggagaaaaa cagagcgaag  63300
ggggaagtgc tacacacttt taaataacag atattgtgag aactctaaca caaggcaaca  63360
ctaggggaat ggtgctaaac cattagaaat cacccccatg atccaatcac ttcccaccag  63420
gtcccacctc cagcagtagg agacggcaaa tttagatgaa atttgggtgg agacacagag  63480
ccaaaccata tcagtctcca ttaaatgtga tatttttctc ttgctgattt gaatattatt  63540
tctttgtctt tgatttttcc taatttgatt acagtgtaac ctgagatatt actgtttgta  63600
ttgaatttga ttggtgagca atggtctttt ctacctagat gctattgtgt ttctccagaa  63660
ctgagaaatt ttcagttatt atttcaataa gtatagtttc taggcctttt tatctctcat  63720
tccatttgga tatttcaatt atgcaaaagt taatgtactt gattgtgtcc cataattttc  63780
ataggcctgc tttacttttt ttttttttcag ctcctctgag aagttagttt caaatgttct  63840
```

```
atcttcaagc ttactgattc tttcctctgt catcaaaact atgggcacgg tggctcacgc   63900
ctataatccc agcactttgg gaggccgaga agggtggatc atctgaggtc aggagtttga   63960
gaccagtctg gccaacatgg tgaaacccca tctctactaa aaaaatacaa agaattagct   64020
gtttgtgatg atgggcacct gtaatcccag ctacttgtga ggctgaggca ggagaatccc   64080
ttgaacccgg ggggcagagt ttgcagtgag ccaagatcgt gccatcgcag tctagcctgg   64140
gcaacaagag cgaaactctg tctcaaaaaa agaaaaagga tagaggaggt tgggaagagg   64200
gaggcaggga gtcagcgtca tagcaatggg tgagaaagat gaaagatgtg tggccattgc   64260
tggctttgga ggtagaatgc gggcagcctc caaaacctgg aaaaagcaag aaagtagatt   64320
ttccctgaga acctccaaaa agaaagcagt cctgccgaca ccttgattct agcccagtaa   64380
gaagcatttt gggctttgga catccagaaa tgcaagacaa aatttgtgtt gttttaaggg   64440
attaaatctg tgatagttta ttatggcagc aacagaaaaa gaatatacct gtcaaaactg   64500
ggttcccatc ttcaaaggct tcccctctgc ttgccgtcca gtccacagct ccacttgcag   64560
gtgcagtaca gttggctttc gagcagggct tggattgaaa attcagcatg taaggaagaa   64620
gtctaaagtc cagacgaacc ttgaacaccc cttaattgcc cctcccgtcg agagcaggga   64680
ccaggatcca ctgagtgtag agcagagcaa cattcctcaa ggtgtcctca cccccaggca   64740
ccctcccaca gggctcaacc agctaacctc tttccaccct ttgaattgtc tctctctccc   64800
ttcaggcata taattaaatt tgcataaatt caaagagcat atgctgcaat cccattgtaa   64860
tttcagattt gtttttattt cctgagtttg ctaaggaaat aataaaaaca aaacctcctt   64920
aaaaaaaaaa aagatttcta atgagttttt aagttcagtt tttgtattct ttatttctgg   64980
gattaatatt tttaaacatt gtttttattt ctctttccaa tttcttattt tcttcctgaa   65040
ttattttcct ttttttttag ttttctgttt tcttataatt tctttttta acatttttct   65100
ttctttaaat attttttttaa attccttatt tcctcagaga tctttgttct gacctgtaat   65160
ttcttgaact tctttaagag gcttatgctg aattcattgt cagacattta atagatcttt   65220
aattgttcag ggtccattgt tgagcctctg ttgatttctt ttggtggtgt catatttccc   65280
ttggttttta taatcttcgc atatttatgt cgatgcctgt gcatttgaag agagagacac   65340
ttccagtttt cgcaggtgtt ctttgttggt cttagatctt tagttcttag tattctttt   65400
tttttttta agacagagtc ttgctctgtt acccatgaat gcagtggtgt gatcttgggt   65460
tactgcagcc tctggctccc aggttcttcc agcgattctc ctgcctcagc ctcccaagta   65520
gctgggatta ccggcataca gcactacgcc tggctaattt ttgtattttt agtagagatg   65580
aggtttacc atggtggcca ggctggtctc gaactcctgg cctcaggtga tccacccgcc   65640
ttggccaccc aaagtgctag gattacaggt gtgagccact gtgcctggcc agtattcact   65700
cttaaatgtt gacttgttgt tgcttctgct ggggtaggct tatagtgacc actgcaacta   65760
aatttctctt ctgtcattgt ttcctagtgt ggggaagtct tattttgtgc actgaagctt   65820
aaatactgtg ttgggactat attgctgtgc tgtcattgtt tccaattccg gaaagttatt   65880
aatcccagtc ttttaattgt tttggggcca ggctggggga ggcttcatga aagaaccttg   65940
ggtttgtgga aaatccggct aagaattctt gctgtactgc caactgtgct tcctgtattt   66000
ctatgacact aatcggtctg ttaaatgtgg catctctact aattacagtg ctgagtagcc   66060
accaggctcc atgcatcagg tactgcattc agtgtcctat tctttgttct cagttcacct   66120
cagatgattc aattctccta gcactcccaa aggtttttat gagagaggac cagagtggat   66180
tactgatgaa gattcctaag ctggaggga gactgaacat ccaattccat ttccccccctt   66240
cctccttagc agacataggt ctagggaaat tctttgtgag tggcattata ctagcttggg   66300
aaagggggta gtgcaaccgg aaatgaccgt ttctttaca ctccacaact ttccttgatt   66360
ctgcacttct cctctgagtt ctgttgtatt tacaatggag ctcccatctt tgaatagctt   66420
ctagttttat ttttatgggg acagtgatgc taggggattt tctattccat catctttctt   66480
ctttctgact ttaccctcca aaagtgtaat cctcaaaatt tcaagatttt tttttgtatg   66540
ccttccatgg agctcataca acaaacaatg atacatttga aattatgaca atatgactga   66600
agcataatta gtttcctaat cccagagtcc tttaattaaa cacaagaggg atgattccag   66660
aagtaacact catcactgct attccttagt ccctctgaga tttgctttaa gagcaggtct   66720
ccacctctca catcttgcta taaatatgac tgcatttaa agcttagaga agcacctaaa   66780
aaccttttta atcaaatatc aaggaaatga gtatatatca gaaccagaat taagtccttg   66840
cattttatg ttctttattt ttggttaaag gggaaatata ttaatgtatt aactgaatct   66900
cacaaaatgt ttgcattttt attattaaaa atcatttttt tcttttactt tgcatatcat   66960
tggggggcat gaatcagttt ctcctctgaa aaattctcag tgccttctct cagaggctgt   67020
gagcaaagaa gtaggaaagg aggttagcta tgaaaagtgt taactccatt tgtaacaata   67080
ctcattacat gcttactata tgcaaatcat ttttctaagc actttaaatg agtaaactat   67140
attattcctc ctaaaaactc catttctcat tttatagctg ggaacactaa cgtaagacag   67200
tttagataat ttgacactgt ggtggtggta cgatttgtta ctgatgaagc tagaatcaaa   67260
atcactaatg gggattagat tcataaaatt gttactttt gaatactaaa atatttactc   67320
agacattcag tatattagag taggcccagt atcatgtaat ctaatttatt ttgcaaaaat   67380
tgcaaatgag cgagatatta accaagttca attagaaagt tagttggtgg cagagctgag   67440
cataggttcc agagccaccc agaactttg tttgcttggg agaatctctg agcacacttg   67500
gatagcttag ggaattgctg cttttgggta tcactggtca tttgcatctg atcataggta   67560
ctagactgct gacaagttgg ccattagtgg acaggtatat tgagagttga tttaagtgtt   67620
```

```
gcatctgtca aggttaacac gaaacattct gttggccctg agtctcacat ttcaatctag   67680
aatccatctg tgtactttac tttccttgca aataaatgat ctagtgaatt tatatatttt   67740
ttccacttag ctcctagcac acatcatttg tatttcaatc atttattttt cttcaccata   67800
ttagaacatt tccaatacca ttaaagaaga aggaaggcaa tgaaaaggag acggagatag   67860
cctcatacat tctcctttcg ctgaaagtaa tatcattttg aaaacagact acgggtccca   67920
tcttcttcct ctctagtttc caacagcata aagctttgta tgtctctgag gacaagatag   67980
aaaactacat tagcaaatat tttcctttgc atctccttat ttcaagtaaa tgagggactt   68040
atattttcaa atattttaag tcaccttgaa ggttgcttct taaaaaataa ctgtttatta   68100
tgcttctact cttcatttta aaaattttgc ttgtttccac ctttacaaac aaaaatggac   68160
aaaatcgtat tttatcctgc agtcctctag gacaaattta actttggggt actctgtttc   68220
ctaaaaatgc atatatgtaa tcttctattt ctagtagcag agtttgaact caattaattt   68280
ccctaacaac agactcacta aaattcgctg tgatattttt caaatagtat tttatggaat   68340
tatcactgat gaaataaaaa acaaaacaag aaagacaggg gaggagccaa gatggccgaa   68400
taggaagagc tcgggtctac agctcccagc gtgagcaaca cagaagacag gtgatttctg   68460
catttccatc tgaggtactg ggttcttctc actagggagt gccagacagt gggcacaggt   68520
cagtgggtgc gcacaccctg cgcgagcgga agcagggcga ggcattgcct cactcaggaa   68580
gcgcaagggg tcagggagtt ccctttccta gtcaaagaaa ggggtgacag atggcacctg   68640
gaaaatcagg tcactcccac cccaatactg cacttttctg acgggattaa aaaacggcgt   68700
gccagattat atcccacacc tggcttggag ggtcctacac ccacggagtc tcactgattg   68760
ctagcacagc agtctgagat caaactgcaa ggtggcagcg aggctagggg aggggcgccc   68820
gccattgccc aggcttgctt aggtaaacaa agcagccctg aagctggaac tgggtggagc   68880
ccaccacagc tcaaggaggc ctgcctgcct ctgtaggctc cacctctggg ggcagggcac   68940
agacaaacaa aaagacagca gtaacctctg cagacttaaa tgtccctgtc tgacagcttt   69000
gaagagagca atggttctcc cagcacacag ctggagatct gcctcctcaa gtgggtccct   69060
gacccctgac ccctgagcag cctaactggg aggcaacccc cagcgggggc agactgacac   69120
ctcacacggc cgggtactcc aacagacctg cagctgaggg tcctgtctgt tagaaggaaa   69180
actaacaaac agaaaggaca tccacaccga aaacccatct gtacatcacc atcatcaaag   69240
accaaaagta gataaaacca caaagatagg gaaaaaacag agcagaaaaa ctggaaaccc   69300
taaaaagcag agcgcctctc ctcctccaaa ggaacgcaat tcctcaccag caatggaaca   69360
aagctggacg gagaatgact ttgacgagct gagagaaggc ttcagacgat caaactactc   69420
caagctacgg gaggacattc aaaccaaagg taaagaactt gaaaactttg aaaaaaattt   69480
agaagaatgt ataactagaa taaccaatag agagaagtgc ttaaaggagc tgatggagct   69540
gaaaaccaag ctcgagaact acatgaagaa tgcagaagcc tcaggagccg atgcgatcaa   69600
ctggaagaaa gggtatcagc aatggaagat gaattgaatg aaatgaagtg agaagggaag   69660
tttagagaaa aaagaataaa aagaaatgag caaagcctcc aagaaatatg ggactatgtg   69720
aaaagaccaa atctacgtct gattggtgta cctgaaagtg atggggagaa tggaaccaag   69780
ttggaaaaca ctctgcagga tattatccaa gagaacttcc ccaatctagc aaggcaggcc   69840
aacatccaga ttcaggaaat acagagaacg ccacaaagac actcctccag aagagcaact   69900
ccaagacaca taattgtcag attcaccaaa gttgaaatga aggaaaaaat gttaagggca   69960
gccagagaga aggtcgggt taccctcaaa gggaagccca tcagactaac agcggatctc   70020
tcggcagaaa ctctacaagc cagaagatag tgggggccaa cattcaacat tcttaaagaa   70080
aagaattttc aacccagaat ttcatatcca gccaaactaa gcttcataag tgaaggagaa   70140
ataaaatact ttacagacaa gcaaatgctg agagattttg tcaccaccag gcctgcccta   70200
aaagagctcc tgaaggaagc gctaaacatg gaaaggaaca accggtacca gccactgaaa   70260
aatcatacca aaatgtaaag accatcgaga ctaggaagaa actgatcaa ctgacgagca   70320
aaataaccag ctaacatcat aatgacagga tcaaattcac acataacaat attaacttta   70380
aaagtaaatg gactaaacac tccaattaaa agacacagac tggcaaattg gataccaaga   70440
gtcaagaccc atcagtgtgc tgtattcagg agacccatct cacgtgcaga gacacacata   70500
ggctcaaaat aaaaggatgg aggaagatct accaagcaaa tggaaaacaa aaaaaggcag   70560
gggttgcaat cctagtctct gataaaacag actttaaaac aacaaagatc aaaagagaca   70620
aagaaggcca ttacataatg gtaaagggat caattcaaca agaagagcta actatcctaa   70680
atatatatgc acccaataca ggagcaccca gattcataaa gcaagtcctg agtgacctac   70740
aaagagactt agactcccac acattaataa tgggagactt aacaaacac cccactgtca   70800
acattagaca gatcaacgag acagaaagtc aacaaggata cccaggaatt gaactcagct   70860
ctgcaccaag cgtacctaat agacatctac agaactctcc accccaaatc aacagaatat   70920
atattttttt cagcaccaca ccacacctac tccaaaactg accacatact ggaagtaaa   70980
cctctactca gcaaatgtaa aagaacagaa attataacaa actatctctc agaccacagt   71040
gcaatcaaac tagaactcag gattaagaat ctaactcaaa accactcaac tatgtagaaa   71100
ctgaacaacc tgctcctgaa tgactgctgg gtacataacg aaatgaaggc agaaataaag   71160
atgttctttg aaaccaacga gaacaaagac acaacatacc agaatctctg gacacattc   71220
aaagcagtgt gtagagggaa atttatagca ctaaatgcct acaagagaaa gcaggaaaga   71280
tccaaaattg acaccctaac atcacaatta aaagaactag aaaagcaaga gcaaacacat   71340
tcaaaagcta gcagaaggca agaaataact aaaatcagag cagaactgaa ggaaatagag   71400
```

```
acacaaaaaa ccccttcaaaa aattaatgaa tccaggagct gttttttttga aaagatcaac   71460
aaaattgata aaccagtagc aagactaata aagaaaataa gagagaagaa tcaaataggc   71520
gtgataaaaa atgataaagg ggatatcacc accgatccca cagaaataca aactaccatc   71580
agagaatact acaaacacct ctatgcaaat agactagaaa atctagaaga aatggataaa   71640
ttcctggaca catacactct cccaaactaa accaggaaga agttgaatct ctgactagac   71700
caataacagg atctgaaatt gtggcaataa tcaatagctt accaaccaaa aagagtccag   71760
gaccagatgg attcacagcc gaattctacc agaggtacaa ggaggagctg gtaccattcc   71820
ttctgaaact attccaacca atagaaaaag agggaatcct ccctaactca ttttatgagg   71880
tcagcatcat cctgatacca aagccgggca gagacacaac caaaaaagga attttagacc   71940
aatatccctg atgaacattg atgcaaaaat cctcagtaaa atactggcaa accgaatcca   72000
gcagcacatc aaaaagcttg tccaccatga tcaagtgggc ttcatccctg ggatgcaagg   72060
ctggttcaat atatgcaaat caataaatgt aatccagcat ataaacagaa ccaaagacaa   72120
aaaccacatg attatctcaa tagatgcaga aaaggccttt gacaaaattc aacaacactt   72180
catgctaaaa actctcaata aattaggtat tgatgggacg tatttcaaaa taataagagc   72240
tatctatgac aaacccacag ccaatatcat actgaatggg caaaaactgg aagcattccc   72300
tttgaaatct ggcacaagac agggatgtcc tctctcacca ctcctattca acatagtgtt   72360
ggaagttctg gccagggcaa ttaggcagga gaaggaaata aatggtattc aattaggaaa   72420
agaggaagtc aaattgtccc tgtttgcaga cgacatgatt gtatatctag aaaaccccat   72480
catctcagcc ccaaatctcc ttaagctgat aagcaacttc agcaaagtct caggatacaa   72540
aatcaatgta caaaatcaca agtattctta tacaccaaca acagacaaac agagagccaa   72600
atcatgagtg aactcccatt cacaattgct tcaaagagaa taaaatacct aggaatccaa   72660
cttacaaggg acgtgaagga cctcttcaag gagaactaca aaccactgct caatgaaata   72720
aaagaggata caaaccaatg gaagaacatt ccatgctcat gggtaggaag aatcaatatc   72780
gtgaaaatgg ccatactgcc caaggtaatt tacagattca atgccatccc catcaagcta   72840
ccaatgactt tcttcacaga attgcaaaaa actactttaa agttcatata gaaccaaaaa   72900
agagcccgca tcgccaagtc aatcctaagc caaaagaaca aagctggagg catcatggta   72960
cctgacttca atctatacta caaggctaca gtaaccaaaa cagcatggta ctggtagcaa   73020
aacagagata tagatgaatg gaacagaaca gagccctcag aaatatcgcc gcatatctac   73080
aactatctga tctttgacaa acctgaggaa aacaagcaat ggggaaagga ttccctattt   73140
aataaatggt gcagggaaaa ctggctagcc atatgtagaa agctgaaact ggatcccttc   73200
cttacacctt atacaaaaat caattcaaga tggattaaag acttaaacgt tagacctaaa   73260
accataaaaa ctctagaaga aaacctaggc tttacctttc aggacatagg catgggcaag   73320
gactttatgt ctaaaacacc aaaagcaatg gcaacaaaag ccaaaattga caaatgggat   73380
ctagttaaac taaagagctt ctgcacagca aagaaacta ccatcagagt gaacaggcaa   73440
cctacaaaat gggagaaaat tttcacaacc tactcatctg acaaagggct aatatccaga   73500
atctacaatg aacttaaaca aatgtacaag aaaatcaaac aaccccatca aaaagtgggc   73560
gaaggacatg aacagacact tctcaaaaga agacatttat gcagccaaaa aacacatgaa   73620
aaaatgctca ccatcactgg ccatcagaga aatgcaaatc aaaaccacaa tgagatacca   73680
tctcacacca gttagaatgg caatcattaa aaagtcagga aaaacaggt gctggagagg   73740
atgtggagaa ataggaacac ttttacactg ttggtgggac tgtaaactag ttcaaccatt   73800
gtggaagtca gtgtggtgat tcctcaggga tctagaacta gaaataccat ttgacccagc   73860
catcccatta ctgggtatat acccaaagga ctataaatca tgctgctata aagacacatg   73920
cacaagtatg tttattgtgg cattattcac aatagcaaag acttggaacc aacccaaatg   73980
tccaacaatg ttagactgga ttcagaaaat gtggcacata tacaccatgg aatactatgc   74040
agccataaaa atgatgagtt catgtccttt gtagggacat ggatgaaatt ggaaatcatc   74100
attctcagta aactatcgca agaacaaaaa accaaacact gcataccctc actcataggt   74160
gggaattgaa caatgagaac actggacaca ggaaggggaa catcacactc tggggagtgt   74220
tgtggggtgg gggaggggg agggatagca ttgggagata aacctaatgc tagatgacga   74280
gttagtgggt gcagcacacc agcatggcac atgtatacat atgtacaaa cctgcatgtt   74340
gtgcacatgt accctaaaac ttaaagtata ataataataa agaaatgggt cttctctacc   74400
caagaacaca cacacacaca cacaaaaaa aaaaaaaaa aaaacaagaa agacaaacag   74460
tatgctcatc acacacaaat gcaaggtcat ttttaggcat tagatggggc ttaatttaat   74520
ctaagttttt catgtacttt gtatcttcta acctgcatac ctctatttcc tcttctagcc   74580
ctctacctct ggtaaccact gttttatttt tatcactgta tatttaattt tttaaatatt   74640
ccccatataa gtgagatcat tcagtatttg tctttctgtg tctggtttat ttcacttaga   74700
ataatgtcct ccaggcttgt acgtgttgta tcaaataaca cgatcttcct tttcagggat   74760
gaataatatt ctattgtaaa tataaccac catttcttta tctatttgtc cttcatgagg   74820
cacttgggtt gtttcaatac cttagctgtg atgaataata ctgcaaaaac atggaagtac   74880
agatgcttta agaggtggtg aattcacagg ataaacaagt ctagagatct aatgaacaac   74940
atgaggacta ggggtaataa aattataccg tatttgggat tcgtgctaaa tgaatatatc   75000
ttagctgatc ttgcacacag acacacaaaa agggtaacta tatgttaatg tttgtgttaa   75060
tttgctttac tatagtaaga ttttactcta tgtatcacat gacattatgt tgtgaacctt   75120
aaatagatgc attaaaattt atttttaaa agggttcatt aactgcggtt caggcaatct   75180
```

```
ataaaccttt tacattttgg aggtgagatt ttcagtatct gcatttatct tggattttca  75240
aggggttcat ttgaacaagc aaacaaacga agaaacaagc ttaagaatct ttcttacaat  75300
gaattcttcc taagtagttt tcttgactgg tttcttttct ttttctgaaa cagtcttttc  75360
ttattcactt gtgattgaat agcctacaaa attgatctag acaattaggc tcttgaaatt  75420
gattacggcc tagtgcattc tcacctggaa taaaagcctt cctttggagc atcttctatt  75480
ttttaattgt tgagagttgg ggactttcct tctcattctg tattttcagt gtcagttttt  75540
atggcttgtg tgttccaggt atggttgggt catggtcatg cagtctattc acaaggcctt  75600
gtgcttagaa gaccatccca agcttggttt aatgctttga tctcatggtc ctgaaatttt  75660
acataatttt tttgtacaag gattcttgca gttttatttc gtattgaaat aggagagttt  75720
ccttatcctc ctcgcatggc aagtgacagg agtgtggctt gcttctttgg tgccccactg  75780
ctcaaatccc taggggtgga atgcagacag tcaggtgtac aggtcgtggg agtgttttg  75840
ggctccaacc ccacagcagc gtctagggtt aagtgtttac agctcctgaa gccccaatgg  75900
gtgtgtgtta cagtgtgatc tttcagcttt gctgtcttca ggcggcttgc attaatcagc  75960
tcagttagac cctctgcatt accacaaggg cagcaggctt tctgtattcc aagttcttgc  76020
ccagtgtatc ggaaaaattg gatcacatgt ggacatggag gatgagtgca aggttttatt  76080
gagtggtgga ggtggatctc aatgagatgg atggggagcc agaaagggga cggagtggga  76140
aattggtctt cccctggagt cgggcagctc atttgccgat gatgctctga ccaccccccag  76200
acgaactccc ctcggtgtct gcatcgttcc accatcactg gtctgctggc atctgctggt  76260
gtctgctgtt gtgctcctct gctcctgtca acatccagcc acttgtgtcc atgcccacta  76320
aggcctcggg tttttttggg cacaggatgg ggcctgtggt gggccagagt ggtcttggaa  76380
aatgcaacat ttgggtgcaa aaacaggaga gcctgttctc acttaggtcc ttgggcaaag  76440
gtctgtgggt ggagccctca ccagggaccc cacccttctc tacacatcac ttcccaaccc  76500
tgctcctgta tcaatattgg attctgtata ctatgtatct gaggtcccag ttctaggttt  76560
tacaacttgt aactttttcc tatccttgac ctactcctct gctcgttctt cctctatcat  76620
gcagaacctt cccaacatac tgacctagca agcccaggtg ttccttattc aagaggtgtt  76680
caccttttat tctgtcctga cacagggtt agacctactg tggttttcct tctttgtaca  76740
cacatcttag ctgtagtctt tttacctctc tccacttatg agcccttctt ctctactgca  76800
attgtgtatt tctggatccc ataaaagcca atgagcctct cagtcaaaac tgtttcagat  76860
ctcacaggca gttattaagc cacatgcaac aaataagtta ttctgcaaat gaactcctct  76920
agtccaattt cctactgtgt cttttttmaat ctgaaattcc cacatcctga tatatttttct  76980
ctcattttttc tttttgtaac cactgaaact gtactctggt gaaggccact gatactcttg  77040
ataggaactt gaaatgagta acacttaacg tgagaaagat ttgaagtgaa taagagtaaa  77100
gtgaaatatc tgtagtttag ggagcttagc tggattttct gcactttgca ttaagtgtgt  77160
gtgtgtgtgt gtttgtgtgt gcacatacac acacaaattt cactcagtga tagtttccaa  77220
agaaccatta catctggtat ccttgtattt gctcgttatc cttctgtaga cccaggaaat  77280
ctgagacagg tctcagttag tttagaaagt ttattttgcc aaggttgagg acacacctgt  77340
gacacagctt ccagaggtcc tgaggacatg tgttgaaggt ggtcatggta cagcttgctt  77400
ttatacattt tagagagaca taatctatca atcaatacat gtaagattta ccttggtttg  77460
gtgcagaaca actcaaagtc caggttgggg caggtggcg tgtcgtttcc aggctgtagg  77520
taaatttaaa cattttctgg ttgacaattg gtttgtctaa agacctgaga tcaatagaaa  77580
agtctgtgtt atgttaatgc tggagaggaa taatgaggca tgtccgaccc ccatttctct  77640
taaccgcctg aactagtctt tcaagttaaa ttttacaagc cctggctgag gaggaagtcc  77700
ctttatttat ttttggttta cacttcttat gatatccttc ttagaagttt tcttgctaca  77760
gttgttgcca taaactttac tttttttttt ttttggtag aaccttattc tgtcgccagg  77820
ctggagtaca gtggctgatc tccgctcact gcaacctctc catcctgggc ttgagcaatt  77880
cttctgcctc agcctccgaa gtagctgaga ttacaggcac gtgccaccac acctgactga  77940
ttttgtatt tttagtagag atggggtttc tccgtgttgg ccaggctggt cttgaactcc  78000
tgacctcagg tgacccacct gcctcagcct cccaaagtgc tcgaactaca ggcatgagcc  78060
atcctgcctg gccaaacatt acttttttaa tgaggtcttc cttgactttc ctttccccaa  78120
aactgtattt cctttatttt tctccacaac agttatttga atattattta tttacttgaa  78180
ataatagctc tctctgtcca ctagaatggg aaaaccaaaa aaagcagaaa tttttgaaag  78240
gtttgttcgc ttctgcatct atagtgccca atcacacaaa atattgagta tcagtaaata  78300
cttgtttcat gaatatctat tttgatgccc aaaatgacat gagaagagga aagataaata  78360
ttattatttc tatttacaca tgggaaaaca cagtgattca ttcagttgca aagcttttaa  78420
attactgaag taactctgta atccagggct cctaaccagc tcctaacatc aagatatgtc  78480
atagcttcta cttgatattt cttagatata tcacatacag gtactcaagg gcacaagtca  78540
gtcacatagt agaacatgac taagtgtaag gagaatgtgt ctggcacaat cctgtttatc  78600
atggtgcact atgtaagaat gccatgacta tctgtgtccc cagaagttcc ttatcatcat  78660
atatctcaag gccttccagg tctatacata caattttatg aaacagttta gctttagaaa  78720
ggtgatatgt attgcagcag cagctaataa aggaagtttt taaaatacat aattttcagt  78780
tcttacctca gattctcaga ttgtatgcac tagtagtgtg acctcggttc aattatttaa  78840
cctttttgta cgttgctttt ctcaatagta acagcaagac agagttttga ttataggcat  78900
tctaaaactt acagtaaaat aaatgaggtg actcattttg agatgagaca agaattgaga  78960
```

```
agcctgtaat aaaaatttca agtatgaaag aatgggcaaa aattaaaaac ttctcgaaag 79020
aaaggaaaat gtgaattagc aaagattctg atgtgaagag aggtaaaaag ccaaaaggat 79080
ttgtaatacc tcttgttaga tacaagttgt gattaaaaga ttaaataaca actctgaaaa 79140
tattaattta ttttctttct aaacacatta agtcattgct ctaaacatcc tcaagatact 79200
atatgaaaat ttattttatt tcacagttct ttgttcattt atttggcata tgtttattga 79260
gccattctga ctgtgcattt tgagctatga tcttggaaca cttgcattag aatcctacag 79320
ataatcatta gagatgaaga ttccagtacc ccacataaga atttctgcaa aaacctgtga 79380
tatgggctaa taaacaagct tcccaagaat tgcttctaca ctaagtttca ataatcactt 79440
aattctcctg agaacatgac atcacgcaag gctacatgga gataaatctg tgagtaaaaa 79500
ttgcaagtca ttcattctta catgctctcc tttttgcatt ttaagaaaat ttagtataaa 79560
aatatgtgtt gagaaagtat attaaaaaat gaacttcact ttgtccctgc tctcaacacc 79620
attatgtgat gagaatactctg gaaataaaga agagagaatt cagtgacacg tattaggaga 79740
aatggatgag aaatgcttca caaagaagtg gcctttaaag tgggtcatgt agcatgaata 79800
gaattaggtt ttaaaaagaa caggaagata gaagagatgt agctcagtca tatagataga 79860
tagatagata gatagatata tagatagata gatagataga tagatgatgg atagatagat 79920
acaggtgtag gtatagatat atctataggt gtagagaaag aatatattag taatgtaatg 79980
cctaggcaaa tgatataatg acattgtaga cttacaaaat tatagtaagt ctaccataat 80040
taccaaaacc aaagtttatg gtagtaccca gaaatagata actttcgatg atatatgaag 80100
atgtggagaa aaactaattc aaatgaacat taacatggta tgtgcatttg tttatattgg 80160
ctttatttcc atagcttgaa gagcaaactg tcaggaaatg tccaacacaa atggcagtgc 80220
aatcacagaa ttcattttac ttgggctcac agattgcccg gaactccagt ctctgctttt 80280
tgtgctgttt ctggttgttt acctcgtcac cctgctaggc aacctgggca tgataatgtt 80340
aatgagactg gactctcgcc ttcacacgcc catgtacttc ttcctcacta acttagcctt 80400
tgtggatttg tgctatacat caaatgcaac cccgcagatg tcgactaata tcgtatctga 80460
gaagaccatt tcctttgctg gttgctttac acagtgctac attttcattg cccttctact 80520
cactgagttt tacatgctgg cagcaatggc ctatgaccgc tatgtggcca tatatgaccc 80580
tctgcgctac agtgtgaaaa cgtccaggag agtttgcatc tgcttggcca catttcccta 80640
tgtctatggc ttctcagatg gactcttcca ggccatcctg accttccgcc tgaccttctg 80700
tagatccaat gtcatcaacc acttctactg tgctgacccg ccgctcatta agctttcttg 80760
ttctgatact tatgtcaaag agcatgccat gttcatatct gctggcttca acctctccag 80820
ctccctcacc atcgtcttgg tgtcctatgc cttcattctt gctgccatcc tccggatcaa 80880
atcagcagag ggaaggcaca aggcattctc cacctgtggt tcccatatga tggctgtcac 80940
cctgttttat gggactctct tttgcatgta tataagacca ccaacagata agactgttga 81000
ggaatctaaa ataatagctg tcttttacac ctttgtgagt ccggtactta atccattgat 81060
ctacagtctg aggaataaag atgtgaagca ggccttgaag aatgtcctga gatgaaatat 81120
tgtcatgacc atggtgatgc ctttgtttcc taataaacat taaatcgaaa tctttggctc 81180
acatgtccta gcgttctgat ggtgagtttt aatattctct gtgagtctat gttgagtgtc 81240
tcagctaaaa agctcatgct gggtaaaaat gagatttttc taggctttgc tcctccacat 81300
atattccatg aatcagcagc atgagctctt ccttggaggt tgttacacgt acagaatcaa 81360
agtctgcacc tcaggtgcac tgtatttaaa tatgtgtttt atccaaactc ctagatgatt 81420
gataagcaca ctgaattttg aggagcactg ctgtgggtga aacgtggcat gccctggaac 81480
actgttgtgc tcttttttgtt tacaacggca aacaaaataa atgtgctccc agcccaattt 81540
cttgaatgta ttctattctt attctcgcct gctgcttcag cagagatgtc tttaagaaac 81600
ccattcttct gcactccaag aaatccattc ttctgtactc ctttcctgac ttgctgtggt 81660
agaccagaaa ctaggggcca tggtgatggc ttctggtttt tataagtgct cttacatagt 81720
gaagagtggc aatggaaaaa gagggaga gaatgattgt acttttctta aacttgagtt 81780
tatggatcca gctctctgag ttacataaac ccaccttccc attctgagcc tccagtgtat 81840
ggaggtcact ttctgtttcg cctgattttg aaaaatttaa gcaggctgat ctgagaataa 81900
ggactaaaat taaaatggga aatgaaagaa ccgagtaaac aataggtcat acgatagagt 81960
atccaccttg ctttgaatat tccttctatt tgtaattaag tttaggtaag taatgttaat 82020
tttttgtttt ccttagcact ggcctgttta tatgtgtcca aggaagtaag gatttcttcc 82080
acaggaagag aagacattgc tctggcatct tcaagaaact ttagaaagta gaaagaattc 82140
ctctttagac attatgctaa aaagaattat ttaaggaaca agtaaaaaat atatttttt 82200
aagatagagt ttcactctgt tgcccaggtt ggagaacagt ggcatgatca tattaataac 82260
ttcctccaac tcctaggctc aagtgaccct cccgcctgag cctccctagt agctgggacc 82320
acaggtgtgt gctaccacac tcggctaatt tttaaatttt tttgtagatc tgatatctgt 82380
ctatattgcc caggcaggtc ttaaactcct gggctcaagt ggctctcctg cctcagcctc 82440
ccaaagtgct gggattatag gcataaatta ctgtgcctgg tcaagattct tctactctcc 82500
aaactttcta cttattgcct caaaatacta aatattttct aaatatcttt attggaaggc 82560
aaattctgcc attacgccat tagaaaataa aaagataaaa tattttgtgt atatattaag 82620
ttgtacatta agtaactgta tttataaggc ttctgcattt tgttcctgtt gttgtttggg 82680
tttgttgtta gttttacaag gaaaaaagag ccccaagcta tctaagtcaa caacggcaat 82740
```

```
ttatgacaaa tatatggtta tatttcacag cttctaaaga caagagtaca gctgaatctc 82800
ggtaatcaac caaaatgctg aactctaagg ccaagagaaa ccgtatgtct cattgtatat 82860
ttcatatcca tttgttacta ggatacataa taattgagct taattatgac ccttgcatcc 82920
agcaaccctg ctcatttgtc ttaattagag tagaattttt gtttgtttct tctataaatt 82980
ctctaaaatt tacttcattt catctgcaaa ttaacagatt ttattccttt ccaatattta 83040
tgagttttat ttattttcc ttcatcattg cagacttaga ctgatattat aatgtcaaat 83100
agaggtagtg aaaacaaata tcaaggcctt gttcctcatt tcatttgtgt tttgtttctt 83160
tgtttgtttt gagacagagc cttgctcttg tcgcccaggt tggagtgcaa tggcacaatc 83220
ttggctcact gcaacctctg cctcccgggt tcaagtgatt ctccttcttc agcctcctgg 83280
gtagctggga ttacaggcac ccaccaccat gcctgactaa ttttgtatt tttaatagag 83340
atgggttttc gccatgttgg tcaggctggt ctcgaactcc tgacctcatg atccacccac 83400
ctcagcctcc caaagttctg ggattatagg cgtgagccac catacccagc cttgctcctt 83460
attttagggg gaacatattt aatgtatcat caggttgtat atcattagtt tgattttttt 83520
tgtggcatta ttaagattcc atttaaaaat ttgacatatt tgttcacgca tctgttgtta 83580
gaagtgggat tgttttatta agtatcaaat tatcttaagt ttcaggctta atgacagtgt 83640
aatttcaggg gcataaggaa gattttccca ctcatccaac atagacttat actgagagag 83700
atgtaattac aattaacaac catgtatttc taatttcaca tgtgcgggat gctttgttct 83760
cttttctca tctgatcaag gcaccatggc tccaacatcc tcatctatgg gatatcttgc 83820
tgacttttgt aggtagaagt aagcattttc tgcattgtgt ccataatcta ctttttaatt 83880
agaaatttta cttaatttca cactatattc atttctgtgg tcaaaaaaat caaataaaat 83940
tgtgaattgg ggtggtggct gaaggatagt aataatatgt ttaggcaatt tgggtaaatc 84000
atggagtatt ttttctttaa tgaagaaata tgctgttctg cttcatccat ttattgcaat 84060
tccaaaaagc aaactaacta tagtcagatt atttggattt tatgagaatt tcataatatt 84120
ataattattg caaaatttat taattttaaa aaatcacgtg aaccaaaact aaacacttgt 84180
ggatataatc aagattcttg ttttcaatat atttactcaa aaaacattta tggataactt 84240
agcatgttcc aggcagtgta ctgagtgttg tgtatacagt gaatataaaa tacagtttct 84300
tcttctcttg gataacaggc tggaggggaa gatatatctt aaacaaacaa aataaactgc 84360
acttaaaatt aagattgtga caagtgtcat aaataagtag aataaggcaa caggagagag 84420
aacaattatg atggtgcaca gatttttactg taggtagaag atgtcttctc ttagggttga 84480
tatttaagct ggcatcctag agatgattag ggaataacta gaagaagttt gggagaaata 84540
gaattcaaag cagtaattag aactaagcac cacatcgaaa tgatagaaag atctcaacaa 84600
cttaacataa caactaaata atataaggag gctgctagct agactaatat gaagaaaaga 84660
gagatggccc aaaaaacaaa attataaatg accaaggaga tgttaccact gaacccctag 84720
aaatacaaat aaccatcaga gactattatg agcacctcta tgcacacaaa cgacaaaatc 84780
tagaagggat ggataaattc ctggacacat acccttcaca agactaagcc aggaagaaat 84840
tgatttcctg aacagaccaa taatgagctc caacattgaa tcagtagtaa gtagcctacc 84900
aaccaaaaga aatcccagta ccagatggat tctctgccaa attctaccag atgtacaaag 84960
aagagatagt accatttgta ttgaacctat gcaaaaaatt taggaagaat gattcttccc 85020
cagtcgttcc ttaaggccag catcattctg atatcaaaac ctggcaaaaa cacaacaaaa 85080
aatgaaaatt ttaggccaat atccttgatg aatattaatg caaaaatctt caacaaaata 85140
gttgcaaact taatccatga gaacatcaaa agcctaatct atcacaatca agtaggcttt 85200
atccctggga tgtgaggttg gttcaacata cataaagtta aatgtgattc atcacacaga 85260
cagaactaga ggcaaaaact atgtgttatt tcaacagata cagaaaaggc ttttattaaa 85320
attcaacatc ccttcatgtt aaaaactctc agtgagctag gtattgaagg aacatacctc 85380
aaaataataa gagccatctg tgacaaaccc acagccaaca tcacacagaa tggggaaaag 85440
ttggaagcat tccccttaaa aacctgcaca aggcaaggat gctgtctctc accactccta 85500
tttaacatgg tattggaagt gttagccata acaattaggc aagagaaaga aataaagggc 85560
atccaaatag gaagagagga attcaagcta tgcctgtttg cagtcaatat aattttatat 85620
ctagaaaacc caaaaacttc ttcagctgat aaacaacttc agcaaagtct cagggtacag 85680
aatcaatgta caaaaatcac ttgctttcct atacaccaat aactgtcagg caaacagtca 85740
aatcaggaat gcaatccaat tcacaattgt tagaagaaaa ataaaatact taggaataca 85800
actaactaga aagatgaaag agcactacaa tgagaattac aaaatctgct caaaaaaatc 85860
agagatgaca caaacaaaag ggaaaacatt ctgtgatggt taataatgag tgagtgtcaa 85920
cttgattgga ttgaaggatg caaagtattg atccttgatg tgtctgtgag ggtgttgcct 85980
aaggagatta acatttgagt cagtgaggtg ggaaaggcag acataccctt aatctggatg 86040
ggcacaatct aatcagctga cagtgtgccc agaatataaa gtaggcagaa aaacatgaaa 86100
aggttagact ggcttagcct cccaatctac atctttctcc cgtgctggat gcttcctgcc 86160
ctcaaacatt gaactccatg ttcttcagct ttgagacttg gactggcttc cttgcccctc 86220
agcttgcaga tggcctattg taggaccttg ccttgtgatc atgtgagtta ataatactta 86280
acaaactccc atatatatat atatacacac acacacacat atatatacat atatatacat 86340
atatatatat gtatatccta ttagttctgt ccctctagag aaccctaata cacattacat 86400
gctcatagat aaggaaaatt aatattatta caatggccat actacccaaa gcaatttaca 86460
gattcaatgc tattcctgtc aaactaccaa tgacattctt catagaatca gaaaaaaagc 86520
```

31

```
tatttaaaaa tttatagggga accttgaacc caaatagcca aagcaatcct aagcaaaaag   86580
aacaaacctg gagcatcacg ttacctgact tcaaactata ctataaggct acaggaagca   86640
aaacagcatg gtactggtgc aaaaacagac aaataaaaca atgaaacaga attgaaaggc   86700
cataaataag accacacacc tacaaccatc tgattttttga caaagctgac aaaagaacag   86760
ggggaaagga caccctattc aataaatggt gctaggctga ctggctagcc atatacagaa   86820
gattgaaacc ggacctgttt cttacaccat acacaaaaat caactaaaga tgaattaaag   86880
acttaaatat aaaaccctga actgtcaaaa ccctgaaaga caacataggc aacaccattc   86940
tggacatagg aactggcaga gatttcataa tgaagacacc aaaaacaatt gcaataaaag   87000
caaaaattga caaatttttg gatataaata aacttaaaag cttctgtgaa agaaactttc   87060
aacagagtaa acagacaacc tacagaatgg aataaaatat ttgcaaacta tccatctgac   87120
aaaggtaata tccagcatct ataaggaact taaacgaatt tacaagaaaa aaatgatccc   87180
attaaaaagt gagaaaagga catgaataga tacttttcaa aagaagacgt aaatgggagc   87240
taaataatga aaacacatgg acacaaaggg gagaacaaca gacactgggg cctacttgaa   87300
gatggaagat gggagtaggg aaaggatcag aaaaaataac tgtttggtac taggcttagt   87360
atgtgggtga tgaaataatc tgtacaacaa accccatga cgtgagttta actgtatcaa   87420
aaaccttcac atataccct gaacctaaaa aaaaaaaaaa aaaaaaaagg ttaaaaaacg   87480
gctctgtgaa ggttctgagt ttgaaaaggg cttgacccaa gaccagtatg gctataccag   87540
ggaatgaggg agacagtgac agataatgct gatttaggtg tagactatag taaaagtttt   87600
tttttttttt ttttttttttt tttttttgagg cggagtttcg ctctgtcgcc caggctggag   87660
tgcagtggcg cgatctcgac tcactgcaag ctccgcctcc cgggtttacg ccattctcct   87720
gcctcagcct cccgtgtagc tgggactaca ggcgcgcgcc accatgcccg gctaattttt   87780
gtattttttag tagagacggg gtttcaccgt gttagccagg atggtctcga tctcctgacc   87840
tcgtgatccg cccgcctcgg cctcccaaag tgctgggatt acaggcgtga gccaccgcgc   87900
ctggcctata gtaaaagttt ttatttcggt atatcattgg aaaaatgtgc ttccaatgaa   87960
gcattcatgt atctcttttg ccttcataat tagggcaaat acatgtacta tttgatcaca   88020
tgtacaggtt acatcttata ttcatatgtc ctagctaagt gaggattgga tacttggtaa   88080
aagggaaaaa aaaggtaggc aaaatatttt gatctttatt ctgtttgttt tcataggttg   88140
gcaaataaat aacatttgc taagttacac attcaccagg ttttccataa aatattactt   88200
cccaacacct ggattaaata ccgtgaacta actcaactac aacaatttg aggtccaaat   88260
tatttaccc agtagatttt acaatttaac ttctttattc taaccatttt gtgaaaggta   88320
gtgtccaaca cacaattcag gctgaaagag aatcacagaa acatcaacgc ttatgaatta   88380
tgtcattatt tttttacctt tattaatcat tccattcatc tgattggaat aatgaaccat   88440
aatgcaaaac cccatgtgaa taaactcctg atccccaaag caatcatctc gtagtgatta   88500
caaattgttg caatcaagtt gcttaagtcc caagtttcta ttgagcacat gagtctgtac   88560
caattactac attttccctg gagttgtgtt ttttagtaac attgcaattg tttcttcaga   88620
gtgtattaaa aaatactta gtgataagag ctccaaatta caagatgggt ataacttatt   88680
cttgttaact catttttgg agcactagtg tctgtgggag tacctttctt ggcatcaggt   88740
aggaataaaa attctgactt ctgcacttgt actttctctt cttgtctcaa ttttggattt   88800
ttatcagtag gagtcaagtg acaataaaag tagcttcaaa tgttagttta gattctcagc   88860
ctattaaaat gagtttgtat acatttctta tctagacggg tgatgagaaa gtattacact   88920
ttaattgaaa ttattcacaa caactgtttc actttacaaa tatcattctc accattcatt   88980
caaatattga acccacttga ataactattg gagtaaacat taatatgaca ataaattcaa   89040
gtgttgaaca caccttgaat aaccactgga gtaaatatta ataagacaat caattcaagt   89100
gtttactaga ataatatctg ttgaaaagac cccttataaa ggaaacgctt tatcaaaagt   89160
tcaaaagaga tcttattttt ttatggctga atagtatttc attgtatcat agatggacac   89220
aatgaaatat catagacatt ttacattaag taaaataagc caggaaaaga atattaaata   89280
ctctatgttc tcactcgtac gtggaaacta aaaaatgttt atgtcagaga agtaaaaagt   89340
agaaagagg atactagagg cttcctagag gctaggaagg gtagagagaa ggaaggatag   89400
gcagaaattt gttaaaggat acaaattata gcaaggtaag agggataagt tctactgttc   89460
tatggtcctg taggattact gtagttcata atatatagtt tcaaatagct agaaaaagga   89520
tagtgaatgt tcccataata aagaaatgat aaatatttga cataagggat atgctaatta   89580
cccttatctg atcactatac atcatatgca tcaaaacatc actgtgtacc cactaaagat   89640
gaacaagtat tatatgtcat ttaaaaataa agtaaaataa aggggaaaaa tttgaaagag   89700
ggacagatca attcattaga aattgtactt tttctagaaa acataaaaca cttatagaac   89760
tttacatatc tttctttaaa ttatcagaga aaatttggag caaatttaat attaactaag   89820
aagtacatga ctagtgatga gtgtagaata gaaaaatcta tgaatgcaaa atcagaatgt   89880
tagaaatgat gggcacttta gaaactattt tgtcaaagtc tgacattata tagattagaa   89940
ttctaaagct cataggaaaa aatcaccata tcgaggtaaa gagactgctt tctaaatgaa   90000
gacttaaatg agtttttatt gacatatcat aggcaagaat aaagccacaa catataacat   90060
gccctagaac ttaggttcat gcactgtgct tagataatgt gccctgttat tttatttgtg   90120
agacactaga atggaaaaca aagagaaagg gatggtgctg aagtccattg tgactgtgta   90180
gacaaggaag gtgctcctgg ctgagaaact gatattcaca ggagttgctt ggctccacca   90240
actactagac ttatctacct ctgtttttaat tgaagatcgt aaaatatcat tatttgccca   90300
```

```
gcagttcttg cagacttatc tatgtcttat tgctcagttg aggtcgttcc tgggctcaat 90360
aactgaaaat aagcttcagt aatctttacc tctgttttct atggtctttt ctttggcttc 90420
aatttctcct agtctcccac acaattcatt ttataggatg acataatggt gacctgatgt 90480
atacagaatg tttagtaact atgaaagcag ttccgtgcta tcttattttg ctatctcaaa 90540
tatttgtatt ctatttatt tcattttatt ttatgagaca ggatctcact gtgtcaccca 90600
ggctaaagtg cagtggtgca atcatggcat actgggccca agggagcctc tcacctcaac 90660
ctccccagta gctgagacca caggcatgca ccaccacacc tggagatggt tttttttttt 90720
aatatttgtt tttgtagaga tggagtctcc ctatgttgcc cagtttgtc ttgaactctt 90780
aggctcaagc ctcagcctac caaagtgcta ggagtaaagg catgagccac attgcctgac 90840
cttgcatttt aactggagcc tgaagaagcc aaacttattc ccaaatgaac atttccacaa 90900
gtaactcaga tatcagtaac atttgtagaa atttactttg cactttttatt gaatcaatgt 90960
aatttttttt ttagttggga ggatgggaaa atcttggaac tccgaatttc acccaaatat 91020
ttaccatgtt taccaattta ccataaatga cacctctagt tttctgttca acaatatatt 91080
caaacagsct actaaatgac aaataatgtt acttgaaaaa tatcttcatg taataaarat 91140
aaacatatgg atatagatat cctgtgaatc aaaatttacc aacatgraaa atatgtgttg 91200
actttgttat ctagtttatc tttagtaatt ccaatacagt gcgaagcaag ttaacattat 91260
tgaagcagtg aaacatttgg agtttttattt tggttatatt tcttgcaata agaaacatag 91320
actttaaaaa actcactgat gtctacactg attcctaatt acccagaaat ttcagactga 91380
acaccaatgt catggaaaaa cccctttgca gaaggacatc tggtttaatc catcattgag 91440
gcttaattat ttttctgtgt gttatttctc acacagagaa caatgtatgt atagctatta 91500
caaaactgat tcagcactct ttctaatgct ttaatgtgaa ttacttggca atctatattg 91560
gaatacaagt tagaaaataa gagtcatgaa agataaattt tgctactttt tacacaaata 91620
ttaaataagt gtgcacttttt tctaagcaca gggcacactg cgcatggtaa acattaaata 91680
agttatcaaa ggcaattcct acaggcatta aacatcacct ttgatacatt tcagcaaccc 91740
agtttaacca ttggcaaata aataacattt tgctaagtta cacattcacc aggctttcca 91800
taaaatatta cttcccagca cctggattaa ataccatgaa ctaactctac tacaagaatt 91860
ttgaggtcca aattattttta cccagtagaa gtttaaataa agaactagaa atgatcttca 91920
gatgacgtgt tattaaacat ttcacaatca ttcagctatt tattttcagt agactaaagg 91980
ctttagctct gatgcagaaa atttgaatat atcatgggag ttatcaaaat tattttaaat 92040
ttaccaatag tatttgtcat atgcatgctt ttagtaatct cagttgagca tatgcccccc 92100
caacatatat atacacatac atgaatatat atagaggtgc ttgtatgtta cactgaggcc 92160
ctctagaagt gaaacttgaa tgtttttaata tgactaagtt cataatctcc tgcccaggaa 92220
attataaatt aaaaacattc cagatctcaa agagcttttc tttactgaaa tattgagaaa 92280
gacatttccc aagtacttta gcctttaaaa tatgattcat gcaagcaact aaaattagaga 92340
gttcttggga agagggctgt ggataacaag agaaaagtga gaagagaaga aactaaggat 92400
gtgtgatcaa agaacaggtt aacatgtaaa aaattcaaaa gaggaaaaaa atgcttgcaa 92460
gttatatgag agtattttaa atatttggac gttgtctcat ggattacatc tatttatcta 92520
tctatctata tctatctatc tatctatcta tctgtctatc tatctctcca tctatctatc 92580
atctatctgt ctgtctatta gtttgactta tgccttacaa ccaataaaca cttaataagc 92640
aaccatgatt atttgttaaa tatgatatga tgaataaaca aatgctagta tttaggattt 92700
cacaatacag attgtttgag agtagaatgg attcacgtcc acctgcaatt gatacgcaga 92760
gctctgatat cacattctgt tttatttttcc tcagagtttta acatttttttt ctcctgtttc 92820
tattctctcc ccatttatgg agtgcctctt cagtgctcag tatttacccc aagcattttt 92880
tttcctataa tcaatgatag ttctctacta gtggcacggc tgaatgaagc tggtttccca 92940
aattgtggag attatgtctt acttccttga attttgttta gtttttgagg ttcagggatg 93000
acagcattcc ctgctgctca gtgtgaaatt agggatttta gcctaaagag aaaatttgat 93060
agtgctcttg ggtctttgaa taaggaaggt tgggacatgc tgaaagcctt tgcccacttt 93120
ctggagcttt actttacaca tgtccatata gaaggatctg tgatgttctg caatagagca 93180
acctatttta cctttcccca cttaaaccca gtatttccaa actttttttt ccccataggc 93240
ctattttgtt gcttaatatt cagtggttct tctgaacaaa gttttgaaaa ttctaaccta 93300
aaaactcaga cgatagcaag attaacatgt ttacaacccc ttttccttac tcctaatggt 93360
acttgctcta catcagttga agggctttc taaaagtgaa atgaaacaga agcggtgtga 93420
tttctttgta gacctaaagt gcctatgtca atgggaggag atactattat ccaaatatga 93480
gttttctctt taagctgtag agggtaggtt gctgcatata tttaaaggaa agagcaggac 93540
atagaaaatt aaattatagt atcttttta tcctttttttc tttatttttg tcattatttt 93600
attatttgtt aagtataata tgatgattaa acagatgata atatacaaga tatattgcat 93660
aaatgtaaag attagataaa tatatttatg ccattaaaac ataagattta tatttactaa 93720
ggtgaatatt ttccaaaatg atgcatcctt ctggagagtg aggaaagggc actttttactc 93780
tttacataaa tctttatttt ctaattattg cattttcctc tcaaaggcca aagttgtaga 93840
tttaagacaa gaaatcattt caatttccaa gtaacaggga acgtcagttc taattcatca 93900
ccatcacttg ggtgccatac acacgcacag gcacacacac tcaaaaactg cgtgtcaaag 93960
acaaattcaa agatgtgctt ccttgtagat ttcaggaggc atgttcactc ttcttggtat 94020
gtgttggaga ctttaagttt tgtttgacta cttaccgctt attaaatgtc ttatttgcca 94080
```

```
caatagaaaa gtcatccctg catctatgtg aaatatgttt aatttctctt gaaagttgcc  94140
taagacaatt ttctgcatgt actgttcata ctagctaaaa ctgctcccca ctcttattcc  94200
tctaggaaat tcctagttat ttttcaagcc ccagttagat tattgtcctt tgatgcttac  94260
cctgattcct gaaacaatta gttattttgt ttgtattttt attattgaac taatcatatt  94320
taactttaat tttcatgctc cttaccatga aaatcaacca gctctttcaa ggcaagcact  94380
gtgatcagtt gtcttcaatt ccccagcaaa gcaacttgca tgcatggagt gttcagtgct  94440
gtttgtgcac aaatgtaacc atattacaat ggttaaatca tttagcatcc tgaaagcatc  94500
acagagtcaa agtagctaac ttgtgtgaac ccttaattca atttccggga agaggttaga  94560
cactgaagta tgtagttgaa gacactggtg ttgcaaggaa ttgtatccca ctagctcaag  94620
cctacagact tctgttttgt gccctggatt aagataaatt taaaaatcga atgaattgcc  94680
aacactatct ttggtagatt tcccataaaa acaatgaatt ctgatattta aaatgtaaag  94740
ctcttaagac cttacaacac aaggtccctg ctaacataaa gcaaaattct attggcctga  94800
gtgacttctg agtctacact gggaaccact ctatgtttca cttcagtgga ctcttaaacc  94860
caacccactt cactcattct tattagctaa agggctccca tagacattta agttttgatc  94920
tcttatctcc tttagtgttt tacttataaa ataacacaag gcaacattgg gaatttataa  94980
taaaaaatta ttgtatagaa tcccagcacc ataatttccc attgtctcat ttcattacaa  95040
ttgatattat ctgaattaat attatctgaa agtataatct gttcattata atttgtattg  95100
tttgaactct aggaataatt ctatctctct tgattacttt tcattttatt attctggaca  95160
ttataatatt ataaagaagt ttgaactaat gctgctagaa acctgaaaca aatttgtgtt  95220
ccactagcag aacaaatttg tcacattctg ttatatgctg taaacccctt aaatgcattc  95280
aggattaaat taaaacataa atggaccagt agataaaatc tatgaaataa catttggcaa  95340
cttctcttgc tttactccta caaactcctt cgactgaaaa ttccttcatt agtaattcat  95400
ataggccctt gttattccaa atttagaaac cttatctttg gtttattcac aaagaaatga  95460
attgcttttg attttgttgg tatagcagta agaaaaaaaa agtgaagaaa aaaaacccag  95520
aatttccttc aaaccccctat gattctggac tctctaatac agcacatagc cagtgaaatt  95580
ctcaaaggtg gagacactaa agcaggggtc ccctaacccc caggccatga actggtatgg  95640
tccatgtcct gttagcaact gggccacaca gcaggaggca agccaccagc aagtgagcat  95700
tcctgcctga gctccgcctc ccgtcagatt agtcttggca ttagattctc atgggagcac  95760
ccaccctatt gtgaactgca tgcgcatgcc agctatctag gttgtgtgct ccttacgaga  95820
atctaatgct tgattatccc caacaacccc accctccaac ccccatccat ggaaaaattg  95880
tcttccacaa aactggtcgt tggtgctaaa aaggttgggg actgttgtta taaaggaagc  95940
ccatgattgt atagtcaact gaaaaaggca gttagtggct taatccattt ttcgacaaac  96000
tttaggacac tattccctca ttccaaaaca cgttggtaac acagaaacca ttcttttttag  96060
gaatcatctg catatgatac acccagttaa ttggggcctt tgcttttttta agaccaccag  96120
gccctatatt cttgagtcct gcctgactgg ctgtgtgagg gagaacaaga gagaagaaa  96180
aagagagaga gcaaataaga gaaagagaaa aaaggtaaca tgtaatggac ttctcattca  96240
ccttgattta ttttcatcca tttaagtgaa aaatgctggt acctaagaaa atggttagag  96300
gaaattctac tttggtgacg gaatttattc tcttgggatt aaaggatctt ccagagcttc  96360
agcccatcct ctttgtactg ttcctgctaa tctacctgat cactgtcggg gggaaccttg  96420
ggatgttggt gttgatcagg atagattcac gcctccacac ccccatgtat ttctttcttg  96480
ctagtttgtc ctgcttggat ttgtattact ccactaatgt gactcccaag atgttggtga  96540
acttcttctc agacaagaaa gccatttcct atgctgcttg tttagtccag tgctattttt  96600
tcattgctgt ggtgattact gaatattata tgctagctgt aatggcctat gataggtatg  96660
tggccatctg taacccttttg ctttacagca gcaagatgtc caaagggctc tgtattcgcc  96720
tgattgctgg tccatatgtc tatgggtttc ttagtggact gatggaaacc atgtggacat  96780
accacttgac cttctgtggc tccaatatca ttaatcactt ctactgtgct gacccacccc  96840
tcatccgact ttcctgctct gacactttca ttaaggaaac atccatgttt gtggtagcat  96900
gatttaacct ctccagctcc ctcatcataa tcctcatctc ctacatcttc attctcattg  96960
ccatcctgag gatgcgttct gctgaaagta ggcacaaagc gttctccacc tgcgggtccc  97020
acctggtggc agtgactgtg ttttatggaa ccctgttctg catgtacgtt agacctccca  97080
cggacaggtc agtggaacag tccaaagtca ttgctgtttt ctacactttt gtaagcccta  97140
tgttgaaccc catcatctat agtttgagga acaaggatgt gaaacaagct ttttggaaac  97200
tgatcagaag aaacgtgctt ttgaagtaaa atcagtgtat ctttattagt caaataaaaa  97260
aatctttcta tttatgagaa ctgtatttaa ctttagtagc tttacagtaa agtcaatttt  97320
agatccccaa tgaaaaacta taatctaaca acaaaacata gacatagata gagaaaattt  97380
atggttttac atgttacata tgagtgaaat atgtgtgtgt gaagggtagg gaggtgtata  97440
tgcatgtatg aggaataatt attcttttat tcataacatg catacattta catgtatgaa  97500
tttacatgtg taacaattta catgtaaatt tacatgtaaa ttacatttat aacaacatat  97560
tttttacatt ataaaaaatt atacattgtt gtaataaaac attaggtctc tatggaaagg  97620
taaaaagtaa gagattaaaa tattttatttt tcttcccac accctgattt tttattctca  97680
cttcctagag ttacaacgat taacagtttc tttagttttt tttttttaat ttcttcgtat  97740
ctacaaacaa atgtgtggtt atatgtacac acatatatac acgattgtta aaacacaagt  97800
tgactgtcat ggttgctttt tagtggtttta caattctgta gcaattacta ccaagaaact  97860
```

34

```
tcagtctcat ggtttagagg aatgtcacaa ctgctggtga gacttgctgt ccctctaggc  97920
tgtttctcta ggagagaaaa cttacgataa cacctctgtg tccatgcctg acacccactt  97980
atgtctctcc acttgtgaga gtcactttca ataagacacc tttctccttc tgccacgaca  98040
ggacatgagg ccagcccagc agttattttt caaatattaa ctctggaagc agacaaagaa  98100
tggctcctat aagggtatat gactggctgc aaataactgt gacttctgca gaacttatca  98160
attcaattct acacttctgg ggactagagt ccttcatgct ttctctcacc tctgcttttt  98220
taatctattt ttcaggatag atcatatatt tttattagta gcatcattca aattttactc  98280
acagtggtac tttgtcacag ttagttatta tatacctaat tttagaatga catatgtcga  98340
cttgtttgta agtattttag tgctaaagga agcaaaggac aagttgatat tttaaggatg  98400
tgacaaatct ggtgactttg cagttgataa cataagcaaa attgatgaat gtgtgctgag  98460
tatctacaat aagtcacact tctcctaaca ccaaggactt ttcaaggagc tcgacaatgg  98520
catagtttta caggggtcat gaaactgtaa acagaaagat caatacaatt tgttaaatgc  98580
tgtaagacta tggaggtgct aacgaaagag aggaaagaaa aaattatctc tgggcaaatt  98640
gaagctagcc ctgtgattgt ccaagactag aacttgttta tgctttatgc accttcctca  98700
gccctcccat agctcctagt atgacgtaat gtcaggtggg gtctgagcaa aataattaag  98760
aaccaatttg tgatcaaata tgtagatgtt agtttcaatg aaaaagaaaa aaccataaaa  98820
ctataacaag tcacaactca aaaagacatg atattttttc tcagttgtat ttcaaagctt  98880
tctttgtacc ttcgagttaa tctctgctta gtatttctac agaaattttc agactcattc  98940
attttatatt attgcatata attattttaa accttgtact actacatgtt cctatttaaa  99000
taccttgatt ttgaaagtca gattgcccac aaattctgtt aaaacacaca tataaataaa  99060
aaagctattt ttactaattt tttacatttta attaacaatt gttgaattcc gcttagacac  99120
atacctagat gtattcctgt ttaaatacac atatgttttt agttatgtga aaccagcttc  99180
ttaattatat aaaattttct gatctcaggg cccatgcttc tatctgtaca gcctagcttg  99240
gcaccgaaga aaggttcaat gactgcagca tgaaagagta cacatcatac acaatttttat  99300
taaaagttaa tgaatgtcca ctttcaaagt aaacaaagtg cctcaatttt agaatttata  99360
agaaaagtgt ctttgaacag accagcagat gactctgagg gaatatgtta ttagtcataa  99420
gccaacttac ttttcagaaa tacaagtaac cataatgtca ttgatgttta tgactgactt  99480
tagcaataca aaaccaatag ttacgcccat atacacaaaa gttcaagata gaaaggaatt  99540
acaccaagtg ctttcatgaa ttgactggct cgctggaatc acgtctatca gcctgttaag  99600
actatctaag tccatatcat attgtattag acataaaata aatatgtgct gatgaaaatt  99660
tttggtatta atatgttatt ttagtaggcc ctggattta gctaaaaagt aaagaataac  99720
tttcttattg atgacattaa aatcccatta ttaaagtctg tcataagaga tttcaagaag  99780
agtctccaat ttcatgtctc tttctcttca aagttaattc tgctgaattc tttatttgtt  99840
ggacaaattg ggtaatacaa tgaagaaata atcagaaaaa ataaagaata tttactgtac  99900
ttttgaaaag aacaataaat atgatatatt attttctcct cacctatcca aaagatcatc  99960
actctgatat tcctttcagg aaaatttata catgtgtata aaatactaaa tgttataggg 100020
agtagtgatg ttatgagcct aatgtcttta ctcatataac agatgttttt gggaacaatg 100080
aataagtgaa aaatatttag acactcacac tcacacatac acacaaaaat aagacagagt 100140
aatacttttt attatagttc aggtaatatt ttaatgtaag ttgttttact taatctgccc 100200
atcaacacta tgcattcagt actataatct ccactttaaa gaaaagacaa cagatttaca 100260
agttgttaac ctaaaagcac ataggtagat tagaagggga gctcaaatat gcctggcttt 100320
aaagtttatt tgtttgtttg tgttactatt atacttttgc cactatactt cattgaaggc 100380
aaaatcatac aatgaaaaat ataattattt tctatcttcc agaagtattg ctgatcatgt 100440
atttgacagc tgcatgcaca ctgaaggata taatgcacta taaaaaattc tttttataat 100500
gtatagataa atttaacttg ttccataaga caaatttttg cagtcagatc ctaactccat 100560
catttattag ctaaatgagt agttatgagc atgaactctg gaatctgatt tactgagcaa 100620
gttatacaac ctctctcggc ctcagtgccc tcttctataa agtgaagaca tagtgatttt 100680
tcataaggat gctgtcttca cagaagatat taattaacac atgaaacaca cttaggacag 100740
tactggatac atagtattta ctcaataaaa ggtacctgtt ttaattatta actggaaagt 100800
tactttacct atcttagact taggttcctt tcataacctt ctatgttttc ttttaataca 100860
tttattactc tttggatata attaatgtct gtgttctcta taatattgta agtgacatga 100920
ggtcagaaac aatgatgttt tgagagcaat tattttctat ttttcagcct ggtatgtagt 100980
atgtgatccc taaaaaatga tagatagatg attgatgggt agatgacaga tagatgatag 101040
atagatagat agatagaaaa aagaagtaa aaaaaataat ggagattata atattagttt 101100
tgtaaggtaa tgggattttc ctgcaaaaca aaacactgat ggtaacttaa atgtgtatat 101160
tttattcatg tataatcagt ctgcttttgt ctccttcaac agaattcatc tggaaatgtg 101220
cagaataaat caaaccagag agaagaaatt tatcttcctg aggttggcca gttgcccggc 101280
gttgcatctt gtcttctttc tcttggttct attaatttgt atttttcttt ttctggaaaa 101340
cttggcccta aatctgcaca tcacatcctc acactgtctc cttgccaatc tctcaatcct 101400
acaaattctg gttaactttt tatttggcaa gttcaattcc atagccaatt tatatgaaca 101460
gcataacatg gtcacattcc cgttaaccca gtgttttgtc cctgcagcca tctgtggcaa 101520
tcacatccac atggtcatct gccttccatg tagtcacaat attgggtcca aagtgctcca 101580
cgtttatatg gctgtccttc tctatgtttg catttcatgt aaacttattt aacatggtgt 101640
```

```
tatccccaga gctgacgaca tggaatagca tcatatcctg ccaccttgtg gctactccga 101700
ccaaataaaa ccaaatttca ccacacgcca tgttgctact ccataatgtg atggaagtgt 101760
atgagagttc taactttata ttttccaaac aaatttggaa tctttctact ctttgtaagc 101820
cagaaaaact tctctgtttt tgaatttcac cttatgaata tgtctagata atgttacctc 101880
cttgaaggaa tcaataacac aaaacagtag ctgccctata tgtttgtgac tcttttgaa 101940
caaccaaata aatagaaata gaaagaacgt aacgtttgaa aatagtagca tgatggttaa 102000
ttttatgtgt caacttgact gggcgacagg gtgcacaaat acttggtaaa atgttatttc 102060
tgggtgtgtc tgtgaatgtg tgtctggaag agattttacc atttgaattg gaagactgag 102120
taaaggagag tgttctcacc aatgtgggct ggcatcatgc aatctgctga gggcctgaat 102180
agaatagaaa ggcaaaagaa gagcagattt gttttctctg ggtgagttgg gacatcaatc 102240
ttcgcctgct cttggacaat gttggtgctc ctggacctcg gacctgcaga ctctgaccag 102300
gacttaaact atttgttccc ctaccaggtc ttcaaactta gactgaatta aaccaccagc 102360
tttcctggtt ttccagcctg caggcggcaa atcacaggac tttttggcct ttatagttgc 102420
atgagccagt ttccattgtg tgtgtgcgtg tgtgtgtgtg taatcatgta atgttatata 102480
tatatatata tatatatata tatgtaaaat cttcattcta tatatagaat gcttctcttt 102540
ctctggagaa ccctgatgaa tacagatttt ggtattgaga gtggttctag agcaacataa 102600
ttttaaggat atattttctt atctgtttct gaggtttctg gaattggctc tttaatttca 102660
ttagatttaa agatgctaat gactatttag agtagtcgaa aaagcattga tagtccatga 102720
cataaactgt ttatacatat atgcaaagta tccacattgg attatcctca tcagacactt 102780
ataagatata aggaactatg tgactctcta tatacttttg tactttctta gaaaactaag 102840
gattataacg atattgattg gttactctta atgtcactgg acaaagtgct gaaagataag 102900
gatgagcttg gggatttta tttccagtcc aaccctgaga gcttctatgt atgtctggaa 102960
ggagatcctt gtctcctgta gcttcaatta gagaattgca gaaagggatc ctatatgttg 103020
cgttgggggt ttgtgggaag atcctgatga agctggaaag actgagcccc taaattctga 103080
taagtgctat ctgacagtga aagaggtttc cctactccta tactcctagt ggaattggcc 103140
tccccgttcc cagtggtatc agctttttcca cctatgtctt gggtaattaa ctccatattg 103200
ccagaataaa tggtaaagac ttcccctgag gcagtttcca tacaagacaa tacagattct 103260
ttttgggggcc cacctttacc acccttcttt gcttctaaac ttataactaa acccaagtac 103320
caacagcccc tgaaagaaga ggtaccaagc aagaccatga ggtggtgcac taaaaaagta 103380
gatgagtttt ctaatttata caaacagaaa tccagggaac atgtgtagga atggatacta 103440
agcatatggt aaaagagtag aatgaagata tagttggatc aggtctaatt tgtcaatatg 103500
agctcattaa acagagattc tccatttaat gttgcaactt ggggagttag aaaaagctct 103560
aagtttggtt gtttggctga aacatgaatc aaaagatggt ccactgtgag taaactggaa 103620
atgtttaact tcccttggtt taatgtagag gaaggaattc aaaggtctag agaaattaaa 103680
attcaagagt ggacttgcca ttgaagacct actcacccat actggaaggg ttcagaagac 103740
aagcttttca ccaatacatt gataaataaa cttgtgaggg gaaactgcaa ccacacaatt 103800
ggaaaatcaa aatgcagtaa tagtaactag atcatggggt ggcagaggcc aggtggtggc 103860
tttcaatggc ccaaggcaag gtgggcatag ttaccataat gaacagcagg ttaaagcatc 103920
aaatagaata gtctgaccca cacgtatcta tgacattggc tagcacaggc tagttaatta 103980
tggtgttccc agttgtataa gtaaatagaa agcccactaa attcttactt gatctgaata 104040
tgcaaaaaca ttttaggtca agtgaacaaa agtctattct gaattataat aactgatagt 104100
tacagtccct caatcaattt gtagacttga ggcagtttac agacccagaa ctccttaaat 104160
gaaggggaga caaggtcttc tcaaggaaga tttccatata ttgctaggtc ccacagagag 104220
ggaccttta tctgggtaac tgcattggag aaaaggagat aatcagactt ttgagtacta 104280
cttgacactg gctctgaact gacaatttca ggctacaac atcattatag ccccttcagt 104340
cagtaggggc ttatgatgat tagattatca gtgaattcca tctcaaagtg ggcccagtgg 104400
gtccctgaac tcagcctgtg gttatttctc tggttctaaa atgcataaat agaatagaca 104460
tactggcaga atccccatgt tggtcctcct acttgtggag cttgggtaaa agaaatagtt 104520
gaaataattt atttaaagtg ttttgtgagc acaaagaaag aaaaaaatta tcttgacaaa 104580
aagctttttg ggtaattctc ccagagaagg taaccactga gatgggtttt gaaagttgag 104640
taggaatttc aaagggtaga ggatgaattg caaagacttt tcctaaagag tgaaccaact 104700
gatcaagaag aatagcttgg ttgtgcttat gacacaaata atagatagga aagtagtaaa 104760
taataaagtt gaatagtaaa ctagatcaga taaggcaaga atgaaatgct tttttaacaa 104820
atttagactt aattggatct acatgatgtg gtgatttgaa cgtatcctca aaaataatgt 104880
gttggaaagt taatccccac cgtaacagtg ttaaaaagta gggcctaatg ggatgtgatt 104940
aggtcacaaa agttacaacc ttgtgggatt gataaaaagg ctaaataaag gattactttt 105000
tttaaaaaag caattataaa tgggcttgag gctgcaagtt ctctaacttg ctgtcccctt 105060
ttcttgccct ctgccttcct ccatgggctg acacagcatg aaggccttta gatagatgtc 105120
agcaccatgc attttgactt ctcggttacc agaactataa aacaggtaca tttctattta 105180
ctataaatta cttagtctgt gttattctgt tgtagcagca taaaacagac taagagaaat 105240
ttggtactca gaagtgtggc tgttctatat cagctgaaca tgtgaaagtg gccttagaac 105300
tgagtaatga gtagaggcca aaagaatttg caggaacagt ctagaaaaag cctagaatgc 105360
catgagtgga ggtttaaggg tgattatggt gagggccagg aaatgtaggg aaagtctgga 105420
```

```
acttcttaaa gactacatgt gtggctatca tcaaagtgct ggtagaaata ggggtagcaa 105480
aggccattct gaaaagatct caggtgaaac tgagaaacaa tgtactggaa actagagtaa 105540
aggccatctt ttttatacag tggcaaataa attggcagaa ttgtgtccat gtagcagggc 105600
tctgtggaat acagaactta agagtggtga gctagactat ctggaagaag aaatatctgc 105660
gaagcaaaaa attaaaggtg gtgcacagct tattttgggt gcttacagta aaatgagaga 105720
agaaagaaaa aaaagataga atttgtaatg aaaaggaagc agcatgaagc gatttagaaa 105780
actcttagcc tggccatgta aataataaaa aagcatgttt gggacagaat actaaggaag 105840
tgttcatgta ggatacagta aattcctctt caaagtttag cctgttaact tcaagaagga 105900
gaaaaattgt taagtacaaa gagttctgag ttccacttca aagaaccaat caatatgtca 105960
gtatgtttag cttccctgtt ctttgttctc cattttaaag tttaacctcc tcgttcttta 106020
catctccttg cccctagttt cagtaaacaa cccctccta gcctctatca cctgttctgt 106080
ccttagtcat cctcagtcac ctgctctgtc cttagttatc tagtcatcta cactgtaacc 106140
gtccttcccg ccgaaactac tcaccctgcc actctggctc ataccctgc tctctttaaa 106200
atagccagtc agaattagct tagactgtgt ggtccaaccc cagccaatag gggaaagaca 106260
gcagtaggga ctagctgctt taggataagc acctcttccc ctcccttgta cggtgtgctc 106320
tcgccatcgc tccatccttg agatgcaccc ttctatagaa gtaaattgcc ttggtgagaa 106380
aacttttgcc tgagtgctag tttcactttg tagcaccgaa catttacttc caacaatcat 106440
ttgctacaga gatgaacata aatagaagga atccaggttg gattatcaa gacaatggga 106500
ggatgaccct gaaagcattt caaagatctt gtggaaaagc tgggattttt agggcaaaga 106560
atccagagag atacataaat atatgtttag tttttaactg gaagtgagct gggatgtact 106620
gtatgtagta caatcatata ttttaacgat gtggaaactg aaatagggtg actagcctaa 106680
aactaatgga ctagcttgtg aaaacaggat ttctcgtctc aaaaaaaaaa aaaaaaaga 106740
aaacagggtt tctcagtaga actaaactgc ctttccttgg ttttatttct agttaaatgt 106800
cgtaataaat ttaccagata ttgcttccgt gtacctggaa agcatagaca ttttgattca 106860
ttgtaatcaa tgtttaatca tgaaattaga tgaaataaca gcaagtgaag catgttagtg 106920
catgttagtg gctagagaga ggagattcat agtcaaagct gctttcttct ctcagtgagc 106980
tcactcaaca gcttttgaa tttgagaaaa ttgaattttc tttctaaggc tcagttcctt 107040
caatatataa tgggtctaat aatatttatt tcatattttt aatatttaca taaaattata 107100
cataaaaagt tctgtacatt gaatttataa aaactttta ttttaagtat acttaattac 107160
cccaaatttt aacatctgta tgtggtacat catggcctag gaaaataaag aataataaaa 107220
attatcctaa tcatttgcac tctagatttc ttcaattata ttcatttact cttggacttt 107280
tctacaaaca aagcaacaca aaataaacaa agaaaaagaa ggggagcaaa aataccctat 107340
gactttttt tttttttcaa atgaatgtat gctcaccgta atgataccgt gtggtagaac 107400
atgtttttgc tgcattagtg gccaagtgaa aagagtgagt aaggtgttcc tttttgagtg 107460
cagttctttc tgccaagtaa tggagggagt gaggtagaac gatgcccagt gatacacgat 107520
aagcaataag taaagtcatt accaagagat gtgaaaaaga ggacacagaa gagatgttaa 107580
gccatttaa aatccatgtt caacatcact gagctgtctt cagggaacat ttaattggca 107640
gaaatgactg cttctttgtg atttctttt aatgcaacag ggaaaaggag tcaactttat 107700
aaacacaagc aaacctttcc ttatttatta tctctgaagg cccattggtt ttcctgcttc 107760
tttataggta gggctgtcta tttgtgtgtg tgtgttagga actagacaaa gtgttgctat 107820
ttatatttag aagccaaata cttattcagt agaaatgatg catgattaga aatagttaaa 107880
taacttcata ggagtatggg tggttatata ggtatcaatg cacacaatct gagaatttgt 107940
atttgttcta actactgaac aaatgggact aagaaagtaa aatttcttgc aatggcttta 108000
tgtgcctcac atgttgtcag atctttacat agattataac ttttaatcct caaaagatat 108060
tccttcaaca acattttgaa gtgagaaaac taaagctcaa aaaagttatg taagctgtct 108120
acaattgtag agctaacatg cagcatagtt gtaattttt aagtcaaata aggcaagttc 108180
caaaactttt gagttggttt tgggagatga ataccagtac taaggatgtt ggaaacattt 108240
tagcacaaaa taatttaat gttttggaaa gtacaaatgt acatggcaga ctatttctaa 108300
ggaaggtggg atgtaaggtt aggacatgaa tatatagaag agtgcaagat gatgttccag 108360
tgttctccag aaaaaaagat gaagaaaaga ttgcaaagca tctaactacc caatcctcat 108420
gaaaacatat gcatgcacac tgaaataatt aaaaactaca tgtgtatgca tgcatgcatg 108480
tacacatgtg tgtattatat atgtctatgt gtatacatac aatatacata gtcagggaga 108540
ctttatatac atagtcaggg gaagagagag agaggttaaa tcaccatcct tctaaagata 108600
atagttccta ttacatgaac agcctttag ttcgtcaaag caccttaatg tgttcactag 108660
gcaaagttgg agctagagta gaatttgaga ttaggagacc ccaaaaggtg aagaacttag 108720
aataaaaata tagagaaaaa tacagttttt gaggtcattt tagaagagaa ggaaggagag 108780
gtgagaaata ggaggggagt agaattaaga gaaaccaggg aggtatcatg aattgggtta 108840
agtgctgtaa ataaccggt gacaaatcct ctatgattag gcaacaggta gaaaatttga 108900
gaaatataat agatttaatg ttttaatttt aatttttatt ctcttttgca acaaatatct 108960
atcttctact tgccttccac agagttgcaa tattatctgt gtctgtgtgt ttgcatactt 109020
gtaaacatta cagatttcta aatggcgtgg aatagatagg agttttaaga tgattttgaa 109080
aggtctcaag ttgctgacat caggattatc taagcattat ccttacattt tataagtcat 109140
accatagtcc ttgaatataa tctctcacag attaatttaa ttctaactaa taacaatcac 109200
```

```
ttcatatgtt ttcatcttat atagcagtca agtttacaat aatcttatta agcaccaacc 109260
ttaagagtat ttatattagt tagataacgg attaaattcc tatgagaaca aaacaaaata 109320
acagttaaac aaaattagaag tttatttctc atttatgtaa aattctgagc tagtatgtca 109380
tatcagctct gccaaggttt taggagctcc aactaattta ctcttctttc tctgctttct 109440
ataaagagtt actctcatct atatgattca ggatggctca gcactatatc cacattacag 109500
ccagtgagag gcagaaaaga agaagggaag ggcaaacctg ttttatcaat ggatggataa 109560
aagtagctta attttctttt attacattct cttggccaga agctaccctt ttgccatagc 109620
aaatctaatt ttagaatttt aaaaaaagga aattctggtc attttgtttt tgttttcttt 109680
ggctttgttt tttaaaattt atttaactta tttatttta agagctgtcc cataattatc 109740
agttctggct ctgaggagca aatacttaac ctggttaagg gaaaggtact agcttctagt 109800
gcaggctcag gctctgtcaa atctgtctgt tgtctggatg tctggatgat cacttagcca 109860
tctaatcact tcgctatgca tgctcagtat gcacaaatat agacagacat gttggacaaa 109920
gtcatttcca tgctctaatt caggtctgtc gctccaaaaa attacctact ctgaagttta 109980
tgaaattaac tagaagcatg ttagtagaca tttttgaaaat ttttctgtaa aattttcaat 110040
tggtatcctc ctcaaatatt tatctttat tttcccccaa aagtagcagc tagtctaaat 110100
tagcatattc tgtttgtcac ataaagaatg agctaaaatg tatttttagt tttttactac 110160
ctatccttat aacaggaacc taagggattt tatctgacat ggcatggaag aattaactgt 110220
aatcagaaaa agaatgtcag gtaccaggtt ctcaacttac agttaagtta gataacttat 110280
agctaagtta tctaaacaat taatttacaa aagtgctgag tattcatttg tttattagca 110340
ctagtggcaa aatctgagca ataaagatgt gagataaaaa agcaaaatgt aaaaaaaaat 110400
agacacagta gaaatgaata tgagtaagaa attaagtgac ataaaccgaa aagattagac 110460
cctgtttcaa ttaaatcact atctctagt tctcctgaca caaaacaaat ttagaaaaac 110520
tgcagaggag caatgcaaaa caatgtttca agaaaatata aaaatgtttg ccctttagaa 110580
aatatctact aatccaacat tctcatttcc cactgaagga aattatgaga agaaactgta 110640
cattggtgac tgagttcatt ctcctgggac tggccaatca ccgggaatta cagattttcc 110700
tcttcacgct gtttctcacc atttacatgg tcacggtggc aggaaatctt ggcatgattg 110760
ccctcatcca ggccaacgcc ccggctccac acgcccatgt acttttttcct gagcaactta 110820
tcctttgtgg atctgtgctt ctcttccaat gtgactccaa ggatgctgga gattttcctt 110880
tcagagaaga aaagcatttc ctatcctgcc cgtcttgtgc agtgttacct ttttatcacc 110940
ttggtccacg ttgagctcta catcctggct gtgatggcct ttgaccggta catggccatc 111000
tgcaaccctc tgctttatgg cagcagaatg tccaagagcg tgtgctcttt cctcatcaca 111060
gtgctttatg tgtatggagc actcactggc ctgatggaga ctatgtggac ctacaaccta 111120
gccttctgtg gccccagtga aattaatcac ttctactgtg tggacccacc actgattaag 111180
ctggcttgtt ctgacaccta caacaaggag gtgtcaatgt ttgttgtggc tggtttcaac 111240
ttcacttatc ctctccttat catcctcatt tcctatctct acatatttcc tgccaccctat 111300
aggatctgct ctacagaagg caggcacaaa gctttttcta cctgtggctc ccatctgaca 111360
gccgttacta ttttctattc agctcttttc ttcatgtatc tcagacgtcc atcagaagag 111420
tccatggagc aggggaaaat ggtagctgta ttttatacca ctgtaatccc catgttgaat 111480
cccatgatct acagtctgag gaacaaagat gtgaaagagg cattatgcaa agaactgttc 111540
aaaagaaaat tgtttttctaa ataaacatta ctactgattt ttgttgtgtt gtcatttat 111600
ttaccctatg atttttcata gagcatagtc tgatacaaat atatccaaaa ttatatattt 111660
tcctagaagt gttggggaat ttttatgaag tgtgaataca agaaaaaatg agtatttaca 111720
tcaattaaca ggaattttga attcaatata gttttgcctg cccataccccc aaagtaagaa 111780
gctctatagt gaagaatcaa tgtaaatttt aaaaaatcta atttatactt tagagaaaaa 111840
aaatccttaa aaccagacct gggtttttctt tttgcaagga gttaggcata tagttttaga 111900
ctgcttctta aacatatatt aagctttttt taaaaaaaac aacaacaaca acagcaacaa 111960
caaaaagaaa acagcatctc actccatcac ccaggatgga cctgagtgca gcggtgtgat 112020
cacagcttac tgcaatcttg atctctggtg ctcaaatcat cctcccacct cagcccctca 112080
cctctgccat agtagttggg actacaggtg tacaccatga tacctgacta attttttgtgt 112140
ttttttttgt agagacggga tttcaccatg ctgcccagac tggtcttgaa ttgctgagct 112200
ccagtaatct acctgcctgg gcttcccaaa atttaggaat tacaggtgta agccactctg 112260
cccagcctat aataagctta aagaaaaata gcagttctgc taaactctac taaatacttt 112320
tgtgtcttac aaagaaagtc aacattccac tttaccatat tcaacctaaa atatgagcct 112380
catcccttgt acactcagct gtcatctcag ctgttgcctc tgcctgtacc aacctcatct 112440
ccagccaaaa acacaccaac actttggtcc acagtgaggc acacttatgt ttccacagtc 112500
catacctggt ttatttcttg gctttttaga ggaaaaataa atggctagta gacttctaaa 112560
ttgaatgtta cctaaaagtc tgtctaagga gatccaaggc taacagacaa tctgttcaat 112620
gcatgtctaa aaccacatca acccaaaagg tgtaacatgt ggttgtaatg atactatcat 112680
cacagatttg catgggatca ctgtcttcca gtcttgaaga tgtgtgtttt tgggtgtgga 112740
ggcctatagt tccctagag gtaacctaga acttaagata taatcacata caaggaagcg 112800
agagactaat gatgaggtgt gtgcaaggtg agaaattaga acacagatgc cctcatgaaa 112860
ttcggattat tgaagggcta caacctctag agtaggacag agtcaacaac agcaacaaca 112920
aggatgaaac tagtccgttt agacttggtt tcatggagga gttaaaaagt cttatttaag 112980
```

```
aatttatgac aataattaat gctcatgtta agtcagcatt tatatttata ctgctttgat 113040
gggctatcaa atctcaagct aaataatgaa gaacataaag aggcccaggt tagaagaagc 113100
ttcatgacac tggaataagc aaacataaac ataagtcaga gaatgggtta tcaaccactg 113160
agacttcaaa gatagcccac tgaaaaagtt ctaattcaca gaaattttcc aggaaaataa 113220
gaaataaaaa gcacaaatga atatctttaa tttatttcag atattaggat tacttgatgc 113280
aaattgtaaa ataaagatat ttaatcattg aaaataaatg tgaaaattta aactctaaga 113340
ccatgtatat atgtgtgtac atatgtatgt gtacatatat atatgcaaag actgattata 113400
gaaaccaata attatatata atatgtagag ttccaagcat atctgcaggc tgaaggagag 113460
tctctgtgtt ttataggcat tgaagcattt ttagagtgga taggcaggta tataaatttt 113520
cacattgaaa ggaagaggaa gaaacagcta agtccctctc atgaggcttt aagtggtctt 113580
ggagagtcag cctttctctt cttcttcctt agtaaatttc atgcagacct tggcagccta 113640
atcactacaa tcctgcatca gtgagtcctc tgaactggca ccatagttca ctaggaaagg 113700
cactcatcca ccaagttcag agaggtggcc atccgcattg ctaaacagaa taaaacaaaa 113760
attcactttg tcatctgcct gacattggcc ttgctataag atagcctcat aaactgcctg 113820
aaaggcctta ttcttttcaa aggattttgt gctgtcttca agtgatattt ttctccatgt 113880
cagaaataaa atatttcagg attgacctgc ctcaaatttt agtttgtctt ggttattggc 113940
cattgcatgt ataagtctaa ttgtgtgaca gaagtttccg atactctgct tcatgaagta 114000
ccctttagga ctatctcctt gtctcttcag ttcttcaatc aatttttcct gaagttcttg 114060
tgtgaggctc tgatacaaag agtaggcagg tgctggcatc cagcccagag ccaccctttc 114120
cagccctagc acatccttaa agcacccctg accagcaccc tcaacctggc caacaggttt 114180
ttcagcatct acaggttaac ctccatgggc ttgagctgca ccttcacaaa tcacaagaga 114240
aaccacaaca cagagtacag ggaaaacagc ttttcaaaat tggtaaggtt agtagtggtg 114300
ttaagatatc accctgtctt cctatttgaa taccctattt tttttttgcc tgattgccct 114360
ggccagatct tccaatactg tgtttaatag gagtggtgag agagggcatc cttgtcttgt 114420
gtcacttttc aaagggaatg tttccagctt ttgcccattc agtatgatat tggctgtgag 114480
tttgtcataa atagctctta ttattttgag atacattcca tcaataccta gtttattgag 114540
agttttcagc atgaaggggt gttgaatttc atagaacgcc ttttttttctt catctattga 114600
gataatcatg tggattttgt cattcgttct gtttatgtga tggattatgt ttattgactt 114660
gggtatgtta agttagcctt gcatcccagc gataaagcca acttgatcgt ggtggataag 114720
ctttttgatg tgctgttgga tttggtttgc cagtatttta ttgaggatat ttgcatcgat 114780
gttcatcagg gatactggcc tgaaattttc tttttttgtt gtgtctctgc caggttttga 114840
tatcaggatg acgctggcct cataaaatga gttagggagg agtccctctt tttctgttat 114900
ttggaatagt ttcagaagga atggtaccag ctcctgtttg tacctctggt agaattcggc 114960
tgtgattcca tctggtcctg ggttttttttt gattggtagg ctattaatta ttgccacaat 115020
ttcagaactt gttattgatc tatccaggga tttggcttct tccttgtttt ggagatgaca 115080
tgactgtata tttagaaaac cccattgtct cagccccaaa tctccttaag ctgatgaaca 115140
tcttcagcaa agtcttagga tacaaaatca atgtgcaaaa atcacaagca ttcctataca 115200
ccaataacag acaaacagag agacaaatca tgagtgaatt cccattcaca attgctacaa 115260
agagaataaa atgcctagga atccaactta caagggatgt gaaggacctc ttcaaggaga 115320
actacaaacc accactcaag gaaataagag aggacacaaa cagatggaaa aacattccat 115380
gctcatggat aggaagaatc aatatcatga aaatggtcaa actgcccaaa gtaatttatt 115440
gattcaatgc tatccctgtc aagctaccat tgactttctt cacagaatta gaaaaatctc 115500
ttgtaaattt catatgaaac tgaaaaagaa cccatatagc caagacaatc ctaagcaaaa 115560
agaactaagc tggaagcatc atactacctg acttcaaact atactacaag gctacagtaa 115620
caaaaacagc atgatactgg taccaaaaca catatataga ccaatggaac agaacagagg 115680
cctcagaaat gatgccacac atctacaacc atctgatctt tgacaaacct ggcaaaagca 115740
agcaatagga taaggattc cctgtttaat aaatgatgtt gggaaaactg gctagccata 115800
tgcagaaaac tgaagctgga cccccttcctt atgccttaga caaaaattaa ctcaagaggg 115860
ataaaagact taaacgtaag acctaaagcc acaaaaaccc tagaagaaaa cctaggcaat 115920
accattcagg acataggaac aggcaaagac ttcatgacta aaacatcaaa agcaatggca 115980
acagaagcca aaactggcaa atgggatctc actaaactaa agagcttctg cacagcaaag 116040
gaaactatca tcagagtgaa caggcaacct acaaaatggg agaaaatttt tgcaatctat 116100
ccatccagaa tctataagga acttaaacaa atttacagga aataaacaaa cgaccccatc 116160
aaaaagtggg caaagatat gaacagacac ttcacagaag aagacattta tgtgggcaat 116220
aaacatgtga aaaaaacctc atcatcactg gtcattagag aaatgcacat caaaaaaaca 116280
caatgagata ccatctcacg ccagttagaa tggcgatcat gaaaaagtca ggaaacaaca 116340
gatgctggag aggacgtgga gaaacaggaa tgctttttaca ttgttagtgg gagtataaat 116400
tagttcaacc attgtggaag acagtgtggt gattcctcga ggatctagaa ccggaaatac 116460
catttgaccc aacaatccca ttactgggtt acatacccaa aagattataa atattctact 116520
ataaagacac atgcacatgt atgttcattg cagcactatt cacaatagca aagacttgaa 116580
accaacacaa atgcccatca accatagact ggataaagaa aatatggcac atatacacca 116640
tggcacacta tgcagacata aaagaggatg agttcatgtc ctatgcaggg aaatggatga 116700
acctggaaac catcattctc agcaaactaa cacaggaaca gaaaacaaaa cactgcatgt 116760
```

```
tgttctcact  tataagtggg  tgtgaacaat  gagaacacat  ggacacagga  aggggaatat  116820
cacacaccag  ggcttgtcag  gggttcgggg  gctagggaag  ggatagcact  aggagaaata  116880
cttaatgtag  attacaggtt  gatgggtgca  gcaaaccacc  atagcacata  tatacctatg  116940
taacaaacct  gcaggttctg  cacatgtatc  ccagaactta  aagtgtaata  aaacaaatgt  117000
atgtcacctt  gttaaaaaac  agatagtaga  aaaaccagca  aaatgagaac  tggtgctata  117060
taaaaatgta  ttcaaagaac  caagtaacat  atgactttgt  gctcaacttt  aataatcatt  117120
agggaagtac  acattacaat  tacaagatat  ttgtgttttt  atatatctgt  acctatatgt  117180
tgctaaatga  caaaaagaaa  aaaatgatat  tgctaagtac  tggtgggact  atggaacaat  117240
tgaatctctc  acataatgtt  agtgagaata  caaatggata  caaccagttt  ggaaaactat  117300
taggcagcat  aaatttaagc  tggacatatt  tatactccat  aagccagcac  ttctactcat  117360
agttacagca  gtcagacatg  catgaatatg  ttcatgaaga  gatatgcaca  agactgaatt  117420
ttgtaatagc  cacatctgga  aataacctat  atataaagtt  tggtgtactt  attatacagc  117480
agtgcagatg  aaggaattat  ttacatattc  atcacactca  tcatcatgaa  taaaaatcac  117540
caacataata  tttagcacca  atgtagtgtt  cattggagac  tagacctaac  aaaatatgca  117600
ctgtataatt  tctattacag  aaaattcaaa  accagacaca  attaatctac  agtgttaaaa  117660
gcaaagatat  agttaatttg  aggttactga  ctaggaaagg  gcatgaagac  agatggtgga  117720
gtactggtaa  tcttctattt  gagaatttag  aagcaagtaa  tacaagtatg  ttcactttgt  117780
aaaaattcat  gaagcaggcc  gggcacggtg  gctcgtgcct  gtaatcccag  gactttggga  117840
ggccgaggca  ggtgaatcac  gaggtcagga  ggttgagacc  atcctggcca  gcacagtgaa  117900
accctgtctc  tactaaaaat  acaaaaaatt  agccaggcgt  ggtggcgggc  acccgtagtc  117960
ccagctacta  gggaggctga  ggcaggagaa  tggcatgaac  ccggaggcgg  agcttgcagt  118020
gagccgagat  cccaccactg  cactccagcc  tgggcaacag  agcgacactc  tgactcaaaa  118080
aaaaaaaaaa  aatcataatt  catgaagctg  tacacttacg  ttttgtgctc  attatttgtg  118140
tgtaaattag  acttcaatat  aaagcttact  aaaaacgaat  aaaaatagta  ctagtcttca  118200
agcaagcaaa  gcttcattcc  aatatcaaag  cattctattt  acctatcagt  acacagaggg  118260
tattagtttg  ctagggctgc  cacaaataag  taccatgaac  ttggtgactt  aaacatgcag  118320
atttatttcc  tcacagttct  agaggctaga  agtccaagat  caaggtgtgg  gcaaaattgg  118380
tttcattctg  agttctcttt  ctggcttgtg  gatgatcatc  ttatcccgac  ctctttacac  118440
tttatttttc  tgtgtgtatc  tgtattctaa  tctcttctta  taaggatgca  agttatattg  118500
gattagggca  cagctcaccc  attaggcttt  attttactaa  atgttctctt  tagatattgt  118560
gtctccaaca  gtcatgctct  gtggtgcttg  gagttagaac  ttcagcatat  gaattttgga  118620
gagggaggga  aggggcacaa  tccagtccat  aacacagatt  aagaaacgtg  aaaggctaat  118680
agaagtttga  cacaaagttt  gtgacactag  tacgagagaa  actgtatcag  aaaagttgaa  118740
ttaagttgaa  agtaacatgg  taaacctaag  gcaatgtgag  aatccatggc  agacatgaat  118800
gttatcttat  ggattttcca  atgtaagaag  gaaaatactg  agaatgaaac  ataaggcaga  118860
gaaggaccag  agagttgtga  gttcccattt  taaatttgtg  ttgtgccaaa  tgtcatatct  118920
ctagagaaat  tattcagtga  gaaaaaaaat  ctgacagagt  aattgcttca  tttttgcata  118980
tctgtgaaat  cccttaggga  aataaagtca  tcatacaaat  attataaatt  attcctgtat  119040
ttgtcaccag  aaaagccatt  tgatattctt  tgtaaggata  gctcttccct  tattcataaa  119100
taagtttctg  catgtgtttg  taatcctgga  acacttgttg  tacaatcata  tgtattttca  119160
gagttagata  tatgattgtg  atgattaaat  gactaggtag  aaagaaaaat  gccaattacc  119220
agaaaaatgt  agacacttag  catttaaggt  acttttattt  gttaaagtct  tgaataatga  119280
ggatggaagt  taatggcata  aaaaataaag  aggcatgctc  taggatcttt  cactcaatat  119340
aaatgaaagc  taatatttat  taagggtttg  ccacacattg  ggcacagtgc  tatgcatatc  119400
acatacccca  ttttgtgaaa  tccgaaaaag  agtgcttttg  tatttgctaa  tttcatctgt  119460
aatagaaaaa  aattatagtc  cagaattatt  aagaaacatg  acccagacta  ctcagatcag  119520
aagttctgac  atcagaatgt  gaactcaacc  agtcgactcc  caaacgtatg  tttctaccag  119580
tacagtatgc  tttatggttt  gtagtggaat  ttctttctgt  actaaccatg  agggaaatat  119640
gttattatcc  atatctatta  taggcaaaat  gtcatagaat  tggtttgagg  gttgaatgtg  119700
ttaaaactta  taaaatagat  tagtgtttgg  cttataagaa  acaccatgta  agtgctggtt  119760
aaattagtgg  taaaactaaa  acacagaata  aggaacatgt  caaaagaaca  gagcagcatt  119820
tcagaaatat  ctaactccag  atcctgtgaa  ttgattttat  gctaaggcta  tcatatttt   119880
atcaaggcat  tcatctttgt  gtttggtcta  gtcctaaaac  ttaagaatgt  caaccggatg  119940
tgtgcatttg  tcaaatacac  aaagttgggc  actttaaata  tatgaatttc  actgtatata  120000
aattattgca  taaacaacat  taaacattaa  acaaagaaac  aaaggtgaaa  tctgacagga  120060
gcttgatata  taaaaatgaa  tgaaggtatg  tagggaaaag  aaagagagat  cagactgtta  120120
ctgtgtctgt  gtagaaagga  aagacataag  agactccatt  ttgaaaaaga  cctgtacttt  120180
aaacaattgc  tttgctgaga  tgttgttaat  ttgtagcttt  gccccagcca  ctttgaccca  120240
accactttga  cccaacctgg  agctcacaaa  aacatgtgtt  gtatgaaatc  aaggtttaag  120300
tgatctaggg  ctgtgcagga  catgccttgt  taacaaaatg  tttacaagca  gtatacattg  120360
gtaaaagtca  tcgccattct  ctagtcttga  taaaccagga  gcacaatgca  ctgtggaaag  120420
ccgcagggac  ctctgccctt  gaaagcggag  tattgtccaa  ggtttctccc  catgtgatag  120480
tctgaaatat  ggtctgaaac  cagggcaca   ttgcactgcg  gaaagccgta  gggacctctg  120540
```

```
ccccttgaaag cggggtattg tccaaggttt ctccccatgt gatagtctga aatatggcct 120600
tgtggcatga gaaagacctg accatccccc agcccgacac ccgtaaaggg tctgtgatga 120660
ggaggattag taaaagagga aagcctcttg cagttgagat agaggaaggc cactgtctcc 120720
tgcctgcccc tggggactga atgtctcggt ataaaacccg atagtacatt tgttcaattc 120780
tgagatcaga taaaaactgc cctatggtgg gaggtgagac acgtttgcag caatgctgcc 120840
ttgttattct ttactccact gagatgtttg ggtggagaga aacataaatc tggcttatgt 120900
gcatgtccag tcatagtacc ttcccttgaa cttaattatg acatagattc tattgctcac 120960
atgtttgttg ctgaccttct tattatcacc ctgccctcct actacattcc tttttgctga 121020
aataatgaag ataataatta ataaaaactg agggaactca gaggctggtg caggtccttg 121080
atatgctgag tgccggtccc ctgggcccat tgttgtttct ctgtactttg tctctgtgtc 121140
ttatttcttt tctcagtctt tcatcccacc caactagaaa tacccacagg tgtggagggg 121200
caggccaccc cttcaaaggt acatcactac tatgattgaa tagatgtaga cacagctttt 121260
actcgatgtt gtataaatca caaataaaat ctttgtttca gatattcaaa aataaccttc 121320
tataagatgt tcttgtgaat atagatgatt tttatataga aaaatagaag gtacatttca 121380
ttaatatcag tgttaacagt ttttgttgtt gttgtaagta acagaacaca gctctggtta 121440
tgctaagcaa aaccggaaca ttctgaaagg atgttagggc tcctaaatca atgtgcggtt 121500
aaaagaccag gcttagagaa cagatagcag cctaggcagg tgtggaggct gagcagatca 121560
aaccacacag aatcagtgtt tctttgcaac atcagcctga tcttcaaacc tcactgtaat 121620
gaattagatg aaaaaaaatt ttgtcaaact tgagtcatta actcactccc ttaagacaag 121680
gagaggctag catctgaccc ctgcttaagc ctttctaaac agagaatctc atctctcagt 121740
ggaaactaga agtggaagat caagaggaca gaatttccat gactctcaac ttgacacatt 121800
ggaaaatttc ctccaaaaaa ttcaagtgga gtgttaatgg ctggaattta atagctgtgc 121860
aaccctcgaa acgcaaatat gtagatattt ttcaaaataa ggggaacaaa tcatgccctg 121920
cctggaaaat ctctattgca ttgagtctgg aggaagaaga aagcaacaag tgagccccgc 121980
ttgtttgctc aggcttctcc aagaggggat tgaactggtg aaatctattc agaaataaca 122040
agatcattca gtcaatattg ttctttgata tcttgttctt tcctctctct aaactcattc 122100
tctgccagaa ttataatcag gaataaagaa attggttagt tttaaatgtt atgttttggg 122160
gcaagtccac ctataaagta catttctcaa atataaagag gggcagaata agagaaggag 122220
aaagaagaga agaagaatag agacagaagc tgaattagaa gggaatgaaa agaaagacaa 122280
agggacataa aacaagaaaa ataaagggca gtatcaaaaa aggcagagag ctgctttgaa 122340
tatccctact ttagtttacc tgaaacaaag ttcattagaa ataaaatgag gaaaactgct 122400
gaaaagaggg gaaaactttt ggtaagaaga ttattactct actggtaata atagtaataa 122460
tcatgttgct attgtattgc aatcaatata tatgtaaagt tcctttctcc cactgaagga 122520
aattatgaga aggaacttca cgttggtgac tgagttcatt ctcctgggac tgacgaatca 122580
ccaggaatta cagattctcc tcttcatgct gtttctggcc atttacatgg tcacagtggc 122640
agggaatctt agcatgattg ccctcatcca ggccaatgcc cggctccaca cgcccatgta 122700
ctttttcctg agccacttat ccttcctgga tctgtgcttc tcttccaatg tgaccccaaa 122760
gatgctggag attttccttt cagagaagaa aagcatttcc tatcctgcct gtcttgttca 122820
gtgttacctt tatatcatct tggtacacgt tgagatctac atcctggctg tgatggcctt 122880
tgactagtac atggccatct gaaaccctct gctttatggc agcaaaatgt ccaaaagtgt 122940
gtgttccttc ctcatcacgg tgccttatgt gtatggagcg ctcactggcc tgatggagac 123000
catgtggacc tacaacctag ccttctgtgg ccccaacgaa attaatcact tctactgtgc 123060
agacccacca ctgattaagc tggcttgttc tgacacctac aacaaggagt tgtcaatgtt 123120
tgttgtggct ggctatcttaa tttcgttttc tctcttcatc atatttattt cctacttta 123180
cattttttcct gctatcttaa ggattcgctc tacagagggc aggcaaaaag cttttctac 123240
ctgtggctcc catctgacag ctgttactat tttctatgca actctgttct tcatgtgtct 123300
cagacctcca tcagaagagt ccatggagca aggacaaatg gtagctgtac tttataccac 123360
tgtgatcccc atgttaatcc catgatctac agtctgagga acaaggatgt gaaaaaggct 123420
ttatccaaag aactgttcaa aagaaaattg tttcctaaat aaacatcagt attgattttt 123480
gtcatgctgt cattttattt agcctataat tttttcatag agcttagtgc aatacaaatt 123540
tatccaaaat tatacatttt ccttgaaggg ttagggaatt tttatgaagt gtgaataaaa 123600
gaaatatgag tatttacatc aattaacaga tagtttgata tcaatatagt tttaactgcc 123660
cataccccaa agtaaaaatt tctatagtga ggaatcaatg taaataaaaa aaaatctaat 123720
ttgtatttta gaaaataaaa cccttaaaac cagacctggg tttctttttt ggaaggagtt 123780
aggcatatag ttttaaactg cttcttaaac atatattaag ctattttttt ttttgaaac 123840
agcatctcac tccatcaccc aggatggact ggagtgcagt ggcatgatca cagcttacag 123900
caaccttgat ctcagggttt caaaccatcc tcccacttac acccctcacc cctgccacag 123960
tagctgggac tacaggtgtg caccaccata ccacactaat ttttgtattt tttgtagaga 124020
cggggtttca tcatgttgcc cagactggtc ttgaactgct gagtgcaagt gatctatctg 124080
cctgggcctc caaaagagtt tgcattacat gggtgagcca ctgtgcccag cctgtaataa 124140
ggtttaaaaa agagcacttc tgctaaactc tactagatac ttttgcctat cttacagagg 124200
aagtcagcat tccactttac catgtccaac ctaaaacgta agcctcatcc cttgcacact 124260
cagttgtcat ctcagctgtt tcctctgcct gtaccaacct catctccagc ctaaaacaca 124320
```

```
ccaatgcttt ggtccacagt gaggcacact tatgtttcca cagtccatat ctggtttatt 124380
tcttggcttt ttagaggaaa aataaatgac cagtaggatt ctaaattgaa tgttacctaa 124440
aagtctgtct aaggagaccc aaggctaaca gataatctgt tcaatgcatg tctaaaacca 124500
catcaaccca aaaggtataa catgtggttg taatgatctt gaagatgtgt gtttttgggt 124560
gtggaggcct atagttcccc tagaggtaac ctagaactta agatataatc acatacaagg 124620
aagacgagag actaatgatg aggtgtgtgc aaggtgagaa attagaacag agatgccctc 124680
aggaaattcg gattattgaa gggctgcaac ctctagagta ggacagagtc aacaacagca 124740
acaacaagga tgaaactagt ccgtttaggc tttgtttcat ggaggagtta aaaagtctta 124800
tttaagaatt tatgacaata gattaacggt catattaatt cagcgtttat atttacactg 124860
ctttgatggg ctatcaaatc tgaagctaaa aaaacatgaa ataggcccgg cgtggtggct 124920
cacacctgaa atcccagcac tttgggaggc ccaggcggtt ggatcacgag gtcaggagat 124980
tgagaccatc tgcctaacac ggtgaaaccc cgtctctact aagagtacaa aaaatcagca 125040
gggcgtggtg gcgggcgccg gtagtcttag ctactcagga gactgaggca gaagaatggc 125100
ctgaacttgg gaggcgcagc ttgcagtgag tggagattga gccactgcac tccagcctgg 125160
gtgacagaag gagactctgt ctcaaaacaa acataaacaa aaacaaaaac aagcaaacaa 125220
aaaacaaaaa caagcaaaca aaaaacaaaa cataaagagg cccaggttag aagaaacctc 125280
atgacactgg aataagcaaa tataaacata agtcagagaa tgaattatca actactcaga 125340
cttcaaagat atcccgcaga taagtttcta attgacagac attttccagg aaaataagaa 125400
ataaaaagca caaatgaata ccttcaactt attacagata ttaggattac ttgatgcaaa 125460
ttataaaata aagatattta atcattgaaa taagtgtgaa aattaaaatt cgaagaccat 125520
atatatgtgt gtatatatat gtatgtgtac atatatatgc aaagactgat tatataaagc 125580
aataattata tataatatgt agagttccga gcatatctgc aggccgaagg agagactctg 125640
tgttttatag gcattgaagc attttacatt ttttttatg ttctcagcac ctttatttat 125700
ttatttattt ttttagtatt tattgatcat tcttgggtgt ttctcgaaga gggggatttg 125760
gcagggtcat aggacaatag tggagggaag gtcagcagat aaacatgtga acaagggtct 125820
ctggtttttcc taggcagagg accctgcggc cttccgcagt gtttgtgtcc ctgggtactt 125880
gagattaggg agtggtgatg actcttaacg agcatgctgc cttcaagcat ctgtttaaca 125940
aagcacatct tgcaccgccc ttaatccatt taaccctgag tggacacagc acatgtttca 126000
gagagcacgg ggttgggggt aaggttatag attaacagca tcccaaggca gaagaatttt 126060
tcttagtaca gaacaaaatg gagtctccta tgtctacttc tttctacaca gacacagtaa 126120
caatctgatt tctctttctt ttccccacat ttccccctta tctatttgac aaaactgcca 126180
tcgtcatcat ggcccattct caatgagctg ttgggtacac ctcccagacg gggtggcggc 126240
cgggcagagg ggctcctcac ttcccagacg ggggggccgg gcagaggcgc cccccacctc 126300
ccgggcgggg tggctgctgg gcgggggctg cccccccacct ccctcccgga tggggcggct 126360
ggccgggtag gggctgcccc ccacctccct cccggacggg gcagctggcc gggcgggggc 126420
tgcccccccac ctccctcccg gacggggcag ctggccgggc aggggctgac ccccacctcc 126480
tggacagggc ggctgctggg tggagacacg cctcacttcc cggatggggc ggctgccagg 126540
cggaggggct cctcacttcc cagacgtggc ggctgccggg cggaggggct cctcacttct 126600
cagatgtggc ggcggccatg cggaggagct cctgacttct caggcagggc agccgggcag 126660
agacggtcct cacctcccag acggggtggc ggtcgggcag agacactcct cagttcccag 126720
acggggtcgc ggccaagcag aggcgctcct cacttcccag actgggtggc cgagcagagg 126780
ggctcctcac atcccagacg atgggcggcc aggcagagac gctcctcact tcccagacag 126840
ggtggcggct gggcagaggc tgcaatctgg gcactttggg aggccaaggc aggcagctgg 126900
gaggtggagg ttgtagcaag ccgagatgac gccactgcac tccagcctgg gtaacattga 126960
gcactgagtg agtgagactc cgtctgcaat cccggcacct cggggggctg aggcgggcag 127020
atcactcgcg gtcaggagct ggagaccagc ccggccaaca cggcgaaacc caccaaaaaa 127080
tacaaaaacc agtcaggtga gcggggcatg cctgcaatcc ccggcactcg gcaggctgag 127140
gcaggagaat caggcaggga ggttgcagtg agccgagatg gcggcagtac agtccagcct 127200
cggctgggca tcagagggat accgtggaga gagagggaga gggaggagacc 127260
gtggagggag agggagaggg agaccgtgga aggagagga gaggagagc attgaagcat 127320
tttagagtgg ataggtaggt atataaattt tcacattgaa aggaagagga agaaacagct 127380
aagtccctct catgagactg tcttggagag ggttacagca gagaggctgc ctttctctcc 127440
ttcctcctca gtaaattttc tacagacctt ggcagcctaa tctctacagt cctgcagcag 127500
tgagtcctct gaactggcac catagtccac tgggaaaggc attcatccat caagttcaga 127560
gaggtggcca tccatgttgc taaacagaat aaaacaaaaa ttcactttgt catctgcctg 127620
acattggcct tgctatgcaa tagcatcata aactgcctga aaggtcttat tattttcaaa 127680
ggattttgtg ctgtctacaa gtggtatttt tctccacctc agaaataaaa tattttagga 127740
ttgacccacc tcaaatttcg gtttgtcttg gttatcggcc actgcttata taagtctaat 127800
tgtgtgacag aagttcccaa tgctctgctt catgaagtac cctttaggac tacctcttgt 127860
ctcttcagtt cttcaatcaa ctttttcctg aagttctcgt gtggggatct gatataaaca 127920
gtaggcagct gctggcatcc agcccagagc cacctcttcc aggcccagga catccttaaa 127980
gcacctctga ccagcaacct caatctggcc aacacttttt tcagcatata caggtaaatc 128040
tccatgggct tgatcagcac cttcacaaat cagaaaagaa accacaaccc agagtaaaga 128100
```

42

```
aaaaacaacc tttcaaagtt agtaaggcta ttggtggtgt taaaatatca cccggttaaa 128160
aaacaaacaa actgatagca gaaaaaaatg gcaaaatatg aactggtgct atataaaaac 128220
atatttaaag aaccaagtaa cttatgactt tgtgctcaac ctgaataata attagggaag 128280
tgtacattac aagatatctg tatctttata tatctgtacc tatatatctg tgtctgtatg 128340
ttgcagaatg acagaaaaac tgatattgtt aagcattgga gagactgtgg aacaactgac 128400
cctctcatat aatgctagtg ggaatgcaaa tggatataaa cagtatggaa aactactagg 128460
cagcataaat ttaagctgca catatttata ctccataaac caacactact gcccaaagta 128520
ctaacaggca gaaatacatg aatatgttcg tgaagagata tgcacaagat tgaattttgt 128580
aacagccaca cctggaagta tcctatatgt gtatcaatag taggaaggat ttattaattt 128640
tggtgtactt actatacagc cgtggagatg aaggaattat ttacatattc atgacactcc 128700
tcattttgaa taaaaatcac caacataata tttagcacca atgtagtgtt cattggaagg 128760
ctagacctaa cagaatatgc actgtataat ttctattatg gaaaactcaa aagcagacac 128820
aattaatgta cagtgttaaa agtgaagatg tagttaattt gaggttagtg actaggaaag 128880
ggcaagcaga gagatagtgc agtactgtta atgttctact tgaggattta gaggcaagta 128940
atacaagtat gttcactttg taaaaattca tgaagctgta cgcctacatt ttgtgcacac 129000
tttctgtgtg taaattagac ttcaatataa aggttactaa aaacgaataa aaatagtact 129060
agacttcaag caagtaaagc ttcattccaa tatcaaagca ttctatttac ccatcagtac 129120
acagagggta ttagtttgct agggctgcca caaataagta ccatgaactt ggtgacttaa 129180
acatgcagat ttatttcctc acagttctag aggctagaag tccaagatca aggtgtgggc 129240
aaaactggtt tcattctgag ttctttttct atcttgtgga tgatcatctt atcccgacct 129300
ctttacactt tcttttttctg tgtgtatctg tattctaatc tcttcttata aggatgcaag 129360
tcatattgga ttagggcaca gctcacccgc tagaccttat cttacttaaa tgttctcttt 129420
cgatatcgtg tctccaacag tcacgctctg tggggcttgg agctggaact tcagcataag 129480
aattttggag agtgagggaa gaggcacaat ccagtccata acacagatta agaaatgtaa 129540
aatgctaata gaattttgac acaaagtttg tgacactggt aggagagaaa ctgtatcaga 129600
aaagttgaat taagttgaaa gtaacatggt aaacctaagg caatgtgaga atccatggca 129660
gtcaggaatg ttattgtatg gattttctaa tgtaagaagg aaaatgctga gactgaaaca 129720
taaggcagag aaggaccaga gagttgtgag ttcccatttt aaatttgtgt tgtgccaaat 129780
gtcatctctc tagagaaatt attcagtgag aaaaaaaatc taacagagta attgcttcat 129840
ttttgcatat ctgtgaaatc ccttagggaa ataaagtcat catacaaata ttataaatta 129900
ttcctgtatt tgtcaccaga aaagccattg atattctttg taaggacagc tcttccctta 129960
ttcataggta agtttctgca tgtgttttta atcctggaac tctacttgct atacaatcgt 130020
atgtattttc agagttagat atatgattgt gatgattaaa tgactaggta gaaagaaaaa 130080
tgccaattac cagaaaaatg tagacagtta gtatttaaga tacttttatt tgttaaagtt 130140
ttgattaatg aggatggaag ttaatggcat aaaaatataa gaggcatgct ctaggatctt 130200
tcactcaata taaatgaaag ctaatattta ttaagggttt accacacatt gggcacagtg 130260
ctacgcatat tacatactcc attttgtgaa atcctaaaaa tagcactttt gtgtttgtta 130320
atttcatcag taatagaaaa aaactatagc ccagagttat taagaaatat gacccagact 130380
actcagatca gaagttctga catcacagtg tgatctcaac cagttgactc caaagcacat 130440
gtttctacca gtacagtatg ctttatggtt cgtagtggaa tttccttctg tactaaccat 130500
gagggaaata tgctattatc cataccatt acaggcagag tgtcatagaa tcggtttgag 130560
ggttgaatgt gttaaaactt ataaaataga ttagcgtttg gattataaga aacaccatgt 130620
aagtgctggt taaattagtt gtaaaactaa aacacagaat aaggaacatg tcaaaagaat 130680
agagcagcat ttcagaaata tctaactcca gatcctgtga actgattta tgctaagcct 130740
attgcatttt tatcaaagca ttcatctttt tgtttggttg agtcctaaaa cttaagaatg 130800
tcaaccagat gtgtgcattt gtcaaacaca caaagttggg cactttaaat atgtgaattt 130860
cactgtatat aaattattgc aaaaacaaca ttaaacaaag aaacaaaggt gaaatctgac 130920
aggagcttga tatataaaaa tgaatgaggg tacatcacta ctatgattga atagatgtag 130980
acacagcttt tactcaatgt tgtataaatc acaaataaaa tctttgtttc agatattcaa 131040
aaataacctt ctataagttg ttcttgtgaa tatagatgat ttttatatag aaaaatagaa 131100
ggtacatttc attaatatca gtgttaacag tttttgttgt tgttgtaagt aacagaacac 131160
agctctggtt atgctaagca aaaccggaac attctgaaag gatgttaggg ctcctaaatc 131220
aatgtgcggt taaaagacca ggctcagaga acagatagca gcctaggcag gtgtggaggc 131280
tgagcagatc aaaccacaca gaatcagtgt ttctttgcaa catcagcctg atcttcaaac 131340
ttcactgtaa tcaattagat gaaaaaatat tttgcaacct tgagtcatga acttacttaa 131400
gacaagcagg gactaacatc tgaccctgc ctactccttt atggttttt ttttttttt 131460
ttttttttt ttttttttt tttttttttg agacagcatc tggctctgtc gtccaggctg 131520
gagtgcagtg gcaccgtctt ggctcactgc aagctccgcc tcccgggttc acgccattct 131580
cctgcctcag cctcctgagt agctgggact acaggcgcct gccaccacac ctgccctgac 131640
tactcctttc taaacagaga atctggtctc tcagtggaaa ctagaagtgg aagatcaaga 131700
ggagagaatt tccatgagtc ttaactccac ataatggaaa atttcctcca aaaaattcaa 131760
agagagtgtt actggctaga gaatttaata gctgtgcaac cctcaaaagg caaatatgca 131820
gacactttc aaaataaggg gaaaaaaatc atgccctgcc tggagaatcc ctattgcact 131880
```

```
gagcctggag gaataagaaa gcaacaaatg agcccaacct gtttgctcag gcttctccag 131940
gaagggatcg gattggtgaa aactattcac aaagaacaag atcctcgggc aaatattgct 132000
ttttgatact tgtcctttc tctctttacg cgcattctct gcccagtatt ataatcggga 132060
aaaaagaaat tgcttagttc tgaatgttat gttttggggc aagtccacct ataaagtaca 132120
tttctcaaat aaaaggagag gcagaataag gggaggagaa acgagagaag aagaatagaa 132180
aaacagaagc tgaatttgaa gggagtgaaa agaaagaaaa tggaaagaaa acaagaaaaa 132240
taaagggcag tatcataaaa ggtagagagc tgctttgaat atccctaatt tagtttacct 132300
gaaacaaagt tcagtagaaa tagaatgagg aaaactgcca aaaagagggg acgtttttgg 132360
taaaagatca ttactgtaat agtaataatc atgttgctat tgtattgtaa tccaatatat 132420
atgtaaagtt cctttcttcc accgaaggaa attatgagaa gaaactgcac gttggtgact 132480
gagttcattc tcctgggact gaccagtcgc cgggaattac aaattctcct cttcacgctg 132540
tttctggcca tttacatggt cacggtggca gggaaccttg gcatgattgt cctcatccag 132600
gccaacgcct ggctccacat gcccatgtac ttttttcctga gccacttatc cttcgtggat 132660
ctgtgcttct cttccaatgt gactccaaag atgctggaga ttttcctttc agagaagaaa 132720
agcatttcct atcctgcctg tcttgtgcag tgttaccttt ttatcgcctt ggtccatgtt 132780
gagatctaca tcctggctgt gatggccttt gaccggtaca tggccatctg caaccctctg 132840
ctttatggca gcagaatgtc caagagtgtg tgctccttcc tcatcacggt gccttatgtg 132900
tatggagcgc tcactggcct gatggagacc atgtggacct acaacctagc cttctgtggc 132960
cccaatgaaa ttaatcactt ctactgtgcg gacccaccac tgattaagct ggcttgttct 133020
gacacctaca acaaggagtt gtcaatgttt attgtggctg ctggaacct ttctttttct 133080
ctcttcatca tatgtatttc ctacctttac attttccctg ctattttaaa gattcgctct 133140
acagagggca ggcaaaaagc ttttttctacc tgtggctccc atctgacagc tgtcactata 133200
ttctatgcaa cccttttctt catgtatctc agacccccct caaaggaatc tgttgaacag 133260
ggtaaaatgg tagctgtatt ttataccaca gtaatcccta tgctgaacct tataatttat 133320
agccttagaa ataaaaatgt aaaagaagca ttaatcaaag agctgtcaat gaagatatac 133380
ttttcttaaa aatcagtatt cttttggttt ctaaagccct tcctagactt ttttctttag 133440
ctgagaaata tagtgcatca atggagaaca ttgcagtttt caaaacttta tttattttta 133500
ttttattatt atattttgag atggagtttc tctctgtctt aggctggagt gcagtggtgt 133560
gatctcggct cactgcaacc tttgcctccc gggttcaagc aattctcctg cctcagcctc 133620
ccgagtagct gggaacacaa gcgcacacca ccatgcccga ctcattttt gtattttagt 133680
agagacaggg tttcaccatg ctggccaggc tcggcctccc aaagtgctgg attacacgc 133740
atgaaacacc gcgccagtc taaaaacttt attttctaaa attcaaatac gtacaatttt 133800
gttcacaaaa gctttatgt tttaagttgt cattcatctt gttcagcagt tattttaagt 133860
tctttgtctt ccgtgcacag aatggctttg tacctccatg cccttaggtt taggtaagat 133920
catgtggcta tttctggaag atgagattaa aattcacata tgtcacttct cagttgaata 133980
cttaattgat tgttagarca tttttgagtg gatctgttgt ttttatttt tccatggtga 134040
ccagcaagac ttaatatagt ggctgcccag tcaggagaca tggaacactg ttctcatccg 134100
actcacaatg gcaatacaaa acggctgata aataacgttt tcataagcta ctatgatatg 134160
tggagtttgc ttgtttccct agcacaaaat agcctattct gattgatgcc atattaatta 134220
tacaaattca cacaggctga attatataat atagaatgag aacatcacaa accttgaaga 134280
aatcacattt gagattttgt tttgtgttct tgtagtcatt tttaatgctt ttacatacac 134340
atgtgtgttc agttaaaatt atttattata attaccattt gaacctactc atgattaatg 134400
tatgtagttt taaatgtcaa ataatattac aagccatata taaactcctg tctcacttct 134460
accttaccac taactcccca tagataatac tttcttgtta tttcctttgg aaattaaccc 134520
attttaaatt atatgcttgt attcctctgt actgatttt caaatatgca cataatttat 134580
tgacatctgt ttattaaaga taaggtgcca tcattctttc accaatcact tcattcttac 134640
cctacaatga tcacttcttt ctcttcattg tcacagtagg atcacatttg aattttttggc 134700
ttaatcagta tctactgtta aaattactat gaatgtatca ttaataatac ctgaagtata 134760
ctataatact ttgagcatca ctaacactag tattaattat taataatatg aatactacta 134820
tgattgtaat tctcttcttg cacagttact ggattttcat aaagttgaca atggcctcca 134880
gttttgctct tcttttgta tagtagctac ttttccccaa actgtcacta aactgtaaag 134940
caccttttata gggtcaaaca caatagatga tctatagttt ccatatttt ttctcagacg 135000
ttctctgtcc tcccattgga ttctgctctg tttgcagagc tgttatttga agataatgat 135060
tccaatcatt ggtttaaggc atttcattca ttcaacttga ttacatgaca atatgcaaca 135120
aactggagat tcaacaaaaa taagacagaa aaaagtctta aagagagttt tatggaacag 135180
ttaatgaact tttctgctgt tatcatgagt ggcacaaggt cagagataac taggtccatg 135240
catgtttgta tttttctgca atgtcagaat tttcttgatg ctatttcaat cataaaatcc 135300
atgagctaca tggggttccc gaggaggcaa ttctccttaa aacttcctgt tcactcagta 135360
gtcagagcca tgggcaaaca ggctcaagtc attcaacaag tcagtcagta ttgcagtcca 135420
tgaattacag tatatttaat cagtctataa atgtaataga ttacacattg tacagcaaac 135480
aaagtaacat ttatcatcaa gaataaaggg actggaaatg ggttaaggaa ccagtccact 135540
gagagtgaca tgaacaaaaa gaatagccta ctcaggccct ggtggtccat caataaactt 135600
gtaaagaaga gttttcgttg tgggcaaagc cttcagtggc aaatgcaaga tgcttatctc 135660
```

44

```
aagtgataac  aagatggtgt  cttttaaggt  ggctgtttca  agctgctgaa  atcctgctct  135720
tttatggaca  cagagtcctc  tagtaagaac  tgatagtgga  agagtgactt  tgttatgtcc  135780
ttatctggtt  ggatgcagtc  tttcttgatt  aggcaaaaca  tctggccctt  gttggcatga  135840
tgcctttaaa  aatgtaagat  gaagtcattt  tctaagatgg  agtaacttat  atcaatgggg  135900
ctctatacta  cgattcagcc  ccaggttccc  ttctacactt  tcctttaccc  ttaccatttc  135960
agccttagct  gaagagctgg  gtgcagtggc  tcatgtttgt  aatcccagca  ctttgggagg  136020
ctgaggtggg  tgaatcacca  gaggtcagga  gttcgccact  agcctggcca  acatggtaaa  136080
accctgtttc  tactaaaaat  acaaaaatta  gctgagcatg  ctggtggaca  cctgtaatcc  136140
cagctatttg  ggaggctgag  gcaggagcat  tgcttggacc  caggagacag  aggttgcagt  136200
gagccgagac  cgcactgttg  ccctccagcc  tgggcaacaa  gagtgaaatt  ctatctcaag  136260
aaaatagact  tagctgaaga  attatctctt  cctgcaaggt  ttctttaaca  cattcaggat  136320
gtgtagtgtc  aactgaggaa  tgatgagatt  cataaattta  gaaaggtgga  ctttctcata  136380
aagggttgta  gcctgtaggg  tgaccgttct  gacaggctgt  gaagcatatc  ctccagctag  136440
aagttggaaa  gagacacttc  gacagtatga  agagtaagac  agggatttat  gctgaatggg  136500
atgaccaaat  atattacaca  tatatgataa  tacatattca  acaggctata  gaaaaaacta  136560
tgaatattca  caaagaagag  gcacaggcat  gaatagtagg  ctaatataag  caacatgcat  136620
cccatgttcc  ctttggagtg  gggacttaac  atttaaatgt  gtcatgatta  gactctatgc  136680
accaaaaggt  gaatcagaag  acaccaagac  cctctgtgca  cagcctctgt  tgactggcaa  136740
gagccactag  gttattggtg  gtctcttatc  aagaaggaat  gctggtcaat  tgctgtgttg  136800
aaaccgcaaa  aagagaagtc  cagtgtcagg  tggtttgcag  atatcagtgg  tggtgcgagt  136860
ctcacaaggg  caggtttctg  tttaaccctt  attgtaggaa  gcctaatggt  gtttagcaag  136920
ggaggggaga  taacgaggca  tgtctgatct  cccatctgtc  atggcaggaa  ctcagatttt  136980
aaagtttttc  tgaggtttcc  ttgaccaaga  ggcagtctgt  tcaattgatt  caggggttag  137040
gattttattt  gtatttctca  ttaggtacca  catgatgatt  cacccacaga  ttcacaatta  137100
tattattgca  ttcataacat  ggttctataa  ttatatgcat  gtaaatctgt  tccttccact  137160
attttagcaa  gttctcaaag  gaaaggacca  catctttttg  tttttatatt  tttaccacct  137220
taagatagtg  ttctataaag  ggaggatgcc  catttttttt  ttgaaactgt  gagaacaatc  137280
ccttccactt  tctacctttg  tctgtaatta  tggccaatta  cagatttctc  tccatgatac  137340
tcgcttctcc  catcctaaca  tatattcaag  gcagaacaat  agatcattta  gtttaagaaa  137400
accatgttca  agttctttat  cataaatggc  ccactgaaag  cccagcaacg  tgaatcataa  137460
ctgagcaaga  attggagaaa  gtaatttcat  tggcagcaga  caggaaagat  cacatactac  137520
atcctattct  tcatagcaga  gagacagata  acaataaatg  ctgaactaca  gtaaaagatg  137580
ttaagggaaa  tatttgtgag  gaataaatct  ttgtagcaat  gtattttcct  tgatatgcaa  137640
tcataattat  ccatagcatt  tgggaaacaa  ctgacaattt  ttatcacctt  tataaatgtt  137700
agttttgatc  tttatagcaa  ggttataatg  gaaaaatcaa  ccactgtgta  ataaaattat  137760
tttaaaatga  acagaattac  actaggctgt  ctgggacaga  ggcaagggaa  gggctgagtc  137820
atgatttaag  gtgcaggaaa  caaaagggac  ctcattgttg  ctcagacaga  aaagaggttt  137880
ggtgggaatc  agacaacagg  tatatattga  gacaacgaaa  tatccaatcc  ttgaaaaagt  137940
acattcttgt  gcatcacttt  ttcatagcca  accgtcctaa  gatttatgcc  atgtgataag  138000
ctgatgataa  aacattctct  tcaagttgaa  acagaataca  gttgtggaaa  aatatttggc  138060
tttgtaatta  ttcagaactg  agcctgaatc  ctagtttat   tactattttg  ttagctgggt  138120
aaacttagag  aagttccctc  tccatatcag  tttattcaaa  tgcaaaaccc  catttcatgg  138180
agttattgtg  aatatcaaat  attatttta   atatacattt  tcctcaattg  cattttgagg  138240
caagtatgct  gagttccagt  gtggactcaa  tttcatgaaa  gttttttaac  atgggaaaca  138300
tgatcaaaac  aataagttaa  atatgttagt  tattcattta  tttaacatat  gattattgtc  138360
cctgtcagtc  actttcatca  ttggcagtca  ccagtctctt  ctacctgttt  cattgtttct  138420
tcatcagtct  cttcctgttg  tattgtttca  tctatctgtt  tctaaaacat  ttcatgtttt  138480
ttccagaaat  tatttgtacc  tagtattatt  tgtttacata  tcttaggcat  cccatcaaaa  138540
tgcaaatccc  tttgttgaag  aaatccttta  aaaatatttt  tattattcag  attaaatagt  138600
attgaagttt  gtacttagta  catattcttg  tgtgaacttg  ataaaggaca  aacaatggag  138660
gaaatatggt  agtgctcttg  agatgggaag  gacaattacc  tgaattcagg  tttcatgaga  138720
agttaagtgt  cctcagacta  ttttaaattt  gtttttcagt  attgtataaa  gtgctaccct  138780
cgttggataa  caggtgattg  ctttgagctc  tactgaagta  taaaatatag  attttttttct  138840
aacatcttga  ttcaagataa  aatagtacaa  ccaattagta  tttcccttga  gaatgttctc  138900
cactgtgatt  tcacttctaa  ttacctcttc  ttacacattt  ggggattctc  ctgagatata  138960
tgctgatgcc  agtgatgtgg  gtatatatct  tccagcactg  gccagaattt  gacctttggt  139020
gtcatgaaaa  agacaccctt  attttcacag  gtaagaaagg  aaatgttttt  gcatattatt  139080
tttcagtatc  taataatgtc  tgtattcact  ttgttaaatt  gtgtacattt  tagacagcaa  139140
tgtgtttaaa  taggtagttt  tgaggcaaat  ttgcacagac  aatgcatttt  ccatgaaaga  139200
aaatctgtag  ggagcttact  tagcttcatc  tttcactttt  ttgatattac  cagtgttatt  139260
gaaacatcct  ggtggaattt  catagtatgg  ctatttcagc  agatgttttc  actgttatta  139320
gtttcaagta  atattatttt  tgtgtttttcc  atttgcctaa  tgtcttggtg  cctactgtca  139380
ccaatcgcca  caagaaaaag  gcaagttgaa  aataatttaa  gtctacatag  cttaattaat  139440
```

```
cacataaaat ttttctgacg tctaagtaaa ataaatgctc aaacaggctt tttattgtga 139500
ccattaaaca tgtgtgaaag tggtccatta gcttcagtat gtggagctaa cgaacttggg 139560
tgagtagatc ttaagttctc ttgggttctc ttattttata agattctggg ttcttttcca 139620
atgccctatt tttgtctaga gacctagttt ttttacaagc aatacttgtg cctcagtgag 139680
actttagttt tcagaatatt attttacttt tttcaacaaa atacttgaaa cataaatcag 139740
cctgattata atcaaatcag tctgattata atcaaatcag tctgattcta atcaaataac 139800
taacttgtgt caaggacctt aaacagtaag ttgatgaatg aaattctcat acctattttt 139860
ctaggctgca caagtagtca cagaatcatt ctcgggtcat tatcaaattc atcatcatca 139920
aagttattga ctgcatttga atgtttgttt tgagtgtttc ttgcctctca gcagcagtgg 139980
acagatttct catgggctct atatctgtat attagctgtc tctgattgcc attgtcccgc 140040
aatgctagaa ttaaaatatg gttaaygata atggtctcca ctaaaagtgc atgtccagat 140100
gaccagtgaa acctgagcaa atttgcaaag ctccttagag actaagtcag gactaaaacc 140160
aagaccctgg attgaagaag ttgctcacca ccagagagtt aaaagaagcc cttgtgcctt 140220
ccttcttgcc aattaagtta caattcatag gcattattct agattcttgg cccagatttt 140280
tcatattctt tacagtttcg gcactgatac ctcggctggc tcgctttctt cttcctcatc 140340
catctcttat ctttgttaga gtgcttgtca ctatcatctg taactcaaag acaactctaa 140400
ctcaaagtcc tcatttattc atatttgttt cctgggacag gataaggagg caataatatt 140460
agataaattg aattttaaca ttttggaaac aatttctgtc attacccaac cagtcaatgg 140520
aaccaaagga agagatagac ctttctggga aagtaaaata ttacagaagg agagcaccgt 140580
tctgagaatt ataatatatg atttgtcttc tgattcttct gcttatgagt tgtaagctgg 140640
gaccagaatg tcaaattttc tgagcctggt tactcaccta actaaattta tttctactat 140700
attgtccact gctctatttc tagcatccag caccatgtct ggaacttgaa aaatgctcaa 140760
taattatctg ctataagcac gcatgcatac acaaatgcat ggctgacaac atattacaaa 140820
gtaaattagt gtttttttaa ctataaaatt tcactttaat aagagtttag caattgttgt 140880
aagatctcat acaatttaat agaaaatatg tgtctgatat tcttagatta ggtgaaaaat 140940
aaagtgctac tcgtattgac ttcctgagac tgctcagaag agataagttt tatcagcttc 141000
tgacaagttc tccactaatg acatttgctc atgtctgaat tgccccatgg aaaaaaatta 141060
gatgtaaatt tcattttacg caattgttag tatactgaaa ttgttttaa ccaaaatttg 141120
gagacagatt aacacatatg atattttaac ttaatttgat attttatata tttaarataa 141180
tttgtgataa attcagtaaa tgcataatgt ctatataaat tgtaagctac aaaatataat 141240
gaatacacat taaaccactc cctagaatta taagtaattt ctgtgcattg tttaaagtaa 141300
atgcacaatt taataatttt cccatttaaa taatctataa tccattaagc caatagtaaa 141360
tactaaaata gtccctcttt ccaaccctga tctgaaatgt catctttgtt atatgccaca 141420
tcacctatat acatgtagct gttcctggac tttctattct ggaacattag ttaaagtgta 141480
tattttttc caatttcatg tcaataacac actgtcctga atactggttt tacagcaaat 141540
cttgatatct aataagtaac tctgcttatt gccctgagag atattgagtc ttacggttat 141600
tttatacttc cgtataaata ttagaatcag ctattccaca agaattgtgt ttgaattttg 141660
attggaattt atttgactct atgggtcact taggaaagac tgaccttttt atgctattga 141720
atccttccct tagtgaacaa agaatctctc tccatttta gttctttctt tctctctctt 141780
ttctttcctt tcctttcctt tcctttcttt cctttccttt cctttctttc tttcttcttt 141840
ctttttcttt ctttctttct ttcttccttc cttccttcct tccttccttc cttccttcct 141900
ttctttgttt ctgagacgaa ctctcgcctc tctttgccac ccaggctgga gtgcagtggc 141960
atgatctcag tgcactacaa cctctgcctc ctgtgttcaa gtgattctcc tgcctcagtc 142020
tcctgagtag ctggggttac aggtgcacac ctccatacct ggctgattg tttttttttt 142080
agtagagaca gggtttcacc atgttggcca ggctggtctc gaactcatga ccagaagtga 142140
tcaacccgtc ttggcctccc aaaatgctgg gattataggc ataagccacc acatccagcc 142200
cattttttaag gcttttaat gttgtgtggc aatggcatca aagtgatcac ataatttatt 142260
ctgggtatat tagcagggag taagtataga ttgagaacct gaaaacattt ttttaatcat 142320
cttagggtga ttgagttaat tcctttatc aggacttctt tatacagaga tataaaagag 142380
ataatggagg aataggaaat tctttgatat aggacttctt tatacagaga tataaaagag 142440
catgtgagcc aagcagggga ctataatgtt ggttctatgc agcatgaatg ttgtaaaata 142500
gcaagaaatt aaaatatagg aacaaattaa aacatagatt gatacctcaa agataataca 142560
tatgaaattt catatagaat tgagatattg atgaaggagc ataaatacac ttgtttaacc 142620
caacagacag acaggctaaa ttgggatgtg caaattggaa aaaatgctta taaacacgtg 142680
atatcaatgt ttaagactca aacgaaaggc tttatttaca taagttccca aaaactaact 142740
tataaacaaa gaaccaatat acatatcaca atgaaaagca ctactactaa aaacaacaaa 142800
atataaaaat acaccgagac agtaagttga actcggtgag atatatagta tattagcaga 142860
tcaccgaatg gggatgtatg agataagcat ctcagtggga ttagtcactt catctctcta 142920
ggattcagtc tctgtagctt tgtatgtata tgtaagcatg tcattagaag ttctaagcat 143040
ttcaaaatct ctattacaat ttaatctta acatataagt tatctagatt tttaaaagaa 143100
atttcccaca gcataaggat actttcgttt ataattttgc attaagcctc caacttaatt 143160
gcacactgtg attacaaatt cagcctcagt ggaaaccact tgttgcaaat gtttagactt 143220
```

46

```
gcttcatagt ataactgttc atcttcagtt acagaactgc tactgagata acataactaa 143280
agccttttgg ctctttttat acaaagcatg atatttaact agggtttttag tgattttttaa 143340
aaagtttctc tttctcctta gatattcaga ccaatgcgtc tcatatgaga tgaagaaatg 143400
tccagaagaa actatactga actgacagaa tttgttctct tgggtctaac aagccgtcca 143460
gagctgcgag ttgctttctt ggcactgttc cttttttgtct acatagccac tgtggtagga 143520
aacttgggga tgattatttt aatcaaagtt gattctcgac ttcacactcc catgtaattt 143580
tttctctcca gtttgtccat tctagatctg tgtttctcca caaatttcac tcccaaaatg 143640
ctagaaaatt tcttatcaga gaagaagacc atttcctatg caggttgttt gatgcagtgc 143700
tatgttgtca ttgctgtggt cccttgcagag cactccatgt tggcagtcat ggcatatgac 143760
cgctatatgg ccatctgtaa tccattgctc tacagtagca aaatgtccca aggtgtttgt 143820
gtccacctgg tcattgtccc ttatgtctat ggctttcttc tcagtgtgat ggaaacctta 143880
aggacctaca acctctcctt ctgtggaaca aatgaaatca accatttcta ctgtgctgat 143940
cctcctctta tcaaactggc atgctctgac acgtacagca aggagctgtc catgtacata 144000
gtagccggct acagcaacgt ccagtctctt ctratcattc tcacatccta catgttcatc 144060
cttgtcgcta tcctcagaag ccattctgca gagggaagga aaaagctttt ttccacatgt 144120
ggttcccacc tgacagttgt cacaatcttc tatggaaccc tcttctgcat gcatttgaga 144180
cgtcccacag acgagtccgt ggagcagggg aaaatggtgg ctgtgtttta caccacagtg 144240
atactcatgc tgaactccat gatctatggc ctcaggaaca aggatgtgaa agaggcgttg 144300
aaaaaagcaa taggaaaaca aacattggga aaataaaaat gctaagctat cattaaaaat 144360
ttgtgaagta atgagatata atatcattgg gttagatgtc acattttagg ctacatttgc 144420
acaattcatt tctaattttc tgttaggtag ctgactgagt                          144460
```

```
<210> 2
<211> 195
<212> DNA
<213> Homo sapiens
```

```
<400> 2
atg agc ttc tta ata aga agt gat tca aca cta cac act cca atg tgc      48
Met Ser Phe Leu Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Cys
1                5                  10                  15
ttg ttc ctc agt cat ctc tcc ttt gta gat ctc tat tat gcc acc aat      96
Leu Phe Leu Ser His Leu Ser Phe Val Asp Leu Tyr Tyr Ala Thr Asn
             20                  25                  30
gcc act cct ccg atg ctg gtt aac ttt ttt ttt cca aga gaa aaa ccg     144
Ala Thr Pro Pro Met Leu Val Asn Phe Phe Phe Pro Arg Glu Lys Pro
         35                  40                  45
ttt cct tta ttg gtt gct tta tcc aat ttc acc ttt tca ttg cac tgg     192
Phe Pro Leu Leu Val Ala Leu Ser Asn Phe Thr Phe Ser Leu His Trp
     50                  55                  60
tga                                                                  195
 *
65
```

```
<210> 3
<211> 948
<212> DNA
<213> Homo sapiens
```

```
<400> 3
atg ttc tcc cca aac cac acc ata gtg aca gaa ttc att ctc ttg gga      48
Met Phe Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
1                5                  10                  15
ctg aca gac gac cca gtg cta gag aag atc ctg ttt ggg gta ttc ctt      96
Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
             20                  25                  30
gcg atc tac cta atc aca ctg gca ggc aac ctg tgc atg atc ctg ctg     144
Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
         35                  40                  45
atc agg acc aat tcc cac ctg caa aca ccc atg tat ttc ttc ctt ggc     192
Ile Arg Thr Asn Ser His Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
     50                  55                  60
cac ctc tcc ttt gta gac att tgc tat tct tcc aat gtt act cca aat     240
```

47

| His | Leu | Ser | Phe | Val | Asp | Ile | Cys | Tyr | Ser | Ser | Asn | Val | Thr | Pro | Asn |
| 65 | | | | 70 | | | | | 75 | | | | | | 80 |

```
atg ctg cac aat ttc ctc tca gaa cag aag acc atc tcc tac gct gga     288
Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
             85                90                95

tgc ttc aca cag tgt ctt ctc ttc atc gcc cta gtg atc act gag ttt     336
Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
         100               105               110

tac ttc ctt gct tca atg gca ttg gat cgc tat gta gcc att tgc agc     384
Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
         115               120               125

cct tta cat tac agt tcc agg atg tcc aag aac att tgc atc tct ctg     432
Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
         130               135               140

gtc act gtg cct tac atg tat ggc ttc ctt aat ggg ctc tct cag aca     480
Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
145               150               155               160

ctg ctg acc ttt cac tta tcc ttc tgt ggc tcc ctt gaa atc aat cat     528
Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
             165               170               175

ttc tac tgc gct gat cct cct ctt atc atg ctg gcc tgc tct gac acc     576
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
             180               185               190

cgt gtc aaa aag atg gca atg ttt gta gtt gca ggc ttt act ctc tca     624
Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
             195               200               205

agc tct ctc ttc atc att ctt ctg tcc tat ctt ttc att ttt gca gcg     672
Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala
         210               215               220

atc ttc agg atc cgt tct gct gaa ggc agg cac aaa gcc ttt tct acg     720
Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr
225               230               235               240

tgt gct tcc cac ctg aca ata gtc act ttg ttt tat gga acc ctc ttc     768
Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe
             245               250               255

tgc atg tac gta agg cct cca tca gag aag tct gta gag gag tcc aaa     816
Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys
             260               265               270

ata act gca gtc ttt tat act ttt ttg acc cca atg ctg aac cca ttg     864
Ile Thr Ala Val Phe Tyr Thr Phe Leu Thr Pro Met Leu Asn Pro Leu
             275               280               285

atc tat agc cta cgg aac aca gat gta atc ctt gcc atg caa caa atg     912
Ile Tyr Ser Leu Arg Asn Thr Asp Val Ile Leu Ala Met Gln Gln Met
         290               295               300

att agg gga aaa tcc ttt cat aaa att gca gtt tag                      948
Ile Arg Gly Lys Ser Phe His Lys Ile Ala Val *
305               310               315
```

<210> 4
<211> 519
<212> DNA
<213> Homo sapiens

<400> 4

```
atg tta aag aaa aac cat aca gcc gtg act gag ttt gtt ctc ctg gga      48
Met Leu Lys Lys Asn His Thr Ala Val Thr Glu Phe Val Leu Leu Gly
1                5                10                15

ctg aca gat cgg gct gag ctg cag tcc ctt ctt ttt gtg gta ttt cta      96
Leu Thr Asp Arg Ala Glu Leu Gln Ser Leu Leu Phe Val Val Phe Leu
             20                25                30

gtc atc tac ctt atc aca gta atc ggc aat gtg agc atg atc ttg tta     144
Val Ile Tyr Leu Ile Thr Val Ile Gly Asn Val Ser Met Ile Leu Leu
             35                40                45
```

48

```
atc aga agt gac tcg aca cta cac act cca atg tac ttc ttc ctc agt       192
Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Tyr Phe Phe Leu Ser
    50              55                  60
cac ctc tcc ttt gta gat ctc tgt tat acc acc aat gtt act cct cag       240
His Leu Ser Phe Val Asp Leu Cys Tyr Thr Thr Asn Val Thr Pro Gln
65              70              75                  80
atg ctg gtt aac ttt tta tcc aag aga aaa acc att tcc ttc atc ggc       288
Met Leu Val Asn Phe Leu Ser Lys Arg Lys Thr Ile Ser Phe Ile Gly
            85              90                  95
tgc ttt atc caa ttt cac ttt ttc att gca ctg gtg att aca gat tat       336
Cys Phe Ile Gln Phe His Phe Phe Ile Ala Leu Val Ile Thr Asp Tyr
                100             105             110
tat atg ctc aca gtg atg gct tat gac cgc tac atg gcc atc tgc aag       384
Tyr Met Leu Thr Val Met Ala Tyr Asp Arg Tyr Met Ala Ile Cys Lys
            115             120             125
ccc ttg tta tat gga agc aaa atg acc agg tgt gtc tgc ctc tgt ctg       432
Pro Leu Leu Tyr Gly Ser Lys Met Thr Arg Cys Val Cys Leu Cys Leu
    130             135             140
gct gct gct ccc tat att tat ggc ttt gca aat ggt cta agc aca gac       480
Ala Ala Ala Pro Tyr Ile Tyr Gly Phe Ala Asn Gly Leu Ser Thr Asp
145             150             155             160
cac cct gat gct tcg tct gtc ctt ctg tgg acc caa tga                   519
His Pro Asp Ala Ser Ser Val Leu Leu Trp Thr Gln  *
                165             170
```

```
<210> 5
<211> 948
<212> DNA
<213> Homo sapiens
```

```
<400> 5
atg ttg tcc cca aac cac acc ata gtg aca gaa ttc att ctc tta gga        48
Met Leu Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
1               5                   10                  15
ctg aca gac gac cca gtg cta gag aag atc ctg ttt ggg gtg ttc ctg        96
Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
            20                  25                  30
gcg atc tac cta atc aca ctg gca ggc aac ctg tgc atg atc ctg ctg       144
Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
        35                  40                  45
atc agg acc aat tcc caa ctg caa aca ccc atg tat ttc ttc ctt ggt       192
Ile Arg Thr Asn Ser Gln Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
    50              55                  60
cac ctc tcc ttt tta gac att tgc tat tct tcc aat gtt act cca aat       240
His Leu Ser Phe Leu Asp Ile Cys Tyr Ser Ser Asn Val Thr Pro Asn
65              70              75                  80
atg ctg cac aat ttc ctc tca gaa cag aag acc atc tcc tac gct gga       288
Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
            85                  90                  95
tgc ttc aca cag tgt ctt ctc ttc atc gcc cta gtg atc act gag ttt       336
Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
                100             105             110
tac ttc ctt gct tca atg gca ttg gat cgc tat gta gcc att tgc agc       384
Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
            115             120             125
cct tta cat tac agt tcc agg atg tcc aag aac att tgc atc tct ctg       432
Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
    130             135             140
gtc act gtg cct tac atg tat ggc ttc ctt aat ggg ctc tct cag aca       480
Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
145             150             155             160
ctg ctg acc ttt cac tta tcc ttc tgt ggc tcc ctt gaa atc aat cat       528
Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
```

<pre>
                165                        170                        175
ttc tac tgc gct gat cct cct ctt atc atg ctg gcc tgc tct gac acc        576
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
            180                        185                        190
cgt gtc aaa aag atg gca atg ttt gta gtt gca ggc ttt act ctc tca        624
Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
            195                        200                        205
agc tct ctc ttc atc att ctt ctg tcc tat ctt ttc att ttt gca gcg        672
Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala
            210                        215                        220
atc ttc agg atc cgt tct gct gaa ggc agg cac aaa gcc ttt tct acg        720
Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr
225                        230                        235                240
tgt gct tcc cac ctg aca ata gtc act ttg ttt tat gga acc ctc ttc        768
Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe
            245                        250                        255
tgc atg tac gta agg cct cca tca gag aag tct gta gag gag tcc aaa        816
Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys
            260                        265                        270
ata att gca gtc ttt tat act ttt ttg agc cca atg ctg aac cca ttg        864
Ile Ile Ala Val Phe Tyr Thr Phe Leu Ser Pro Met Leu Asn Pro Leu
            275                        280                        285
atc tat agc cta cgg aac aga gat gta atc ctt gcc ata caa caa atg        912
Ile Tyr Ser Leu Arg Asn Arg Asp Val Ile Leu Ala Ile Gln Gln Met
            290                        295                        300
att agg gga aaa tcc ttt tgt aaa att gca gtt tag                        948
Ile Arg Gly Lys Ser Phe Cys Lys Ile Ala Val *
305                        310                        315


<210> 6
<211> 918
<212> DNA
<213> Homo sapiens


<400> 6
atg tcc aac aca aat ggc agt gca atc aca gaa ttc att tta ctt ggg         48
Met Ser Asn Thr Asn Gly Ser Ala Ile Thr Glu Phe Ile Leu Leu Gly
1                       5                          10                      15
ctc aca gat tgc ccg gaa ctc cag tct ctg ctt ttt gtg ctg ttt ctg         96
Leu Thr Asp Cys Pro Glu Leu Gln Ser Leu Leu Phe Val Leu Phe Leu
            20                         25                          30
gtt gtt tac ctc gtc acc ctg cta ggc aac ctg ggc atg ata atg tta        144
Val Val Tyr Leu Val Thr Leu Leu Gly Asn Leu Gly Met Ile Met Leu
            35                         40                          45
atg aga ctg gac tct cgc ctt cac acg ccc atg tac ttc ttc ctc act        192
Met Arg Leu Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Thr
            50                         55                          60
aac tta gcc ttt gtg gat ttg tgc tat aca tca aat gca acc ccg cag        240
Asn Leu Ala Phe Val Asp Leu Cys Tyr Thr Ser Asn Ala Thr Pro Gln
65                         70                          75                      80
atg tcg act aat atc gta tct gag aag acc att tcc ttt gct ggt tgc        288
Met Ser Thr Asn Ile Val Ser Glu Lys Thr Ile Ser Phe Ala Gly Cys
                        85                         90                      95
ttt aca cag tgc tac att ttc att gcc ctt cta ctc act gag ttt tac        336
Phe Thr Gln Cys Tyr Ile Phe Ile Ala Leu Leu Leu Thr Glu Phe Tyr
            100                        105                        110
atg ctg gca gca atg gcc tat gac cgc tat gtg gcc ata tat gac cct        384
Met Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Tyr Asp Pro
            115                        120                        125
ctg cgc tac agt gtg aaa acg tcc agg aga gtt tgc atc tgc ttg gcc        432
Leu Arg Tyr Ser Val Lys Thr Ser Arg Arg Val Cys Ile Cys Leu Ala
            130                        135                        140
aca ttt ccc tat gtc tat ggc ttc tca gat gga ctc ttc cag gcc atc        480
</pre>

50

```
Thr Phe Pro Tyr Val Tyr Gly Phe Ser Asp Gly Leu Phe Gln Ala Ile
145             150             155             160
ctg acc ttc cgc ctg acc ttc tgt aga tcc aat gtc atc aac cac ttc    528
Leu Thr Phe Arg Leu Thr Phe Cys Arg Ser Asn Val Ile Asn His Phe
            165             170             175
tac tgt gct gac ccg ccg ctc att aag ctt tct tgt tct gat act tat    576
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ser Cys Ser Asp Thr Tyr
            180             185             190
gtc aaa gag cat gcc atg ttc ata tct gct ggc ttc aac ctc tcc agc    624
Val Lys Glu His Ala Met Phe Ile Ser Ala Gly Phe Asn Leu Ser Ser
        195             200             205
tcc ctc acc atc gtc ttg gtg tcc tat gcc ttc att ctt gct gcc atc    672
Ser Leu Thr Ile Val Leu Val Ser Tyr Ala Phe Ile Leu Ala Ala Ile
        210             215             220
ctc cgg atc aaa tca gca gag gga agg cac aag gca ttc tcc acc tgt    720
Leu Arg Ile Lys Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr Cys
225             230             235             240
ggt tcc cat atg atg gct gtc acc ctg ttt tat ggg act ctc ttt tgc    768
Gly Ser His Met Met Ala Val Thr Leu Phe Tyr Gly Thr Leu Phe Cys
            245             250             255
atg tat ata aga cca cca aca gat aag act gtt gag gaa tct aaa ata    816
Met Tyr Ile Arg Pro Pro Thr Asp Lys Thr Val Glu Glu Ser Lys Ile
            260             265             270
ata gct gtc ttt tac acc ttt gtg agt ccg gta ctt aat cca ttg atc    864
Ile Ala Val Phe Tyr Thr Phe Val Ser Pro Val Leu Asn Pro Leu Ile
        275             280             285
tac agt ctg agg aat aaa gat gtg aag cag gcc ttg aag aat gtc ctg    912
Tyr Ser Leu Arg Asn Lys Asp Val Lys Gln Ala Leu Lys Asn Val Leu
        290             295             300
aga tga                                                            918
Arg *
305


<210> 7
<211> 612
<212> DNA
<213> Homo sapiens


<400> 7
atg gtt aga gga aat tct act ttg gtg acg gaa ttt att ctc ttg gga     48
Met Val Arg Gly Asn Ser Thr Leu Val Thr Glu Phe Ile Leu Leu Gly
1               5               10              15
tta aag gat ctt cca gag ctt cag ccc atc ctc ttt gta ctg ttc ctg     96
Leu Lys Asp Leu Pro Glu Leu Gln Pro Ile Leu Phe Val Leu Phe Leu
            20              25              30
cta atc tac ctg atc act gtc ggg ggg aac ctt ggg atg ttg gtg ttg    144
Leu Ile Tyr Leu Ile Thr Val Gly Gly Asn Leu Gly Met Leu Val Leu
        35              40              45
atc agg ata gat tca cgc ctc cac acc ccc atg tat ttc ttt ctt gct    192
Ile Arg Ile Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ala
        50              55              60
agt ttg tcc tgc ttg gat ttg tat tac tcc act aat gtg act ccc aag    240
Ser Leu Ser Cys Leu Asp Leu Tyr Tyr Ser Thr Asn Val Thr Pro Lys
65              70              75              80
atg ttg gtg aac ttc ttc tca gac aag aaa gcc att tcc tat gct gct    288
Met Leu Val Asn Phe Phe Ser Asp Lys Lys Ala Ile Ser Tyr Ala Ala
            85              90              95
tgt tta gtc cag tgc tat ttt ttc att gct gtg gtg att act gaa tat    336
Cys Leu Val Gln Cys Tyr Phe Phe Ile Ala Val Val Ile Thr Glu Tyr
            100             105             110
tat atg cta gct gta atg gcc tat gat agg tat gtg gcc atc tgt aac    384
Tyr Met Leu Ala Val Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn
        115             120             125
```

```
cct ttg ctt tac agc agc aag atg tcc aaa ggg ctc tgt att cgc ctg       432
Pro Leu Leu Tyr Ser Ser Lys Met Ser Lys Gly Leu Cys Ile Arg Leu
    130                 135                 140

att gct ggt cca tat gtc tat ggg ttt ctt agt gga ctg atg gaa acc       480
Ile Ala Gly Pro Tyr Val Tyr Gly Phe Leu Ser Gly Leu Met Glu Thr
145                 150                 155                 160

atg tgg aca tac cac ttg acc ttc tgt ggc tcc aat atc att aat cac       528
Met Trp Thr Tyr His Leu Thr Phe Cys Gly Ser Asn Ile Ile Asn His
                    165                 170                 175

ttc tac tgt gct gac cca ccc ctc atc cga ctt tcc tgc tct gac act       576
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Arg Leu Ser Cys Ser Asp Thr
                180                 185                 190

ttc att aag gaa aca tcc atg ttt gtg gta gca tga                       612
Phe Ile Lys Glu Thr Ser Met Phe Val Val Ala  *
            195                 200
```

<210> 8
<211> 807
<212> DNA
<213> Homo sapiens

<400> 8
```
ttg ccc tca tcc agg cca acg ccc cgg ctc cac acg ccc atg tac ttt        48
Leu Pro Ser Ser Arg Pro Thr Pro Arg Leu His Thr Pro Met Tyr Phe
1               5                   10                  15

ttc ctg agc aac tta tcc ttt gtg gat ctg tgc ttc tct tcc aat gtg        96
Phe Leu Ser Asn Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val
                20                  25                  30

act cca agg atg ctg gag att ttc ctt tca gag aag aaa agc att tcc       144
Thr Pro Arg Met Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser
            35                  40                  45

tat cct gcc cgt ctt gtg cag tgt tac ctt ttt atc acc ttg gtc cac       192
Tyr Pro Ala Arg Leu Val Gln Cys Tyr Leu Phe Ile Thr Leu Val His
        50                  55                  60

gtt gag ctc tac atc ctg gct gtg atg gcc ttt gac cgg tac atg gcc       240
Val Glu Leu Tyr Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala
65                  70                  75                  80

atc tgc aac cct ctg ctt tat ggc agc aga atg tcc aag agc gtg tgc       288
Ile Cys Asn Pro Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys
                85                  90                  95

tct ttc ctc atc aca gtg ctt tat gtg tat gga gca ctc act ggc ctg       336
Ser Phe Leu Ile Thr Val Leu Tyr Val Tyr Gly Ala Leu Thr Gly Leu
                100                 105                 110

atg gag act atg tgg acc tac aac cta gcc ttc tgt ggc ccc agt gaa       384
Met Glu Thr Met Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Ser Glu
            115                 120                 125

att aat cac ttc tac tgt gtg gac cca cca ctg att aag ctg gct tgt       432
Ile Asn His Phe Tyr Cys Val Asp Pro Pro Leu Ile Lys Leu Ala Cys
        130                 135                 140

tct gac acc tac aac aag gag gtg tca atg ttt gtt gtg gct ggt ttc       480
Ser Asp Thr Tyr Asn Lys Glu Val Ser Met Phe Val Val Ala Gly Phe
145                 150                 155                 160

aac ttc act tat cct ctc ctt atc atc ctc att tcc tat ctc tac ata       528
Asn Phe Thr Tyr Pro Leu Leu Ile Ile Leu Ile Ser Tyr Leu Tyr Ile
                165                 170                 175

ttt cct gcc acc cta agg atc tgc tct aca gaa ggc agg cac aaa gct       576
Phe Pro Ala Thr Leu Arg Ile Cys Ser Thr Glu Gly Arg His Lys Ala
                180                 185                 190

ttt tct acc tgt ggc tcc cat ctg aca gcc gtt act att ttc tat tca       624
Phe Ser Thr Cys Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ser
                195                 200                 205

gct ctt ttc ttc atg tat ctc aga cgt cca tca gaa gag tcc atg gag       672
Ala Leu Phe Phe Met Tyr Leu Arg Arg Pro Ser Glu Glu Ser Met Glu
```

```
      210                 215                 220
cag ggg aaa atg gta gct gta ttt tat acc act gta atc ccc atg ttg    720
Gln Gly Lys Met Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu
225                 230                 235                 240
aat ccc atg atc tac agt ctg agg aac aaa gat gtg aaa gag gca tta    768
Asn Pro Met Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Glu Ala Leu
                    245                 250                 255
tgc aaa gaa ctg ttc aaa aga aaa ttg ttt tct aaa taa               807
Cys Lys Glu Leu Phe Lys Arg Lys Leu Phe Ser Lys  *
                260                 265
```

```
<210> 9
<211> 363
<212> DNA
<213> Homo sapiens
```

```
<400> 9
atg aga agg aac ttc acg ttg gtg act gag ttc att ctc ctg gga ctg    48
Met Arg Arg Asn Phe Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
1               5                   10                  15
acg aat cac cag gaa tta cag att ctc ctc ttc atg ctg ttt ctg gcc    96
Thr Asn His Gln Glu Leu Gln Ile Leu Leu Phe Met Leu Phe Leu Ala
                20                  25                  30
att tac atg gtc aca gtg gca ggg aat ctt agc atg att gcc ctc atc   144
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Ser Met Ile Ala Leu Ile
                35                  40                  45
cag gcc aat gcc cgg ctc cac acg ccc atg tac ttt ttc ctg agc cac   192
Gln Ala Asn Ala Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ser His
        50                  55                  60
tta tcc ttc ctg gat ctg tgc ttc tct tcc aat gtg acc cca aag atg   240
Leu Ser Phe Leu Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
65                  70                  75                  80
ctg gag att ttc ctt tca gag aag aaa agc att tcc tat cct gcc tgt   288
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
                85                  90                  95
ctt gtt cag tgt tac ctt tat atc atc ttg gta cac gtt gag atc tac   336
Leu Val Gln Cys Tyr Leu Tyr Ile Ile Leu Val His Val Glu Ile Tyr
                100                 105                 110
atc ctg gct gtg atg gcc ttt gac tag                               363
Ile Leu Ala Val Met Ala Phe Asp  *
        115                 120
```

```
<210> 10
<211> 936
<212> DNA
<213> Homo sapiens
```

```
<400> 10
atg aga aga aac tgc acg ttg gtg act gag ttc att ctc ctg gga ctg    48
Met Arg Arg Asn Cys Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
1               5                   10                  15
acc agt cgc cgg gaa tta caa att ctc ctc ttc acg ctg ttt ctg gcc    96
Thr Ser Arg Arg Glu Leu Gln Ile Leu Leu Phe Thr Leu Phe Leu Ala
                20                  25                  30
att tac atg gtc acg gtg gca ggg aac ctt ggc atg att gtc ctc atc   144
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Gly Met Ile Val Leu Ile
                35                  40                  45
cag gcc aac gcc tgg ctc cac atg ccc atg tac ttt ttc ctg agc cac   192
Gln Ala Asn Ala Trp Leu His Met Pro Met Tyr Phe Phe Leu Ser His
        50                  55                  60
tta tcc ttc gtg gat ctg tgc ttc tct tcc aat gtg act cca aag atg   240
Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
65                  70                  75                  80
```

53

```
ctg gag att ttc ctt tca gag aag aaa agc att tcc tat cct gcc tgt       288
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
                  85                  90                  95
ctt gtg cag tgt tac ctt ttt atc gcc ttg gtc cat gtt gag atc tac       336
Leu Val Gln Cys Tyr Leu Phe Ile Ala Leu Val His Val Glu Ile Tyr
                 100                 105                 110
atc ctg gct gtg atg gcc ttt gac cgg tac atg gcc atc tgc aac cct       384
Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala Ile Cys Asn Pro
             115                 120                 125
ctg ctt tat ggc agc aga atg tcc aag agt gtg tgc tcc ttc ctc atc       432
Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys Ser Phe Leu Ile
             130                 135                 140
acg gtg cct tat gtg tat gga gcg ctc act ggc ctg atg gag acc atg       480
Thr Val Pro Tyr Val Tyr Gly Ala Leu Thr Gly Leu Met Glu Thr Met
145                 150                 155                 160
tgg acc tac aac cta gcc ttc tgt ggc ccc aat gaa att aat cac ttc       528
Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Asn Glu Ile Asn His Phe
                 165                 170                 175
tac tgt gcg gac cca cca ctg att aag ctg gct tgt tct gac acc tac       576
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ala Cys Ser Asp Thr Tyr
             180                 185                 190
aac aag gag ttg tca atg ttt att gtg gct ggc tgg aac ctt tct ttt       624
Asn Lys Glu Leu Ser Met Phe Ile Val Ala Gly Trp Asn Leu Ser Phe
             195                 200                 205
tct ctc ttc atc ata tgt att tcc tac ctt tac att ttc cct gct att       672
Ser Leu Phe Ile Ile Cys Ile Ser Tyr Leu Tyr Ile Phe Pro Ala Ile
             210                 215                 220
tta aag att cgc tct aca gag ggc agg caa aaa gct ttt tct acc tgt       720
Leu Lys Ile Arg Ser Thr Glu Gly Arg Gln Lys Ala Phe Ser Thr Cys
225                 230                 235                 240
ggc tcc cat ctg aca gct gtc act ata ttc tat gca acc ctt ttc ttc       768
Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ala Thr Leu Phe Phe
             245                 250                 255
atg tat ctc aga ccc ccc tca aag gaa tct gtt gaa cag ggt aaa atg       816
Met Tyr Leu Arg Pro Pro Ser Lys Glu Ser Val Glu Gln Gly Lys Met
             260                 265                 270
gta gct gta ttt tat acc aca gta atc cct atg ctg aac ctt ata att       864
Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu Asn Leu Ile Ile
             275                 280                 285
tat agc ctt aga aat aaa aat gta aaa gaa gca tta atc aaa gag ctg       912
Tyr Ser Leu Arg Asn Lys Asn Val Lys Glu Ala Leu Ile Lys Glu Leu
             290                 295                 300
tca atg aag ata tac ttt tct taa                                       936
Ser Met Lys Ile Tyr Phe Ser  *
305                 310
```

```
<210> 11
<211> 180
<212> DNA
<213> Homo sapiens
```

```
<400> 11
atg tcc aga aga aac tat act gaa ctg aca gaa ttt gtt ctc ttg ggt        48
Met Ser Arg Arg Asn Tyr Thr Glu Leu Thr Glu Phe Val Leu Leu Gly
1                   5                  10                  15
cta aca agc cgt cca gag ctg cga gtt gct ttc ttg gca ctg ttc ctt        96
Leu Thr Ser Arg Pro Glu Leu Arg Val Ala Phe Leu Ala Leu Phe Leu
                  20                  25                  30
ttt gtc tac ata gcc act gtg gta gga aac ttg ggg atg att att tta       144
Phe Val Tyr Ile Ala Thr Val Val Gly Asn Leu Gly Met Ile Ile Leu
                  35                  40                  45
atc aaa gtt gat tct cga ctt cac act ccc atg taa                       180
Ile Lys Val Asp Ser Arg Leu His Thr Pro Met  *
```

50                          55                          60

<210> 12
<211> 64
<212> PRT
<213> Homo sapiens


<400> 12
Met Ser Phe Leu Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Cys
1                5                   10                  15
Leu Phe Leu Ser His Leu Ser Phe Val Asp Leu Tyr Tyr Ala Thr Asn
            20                  25                  30
Ala Thr Pro Pro Met Leu Val Asn Phe Phe Phe Pro Arg Glu Lys Pro
        35                  40                  45
Phe Pro Leu Leu Val Ala Leu Ser Asn Phe Thr Phe Ser Leu His Trp
    50                  55                  60


<210> 13
<211> 315
<212> PRT
<213> Homo sapiens


<400> 13
Met Phe Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
1                5                   10                  15
Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
            20                  25                  30
Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
        35                  40                  45
Ile Arg Thr Asn Ser His Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
    50                  55                  60
His Leu Ser Phe Val Asp Ile Cys Tyr Ser Ser Asn Val Thr Pro Asn
65                  70                  75                  80
Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
                85                  90                  95
Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
            100                 105                 110
Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
        115                 120                 125
Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
    130                 135                 140
Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
145                 150                 155                 160
Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
                165                 170                 175
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
            180                 185                 190
Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
        195                 200                 205
Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala
    210                 215                 220
Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr
225                 230                 235                 240
Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe
            245                 250                 255
Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys
        260                 265                 270
Ile Thr Ala Val Phe Tyr Thr Phe Leu Thr Pro Met Leu Asn Pro Leu
    275                 280                 285
Ile Tyr Ser Leu Arg Asn Thr Asp Val Ile Leu Ala Met Gln Gln Met
    290                 295                 300
Ile Arg Gly Lys Ser Phe His Lys Ile Ala Val
305                 310                 315

```
<210> 14
<211> 172
<212> PRT
<213> Homo sapiens


<400> 14
Met Leu Lys Lys Asn His Thr Ala Val Thr Glu Phe Val Leu Leu Gly
1               5                  10                  15
Leu Thr Asp Arg Ala Glu Leu Gln Ser Leu Leu Phe Val Val Phe Leu
            20                  25                  30
Val Ile Tyr Leu Ile Thr Val Ile Gly Asn Val Ser Met Ile Leu Leu
            35                  40                  45
Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Tyr Phe Phe Leu Ser
        50                  55                  60
His Leu Ser Phe Val Asp Leu Cys Tyr Thr Thr Asn Val Thr Pro Gln
65                  70                  75                  80
Met Leu Val Asn Phe Leu Ser Lys Arg Lys Thr Ile Ser Phe Ile Gly
                85                  90                  95
Cys Phe Ile Gln Phe His Phe Phe Ile Ala Leu Val Ile Thr Asp Tyr
            100                 105                 110
Tyr Met Leu Thr Val Met Ala Tyr Asp Arg Tyr Met Ala Ile Cys Lys
            115                 120                 125
Pro Leu Leu Tyr Gly Ser Lys Met Thr Arg Cys Val Cys Leu Cys Leu
        130                 135                 140
Ala Ala Ala Pro Tyr Ile Tyr Gly Phe Ala Asn Gly Leu Ser Thr Asp
145                 150                 155                 160
His Pro Asp Ala Ser Ser Val Leu Leu Trp Thr Gln
                165                 170


<210> 15
<211> 315
<212> PRT
<213> Homo sapiens


<400> 15
Met Leu Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
1               5                  10                  15
Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
            20                  25                  30
Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
            35                  40                  45
Ile Arg Thr Asn Ser Gln Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
        50                  55                  60
His Leu Ser Phe Leu Asp Ile Cys Tyr Ser Ser Asn Val Thr Pro Asn
65                  70                  75                  80
Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
                85                  90                  95
Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
            100                 105                 110
Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
            115                 120                 125
Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
        130                 135                 140
Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
145                 150                 155                 160
Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
                165                 170                 175
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
            180                 185                 190
Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
        195                 200                 205
Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala
```

```
            210                   215                   220
Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr
225                   230                   235                   240
Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe
                245                   250                   255
Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys
            260                   265                   270
Ile Ile Ala Val Phe Tyr Thr Phe Leu Ser Pro Met Leu Asn Pro Leu
            275                   280                   285
Ile Tyr Ser Leu Arg Asn Arg Asp Val Ile Leu Ala Ile Gln Gln Met
            290                   295                   300
Ile Arg Gly Lys Ser Phe Cys Lys Ile Ala Val
305                   310                   315
```

```
<210> 16
<211> 305
<212> PRT
<213> Homo sapiens
```

```
<400> 16
Met Ser Asn Thr Asn Gly Ser Ala Ile Thr Glu Phe Ile Leu Leu Gly
1               5               10                  15
Leu Thr Asp Cys Pro Glu Leu Gln Ser Leu Leu Phe Val Leu Phe Leu
            20              25                  30
Val Val Tyr Leu Val Thr Leu Leu Gly Asn Leu Gly Met Ile Met Leu
            35              40                  45
Met Arg Leu Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Thr
        50                  55                  60
Asn Leu Ala Phe Val Asp Leu Cys Tyr Thr Ser Asn Ala Thr Pro Gln
65                  70                  75                  80
Met Ser Thr Asn Ile Val Ser Glu Lys Thr Ile Ser Phe Ala Gly Cys
                85                  90                  95
Phe Thr Gln Cys Tyr Ile Phe Ile Ala Leu Leu Leu Thr Glu Phe Tyr
            100                 105                 110
Met Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Tyr Asp Pro
        115                 120                 125
Leu Arg Tyr Ser Val Lys Thr Ser Arg Arg Val Cys Ile Cys Leu Ala
        130                 135                 140
Thr Phe Pro Tyr Val Tyr Gly Phe Ser Asp Gly Leu Phe Gln Ala Ile
145                 150                 155                 160
Leu Thr Phe Arg Leu Thr Phe Cys Arg Ser Asn Val Ile Asn His Phe
            165                 170                 175
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ser Cys Ser Asp Thr Tyr
            180                 185                 190
Val Lys Glu His Ala Met Phe Ile Ser Ala Gly Phe Asn Leu Ser Ser
        195                 200                 205
Ser Leu Thr Ile Val Leu Val Ser Tyr Ala Phe Ile Leu Ala Ala Ile
        210                 215                 220
Leu Arg Ile Lys Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr Cys
225                 230                 235                 240
Gly Ser His Met Met Ala Val Thr Leu Phe Tyr Gly Thr Leu Phe Cys
                245                 250                 255
Met Tyr Ile Arg Pro Pro Thr Asp Lys Thr Val Glu Glu Ser Lys Ile
            260                 265                 270
Ile Ala Val Phe Tyr Thr Phe Val Ser Pro Val Leu Asn Pro Leu Ile
            275                 280                 285
Tyr Ser Leu Arg Asn Lys Asp Val Lys Gln Ala Leu Lys Asn Val Leu
        290                 295                 300
Arg
305
```

```
<210> 17
<211> 203
```

```
<212> PRT
<213> Homo sapiens

<400> 17
Met Val Arg Gly Asn Ser Thr Leu Val Thr Glu Phe Ile Leu Leu Gly
1               5                   10                  15
Leu Lys Asp Leu Pro Glu Leu Gln Pro Ile Leu Phe Val Leu Phe Leu
            20                  25                  30
Leu Ile Tyr Leu Ile Thr Val Gly Gly Asn Leu Gly Met Leu Val Leu
        35                  40                  45
Ile Arg Ile Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ala
    50                  55                  60
Ser Leu Ser Cys Leu Asp Leu Tyr Tyr Ser Thr Asn Val Thr Pro Lys
65                  70                  75                  80
Met Leu Val Asn Phe Phe Ser Asp Lys Lys Ala Ile Ser Tyr Ala Ala
                85                  90                  95
Cys Leu Val Gln Cys Tyr Phe Phe Ile Ala Val Val Ile Thr Glu Tyr
            100                 105                 110
Tyr Met Leu Ala Val Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn
        115                 120                 125
Pro Leu Leu Tyr Ser Ser Lys Met Ser Lys Gly Leu Cys Ile Arg Leu
        130                 135                 140
Ile Ala Gly Pro Tyr Val Tyr Gly Phe Leu Ser Gly Leu Met Glu Thr
145                 150                 155                 160
Met Trp Thr Tyr His Leu Thr Phe Cys Gly Ser Asn Ile Ile Asn His
                165                 170                 175
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Arg Leu Ser Cys Ser Asp Thr
                180                 185                 190
Phe Ile Lys Glu Thr Ser Met Phe Val Val Ala
            195                 200

<210> 18
<211> 268
<212> PRT
<213> Homo sapiens

<400> 18
Leu Pro Ser Ser Arg Pro Thr Pro Arg Leu His Thr Pro Met Tyr Phe
1               5                   10                  15
Phe Leu Ser Asn Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val
            20                  25                  30
Thr Pro Arg Met Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser
        35                  40                  45
Tyr Pro Ala Arg Leu Val Gln Cys Tyr Leu Phe Ile Thr Leu Val His
    50                  55                  60
Val Glu Leu Tyr Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala
65                  70                  75                  80
Ile Cys Asn Pro Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys
                85                  90                  95
Ser Phe Leu Ile Thr Val Leu Tyr Val Tyr Gly Ala Leu Thr Gly Leu
            100                 105                 110
Met Glu Thr Met Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Ser Glu
        115                 120                 125
Ile Asn His Phe Tyr Cys Val Asp Pro Pro Leu Ile Lys Leu Ala Cys
        130                 135                 140
Ser Asp Thr Tyr Asn Lys Glu Val Ser Met Phe Val Val Ala Gly Phe
145                 150                 155                 160
Asn Phe Thr Tyr Pro Leu Leu Ile Ile Leu Ile Ser Tyr Leu Tyr Ile
                165                 170                 175
Phe Pro Ala Thr Leu Arg Ile Cys Ser Thr Glu Gly Arg His Lys Ala
                180                 185                 190
Phe Ser Thr Cys Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ser
            195                 200                 205
```

```
Ala Leu Phe Phe Met Tyr Leu Arg Arg Pro Ser Glu Glu Ser Met Glu
    210                 215                 220
Gln Gly Lys Met Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu
225                 230                 235                 240
Asn Pro Met Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Glu Ala Leu
                245                 250                 255
Cys Lys Glu Leu Phe Lys Arg Lys Leu Phe Ser Lys
                260             265
```

```
<210> 19
<211> 120
<212> PRT
<213> Homo sapiens

<400> 19
Met Arg Arg Asn Phe Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
1               5                   10                  15
Thr Asn His Gln Glu Leu Gln Ile Leu Leu Phe Met Leu Phe Leu Ala
            20                  25                  30
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Ser Met Ile Ala Leu Ile
        35                  40                  45
Gln Ala Asn Ala Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ser His
    50                  55                  60
Leu Ser Phe Leu Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
65                  70                  75                  80
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
                85                  90                  95
Leu Val Gln Cys Tyr Leu Tyr Ile Ile Leu Val His Val Glu Ile Tyr
                100                 105                 110
Ile Leu Ala Val Met Ala Phe Asp
                115                 120
```

```
<210> 20
<211> 311
<212> PRT
<213> Homo sapiens

<400> 20
Met Arg Arg Asn Cys Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
1               5                   10                  15
Thr Ser Arg Arg Glu Leu Gln Ile Leu Leu Phe Thr Leu Phe Leu Ala
            20                  25                  30
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Gly Met Ile Val Leu Ile
        35                  40                  45
Gln Ala Asn Ala Trp Leu His Met Pro Met Tyr Phe Phe Leu Ser His
    50                  55                  60
Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
65                  70                  75                  80
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
                85                  90                  95
Leu Val Gln Cys Tyr Leu Phe Ile Ala Leu Val His Val Glu Ile Tyr
                100                 105                 110
Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala Ile Cys Asn Pro
                115                 120                 125
Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys Ser Phe Leu Ile
        130                 135                 140
Thr Val Pro Tyr Val Tyr Gly Ala Leu Thr Gly Leu Met Glu Thr Met
145                 150                 155                 160
Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Asn Glu Ile Asn His Phe
                165                 170                 175
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ala Cys Ser Asp Thr Tyr
                180                 185                 190
Asn Lys Glu Leu Ser Met Phe Ile Val Ala Gly Trp Asn Leu Ser Phe
```

```
              195                  200                  205
Ser Leu Phe Ile Ile Cys Ile Ser Tyr Leu Tyr Ile Phe Pro Ala Ile
     210                  215                  220
Leu Lys Ile Arg Ser Thr Glu Gly Arg Gln Lys Ala Phe Ser Thr Cys
225                  230                  235                  240
Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ala Thr Leu Phe Phe
              245                  250                  255
Met Tyr Leu Arg Pro Pro Ser Lys Glu Ser Val Glu Gln Gly Lys Met
              260                  265                  270
Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu Asn Leu Ile Ile
          275                  280                  285
Tyr Ser Leu Arg Asn Lys Asn Val Lys Glu Ala Leu Ile Lys Glu Leu
     290                  295                  300
Ser Met Lys Ile Tyr Phe Ser
305                  310
```

```
<210> 21
<211> 59
<212> PRT
<213> Homo sapiens

<400> 21
Met Ser Arg Arg Asn Tyr Thr Glu Leu Thr Glu Phe Val Leu Leu Gly
1               5                  10                  15
Leu Thr Ser Arg Pro Glu Leu Arg Val Ala Phe Leu Ala Leu Phe Leu
              20                  25                  30
Phe Val Tyr Ile Ala Thr Val Val Gly Asn Leu Gly Met Ile Ile Leu
          35                  40                  45
Ile Lys Val Asp Ser Arg Leu His Thr Pro Met
     50                  55
```

```
<210> 22
<211> 30
<212> DNA
<213> Artificial Sequence

<400> 22
cctggagggt ttcaaaggct gatactttag                                      30

<210> 23
<211> 26
<212> DNA
<213> Artificial Sequence

<400> 23
ctccagcctg agcaacagag caatac                                          26

<210> 24
<211> 30
<212> DNA
<213> Artificial Sequence

<400> 24
ctcacattca ttgttcttca cagacccagc                                      30

<210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 25
ccctgctggg atctggatca agac                                            24
```

```
<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerPU

<400> 26
tgtaaaacga cggccagt                                                      18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerRP

<400> 27
caggaaacag ctatgacc                                                      18
```

| (51) International Patent Classification 7 : <br> C12N 15/12, C07K 14/705, G01N 33/566 | A3 | (11) International Publication Number: **WO 00/21985** <br><br> (43) International Publication Date: 20 April 2000 (20.04.00) |
|---|---|---|

(54) Title: GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF

(57) Abstract

The invention concerns the genomic sequence and coding regions of a new olfactory receptor gene cluster. The invention also concerns polypeptides encoded by the olfactory receptor genes as well as to methods and kits for detecting these polynucleotides and screening substances interacting with these polypeptides. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the olfactory receptor gene useful in genetic analysis.

**A. CLASSIFICATION OF SUBJECT MATTER**
IPC 7   C12N15/12     C07K14/705    G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C12N   C07K   G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X | BUETTNER J A ET AL: "Organization and evolution of olfactory receptor genes on human chromosome 11." GENOMICS, (1998 OCT 1) 53 (1) 56-68., XP002135640 the whole document | 1-37 |
| X | WO 95 18140 A (YEDA RES & DEV ;RYCUS AVIGAIL (IL); BEN ARIE NISSIM (IL); LANCET D) 6 July 1995 (1995-07-06) page 4, line 19 - line 21 page 6, line 9 -page 8, line 5 | 1-37 |

-/--

| X | Further documents are listed in the continuation of box C. | X | Patent family members are listed in annex. |

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 13 April 2000 | 3 1. 05. 00 |

| Name and mailing address of the ISA | Authorized officer |
|---|---|
| European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | Chakravarty, A |

Form PCT/ISA/210 (second sheet) (July 1992)

1

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|---|---|---|
| Category* | Citation of document, with indication,where appropriate, of the relevant passages | Relevant to claim No. |
| X | TRASK BARBARA J ET AL: "Members of the olfactory receptor gene family are contained in large blocks of DNA duplicated polymorphically near the ends of human chromosomes." HUMAN MOLECULAR GENETICS JAN., 1998, vol. 7, no. 1, January 1998 (1998-01), pages 13-26, XP002135641 ISSN: 0964-6906 figure 2 --- | 1-37 |
| X | ROUQUIER S ET AL: "Distribution of olfactory receptor genes in the human genome" NATURE GENETICS, vol. 18, no. 3, 18 March 1998 (1998-03-18), pages 243-250, XP002111208 page 244, column 1, paragraph 2; figure 1 --- | 1-37 |
| X | DATABASE EMBL [Online] EBI accesssion no. AC004474, 30 March 1998 (1998-03-30) BIRREN B. ET AL.: " Homo sapiens chromosome Y, clone 475I1, complete sequence" XP002135642 compare with present SEQ ID 1 abstract ----- | 1-15, 19-21 |

1

# INTERNATIONAL SEARCH REPORT

| Box I | Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) |

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

| Box II | Observations where unity of invention is lacking (Continuation of item 2 of first sheet) |

This International Searching Authority found multiple inventions in this international application, as follows:

SEE ADDITIONAL SHEET

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1,2,7,13,16-24 (all part)

**Remark on Protest**  ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

**FURTHER INFORMATION CONTINUED FROM    PCT/ISA/ 210**

Continuation of Box I.2


Present claims 1-37 relate to an extremely large number of possible
compunds/apparatus/methods. In fact, the claims contain so many possible
permutations that a lack of clarity (and/or conciseness) within the
meaning of Article 6 PCT arises to such an extent as to render a
meaningful search of the claims impossible. Consequently, the search has
been carried out for those parts of the application which do appear to be
clear (and/or concise), namely SEQ ID 1.

The applicant's attention is drawn to the fact that claims, or parts of
claims, relating to inventions in respect of which no international
search report has been established need not be the subject of an
international preliminary examination (Rule 66.1(e) PCT). The applicant
is advised that the EPO policy when acting as an International
Preliminary Examining Authority is normally not to carry out a
preliminary examination on matter which has not been searched. This is
the case irrespective of whether or not the claims are amended following
receipt of the search report or during any Chapter II procedure.

**FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210**

1. Claims: 1, 2, 7, 13, 16-24 (all part)

    Olfactory receptor genomic sequence SEQ ID 1

2. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 2 and 12)

3. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 3 and 13)

4. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 4 and 14)

5. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 5 and 15)

6. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 6 and 16)

7. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 7 and 17)

8. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 8 and 18)

9. Claims: 1, 2, 7, 13-26, 35-37 (all part)

    OLF1 polypeptide and encoding polynucleotide (SEQ IDs 9 and 19)

10. Claims: 1, 2, 7, 13-26, 35-37 (all part)

**FURTHER INFORMATION CONTINUED FROM     PCT/ISA/  210**

OLF1 polypeptide and encoding polynucleotide (SEQ IDs 10 and 20)


11. Claims: 1, 2, 7, 13-26, 35-37 (all part)

OLF1 polypeptide and encoding polynucleotide (SEQ IDs 11 and 21)

*12-24*

12. Claims: claims 1-3, 5-10, 13-24 (all part)

Groups 12-24:
Polynucleotides of 8-50 bp in length from SEQ ID 1, including an olfactory related biallelic marker selected from A1-A13

*25*

13. Claims: 1-3, 5, 7-10, 13-24 (all part)

Group 25:
Polynucleotides of 8-50 bp in length from SEQ ID 1 including an olfactory related biallelic marker other than A1-A13. Note that in this group further non-unity is present, since each group of fragments not linked to other by a common structural feature is regarded as a separate invention. Moreover, this group is not searchable since the markers are not defined.

*26 - 29*

14. Claims: 11,12

Groups 26-29: Oligonucleotide primers D1-D13 (group 26), E1-E13 (group 27) and B1-B11 (group 28) and C1-C11 (group 29)

*30*

15. Claim : 1 (part)

Polynucleotides encoding of at least 12 nucleotides of SEQ ID 1 as defined in claim 1 and not falling into another group- Note that in this group further non-unity is present, since each group of fragments not linked to other by a common structural feature is regarded as a separate invention. e.g. the claims define 114448 separate 12mer oligonucleotide fragments which each may be a separate group.

# INTERNATIONAL SEARCH REPORT

information on patent family members

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| WO 9518140 A | 06-07-1995 | NONE | |